Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease

ABSTRACT

The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I):or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.

CROSS-REFERENCE

This application is a continuation of U.S. application Ser. No. 17/221,209, filed Apr. 2, 2021, which claims priority to U.S. Provisional Application No. 63/005,096, filed Apr. 3, 2020, the content of each of which is herein incorporated by reference in its entirety.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in ST.26 XML format. The Sequence Listing is provided as a file titled “X22826A” created 18 Apr. 2023 and is 4.64 kilobytes in size. The Sequence Listing information in the ST.26 XML format is incorporated herein by reference in its entirety.

FIELD

The present disclosure is directed to allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation.

The disclosure is directed toward compounds and compositions which inhibit PI3K, methods of treating a disease or disorder associated with PI3K (e.g., CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome), PIK3CA-related overgrowth syndrome (PROS), breast cancer, brain cancer, prostate cancer, endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, or head and neck cancer), and methods of using PI3K inhibitors in combination with one or more additional disorder or cancer therapy.

BACKGROUND

The activity of cells can be regulated by external signals that stimulate or inhibit intracellular events. The process by which stimulatory or inhibitory signals are transmitted into and within a cell to elicit an intracellular response is referred to as signal transduction. Over the past decades, cascades of signal transduction events have been elucidated and found to play a central role in a variety of biological responses. Defects in various components of signal transduction pathways have been found to account for a vast number of diseases, including numerous forms of cancer, inflammatory disorders, metabolic disorders, vascular and neuronal diseases (Gaestel et al. Current Medicinal Chemistry (2007) 14:2214-2234).

Kinases represent a class of important signaling molecules. Kinases can generally be classified into protein kinases and lipid kinases, and certain kinases exhibit dual specificities. Protein kinases are enzymes that phosphorylate other proteins and/or themselves (i.e., autophosphorylation). Protein kinases can be generally classified into three major groups based upon their substrate utilization: tyrosine kinases which predominantly phosphorylate substrates on tyrosine residues (e.g., erb2, PDGF receptor, EGF receptor, VEGF receptor, src, abl), serine/threonine kinases which predominantly phosphorylate substrates on serine and/or threonine residues (e.g., mTorC1, mTorC2, ATM, ATR, DNA-PK, Akt), and dual-specificity kinases which phosphorylate substrates on tyrosine, serine and/or threonine residues.

Lipid kinases are enzymes that catalyze the phosphorylation of lipids within cells. These enzymes, and the resulting phosphorylated lipids and lipid-derived biologically active organic molecules, play a role in many different physiological processes, including cell proliferation, migration, adhesion, and differentiation. A particular group of lipid kinases comprises membrane lipid kinases, i.e., kinases that catalyze the phosphorylation of lipids contained in or associated with cell membranes. Examples of such enzymes include phosphinositide(s) kinases (such as PI3-kinases, PI4-Kinases), diacylglycerol kinases, and sphingosine kinases.

The phosphoinositide 3-kinases (PI3Ks) signaling pathway is one of the most highly mutated systems in human cancers. PI3K signaling is involved in many other disease states including allergic contact dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder, psoriasis, multiple sclerosis, asthma, disorders related to diabetic complications, and inflammatory complications of the cardiovascular system such as acute coronary syndrome.

PI3Ks are members of a unique and conserved family of intracellular lipid kinases that phosphorylate the 3′—OH group on phosphatidylinositols or phosphoinositides. The PI3K family comprises 15 kinases with distinct substrate specificities, expression patterns, and modes of regulation (Katso et al., 2001). The class I PI3Ks (p110α, p110β, p110δ, and p110γ) are typically activated by tyrosine kinases or G-protein coupled receptors to generate PIP3, which engages downstream effectors such as those in the pathways of Akt/PDK1, mTOR, the Tec family kinases, and the Rho family GTPases. The class II and III PI3-Ks play a key role in intracellular trafficking through the synthesis of PI(3)P and PI(3,4)P2.

The PI3K isoforms have been implicated, for example, in a variety of human cancers and disorders. Mutations in the gene coding for PI3K isoforms or mutations which lead to upregulation of a PI3K isoform are believed to occur in many human cancers. Mutations in the gene coding for a PI3K isoform are point mutations clustered within several hotspots in helical and kinase domains. Because of the high rate of PI3K mutations, targeting of this pathway may provide valuable therapeutic opportunities.

Genetic alterations in genes in PI3K signaling are believed to be involved in a range of cancers such as endometrial cancer, breast cancer, esophageal squamous-cell cancer, cervical squamous-cell carcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, bladder urothelial carcinoma, glioblastoma, ovarian cancer, non-small-cell lung cancer, esophagogastric cancer, nerve-sheath tumor, head and neck squamous-cell carcinoma, melanoma, esophagogastric adenocarcinoma, soft-tissue sarcoma, prostate cancer, fibrolamellar carcinoma, hepatocellular carcinoma, diffuse glioma, colorectal cancer, pancreatic cancer, cholangiocarcinoma, B-cell lymphoma, mesothelioma, adrenocortical carcinoma, renal non-clear-cell carcinoma, renal clear-cell carcinoma, germ-cell carcinoma, thymic tumor, pheochromocytoma, miscellaneous neuroepithelial tumor, thyroid cancer, leukemia, and encapsulated glioma (Goncalves M D, Hopkins B D, Cantley L C. Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N Engl J Med. 2018 Nov. 22; 379(21):2052-2062).

The alpha (α) isoform of PI3K has been implicated, for example, in a variety of human cancers. Angiogenesis has been shown to selectively require the α isoform of PI3K in the control of endothelial cell migration. (Graupera et al, Nature 2008; 453; 662-6). Mutations in the gene coding for PI3Kα or mutations which lead to upregulation of PI3Kα are believed to occur in many human cancers such as lung, stomach, endometrial, ovarian, bladder, breast, colon, brain, prostate, and skin cancers. Mutations in the gene coding for PI3Kα are point mutations clustered within several hotspots in helical and kinase domains, such as E542K, E545K, and H1047R. Many of these mutations have been shown to be oncogenic gain-of-function mutations. Because of the high rate of PI3Kα mutations, targeting of this pathway may provide valuable therapeutic opportunities. While other PI3K isoforms such as PI3Kδ or PI3Kγ are expressed primarily in hematopoietic cells, PI3Kα, along with PI3Kβ, is expressed constitutively.

Due to the central role of PI3Kα in regulating organismal glucose homeostasis, PI3K inhibition in patients often gives rise to hyperglycemia and/or hyperinsulinemia (Busaidy N L, et al, Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012; 30:2919-28). High levels of circulating insulin could potentially be mitogenic and/or antiapoptotic for cancer cells and thus negate the antiproliferative effects of PI3K inhibitors (Blouin M-J, et al, Abstract 4615: the hyperinsulinemia caused by PI3K inhibitors attenuates their antineoplastic efficacy, but can be minimized by co-administration of metformin. Cancer Res 2013; 73:4615).

In the setting of cancer with mutated PI3Kα, one way to overcome the problem of compensatory production of insulin and/or glucose upon systemic PI3Kα inhibition would be to develop inhibitors with enhanced selectivity for mutant PI3Kα over wild-type PI3Kα. This would create an increased window for drug dosing to selectively inhibit the pathologic signaling of mutant PI3Kα in the cancer cells without affecting the wild-type PI3Kα in the host tissues that control systemic metabolism (Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discov. 2016 October; 6(10):1090-1105), thus limiting toxicities and permitting higher doses and more complete inhibition of the drug target (Ariella B. Hanker, et al, Challenges for the clinical development of PI3K inhibitors: Strategies to improve their impact in solid tumors. Cancer Discov. 2019 April; 9(4): 482-491).

Currently PI3Kα inhibitors are nearly equipotent to wild-type and mutant PI3Kα. Mutant selective inhibitors have been elusive due to the PI3Ka mutations location far from the active site. As such, inhibitors which target a second, peripheral binding pocket near a known mutation (e.g., H1047R) may provide a route to selective PI3Kα inhibition. Thus, targeting a mutated, peripheral binding pocket of PI3Kα, may in turn provide a valuable therapeutic target for drug development.

As such, kinases, for example lipid kinases such as PI3Ks, are prime targets for drug development. The present disclosure provides a new class of kinase inhibitors.

SUMMARY

In one aspect, the present disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof:

wherein:

-   -   X is —NR₁₂— or —O—;     -   Y is —C(R₁₁)₂—, —O—, —NR₁₁—, or —S—;     -   W is —N—, —O—, or —S—, wherein when W is —O— or —S—, R₁ or R₂ is         absent;     -   each R₁ and R₂ is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl,         C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂,         —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂,         —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl,         heterocycle, aryl, or heteroaryl, wherein the cycloalkyl,         heterocycle, aryl, and heteroaryl are optionally substituted         with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl,         C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy,         —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂,         —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂,         C₃-C₆ cycloalkyl, aryl, heteroaryl, or R₁₅; or     -   R₁ and R₂, together with the nitrogen to which they are         attached, form a heterocycle comprising 1-4 heteroatoms selected         from O, N, and S, wherein the heterocycle is optionally         substituted with one or more R₁₀;     -   each R₃, R₄, R₅, and R₆ is independently H, halogen, —CN, C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆         alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂,         —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂,         C₃-C₁₀ cycloalkyl, aryl, heterocycle comprising 1-4 heteroatoms         selected from O, N, and S, or heteroaryl comprising 1-4         heteroatoms selected from O, N, and S;     -   each R₇ and R₅ is independently H, halogen, —CN, C₁-C₆ alkyl,         C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy;     -   R₉ at each occurrence is independently oxo, ═NR₁₁, halogen, —CN,         —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—OR₁₂,         —(CH₂)_(m)—CR₁₃(OH)—R₁₂, —(CH₂)_(m)—C(O)R₁₂,         —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂,         —(CH₂)_(m)—C(O)N(OH)R₁₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂—OR₁₂,         —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₂)₂,         —(CH₂)_(m)—P(O)(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₃)R₁₂,         —(CH₂)_(m)—B(OH)₂, —(CH₂)_(m)—B(R₁₂)₂,         —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃,         —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃, C₃-C₁₀ cycloalkyl, aryl, heterocycle         comprising 1-4 heteroatoms selected from O, N, and S, or         heteroaryl comprising 1-4 heteroatoms selected from N, O, and S,         wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, C₁-C₆ alkoxy, C₃-C₁₀ cycloalkyl, aryl, heterocycle,         or heteroaryl is optionally substituted with one or more oxo,         halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, or two R₉, together         with the atoms to which they are attached form a C₃-C₁₀         cycloalkyl, an aryl, or a heterocycle comprising 1-4 heteroatoms         selected from O, N, and S, wherein the cycloalkyl, aryl, or         heterocycle is optionally substituted with one or more oxo,         halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl,         C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy;     -   R₁₀ at each occurrence is independently oxo, halogen, —CN, C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆         alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂,         —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂,         —(CH₂)_(n)—O—(CH₂CH₂—O)_(r)R₁₃, C₃-C₁₀ cycloalkyl, heterocycle,         —(CH₂)_(n)-aryl, or heteroaryl, wherein the cycloalkyl,         heterocycle, aryl, and heteroaryl is optionally substituted with         halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —(CH₂)_(n)—SO₂R₁₂,         —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, or         —(CH₂)_(n)—C(O)N(R₁₂)₂, or two R₁₀, together with the atoms to         which they are attached, form a C₃-C₁₀ cycloalkyl, an aryl, a         heterocycle comprising 1-4 heteroatoms selected from O, N, and         S, or a heteroaryl, wherein the cycloalkyl, aryl, heterocycle,         and heteroaryl are optionally substituted with one or more oxo,         ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂,         —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂,         —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂, C₃-C₆ cycloalkyl,         aryl, heteroaryl, or R₁₅;     -   R₁₁ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl;     -   each R₁₂ and R₁₃ at each occurrence is independently H, C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆         alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄,         —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄,         —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄,         —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄,         —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄,         —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle         comprising 1-4 heteroatoms selected from O, N, and S,         —(CH₂)_(q)-aryl, or heteroaryl comprising 1-4 heteroatoms         selected from N, O, and S, wherein the cycloalkyl, heterocycle,         aryl, and heteroaryl are optionally substituted with one or more         halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆         haloalkoxy; Ring A is C₃-C₁₀ cycloalkyl, aryl, heterocycle         comprising 1-4 heteroatoms selected from N, O, and S, or         heteroaryl comprising 1-4 heteroatoms selected from N, O, and S;     -   R₁₄ is

-   -   two R₁₅, together with the atoms to which they are attached form         a cycloalkyl, an aryl, a heterocycle comprising 1-4 heteroatoms         selected from O, N, and S, or a heteroaryl, wherein the         cycloalkyl, aryl, heterocycle, and heteroaryl are optionally         substituted with one or more C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆         alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂,         —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, or         —(CH₂)_(n)—SO₂R₁₂; and     -   each n, m, q, r, or s is independently at each occurrence 0, 1,         2, 3, 4, 5, or 6;     -   provided that when R₁ and R₂ together with the nitrogen atom to         which they are attached form a morpholine and:         -   i. when Y is —O—; R₃, R₄, and R₆ are hydrogen; R₇ is methyl;             X is —NR₁₂— and Ring A is aryl; then R₅ is not —C(O)N(R₁₂)₂             or C(O)OR₁₂;         -   ii. when Y is —O—, or —NR₁₁—; R₃, R₄, R₆ and R₈ are             hydrogen; R₇ is H or C₁-C₆ alkyl; X is —NR₁₂— and Ring A is             phenyl or pyridyl; then R₅ is not H, OH, OCH₃, OCF₃, F, Cl,             CF₃, C₁-C₆ alkyl, or —(CH₂)_(m)-aryl; or         -   iii. when R₅ is —CH₃, then either (a) the morpholine is             substituted or (b) Ring A is not phenyl.

In a preferred embodiment of Formula (I), s is at least 1 and at least one R₉ is —C(O)OR₁₂.

In another preferred embodiment of Formula (I), W is —N—, and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀, and wherein said heterocycle is not an optionally substituted morpholine.

In another preferred embodiment of Formula (I), s is at least 1, at least one R₉ is —C(O)OR₁₂, W is —N—, and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀, and wherein said heterocycle is not an optionally substituted morpholine.

In another aspect, the present disclosure generally relates to methods for treating cancer. These methods comprise administering to a subject in need thereof, a therapeutically effective amount of a PI3K inhibitor (e.g., PI3Kα inhibitor or PI3KA H1047R mutant inhibitor).

In some embodiments, the PI3K inhibitor (e.g., PI3Kα inhibitor or PI3KA H1047R mutant inhibitor) is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof.

In another aspect, the present disclosure provides a compound obtainable by, or obtained by, a method for preparing a compound as described herein (e.g., a method comprising one or more steps described in the Schemes).

In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, and a pharmaceutically acceptable diluent or carrier.

In another aspect, the present disclosure provides an intermediate as described herein, being suitable for use in a method for preparing a compound as described herein (e.g., the intermediate is selected from the intermediates described in the Examples).

In another aspect, the present disclosure provides a method of modulating PI3K (e.g., PI3Kα) activity (e.g., in vitro or in vivo), comprising contacting a cell with a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof.

In some embodiments, the PI3Kα sequence correlates with NCBI Reference Sequence: NP_006209.2. In some embodiments, the PI3Kβsequence correlates with NCBI Reference Sequence: NP_006210.1.

In some aspects, an amino acid sequence encoding PI3Kα comprises or consists of an amino acid sequence:

(SEQ ID NO: 1) MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHEL FKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPF LKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVC KEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWV IVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLE YQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLY SQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATY VNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIY IPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKM ALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMS VIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDP LSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVK DWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQ VLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGL LLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFL VEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWE NPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRM LPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLK DKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFH IDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERF QEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALD KTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN.

In some aspects, an amino acid sequence encoding PI3Kα with a H1047R mutation comprises or consists of an amino acid sequence:

(SEQ ID NO: 2) MPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLITIKHEL FKEARKYPLHQLLQDESSYIFVSVTQEAEREEFFDETRRLCDLRLFQPF LKVIEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVC KEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWV IVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLE YQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLY SQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATY VNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIY IPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKM ALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMS VIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDP LSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVK DWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQ VLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGL LLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFL VEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWE NPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRM LPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLK DKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFH IDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERF QEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALD KTEQEALEYFMKQMNDA R HGGWTTKMDWIFHTIKQHALN.

In some aspects, the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof.

In some aspects, the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof.

In some aspects, the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof.

In some aspects, the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof.

In another aspect, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof for use in modulating PI3K (e.g., PI3Kα) activity (e.g., in vitro or in vivo).

In another aspect, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, for use in selective inhibition for mutant PI3Kα over wild-type PI3Kα.

In another aspect, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, for use in treating or preventing a disease or disorder disclosed herein.

In another aspect, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, for use in treating a disease or disorder disclosed herein.

In another aspect, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, in the manufacture of a medicament for modulating P13K (e.g., PI3Kα) activity (e.g., in vitro or in vivo).

In another aspect, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.

In another aspect, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder disclosed herein.

In another aspect, the present disclosure provides a method of preparing a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof.

In another aspect, the present disclosure provides a method of preparing a compound, comprising one or more steps described herein.

Other features and advantages of the disclosure will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION

The present disclosure provides methods of treating, preventing, or ameliorating a disease or disorder in which PI3K plays a role by administering to a patient in need thereof a therapeutically effective amount of a PI3K inhibitor. The methods of the present disclosure can be used in the treatment of a variety of PI3K-dependent diseases and disorders.

In some embodiments, the disease of disorder is a cancer (e.g., breast cancer, brain cancers, prostate cancer, endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, and head and neck cancer). In some embodiments, the disease or disorder associated with PI3K includes, but is not limited to, CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome), PIK3CA-related overgrowth syndrome (PROS), endometrial cancer, breast cancer, esophageal squamous-cell cancer, cervical squamous-cell carcinoma, cervical adenocarcinoma, colorectal adenocarcinoma, bladder urothelial carcinoma, glioblastoma, ovarian cancer, non-small-cell lung cancer, esophagogastric cancer, nerve-sheath tumor, head and neck squamous-cell carcinoma, melanoma, esophagogastric adenocarcinoma, soft-tissue sarcoma, prostate cancer, fibrolamellar carcinoma, hepatocellular carcinoma, diffuse glioma, colorectal cancer, pancreatic cancer, cholangiocarcinoma, B-cell lymphoma, mesothelioma, adrenocortical carcinoma, renal non-clear-cell carcinoma, renal clear-cell carcinoma, germ-cell carcinoma, thymic tumor, pheochromocytoma, miscellaneous neuroepithelial tumor, thyroid cancer, leukemia, and encapsulated glioma.

The details of the disclosure are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, illustrative methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.

Definitions

The articles “a” and “an” are used in this disclosure to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

The term “and/or” is used in this disclosure to mean either “and” or “or” unless indicated otherwise.

The term “optionally substituted” is understood to mean that a given chemical moiety (e.g., an alkyl group) can (but is not required to) be bonded to other substituents (e.g., heteroatoms).

For instance, an alkyl group that is optionally substituted can be a fully saturated alkyl chain (i.e., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have one or more substituents different from hydrogen. For instance, it can, at any point along the chain be bonded to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus, the term “optionally substituted” means that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any further functional groups. Suitable substituents used in the optional substitution of the described groups include, without limitation, halogen, oxo, —OH, —CN, —COOH, —CH₂CN, —O—(C₁-C₆) alkyl, (C₁-C₆) alkyl, (C₁-C₆) alkoxy, (C₁-C₆) haloalkyl, (C₁-C₆) haloalkoxy, —O—(C₂-C₆) alkenyl, —O—(C₂-C₆) alkynyl, (C₂-C₆) alkenyl, (C₂-C₆) alkynyl, —OH, —OP(O)(OH)₂, —OC(O)(C₁-C₆) alkyl, —C(O)(C₁-C₆) alkyl, —OC(O)O(C₁-C₆) alkyl, —NH₂, —NH((C₁-C₆) alkyl), —N((C₁-C₆) alkyl)₂, —NHC(O)(C₁-C₆) alkyl, —C(O)NH(C₁-C₆) alkyl, —S(O)₂(C₁-C₆) alkyl, —S(O)NH(C₁-C₆)alkyl, and —S(O)N((C₁-C₆)alkyl)₂. The substituents can themselves be optionally substituted. “Optionally substituted” as used herein also refers to substituted or unsubstituted whose meaning is described below.

As used herein, the term “substituted” means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.

As used herein, the term “unsubstituted” means that the specified group bears no substituents.

Unless otherwise specifically defined, the term “aryl” refers to cyclic, aromatic hydrocarbon groups that have 1 to 3 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl). The aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. Exemplary substituents include, but are not limited to, —H, -halogen, —O—(C₁-C₆)alkyl, (C₁-C₆)alkyl, —O—(C₂-C₆)alkenyl, —O—(C₂-C₆) alkynyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, —OH, —OP(O)(OH)₂, —OC(O)(C₁-C₆)alkyl, —C(O)(C₁-C₆) alkyl, —OC(O)O(C₁-C₆)alkyl, —NH₂, —NH((C₁-C₆)alkyl), —N((C₁-C₆)alkyl)₂, —S(O)₂—(C₁-C₆) alkyl, —S(O)NH(C₁-C₆)alkyl, and —S(O)N((C₁-C₆)alkyl)₂. The substituents can themselves be optionally substituted. Furthermore, when containing two fused rings the aryl groups herein defined may have one or more saturated or partially unsaturated ring fused with a fully unsaturated aromatic ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.

Unless otherwise specifically defined, “heteroaryl” means a monovalent monocyclic or a polycyclic aromatic radical of 5 to 24 ring atoms, preferably 5 to 10 rings atoms, containing one or more ring heteroatoms selected from N, O, S, P, or B, preferably 1, 2, 3, or 4 ring heteroatoms selected from N, O, or S, the remaining ring atoms being C. A polycyclic aromatic radical includes two or more fused rings and may further include two or more spiro-fused rings, e.g., bicyclic, tricyclic, tetracyclic, and the like. Unless otherwise specifically defined, “fused” means two rings sharing two ring atoms. Unless otherwise specifically defined, “spiro-fused” means two rings sharing one ring atom. Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, O, S, P, or B, preferably N, O, or S. Heteroaryl as herein defined also means a tricyclic heteroaromatic group containing one or more ring heteroatoms selected from N, O, S, P, or B, preferably N, O, or S. Heteroaryl as herein defined also means a tetracyclic heteroaromatic group containing one or more ring heteroatoms selected from N, O, S, P, or B, preferably N, O, or S. The aromatic radical is optionally substituted independently with one or more substituents described herein. Examples of heteroaromatic groups include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuranyl, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazinyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, tetrahydro pyrrolo[1,2-a]pyrimidinyl, 3,4-dihydro-2H-1-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d]thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1H-pyrido[3,4-b][1,4]thiazinyl, benzooxazolyl, benzoisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [1,2,4]triazolo[1,5-a]pyridinyl, benzo [1,2,3]triazolyl, imidazo[1,2-a]pyrimidinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo [1,5-b][1,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. Furthermore, when containing two or more fused rings, the heteroaryl groups defined herein may have one or more saturated or partially unsaturated ring fused with one or more fully unsaturated aromatic ring. In heteroaryl ring systems containing more than two fused rings, a saturated or partially unsaturated ring may further be fused with a saturated or partially unsaturated ring described herein. Furthermore, when containing three or more fused rings, the heteroaryl groups defined herein may have one or more saturated or partially unsaturated ring spiro-fused. Any saturated or partially unsaturated ring described herein is optionally substituted with one or more oxo. Exemplary ring systems of these heteroaryl groups include, for example, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H-isoquinolinyl, 2,3-dihydrobenzofuranyl, benzofuranonyl, indolinyl, oxindolyl, indolyl, 1,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-onyl, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolizinyl, 8H-pyrido[3,2-b]pyrrolizinyl, 1,5,6,7-tetrahydrocyclopenta[b]pyrazolo[4,3-e]pyridinyl, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolizinyl, pyrazolo[1,5-a]pyrimidin-7(4H)-only, 3,4-dihydropyrazino[1,2-a]indol-1(2H)-onyl, benzo[c][1,2]oxaborol-1(3H)-olyl, 6,6a,7,8-tetrahydro-9H-pyrido[2,3-b]puyrrolo[1,2-d][1,4]oxazin-9-onyl, or 6a′,7′-dihydro-6′H,9′H-spiro[cyclopropane-1,8′-pyrido[2,3-b]pyrrolo[1,2-d][1,4]oxazin]-9′-onyl.

Halogen or “halo” refers to fluorine, chlorine, bromine, or iodine.

Alkyl refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms, preferably 1-6 carbon atoms. Examples of a (C₁-C₆) alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.

“Alkoxy” refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms containing a terminal “O” in the chain, i.e., —O(alkyl). Examples of alkoxy groups include without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.

“Alkenyl” refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The “alkenyl” group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group.

Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted. Alkenyl, as herein defined, may be straight or branched.

“Alkynyl” refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The “alkynyl” group contains at least one triple bond in the chain. Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl. An alkynyl group can be unsubstituted or substituted.

The term “alkylene” or “alkylenyl” refers to a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. As herein defined, alkylene may also be a C₁-C₆ alkylene. An alkylene may further be a C₁-C₄ alkylene. Typical alkylene groups include, but are not limited to, —CH₂—, —CH(CH₃)—, —C(CH₃)₂—, —CH₂CH₂—, —CH₂CH(CH₃)—, —CH₂C(CH₃)₂—, —CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂—, and the like.

“Cycloalkyl” means mono or polycyclic saturated carbon rings containing 3-18 carbon atoms, preferably 3-10 carbon atoms. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norbornyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl.

“Cycloalkylalkyl” means monocyclic saturated carbon rings containing 3-24 carbon atoms, preferably 3-10 carbon atoms, further substituted with (C₁-C₆) alkyl groups. In general, cycloalkylalkyl groups herein described display the following formula

where m is an integer from 1 to 6 and n is an integer from 1 to 16. The cycloalkyl ring or carbocycle may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. The substituents can themselves be optionally substituted. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norbornyl, norborenyl, bicyclo[2.2.2]octanyl, bicyclo[2.2.2]octenyl, decahydronaphthalenyl, octahydro-1H-indenyl, cyclopentenyl, cyclohexenyl, cyclohexa-1,4-dienyl, cyclohexa-1,3-dienyl, 1,2,3,4-tetrahydronaphthalenyl, octahydropentalenyl, 3a,4,5,6,7,7a-hexahydro-1H-indenyl, 1,2,3,3a-tetrahydropentalenyl, bicyclo[3.1.0]hexanyl, bicyclo[2.1.0]pentanyl, spiro[3.3]heptanyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]hept-2-enyl, bicyclo[2.2.2]octanyl, 6-methylbicyclo[3.1.1]heptanyl, 2,6,6-trimethylbicyclo[3.1.1]heptanyl, and derivatives thereof.

“Heterocyclyl”, “heterocycle” or “heterocycloalkyl” means mono or polycyclic rings containing 3-24 atoms, preferably 3-10 atoms, which include carbon and one or more heteroatoms selected from N, O, S, P, or B, preferably 1, 2, 3, or 4 heteroatoms selected from N, O, and S, and wherein the rings are not aromatic. The heterocycloalkyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted. Examples of heterocyclyl rings include, but are not limited to, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, and homotropanyl.

The term “aromatic” means a planar ring having 4n+2 electrons in a conjugated system. As used herein, “conjugated system” means a system of connected p-orbitals with delocalized electrons, and the system may include lone electron pairs.

The term “haloalkyl” as used herein refers to an alkyl group, as defined herein, which is substituted one or more halogen. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.

The term “haloalkoxy” as used herein refers to an alkoxy group, as defined herein, which is substituted with one or more halogen. Examples of haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.

The term “cyano” as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond, i.e., C≡N or —CN.

“Spirocycloalkyl” or “spirocyclyl” means carbogenic bicyclic ring systems with both rings connected through a single atom. The ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spriohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring. One or more of the carbon atoms in the spirocycle can be substituted with a heteroatom (e.g., O, N, S, or P). A (C₃-C₁₂) spirocycloalkyl is a spirocycle containing between 3 and 12 carbon atoms. One or more of the carbon atoms can be substituted with a heteroatom.

The term “spiroheterocycloalkyl”, “spiroheterocycle”, or “spiroheterocyclyl” is understood to mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperidinyl).

The term “solvate” refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the disclosure may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.

The term “isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers.

The present disclosure also contemplates isotopically-labelled compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) (e.g., those labeled with ²H and ¹⁴C). Deuterated (i.e., ²H or D) and carbon-14 (i.e., ¹⁴C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labelled compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.

The disclosure also includes pharmaceutical compositions comprising a therapeutically effective amount of a disclosed compound and a pharmaceutically acceptable carrier.

A “patient” or “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus. Preferably, the mammal is human.

An “effective amount” when used in connection with a compound refers to the amount or dose of the compound which upon single or multiple dose administration to the patient, provides the desired effect in the patient under diagnosis or treatment. An effective amount can be determined by one skilled in the art by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount for a patient, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of patient; its size, age, and general health; the specific disease or disorder involved; the degree of or involvement or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

The term “carrier”, as used in this disclosure, encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.

The term “treating” with regard to a subject, includes restraining, slowing, stopping, or reversing the progression or severity of an existing symptom or disorder.

The term “disorder” is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.

The term “administer”, “administering”, or “administration” as used in this disclosure refers to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.

The term “prodrug,” as used in this disclosure, means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound.

The term “salts” refers to pharmaceutically acceptable salts. Salt formation can occur upon the addition of a pharmaceutically acceptable acid to form the acid addition salt, or by the addition of a pharmaceutically acceptable base to form a base addition salt. Salts can also form simultaneously upon deprotection of a nitrogen or oxygen. Pharmaceutically acceptable salts and common methodology for preparing them are well known in the art (see, e.g., P. Stahl, et al. Handbook of Pharmaceutical Salts: Properties, Selection and Use, 2d Revised Edition (Wiley-VCH, 2011); S. M. Berge, et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977). Representative “pharmaceutically acceptable salts” include, e.g., water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulanate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate, pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.

The term “pharmaceutically acceptable salt” also refers to a salt of the compositions of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), having, for example, an acidic functional group, such as a carboxylic acid functional group, and a base.

The term “modulate”, “modulation” or “modulating” as used herein refers to a biological activity of a compound or substrate that inhibits and/or activates PI3K.

“PI3K inhibitors” as used herein refer to compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) and/or compositions comprising a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) which inhibits PI3K.

The amount of compound of composition described herein needed for achieving a therapeutic effect may be determined empirically in accordance with conventional procedures for the particular purpose. Generally, for administering therapeutic agents (e.g. compounds or compositions of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) (and/or additional agents) described herein) for therapeutic purposes, the therapeutic agents are given at a pharmacologically effective dose. A “pharmacologically effective amount,” “pharmacologically effective dose,” “therapeutically effective amount,” or “effective amount” refers to an amount sufficient to produce the desired physiological effect or amount capable of achieving the desired result, particularly for treating the disorder or disease. An effective amount as used herein would include an amount sufficient to, for example, delay the development of a symptom of the disorder or disease, alter the course of a symptom of the disorder or disease (e.g., slow the progression of a symptom of the disease), reduce or eliminate one or more symptoms or manifestations of the disorder or disease, and reverse a symptom of a disorder or disease. For example, administration of therapeutic agents to a patient suffering from cancer provides a therapeutic benefit not only when the underlying condition is eradicated or ameliorated, but also when the patient reports a decrease in the severity or duration of the symptoms associated with the disease, e.g., a decrease in tumor burden, a decrease in circulating tumor cells, an increase in progression free survival. Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is realized.

Compounds of the Present Disclosure

In one aspect, the present disclosure provides compounds of Formula (I) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof.

wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, W, X, Y, s, and Ring A are as described in the Summary for Formula (I).

In a preferred embodiment of Formula (I), X is —NR₁₂— or —O—; Y is —C(R₁₁)₂—, —O—, —NR₁₁—, or —S—; WR₁R₂ is a group of the formula:

R₁₀ at each occurrence is independently oxo, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂, —(CH₂)_(n)—O—(CH₂CH₂—O)_(r)R₁₃, C₃-C₁₀ cycloalkyl, heterocycle, —(CH₂)_(n)-aryl, or heteroaryl, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl is optionally substituted with halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —(CH₂)_(n)—SO₂R₁₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, or —(CH₂)_(n)—C(O)N(R₁₂)₂, or two R₁₀, together with the atoms to which they are attached, form a C₃-C₁₀ cycloalkyl, an aryl, a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, or a heteroaryl, wherein the cycloalkyl, aryl, heterocycle, and heteroaryl are optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂, C₃-C₆ cycloalkyl, aryl, heteroaryl, or R₁₅; R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂; -L₁- is absent, —(CH₂)— or —(CH₂)₂—; u at each occurrence is independently 0, 1, 2, 3 or 4; each R₃, R₄, R₅, and R₆ is independently H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, aryl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S; each R₇ and R₅ is independently H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; at least one R₉ is —C(O)OR₁₂ and each of the remaining R₉ at each occurrence is independently oxo, ═NR₁₁, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—CR₁₃(OH)—R₁₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, —(CH₂)_(m)—C(O)N(OH)R₁₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂—OR₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₂)₂, —(CH₂)_(m)—P(O)(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₃)R₁₂, —(CH₂)_(m)—B(OH)₂, —(CH₂)_(m)—B(R₁₂)₂, —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃, C₃-C₁₀ cycloalkyl, aryl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₃-C₁₀ cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, or two R₉, together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl, an aryl, or a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the cycloalkyl, aryl, or heterocycle is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; R₁₁ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; each R₁₂ and R₁₃ at each occurrence is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, —(CH₂)_(q)-aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl are optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy; Ring A is C₃-C₁₀ cycloalkyl, aryl, heterocycle comprising 1-4 heteroatoms selected from N, O, and S, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S; R₁₄ is

two R₁₅, together with the atoms to which they are attached form a cycloalkyl, an aryl, a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, or a heteroaryl, wherein the cycloalkyl, aryl, heterocycle, and heteroaryl are optionally substituted with one or more C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, or —(CH₂)_(n)—SO₂R₁₂; each n, m, q, or r, is independently at each occurrence 0, 1, 2, 3, 4, 5, or 6; and s is 1, 2, 3, 4, 5, or 6.

In another preferred embodiment of Formula (I), X is —NR₁₂— or —O—; Y is —C(R₁)₂—, —O—, —NR₁₁—, or —S—; WR₁R₂ is a group of the formula:

-   -   R₁₀ at each occurrence is independently oxo, halogen, —CN, C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆         alkoxy, —(CH₂)_(n)—OR₂, —(CH₂)_(n)—N(R₂)₂, —(CH₂)—C(O)R₂,         —(CH₂)_(n)—C(O)OR₂, —(CH₂)_(n)—C(O)N(R₂)₂, —(CH₂) SO₂R₂,         —(CH₂)_(n)—O—(CH₂CH₂—O)_(r)R₁₃, C₃-C₁₀ cycloalkyl, heterocycle,         —(CH₂)_(n)-aryl, or heteroaryl, wherein the cycloalkyl,         heterocycle, aryl, and heteroaryl is optionally substituted with         halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, or —(CH₂)—SO₂R₁₂;         R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆         alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂; -L₁-         is —(CH₂)— or —(CH₂)₂—; u at each occurrence is independently 0,         1, 2, 3 or 4; each R₃, R₄, R₅, and R₆ is independently H,         halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂,         —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂,         —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, aryl, heterocycle         comprising 1-4 heteroatoms selected from O, N, and S, or         heteroaryl comprising 1-4 heteroatoms selected from O, N, and S;         each R₇ and R₈ is independently H, halogen, —CN, C₁-C₆ alkyl,         C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy;         at least one R₉ is —C(O)OR₁₂ and each of the remaining R₉ at         each occurrence is independently oxo, ═NR₁₁, halogen, —CN, —NO₂,         C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl,         C₁-C₆ alkoxy, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—OR₁₂,         —(CH₂)_(m)—CR₁₃(OH)—R₁₂, —(CH₂)_(m)—C(O)R₁₂,         —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂,         —(CH₂)_(m)—C(O)N(OH)R₁₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂—OR₁₂,         —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₂)₂,         —(CH₂)_(m)—P(O)(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₃)R₁₂,         —(CH₂)_(m)—B(OH)₂, —(CH₂)_(m)—B(R₁₂)₂,         —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃,         —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃, C₃-C₁₀ cycloalkyl, aryl, heterocycle         comprising 1-4 heteroatoms selected from O, N, and S, or         heteroaryl comprising 1-4 heteroatoms selected from N, O, and S,         wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, C₁-C₆ alkoxy, C₃-C₁₀ cycloalkyl, aryl, heterocycle,         or heteroaryl is optionally substituted with one or more oxo,         halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; or two R₉, together         with the atoms to which they are attached form a C₃-C₁₀         cycloalkyl, an aryl, or a heterocycle comprising 1-4 heteroatoms         selected from O, N, and S, wherein the cycloalkyl, aryl or         heterocycle is optionally substituted with one or more oxo,         halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl,         C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; R₁₁ is H, C₁-C₆         alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; each R₁₂ and R₁₃ at each         occurrence is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy,         —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄,         —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄,         —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄,         —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄,         —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄,         —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle         comprising 1-4 heteroatoms selected from O, N, and S,         —(CH₂)_(q)-aryl, or heteroaryl comprising 1-4 heteroatoms         selected from N, O, and S, wherein the cycloalkyl, heterocycle,         aryl, and heteroaryl are optionally substituted with one or more         halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆         haloalkoxy; Ring A is C₃-C₁₀ cycloalkyl, aryl, heterocycle         comprising 1-4 heteroatoms selected from N, O, and S, or         heteroaryl comprising 1-4 heteroatoms selected from N, O, and S;         R₁₄ is

each n, m, q, or r, is independently at each occurrence 0, 1, 2, 3, 4, 5, or 6; and s is 1, 2, 3, 4, 5, or 6.

In a further aspect, the present disclosure provides compounds of Formula (Ia) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof:

wherein R₈ is H and R₇ is not H, and R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₉, W, X, Y, s, and Ring A are as otherwise described in the Summary for Formula (I).

In yet a further aspect, the present disclosure provides compounds of Formula (Ib) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof:

wherein R₈ is H and R₇ is not H, and R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₉, W, X, Y, s, and Ring A are as otherwise described in the Summary for Formula (I).

In yet a further aspect, the present disclosure provides compounds of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof:

wherein R₇ is not H and R₁, R₂, R₅, R₇, R₉, W, X, s, and Ring A are as otherwise described in the Summary for Formula (I), and wherein R₃ is halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, aryl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In yet a further aspect, the present disclosure provides compounds of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof:

wherein R₇ is not H and R₁, R₂, R₅, R₇, R₉, X, W, s, and Ring A are as otherwise described in the Summary for Formula (I).

In yet a further aspect, the present disclosure provides compounds of Formula (Ie) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof:

wherein R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₂, X, Y, and Ring A are as described in the Summary for Formula (I), W is —N—, and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀, and wherein said heterocycle is not an optionally substituted morpholine, and s is 1, 2, 3, 4, 5, or 6.

In yet a further aspect, the present disclosure provides compounds of Formula (If) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof:

wherein R₃, R₅, and R₉ are as described in the Summary for Formula (I), R_(10a) is halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, s is 0 or 1, u is 0 or 1, J is C or N, and * indicates a stereocenter.

In yet a further aspect, the present disclosure provides compounds of Formula (Ig) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof:

wherein R₃, R₅, R₉, R₁₀ are as described in the Summary for Formula (I), s is 0 or 1, u is 0, 1, or 2, J is C or N, and * indicates a stereocenter.

In yet a further aspect, the present disclosure provides compounds of Formula (Ih) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof:

wherein R₃, R₅, R₉, R₁₀ are as described in the Summary for Formula (I), s is 0 or 1, u is 0, 1, or 2, J is C or N, and * indicates a stereocenter.

In yet a further aspect, the present disclosure provides compounds of Formula (II):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein

-   -   X is —NR₁₂— or —O—;     -   Y is —C(R₁₁)₂—, —O—, —NR₁₁—, or —S—;     -   W is —N—, —O—, or —S—, wherein when W is —O— or —S—, R₁ or R₂ is         absent;     -   each R₁ and R₂ is independently absent, H, C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy,         —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂,         —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂,         C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl, or R₁ and         R₂, together with the nitrogen to which they are attached, form         a heterocycle comprising 1-4 heteroatoms selected from O, N, and         S, wherein the heterocycle is optionally substituted with one or         more R₁₀;     -   each R₃, R₄, R₅, and R₆ is independently H, halogen, —CN, C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆         alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂,         —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂,         C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms         selected from O, N, and S, aryl, or heteroaryl comprising 1-4         heteroatoms selected from O, N, and S;     -   each R₇ and R₈ is independently H, halogen, —CN, C₁-C₆ alkyl,         C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy;     -   each R₉ at each occurrence is independently oxo, ═NR₁₁, halogen,         —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—OR₁₂,         —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂,         —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂—OR₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂,         —(CH₂)_(m)—CON(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₂)₂,         —(CH₂)_(m)—P(O)(R₁₂)₂, —(CH₂)_(m)—B(OH)₂, —(CH₂)_(m)—B(R₁₂)₂,         —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃,         —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃,         —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃, C₃-C₁₀ cycloalkyl, heterocycle         comprising 1-4 heteroatoms selected from O, N, and S, aryl, or         heteroaryl comprising 1-4 heteroatoms selected from N, O, and S,         wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, C₁-C₆ alkoxy, C₃-C₁₀ cycloalkyl, heterocycle, aryl,         or heteroaryl is optionally substituted with one or more oxo,         halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆         alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, or two R₉ together         with the atoms to which they are attached form a C₃-C₁₀         cycloalkyl or heterocycle comprising 1-4 heteroatoms selected         from O, N, and S wherein the cycloalkyl or heterocycle is         optionally substituted with one or more oxo, halogen, —CN, —OH,         —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,         C₁-C₆ haloalkyl, or C₁-C₆ alkoxy;     -   each R₁₀ at each occurrence is independently oxo, halogen, —CN,         C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl,         C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂,         —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂,         —(CH₂)_(n)—SO₂R₁₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, and         heteroaryl, wherein the cycloalkyl, heterocycle, aryl, and         heteroaryl is optionally substituted with C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆         haloalkoxy, or     -   two R₁₀, together with the atoms to which they are attached,         form aryl or heteroaryl, wherein the aryl and heteroaryl are         optionally substituted with one or more oxo, ═NR₁₂, halogen,         —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆         haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂,         —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂,         —(CH₂)_(n)—SO₂R₁₂;     -   R₁₁ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl;     -   each R₁₂ and R₁₃ at each occurrence is independently H, C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆         alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄,         —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄,         —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄,         —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄,         —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄,         —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle         comprising 1-4 heteroatoms selected from O, N, and S, aryl, or         heteroaryl comprising 1-4 heteroatoms selected from N, O, and S;     -   Ring A is C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4         heteroatoms selected from N, O, and S, aryl, or heteroaryl         comprising 1-4 heteroatoms selected from N, O, and S;     -   R₁₄ is

-   -    and     -   each n, m, q, r, or s is independently at each occurrence 0, 1,         2, 3, 4, 5, or 6,     -   provided that, when R₁ and R₂ together with the nitrogen atom to         which they are attached form a heterocycle, wherein the         heterocycle is morpholine and R₅ is —CH₃, then either (a) the         morpholine is substituted or (b) Ring A is not phenyl.

In preferred embodiment (1) of Formula (I), (Ia), (Ib), or (II), s is at least 1 and at least one R₉ is —C(O)OR₁₂.

In preferred embodiment (2) of Formula (I), (Ia), (Ib), or (II), W is —N—, and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀, and wherein said heterocycle is not an optionally substituted morpholine.

In preferred embodiment (3) of Formula (I), (Ia), (Ib), or (II), s is at least 1, at least one R₉ is —C(O)OR₁₂, W is —N—, and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀, and wherein said heterocycle is not an optionally substituted morpholine.

It is understood that, for a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, X, Y, W, s and Ring A can each be, where applicable, selected from the groups described herein, and any group described herein for any of R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, X, Y, W, s and Ring A can be combined, where applicable, with any group described herein for one or more of the remainder of R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, X, Y, W, s and Ring A.

In an embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Y is —O—.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl or isoxazole; more preferably R₃ is —CN or C₁-C₃ alkyl; most preferably R₃ is —CN or methyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₄ is H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; more preferably R₅ is H, halogen, methyl, or trifluoromethyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₆ is H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, and R₄ is H; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl, or isoxazole, and R₄ is H; more preferably R₃ is —CN or C₁-C₃ alkyl, and R₄ is H; most preferably R₃ is —CN or methyl, and R₄ is H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₄ is H, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl, or isoxazole, R₄ is H, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; more preferably R₃ is —CN or C₁-C₃ alkyl, R₄ is H, and R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; most preferably R₃ is —CN or methyl, R₄ is H, and R₅ is H, halogen, methyl, or trifluoromethyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, and R₄ and R₆ are each H; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl, or isoxazole, and R₄ and R₆ are each H; more preferably R₃ is —CN or C₁-C₃ alkyl, and R₄ and R₆ are each H; most preferably R₃ is —CN or methyl, and R₄ and R₆ are each H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl, or isoxazole, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; more preferably R₃ is —CN or C₁-C₃ alkyl, and R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; most preferably R₃ is —CN or methyl, and R₅ is H, halogen, methyl, or trifluoromethyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, and R₆ is H; more preferably R₃ is —CN or C₁-C₃ alkyl, and R₆ is H; most preferably R₃ is —CN or methyl, and R₆ is H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, and R₆ is H; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl, or isoxazole, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, and R₆ is H; more preferably R₃ is —CN or C₁-C₃ alkyl, R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, and R₆ is H; most preferably R₃ is —CN or methyl, R₅ is H, halogen, methyl, or trifluoromethyl, and R₆ is H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ and R₄ are each H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ and R₄ are each H, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₃ and R₄ are each H, and R₅ is H, halogen, methyl, or trifluoromethyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃, R₄, and R₆ are each H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is H, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₃ is H, and R₅ is H, halogen, methyl, or trifluoromethyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ and R₆ are each H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ and R₆ are each H, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₃ and R₆ are each H, and R₅ is H, halogen, methyl, or trifluoromethyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₄ is H, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₅ is H, halogen, methyl, or trifluoromethyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, and R₆ is H; preferably R₅ is H, halogen, methyl, or trifluoromethyl, and R₆ is H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, and R₄ and R₆ are each H; preferably R₅ is H, halogen, methyl, or trifluoromethyl, and R₄ and R₆ are each H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₄ and R₆ are each H, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl, or isoxazole, R₄ and R₆ are each H, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; more preferably R₃ is —CN or C₁-C₃ alkyl, R₄ and R₆ are each H, and R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; most preferably R₃ is —CN or methyl, R₄ and R₆ are each H, and R₅ is H, halogen, methyl, or trifluoromethyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃, R₄, and R₆ are each H, and R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₃, R₄, and R₆ are each H, and R₅ is H, halogen, methyl, or trifluoromethyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, X is —NR₁₂—, preferably —NH—.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₆ alkyl, or C₁-C₆ haloalkyl. In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₃ alkyl (preferably methyl).

In yet a further embodiment of a compound of Formula (I), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₈ is H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₆ alkyl, or C₁-C₆ haloalkyl, and X is —NR₁₂—, preferably —NH—. In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₃ alkyl (preferably methyl) and X is —NR₁₂—, preferably —NH—.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₈ is H and X is —NR₁₂—, preferably —NH—.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₆ alkyl, or C₁-C₆ haloalkyl, and R₈ is H. In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₃ alkyl (preferably methyl) and R₈ is H.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₈ is H, and X is —NR₁₂—, preferably —NH—. In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₃ alkyl (preferably methyl), R₈ is H, and X is —NR₁₂—, preferably —NH—.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₃ alkyl. In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₃ alkyl, preferably R₇ is methyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, each R₉ at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—CON(R₁₂)₂, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, or tetrazole.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, each R₉ at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—CON(R₁₂)₂, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, C₃-C₁₀ cycloalkyl, or tetrazole, and each R₁₂ and R₁₃ at each occurrence is independently H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or —(CH₂)_(q)-phenyl.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₉ is —C(O)OR₁₂ or —CON(R₁₂)₂, preferably —C(O)OH or —CONHR₁₂, most preferably —C(O)OH.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is phenyl, pyridine, pyridazine, pyrimidine, thiophene, furane, pyrazole, thiazole, imidazole, isoxazole, oxadiazole, indazole, benzothiophene, benzoxazole, benzimidazole, isoindole, indene or quinazoline; each of which is optionally substituted with (R₉)s.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is phenyl, pyridine, pyrimidine, thiophene, pyrazole, benzothiophene, or benzoxazole, each of which is optionally substituted with (R₉)s. In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is phenyl, pyridine, pyrimidine, thiophene, pyrazole, benzothiophene, or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OR₁₂ or —CON(R₁₂)₂, preferably —C(O)OH or —CONHR₁₂, most preferably —C(O)OH.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R_(9a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₃-C₁₀ cycloalkyl, v is 0, 1, 2, 3, or 4, w is 0, 1, 2, or 3, x is 0, 1, or 2, y is 0 or 1, z is 0, 1, 2, or 3, and R₉ is —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—CON(R₁₂)₂, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₉ is —C(O)OR₁₂ or —C(O)NHR₁₂. Most preferably R₉ is —C(O)OH.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R_(9a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₃-C₁₀ cycloalkyl, v is 0, 1, 2, 3, or 4, w is 0, 1, 2 or 3, x is 0, 1, or 2, y is 0 or 1, z is 0, 1, 2, or 3, and R₉ is —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—CON(R₁₂)₂, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; preferably R₉ is —C(O)OR₁₂ or —C(O)NHR₁₂. Most preferably R₉ is —C(O)OH.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is phenyl, pyridine, pyrimidine or benzothiophene, each of which is optionally substituted with (R₉)_(s), preferably Ring A is a group of the formula:

wherein R₉ is —C(O)OR₁₂; R_(9a) is H, halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, or C₃-C₅ cycloalkyl, v is 0, 1, 2, 3, or 4, w is 0, 1, 2, or 3, x is 0, 1, or 2, y is 0 or 1, and z is 0, 1, 2, or 3; preferably R₉ is —C(O)OH, R_(9a) is halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, or C₃-C₅ cycloalkyl, v is 0, 1, or 2, w is 0, 1, or 2, x is 0 or 1, y is 0 or 1, and z is 0, 1, or 2.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R₉ is —C(O)OR₁₂; R_(9a) is H, halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, or C₃-C₅ cycloalkyl, v is 0, 1, 2, 3, or 4, w is 0, 1, 2, or 3, x is 0, 1, or 2, y is 0 or 1, and z is 0, 1, 2, or 3; preferably R₉ is —C(O)OH, R_(9a) is halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, or C₃-C₅ cycloalkyl, v is 0, 1, or 2, w is 0, 1, or 2, x is 0 or 1, y is 0 or 1, and z is 0, 1, or 2.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl; v is 0 or 1; and w is 0 or 1.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably chloro.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, W is —N—, and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with 0, 1, 2, 3, 4 or 5 R₁₀, preferably 0, 1, 2, 3, or 4 R₁₀.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, W is —N—, and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀, and two R₁₀, together with the atoms to which they are attached, form a C₃-C₁₀ cycloalkyl, a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, an aryl, or a heteroaryl, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl are optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂, phenyl, C₃-C₆ cycloalkyl, or R₁₅.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, W is —N—, and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀, and two R₁₀, together with the atoms to which they are attached, form a 4 to 6 membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, aryl, heteroaryl, or R₁₅.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, W is —N—, and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀; two R₁₀, together with the atoms to which they are attached, form an aryl or a heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂, phenyl, C₃-C₆ cycloalkyl, or R₁₅ and optionally a further two R₁₀, together with the atoms to which they are attached, form a C₃-C₁₀ cycloalkyl optionally substituted with one or more oxo, halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently oxo, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)—OR₂, —(CH₂)_(n)—N(R₂)₂, —(CH₂)—C(O)R₂, —(CH₂)_(n)—C(O)OR₂, —(CH₂)_(n)—C(O)N(R₂)₂, —(CH₂) SO₂R₂, —(CH₂)_(n)—O—(CH₂CH₂—O),R₃, C₃-C₁₀ cycloalkyl, heterocycle, —(CH₂)_(n)-aryl, or heteroaryl, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl is optionally substituted with halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, or —(CH₂)—SO₂R₁₂; R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u at each occurrence is independently 0, 1, 2, 3 or 4. Preferably R₁₀ is halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, -L₁- is —(CH₂)— or —(CH₂)₂—, and u at each occurrence is independently 0, 1 or 2.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently oxo, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)—OR₂, —(CH₂)_(n)—N(R₂)₂, —(CH₂)—C(O)R₂, —(CH₂)_(n)—C(O)OR₂, —(CH₂)_(n)—C(O)N(R₂)₂, —(CH₂) SO₂R₂, —(CH₂)_(n)—O—(CH₂CH₂—O),R₃, C₃-C₁₀ cycloalkyl, heterocycle, —(CH₂)_(n)-aryl, or heteroaryl, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl is optionally substituted with halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, or —(CH₂)—SO₂R₁₂; R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂; -L₁- is —(CH₂)— or —(CH₂)₂—, and u at each occurrence is independently 0, 1, 2, 3 or 4. Preferably R₁₀ is halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, -L₁- is —(CH₂)— or —(CH₂)₂—, and u at each occurrence is independently 0, 1 or 2.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen; R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, and -L₁- is —(CH₂)— or —(CH₂)₂—.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, WR₁R₂ is a group of the formula:

wherein -L₁- is —(CH₂)— or —(CH₂)₂—, preferably —(CH₂)₂—.

In yet a further embodiment of a compound of formula (Ic):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, and —X— is —NR₁₂—; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl, or isoxazole, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy and —X— is —NH—; more preferably R₃ is —CN or C₁-C₃ alkyl, R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, C₁-C₃ alkyl and —X— is —NH—; most preferably R₃ is —CN or methyl, R₅ is H, halogen, methyl or trifluoromethyl and —X— is —NH—.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl; preferably R₇ is C₁-C₃ alkyl; most preferably methyl.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl and —X— is —NR₁₂—; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl or isoxazole, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl and —X— is —NH—; more preferably R₃ is —CN or C₁-C₃ alkyl, R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl and —X— is —NH—; most preferably R₃ is —CN or methyl, R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl and —X— is —NH—.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OR₁₂ or —CON(R₁₂)₂, preferably —C(O)OH or —CONHR₁₂, most preferably —C(O)OH.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl —X— is —NR₁₂— and Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OR₁₂ or —CON(R₁₂)₂; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl or isoxazole, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH— and Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH or —CONHR₁₂; more preferably R₃ is —CN or C₁-C₃ alkyl, R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl, —X— is —NH— and Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH; most preferably R₃ is —CN or methyl, R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl, —X— is —NH— and Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R₉ is —C(O)OH, R_(9a) at each occurrence is independently halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy or C₃-C₅ cycloalkyl, v is 0, 1 or 2, w is 0, 1, or 2, x is 0 or 1, y is 0 or 1, and z is 0, 1, or 2.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl; v is 0 or 1; and w is 0 or 1.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl; preferably R_(9a) is chloro.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl or a 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl —X— is —NR₁₂—, and Ring A is a group of the formula:

wherein R₉ is —C(O)OH, R_(9a) at each occurrence is independently halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy or C₃-C₅ cycloalkyl, v is 0, 1 or 2, w is 0, 1, or 2, x is 0 or 1, y is 0 or 1, and z is 0, 1, or 2; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl or isoxazole, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH— and Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl; v is 0 or 1; and w is 0 or 1; more preferably R₃ is —CN or C₁-C₃ alkyl, R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl, —X— is —NH—, and Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably R_(9a) is chloro; most preferably R₃ is —CN or methyl, R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl, —X— is —NH— and Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably R_(9a) is chloro.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, W is —N— and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀ and two R₁₀, together with the atoms to which they are attached, form a 4 to 6 membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, aryl or heteroaryl, or R₁₅.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂, —(CH₂)_(n)—O—(CH₂CH₂—O)_(r)R₁₃, C₃-C₁₀ cycloalkyl, heterocycle, —(CH₂)_(n)-aryl, or heteroaryl, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl is optionally substituted with halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, or —(CH₂)_(n)—SO₂R₁₂; R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1, 2, 3 or 4. Preferably R₁₀ is halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is independently 0, 1 or 2.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, WR₁R₂ is a group of the formula:

wherein -L₁- is —(CH₂)— or —(CH₂)₂—, preferably —(CH₂)₂—.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NR₁₂— and W is —N— and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀ and two R₁₀, together with the atoms to which they are attached, form a 4 to 6 membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, aryl, heteroaryl, or R₁₅; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl or isoxazole, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH— and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; more preferably R₃ is —CN or C₁-C₃ alkyl, R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl and —X— is —NH—; most preferably R₃ is —CN or methyl, R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl, —X— is —NH— and WR₁R₂ is a group of the formula:

wherein -L₁- is —(CH₂)— or —(CH₂)₂—, preferably —(CH₂)₂—.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NR₁₂—, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OR₁₂ or —CON(R₁₂)₂ and W is —N— and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀ and two R₁₀, together with the atoms to which they are attached, form a 4 to 6 membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, aryl or heteroaryl, or R₁₅; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl or isoxazole, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH—, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH or —CONHR₁₂; and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; more preferably R₃ is —CN or C₁-C₃ alkyl, R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl, —X— is —NH—, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; most preferably R₃ is —CN or methyl, R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl, —X— is —NH—, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH and WR₁R₂ is a group of the formula:

wherein, -L₁- is —(CH₂)— or —(CH₂)₂—, preferably —(CH₂)₂—.

In yet a further embodiment of a compound of Formula (Ic) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₃ is —CN, C₁-C₆ alkyl, C₁-C₆haloalkyl, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₂, C₃-C₁₀ cycloalkyl, aryl or 5 to 6 membered heteroaryl comprising 1-3 heteroatoms selected from O, N, and S, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl —X— is —NR₁₂—, Ring A is a group of the formula:

wherein R₉ is —C(O)OH, R_(9a) at each occurrence is independently halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy or C₃-C₅ cycloalkyl, v is 0, 1 or 2, w is 0, 1, or 2, x is 0 or 1, y is 0 or 1, and z is 0, 1, or 2 and W is —N— and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀ and two R₁₀, together with the atoms to which they are attached, form a 4 to 6 membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, aryl or heteroaryl, or R₁₅; preferably R₃ is —CN, C₁-C₃ alkyl, —(CH₂)_(m)—OH, cyclopropyl or isoxazole, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH—, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl; v is 0 or 1; and w is 0 or 1 and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; more preferably R₃ is —CN or C₁-C₃ alkyl, R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl, —X— is —NH—, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably chloro, and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; most preferably R₃ is —CN or methyl, R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl, —X— is —NH—, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably chloro, and WR₁R₂ is a group of the formula:

wherein -L₁- is —(CH₂)— or —(CH₂)₂—, preferably —(CH₂)₂—.

In yet a further embodiment of a compound of formula (Id):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, and —X— is —NR₁₂—; preferably R₅ is H, halogen, methyl or trifluoromethyl and —X— is —NH—.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl; preferably R₇ is C₁-C₃ alkyl (most preferably methyl).

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl and —X— is —NR₁₂—; preferably R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl and —X— is —NH—; more preferably R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl and —X— is —NH—.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OR₁₂ or —CON(R₁₂)₂, preferably —C(O)OH or —CONHR₁₂, most preferably —C(O)OH.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl —X— is —NR₁₂— and Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OR₁₂ or —CON(R₁₂)₂; preferably R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH— and Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH or —CONHR₁₂; more preferably R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl, —X— is —NH— and Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH; most preferably R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl, —X— is —NH— and Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R₉ at each occurrence is independently —C(O)OH, R_(9a) is halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy or C₃-C₅ cycloalkyl, v is 0, 1 or 2, w is 0, 1, or 2, x is 0 or 1, y is 0 or 1, and z is 0, 1, or 2.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl; v is 0 or 1; and w is 0 or 1.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably chloro.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl —X— is —NR₁₂—, Ring A is a group of the formula:

wherein R₉ at each occurrence is independently —C(O)OH, R_(9a) is halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy or C₃-C₅ cycloalkyl, v is 0, 1 or 2, w is 0, 1, or 2, x is 0 or 1, y is 0 or 1, and z is 0, 1, or 2; preferably R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH— and Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl; v is 0 or 1; and w is 0 or 1; more preferably R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl, —X— is —NH— and Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably chloro; most preferably R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl, —X— is —NH—, and Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably chloro.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, W is —N— and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀ and two R₁₀, together with the atoms to which they are attached, form a 4 to 6 membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, aryl or heteroaryl, or R₁₅.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂, —(CH₂)_(n)—O—(CH₂CH₂—O)_(r)R₁₃, C₃-C₁₀ cycloalkyl, heterocycle, —(CH₂)_(n)-aryl, or heteroaryl, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl is optionally substituted with halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, or —(CH₂)_(n)—SO₂R₁₂; R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1, 2, 3 or 4. Preferably R₁₀ is halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is independently 0, 1 or 2.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, WR₁R₂ is a group of the formula:

wherein -L₁- is —(CH₂)— or —(CH₂)₂—, preferably —(CH₂)₂—.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NR₁₂— and W is —N— and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀ and two R₁₀, together with the atoms to which they are attached, form a 4 to 6 membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, aryl or heteroaryl, or R₁₅; preferably R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH— and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; more preferably R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl and —X— is —NH—; most preferably R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl, —X— is —NH— and WR₁R₂ is a group of the formula:

wherein -L₁- is —(CH₂)— or —(CH₂)₂—, preferably —(CH₂)₂—.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl —X— is —NR₁₂—, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OR₁₂ or —CON(R₁₂)₂ and W is —N— and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀ and two R₁₀, together with the atoms to which they are attached, form a 4 to 6 membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, aryl or heteroaryl, or R₁₅; preferably R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH—, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH or —CONHR₁₂; and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; more preferably R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl, —X— is —NH—, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; most preferably R₇ is methyl, —X— is —NH—, Ring A is phenyl, pyridine, thiophene, pyrazole, benzothiophene or benzoxazole, each of which is optionally substituted with (R₉)_(s), wherein s is at least 1 and at least one substituent R₉ is —C(O)OH and WR₁R₂ is a group of the formula:

wherein -L₁- is —(CH₂)— or —(CH₂)₂—, preferably —(CH₂)₂—.

In yet a further embodiment of a compound of Formula (Id) or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl —X— is —NR₁₂—, Ring A is a group of the formula:

wherein R₉ at each occurrence is independently —C(O)OH, R_(9a) is halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy or C₃-C₅ cycloalkyl, v is 0, 1 or 2, w is 0, 1, or 2, W is —N— and R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀ and two R₁₀, together with the atoms to which they are attached, form a 4 to 6 membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, aryl or heteroaryl, or R₁₅; preferably R₅ is H, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy, R₇ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, —X— is —NH—, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl; v is 0 or 1; and w is 0 or 1 and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; more preferably R₅ is H, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₇ is C₁-C₃ alkyl, —X— is —NH—, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably chloro, and WR₁R₂ is a group of the formula:

wherein R₁₀ at each occurrence is independently halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl or phenyl optionally substituted with halogen, R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂, -L₁- is —(CH₂)— or —(CH₂)₂—, and u is at each occurrence independently 0, 1 or 2; most preferably R₅ is H, halogen, methyl or trifluoromethyl, R₇ is methyl, —X— is —NH—, Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl, preferably chloro, and WR₁R₂ is a group of the formula:

wherein -L₁- is —(CH₂)— or —(CH₂)₂—, preferably —(CH₂)₂—.

In yet a further embodiment of a compound of formula (If):

or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, wherein R₃ is H or C₁-C₆ alkyl, R₅ is halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₉ is halogen, R_(10a) is halogen, s is 0 or 1, u is 0 or 1, J is C or N, and * indicates a stereocenter. In a preferred embodiment, R₃ is H or methyl, R₅ is fluoro, methyl, or trifluoromethyl, R₉ is chloro, R_(10a) is fluoro, s is 0 or 1, u is 0 or 1, J is C or N, and the stereocenter has the (R)-configuration.

In yet a further embodiment of a compound of Formula (Ig):

or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, wherein R₃ is H or C₁-C₆ alkyl, R₅ is halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₉ is halogen, R₁₀ is independently halogen, —CN, C₁-C₆ alkyl, or aryl, or two R₁₀ together with the carbon atom to which they are attached form a C₃-C₁₀ cycloalkyl, s is 0 or 1, u is 0, 1, or 2, J is C or N, and * indicates a stereocenter. In a preferred embodiment, R₃ is H or methyl, R₅ is fluoro, methyl, or trifluoromethyl, R₉ is chloro, R₁₀ is independently fluoro or methyl, or two R₁₀ together with the carbon atom to which they are attached form a cyclopropyl, s is 0 or 1, u is 0, 1, or 2, J is C or N, and the stereocenter has the (R)-configuration.

In yet a further embodiment of a compound of Formula (Ih):

or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, wherein R₃ is H or C₁-C₆ alkyl, R₅ is halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl, R₉ is halogen, R₁₀ is independently halogen, —CN, C₁-C₆ alkyl, or aryl, or two R₁₀ together with the carbon atom to which they are attached form a C₃-C₁₀ cycloalkyl, s is 0 or 1, u is 0, 1, or 2, J is C or N, and * indicates a stereocenter. In a preferred embodiment, R₃ is H or methyl, R₅ is fluoro, methyl, or trifluoromethyl, R₉ is chloro, R₁₀ is independently methyl or aryl, or two R₁₀ together with the carbon atom to which they are attached form a cyclobutyl, s is 0 or 1, u is 0, 1, or 2, J is C or N, and the stereocenter has the (R)-configuration.

In yet a further embodiment of a compound of Formula (I), (Ia), (Ib), (Ie), or (II), or pharmaceutically acceptable salts thereof, or prodrugs, solvates, hydrates, isomers, or tautomers thereof, the compound is selected from:

wherein the bond at the * position is as represented,

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

A further embodiment is a compound of Formula

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In yet a further embodiment, the bond at the * position is

In yet a further embodiment, the bond at the * position is

The embodiments in the following paragraphs, as applicable, refer to embodiments of compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments X is —NR₁₂— or —O—. In some embodiments X is —NR₁₂—. In some embodiments X is —O—.

In some embodiments, Y is —C(R₁₁)₂—, —O—, —NR₁₁—, or —S—.

In some embodiments, Y is —C(R₁₁)₂—. In some embodiments, Y is —O—. In some embodiments, Y is —NR₁₁—. In some embodiments, Y is —S—.

In some embodiments, W is —O—, —N—, or —S—.

In some embodiments, W is —O—. In some embodiments, W is —N—. In some embodiments, W is —S—.

In some embodiments, each R₁ and R₂ is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, each R₁ and R₂ is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₁ is absent, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₁ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₁ is absent.

In some embodiments, R₁ is H.

In some embodiments, R₁ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₁ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₁ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₁ is C₁-C₆ alkyl.

In some embodiments, R₁ is methyl. In some embodiments, R₁ is ethyl. In some embodiments, R₁ is propyl. In some embodiments, R₁ is n-propyl. In some embodiments, R₁ is isopropyl. In some embodiments, R₁ is butyl. In some embodiments, R₁ is n-butyl. In some embodiments, R₁ is isobutyl. In some embodiments, R₁ is sec-butyl. In some embodiments, R₁ is tert-butyl. In some embodiments, R₁ is pentyl. In some embodiments, R₁ is hexyl.

In some embodiments, R₁ is C₂-C₆ alkenyl.

In some embodiments, R₁ is C₂ alkenyl. In some embodiments, R₁ is C₃ alkenyl. In some embodiments, R₁ is C₄ alkenyl. In some embodiments, R₁ is C₅ alkenyl. In some embodiments, R₁ is C₆ alkenyl.

In some embodiments, R₁ is C₂-C₆ alkynyl.

In some embodiments, R₁ is C₂ alkynyl. In some embodiments, R₁ is C₃ alkynyl. In some embodiments, R₁ is C₄ alkynyl. In some embodiments, R₁ is C₅ alkynyl. In some embodiments, R₁ is C₆ alkynyl.

In some embodiments, R₁ is C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₁ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₁ is C₁-C₆ haloalkyl.

In some embodiments, R₁ is halomethyl. In some embodiments, R₁ is haloethyl. In some embodiments, R₁ is halopropyl. In some embodiments, R₁ is halobutyl. In some embodiments, R₁ is halopentyl. In some embodiments, R₁ is halohexyl.

In some embodiments, R₁ is C₁-C₆ alkoxy.

In some embodiments, R₁ is methoxy. In some embodiments, R₁ is ethoxy. In some embodiments, R₁ is propoxy. In some embodiments, R₁ is butoxy. In some embodiments, R₁ is pentoxy. In some embodiments, one R₁ is hexoxy.

In some embodiments, R₁ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₁ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, or —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₁ is —(CH₂)_(m)—R₁₂. In some embodiments, R₁ is —(CH₂)_(m)—OR₁₂. In some embodiments, R₁ is —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₁ is —R₁₂. In some embodiments, R₁ is —CH₂—R₁₂. In some embodiments, R₁ is —CH₂CH₂—R₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂—R₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂CH₂—R₁₂.

In some embodiments, R₁ is —OR₁₂. In some embodiments, R₁ is —CH₂—OR₁₂. In some embodiments, R₁ is —CH₂CH₂—OR₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂—OR₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂CH₂—OR₁₂.

In some embodiments, R₁ is —N(R₁₂)₂. In some embodiments, R₁ is —CH₂—N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂—N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂.

In some embodiments, R₁ is —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₁ is —(CH₂)_(m)—C(O)R₁₂. In some embodiments, R₁ is —(CH₂)_(m)—C(O)OR₁₂. In some embodiments, R₁ is —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₁ is —C(O)R₁₂. In some embodiments, R₁ is —CH₂—C(O)R₁₂. In some embodiments, R₁ is —CH₂CH₂—C(O)R₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂.

In some embodiments, R₁ is —C(O)OR₁₂. In some embodiments, R₁ is —CH₂—C(O)OR₁₂. In some embodiments, R₁ is —CH₂CH₂—C(O)OR₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂.

In some embodiments, R₁ is —C(O)N(R₁₂)₂. In some embodiments, R₁ is —CH₂—C(O)N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₁ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂.

In some embodiments, R₁ is —CH₂—C(O)NH₂.

In some embodiments, R₁ is C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₁ is C₃-C₁₀ cycloalkyl or heterocycle.

In some embodiments, R₁ is aryl or heteroaryl.

In some embodiments, R₁ is C₃-C₁₀ cycloalkyl.

In some embodiments, R₁ is a monocyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₁ is a polycyclic C₃-C₁₀ cycloalkyl.

In some embodiments, R₁ is C₅-C₆ cycloalkyl.

In some embodiments, R₁ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, R₁ is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₁ is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₁ is a C₃-C₁₀ spirocycloalkyl.

In some embodiments, R₁ is heterocycle.

In some embodiments, R₁ is a monocyclic heterocycle. In some embodiments, R₁ is a polycyclic heterocycle.

In some embodiments, R₁ is 3-membered heterocycle. In some embodiments, R₁ is 4-membered heterocycle. In some embodiments, R₁ is 5-membered heterocycle. In some embodiments, R₁ is 6-membered heterocycle. In some embodiments, R₁ is 7-membered heterocycle. In some embodiments, R₁ is 8-membered heterocycle. In some embodiments, R₁ is 9-membered heterocycle. In some embodiments, R₁ is 10-membered heterocycle.

In some embodiments, R₁ is 5- to 6-membered heterocycle.

In some embodiments, R₁ is heterocycle comprising one, two, or three heteroatoms.

In some embodiments, R₁ is heterocycle comprising one, two, or three heteroatoms selected from N, O, and S.

In some embodiments, R₁ is heterocycle comprising one, two, or three heteroatoms selected from N and O.

In some embodiments, R₁ is heterocycle comprising one heteroatom selected from N and O. In some embodiments, R₁ is heterocycle comprising two heteroatoms selected from N and O.

In some embodiments, R₁ is heterocycle comprising three heteroatoms selected from N and O.

In some embodiments, R₁ is aryl.

In some embodiments, R₁ is C₆ aryl (e.g., phenyl).

In some embodiments, R₁ is a heteroaryl.

In some embodiments, R₁ is 5- to 6-membered heteroaryl.

In some embodiments, R₁ is heteroaryl comprising one, two, or three heteroatoms.

In some embodiments, R₁ is heteroaryl comprising one, two, or three heteroatoms selected from N, O, and S.

In some embodiments, R₁ is heteroaryl comprising one, two, or three heteroatoms selected from N and O.

In some embodiments, R₁ is heteroaryl comprising one heteroatom selected from N and O.

In some embodiments, R₁ is heteroaryl comprising two heteroatoms selected from N and O. In some embodiments, R₁ is heteroaryl comprising three heteroatoms selected from N and O.

In some embodiments, R₁ is ethyl, isobutyl, or —CH₂—C(O)NH₂.

In some embodiments, R₂ is absent, H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₂ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₂ is absent.

In some embodiments, R₂ is H.

In some embodiments, R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₂ is C₁-C₆ alkyl (e.g. linear or branched).

In some embodiments, R₂ is methyl. In some embodiments, R₂ is ethyl. In some embodiments, R₂ is propyl. In some embodiments, R₂ is n-propyl. In some embodiments, R₂ is isopropyl. In some embodiments, R₂ is butyl. In some embodiments, R₂ is n-butyl. In some embodiments, R₂ is isobutyl. In some embodiments, R₂ is sec-butyl. In some embodiments, R₂ is tert-butyl. In some embodiments, R₂ is pentyl. In some embodiments, R₂ is hexyl.

In some embodiments, R₂ is C₂-C₆ alkenyl.

In some embodiments, R₂ is C₂ alkenyl. In some embodiments, R₂ is C₃ alkenyl. In some embodiments, R₂ is C₄ alkenyl. In some embodiments, R₂ is C₅ alkenyl. In some embodiments, R₂ is C₆ alkenyl.

In some embodiments, R₂ is C₂-C₆ alkynyl.

In some embodiments, R₂ is C₂ alkynyl. In some embodiments, R₂ is C₃ alkynyl. In some embodiments, R₂ is C₄ alkynyl. In some embodiments, R₂ is C₅ alkynyl. In some embodiments, R₂ is C₆ alkynyl.

In some embodiments, R₂ is C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₂ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₂ is C₁-C₆ haloalkyl.

In some embodiments, R₂ is halomethyl. In some embodiments, R₂ is haloethyl. In some embodiments, R₂ is halopropyl. In some embodiments, R₂ is halobutyl. In some embodiments, R₂ is halopentyl. In some embodiments, R₂ is halohexyl.

In some embodiments, R₂ is C₁-C₆ alkoxy.

In some embodiments, R₂ is methoxy. In some embodiments, R₂ is ethoxy. In some embodiments, R₂ is propoxy. In some embodiments, R₂ is butoxy. In some embodiments, R₂ is pentoxy. In some embodiments, one R₂ is hexoxy.

In some embodiments, R₂ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₂ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, or —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₂ is —(CH₂)_(m)—R₁₂. In some embodiments, R₂ is —(CH₂)_(m)—OR₁₂. In some embodiments, R₂ is —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₂ is —CH₂—R₁₂. In some embodiments, R₂ is —CH₂CH₂—R₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂—R₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂CH₂—R₁₂.

In some embodiments, R₂ is —CH₂—OR₁₂. In some embodiments, R₂ is —CH₂CH₂—OR₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂—OR₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂CH₂—OR₁₂.

In some embodiments, R₂ is —CH₂—N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂—N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂.

In some embodiments, R₂ is —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₂ is —(CH₂)_(m)—C(O)R₁₂. In some embodiments, R₂ is —(CH₂)_(m)—C(O)OR₁₂. In some embodiments, R₂ is —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₂ is —CH₂—C(O)R₁₂. In some embodiments, R₂ is —CH₂CH₂—C(O)R₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂.

In some embodiments, R₂ is —CH₂—C(O)OR₁₂. In some embodiments, R₂ is —CH₂CH₂—C(O)OR₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂.

In some embodiments, R₂ is —CH₂—C(O)N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₂ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂.

In some embodiments, R₂ is —CH₂—C(O)NH₂.

In some embodiments, R₂ is C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₂ is C₃-C₁₀ cycloalkyl or heterocycle.

In some embodiments, R₂ is aryl or heteroaryl.

In some embodiments, R₂ is C₃-C₁₀ cycloalkyl.

In some embodiments, R₂ is a monocyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₂ is a polycyclic C₃-C₁₀ cycloalkyl.

In some embodiments, R₂ is C₅-C₆ cycloalkyl.

In some embodiments, R₂ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, R₂ is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₂ is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₂ is a C₃-C₁₀ spirocycloalkyl.

In some embodiments, R₂ is heterocycle.

In some embodiments, R₂ is a monocyclic heterocycle. In some embodiments, R₂ is a polycyclic heterocycle.

In some embodiments, R₂ is 3-membered heterocycle. In some embodiments, R₂ is 4-membered heterocycle. In some embodiments, R₂ is 5-membered heterocycle. In some embodiments, R₂ is 6-membered heterocycle. In some embodiments, R₂ is 7-membered heterocycle. In some embodiments, R₂ is 8-membered heterocycle. In some embodiments, R₂ is 9-membered heterocycle. In some embodiments, R₂ is 10-membered heterocycle.

In some embodiments, R₂ is 5- to 6-membered heterocycle.

In some embodiments, R₂ is heterocycle comprising one, two, or three heteroatoms.

In some embodiments, R₂ is heterocycle comprising one, two, or three heteroatoms selected from N, O, and S.

In some embodiments, R₂ is heterocycle comprising one, two, or three heteroatoms selected from N and O.

In some embodiments, R₂ is heterocycle comprising one heteroatom selected from N and O. In some embodiments, R₂ is heterocycle comprising two heteroatoms selected from N and O. In some embodiments, R₂ is heterocycle comprising three heteroatoms selected from N and O.

In some embodiments, R₂ is aryl.

In some embodiments, R₂ is C₆ aryl (e.g., phenyl).

In some embodiments, R₂ is a heteroaryl.

In some embodiments, R₂ is 5- to 6-membered heteroaryl.

In some embodiments, R₂ is heteroaryl comprising one, two, or three heteroatoms.

In some embodiments, R₂ is heteroaryl comprising one, two, or three heteroatoms selected from N, O, and S.

In some embodiments, R₂ is heteroaryl comprising one, two, or three heteroatoms selected from N and O.

In some embodiments, R₂ is heteroaryl comprising one heteroatom selected from N and O.

In some embodiments, R₂ is heteroaryl comprising two heteroatoms selected from N and O. In some embodiments, R₂ is heteroaryl comprising three heteroatoms selected from N and O.

In some embodiments, R₂ is ethyl, isobutyl, or —CH₂—C(O)NH₂.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀.

In some embodiments R₁ and R₂, together with the nitrogen to which they are attached, form a saturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments R₁ and R₂, together with the nitrogen to which they are attached, form a partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising one heteroatom which is N, wherein the heterocycle is unsubstituted. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising one N heteroatom, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising two heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising three heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising four heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising one N heteroatom, wherein the heterocycle is substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising two heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising three heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising four heteroatoms selected from O, N, and S, wherein the heterocycle is substituted with one or more R₁₀.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 3- to 10-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 3- to 9-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 3- to 8-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 3- to 7-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 3- to 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 3- to 5-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 4- to 10-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 4- to 9-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 4- to 8-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 4- to 7-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 4- to 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 4- to 5-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 5- to 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 5- to 7-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 5- to 9-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 5- to 10-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 6- to 10-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 6- to 9-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 6- to 8-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 6- to 7-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 7- to 8-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 7- to 9-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 7- to 10-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 8- to 10-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 8- to 9-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 9- to 10-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 3- to 15-membered saturated or partially unsaturated monocyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 3- to 15-membered saturated or partially unsaturated polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a fused polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a bridged polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a spiroheterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with two R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with three R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with four R₁₀.

In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 3-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 4-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 5-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 7-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 8-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 9-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 10-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 11-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 12-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 13-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 14-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀. In some embodiments, R₁ and R₂, together with the nitrogen to which they are attached, form a 15-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more R₁₀.

In some embodiments, R₃ is H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₃ is H.

In some embodiments, R₃ is halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₃ is halogen. In some embodiments, R₃ is F, Cl, Br, or I. In some embodiments, R₃ is F, Cl, or Br. In some embodiments, R₃ is F. In some embodiments, R₃ is C₁.

In some embodiments, R₃ is Br. In some embodiments, R₃ is I.

In some embodiments, R is —CN.

In some embodiments, R₃ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₃ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₃ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₃ is C₁-C₆ alkyl (e.g. linear or branched).

In some embodiments, R₃ is methyl. In some embodiments, R₃ is ethyl. In some embodiments, R₃ is propyl. In some embodiments, R₃ is n-propyl. In some embodiments, R₃ is isopropyl. In some embodiments, R₃ is butyl. In some embodiments, R₃ is n-butyl. In some embodiments, R₃ is isobutyl. In some embodiments, R₃ is sec-butyl. In some embodiments, R₃ is tert-butyl. In some embodiments, R₃ is pentyl. In some embodiments, R₃ is hexyl.

In some embodiments, R₃ is C₂-C₆ alkenyl.

In some embodiments, R₃ is C₂ alkenyl. In some embodiments, R₃ is C₃ alkenyl. In some embodiments, R₃ is C₄ alkenyl. In some embodiments, R₃ is C₅ alkenyl. In some embodiments, R₃ is C₆ alkenyl.

In some embodiments, R₃ is C₂-C₆ alkynyl.

In some embodiments, R₃ is C₂ alkynyl. In some embodiments, R₃ is C₃ alkynyl. In some embodiments, R₃ is C₄ alkynyl. In some embodiments, R₃ is C₅ alkynyl. In some embodiments, R₃ is C₆ alkynyl.

In some embodiments, R₃ is C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₃ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₃ is C₁-C₆ haloalkyl.

In some embodiments, R₃ is halomethyl. In some embodiments, R₃ is haloethyl. In some embodiments, R₃ is halopropyl. In some embodiments, R₃ is halobutyl. In some embodiments, R₃ is halopentyl. In some embodiments, R₃ is halohexyl.

In some embodiments, R₃ is CH₂F. In some embodiments, R₃ is CHF₂. In some embodiments, R is CF₃.

In some embodiments, R₃ is C₁-C₆ alkoxy.

In some embodiments, R₃ is methoxy. In some embodiments, R₃ is ethoxy. In some embodiments, R₃ is propoxy. In some embodiments, R₃ is butoxy. In some embodiments, R₃ is pentoxy. In some embodiments, one R₃ is hexoxy.

In some embodiments, R₃ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₃ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, or —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₃ is —(CH₂)_(m)—R₁₂. In some embodiments, R₃ is —(CH₂)_(m)—OR₁₂. In some embodiments, R₃ is —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₃ is —CH₂—R₁₂. In some embodiments, R₃ is —R₁₂. In some embodiments, R₃ is —CH₂CH₂—R₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂—R₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂CH₂—R₁₂.

In some embodiments, R₃ is —OR₁₂. In some embodiments, R₃ is —CH₂—OR₁₂. In some embodiments, R₃ is —CH₂CH₂—OR₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂—OR₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂CH₂—OR₁₂.

In some embodiments, R₃ is —OR₁₂, wherein R₁₂ is H. In some embodiments, R₃ is —OR₁₂, wherein R₁₂ is C₃₋₁₀ cycloalkyl. In some embodiments, R₃ is

In some embodiments, R₃ is —N(R₁₂)₂. In some embodiments, R₃ is —CH₂—N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂—N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂.

In some embodiments, R₃ is —N(CH₃)₂.

In some embodiments, R₃ is —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₃ is —(CH₂)_(m)—C(O)R₁₂. In some embodiments, R₃ is —(CH₂)_(m)—C(O)OR₁₂. In some embodiments, R₃ is —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₃ is —CH₂—C(O)R₁₂. In some embodiments, R₃ is —CH₂CH₂—C(O)R₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂.

In some embodiments, R₃ is —CH₂—C(O)OR₁₂. In some embodiments, R₃ is —CH₂CH₂—C(O)OR₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂.

In some embodiments, R₃ is —CH₂—C(O)N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₃ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂.

In some embodiments, R₃ is —CH₂—C(O)NH₂.

In some embodiments, R₃ is C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₃ is C₃-C₁₀ cycloalkyl or heterocycle.

In some embodiments, R₃ is aryl or heteroaryl.

In some embodiments, R₃ is C₃-C₁₀ cycloalkyl.

In some embodiments, R₃ is a monocyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₃ is a polycyclic C₃-C₁₀ cycloalkyl.

In some embodiments, R₃ is C₅-C₆ cycloalkyl.

In some embodiments, R₃ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, R₃ is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₃ is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₃ is a C₃-C₁₀ spirocycloalkyl.

In some embodiments, R₃ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₃ is a monocyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is a polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₃ is 3-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 4-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 5-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 7-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 8-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 9-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 10-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₃ is 3-membered heterocycle comprising one N heteroatom. In some embodiments, R₃ is 4-membered heterocycle comprising one N heteroatom. In some embodiments, R₃ is 5-membered heterocycle comprising one N heteroatom. In some embodiments, R₃ is 6-membered heterocycle comprising one N heteroatom. In some embodiments, R₃ is 7-membered heterocycle comprising one N heteroatom. In some embodiments, R₃ is 8-membered heterocycle comprising one N heteroatom. In some embodiments, R₃ is 9-membered heterocycle comprising one N heteroatom. In some embodiments, R₃ is 10-membered heterocycle comprising one N heteroatom.

In some embodiments, R₃ is heterocycle comprising one heteroatom selected from O, N, and S. In some embodiments, R₃ is heterocycle comprising two heteroatoms selected from O, N, and S. In some embodiments, R₃ is heterocycle comprising three heteroatoms selected from O, N, and S. In some embodiments, R₃ is heterocycle comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₃ is aryl.

In some embodiments, R₃ is C₆ aryl (e.g., phenyl).

In some embodiments, R₃ is a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S

In some embodiments, R₃ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₃ is 5-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 7-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 8-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 9-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₃ is 10-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₃ is heteroaryl comprising one heteroatom selected from O, N, and S. In some embodiments, R₃ is heteroaryl comprising two heteroatoms selected from O, N, and S. In some embodiments, R₃ is heteroaryl comprising three heteroatoms selected from O, N, and S. In some embodiments, R₃ is heteroaryl comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₃ is a monocyclic heterocycle. In some embodiments, R₃ is a 5-membered monocyclic heterocycle. In some embodiments, R₃ is

In some embodiments, R₄ is a 6-membered monocyclic heterocycle. In some embodiments, R₃ is

In some embodiments, R₄ is H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, Aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R is H.

In some embodiments, R₄ is halogen, C₁C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R is halogen. In some embodiments, R is F, Cl, Br, or I. In some embodiments, R₄ is F, Cl, or Br. In some embodiments, R₄ is F. In some embodiments, R₄ is C₁.

In some embodiments, R₄ is Br. In some embodiments, R₄ is I.

In some embodiments, R₄ is —CN.

In some embodiments, R₄ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₄ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₄ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₄ is C₁-C₆ alkyl (e.g. linear or branched).

In some embodiments, R₄ is methyl. In some embodiments, R₄ is ethyl. In some embodiments, R₄ is propyl. In some embodiments, R₄ is n-propyl. In some embodiments, R₄ is isopropyl. In some embodiments, R₄ is butyl. In some embodiments, R₄ is n-butyl. In some embodiments, R₄ is isobutyl. In some embodiments, R₄ is sec-butyl. In some embodiments, R₄ is tert-butyl. In some embodiments, R₄ is pentyl. In some embodiments, R₄ is hexyl.

In some embodiments, R₄ is C₂-C₆ alkenyl.

In some embodiments, R₄ is C₃-C₆ alkenyl. In some embodiments, R₄ is C₄-C₆ alkenyl. In some embodiments, R₄ is C₅-C₆ alkenyl. In some embodiments, R₄ is C₂-C₅ alkenyl. In some embodiments, R₄ is C₂-C₄ alkenyl. In some embodiments, R₄ is C₂-C₃ alkenyl. In some embodiments, R₄ is C₃-C₄ alkenyl. In some embodiments, R₄ is C₃-C₅ alkenyl. In some embodiments, R₄ is C₃-C₆ alkenyl. In some embodiments, R₄ is C₄-C₆ alkenyl. In some embodiments, R₄ is C₄-C₅ alkenyl. In some embodiments, R₄ is C₅-C₆ alkenyl.

In some embodiments, R₄ is C₂ alkenyl. In some embodiments, R₄ is C₃ alkenyl. In some embodiments, R₄ is C₄ alkenyl. In some embodiments, R₄ is C₅ alkenyl. In some embodiments, R₄ is C₆ alkenyl.

In some embodiments, R₄ is C₂-C₆ alkynyl.

In some embodiments, R₄ is C₃-C₆ alkynyl. In some embodiments, R₄ is C₄-C₆ alkynyl. In some embodiments, R₄ is C₅-C₆ alkynyl. In some embodiments, R₄ is C₂-C₅ alkynyl. In some embodiments, R₄ is C₂-C₄ alkynyl. In some embodiments, R₄ is C₂-C₃ alkynyl. In some embodiments, R₄ is C₃-C₄ alkynyl. In some embodiments, R₄ is C₃-C₅ alkynyl. In some embodiments, R₄ is C₃-C₆ alkynyl. In some embodiments, R₄ is C₄-C₆ alkynyl. In some embodiments, R₄ is C₄-C₅ alkynyl. In some embodiments, R₄ is C₅-C₆ alkynyl.

In some embodiments, R₄ is C₂ alkynyl. In some embodiments, R₄ is C₃ alkynyl. In some embodiments, R₄ is C₄ alkynyl. In some embodiments, R₄ is C_(S) alkynyl. In some embodiments, R₄ is C₆ alkynyl.

In some embodiments, R₄ is C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₄ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₄ is C₁-C₆ haloalkyl.

In some embodiments, R₄ is halomethyl. In some embodiments, R₄ is haloethyl. In some embodiments, R₄ is halopropyl. In some embodiments, R₄ is halobutyl. In some embodiments, R₄ is halopentyl. In some embodiments, R₄ is halohexyl.

In some embodiments, R₄ is CH₂F. In some embodiments, R₄ is CHF₂. In some embodiments, R₄ is CF₃.

In some embodiments, R₄ is C₁-C₆ alkoxy.

In some embodiments, R₄ is C₁-C₆ alkoxy. In some embodiments, R₄ is methoxy. In some embodiments, R₄ is ethoxy. In some embodiments, R₄ is propoxy. In some embodiments, R₄ is butoxy. In some embodiments, R₄ is pentoxy. In some embodiments, one R₄ is hexoxy.

In some embodiments, R₄ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₄ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, or —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₄ is —(CH₂)_(m)—R₁₂. In some embodiments, R₄ is —(CH₂)_(m)—OR₁₂. In some embodiments, R₄ is —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₄ is —R₁₂. In some embodiments, R₄ is —CH₂—R₁₂. In some embodiments, R₄ is —CH₂CH₂—R₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂—R₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂CH₂—R₁₂.

In some embodiments, R₄ is —OR₁₂. In some embodiments, R₄ is —CH₂—OR₁₂. In some embodiments, R₄ is —CH₂CH₂—OR₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂—OR₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂CH₂—OR₁₂.

In some embodiments, R₄ is —OR₁₂, wherein R₁₂ is H. In some embodiments, R₄ is —OR₁₂, wherein R₁₂ is C₃₋₁₀ cycloalkyl. In some embodiments, R₄ is

In some embodiments, R₄ is —N(R₁₂)₂. In some embodiments, R₄ is —CH₂—N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂—N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂.

In some embodiments, R₄ is —N(CH₃)₂.

In some embodiments, R₄ is —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₄ is —(CH₂)_(m)—C(O)R₁₂. In some embodiments, R₄ is —(CH₂)_(m)—C(O)OR₁₂. In some embodiments, R₄ is —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₄ is —CH₂—C(O)R₁₂. In some embodiments, R₄ is —CH₂CH₂—C(O)R₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂.

In some embodiments, R₄ is —CH₂—C(O)OR₁₂. In some embodiments, R₄ is —CH₂CH₂—C(O)OR₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂.

In some embodiments, R₄ is —CH₂—C(O)N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₄ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂.

In some embodiments, R₄ is —CH₂—C(O)NH₂.

In some embodiments, R₄ is C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₄ is C₃-C₁₀ cycloalkyl or heterocycle.

In some embodiments, R₄ is aryl or heteroaryl.

In some embodiments, R₄ is C₃-C₁₀ cycloalkyl.

In some embodiments, R₄ is a monocyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₄ is a polycyclic C₃-C₁₀ cycloalkyl.

In some embodiments, R₄ is C₅-C₆ cycloalkyl.

In some embodiments, R₄ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, R₄ is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₄ is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₄ is a C₃-C₁₀ spirocycloalkyl.

In some embodiments, R₄ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₄ is a monocyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is a polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₄ is 3-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 4-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 5-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 7-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 8-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 9-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 10-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₄ is 3-membered heterocycle comprising one N heteroatom. In some embodiments, R₄ is 4-membered heterocycle comprising one N heteroatom. In some embodiments, R₄ is 5-membered heterocycle comprising one N heteroatom. In some embodiments, R₄ is 6-membered heterocycle comprising one N heteroatom. In some embodiments, R₄ is 7-membered heterocycle comprising one N heteroatom. In some embodiments, R₄ is 8-membered heterocycle comprising one N heteroatom. In some embodiments, R₄ is 9-membered heterocycle comprising one N heteroatom. In some embodiments, R₃ is 10-membered heterocycle comprising one N heteroatom.

In some embodiments, R₄ is heterocycle comprising one heteroatom selected from O, N, and S. In some embodiments, R₄ is heterocycle comprising two heteroatoms selected from O, N, and S. In some embodiments, R₄ is heterocycle comprising three heteroatoms selected from O, N, and S. In some embodiments, R₄ is heterocycle comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₄ is aryl. In some embodiments, R₄ is C₆ aryl (e.g., phenyl).

In some embodiments, R₄ is a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S

In some embodiments, R₄ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₄ is 5-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 7-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 8-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₄ is 9-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 10-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₄ is heteroaryl comprising one heteroatom selected from O, N, and S. In some embodiments, R₄ is heteroaryl comprising two heteroatoms selected from O, N, and S. In some embodiments, R₄ is heteroaryl comprising three heteroatoms selected from O, N, and S. In some embodiments, R₄ is heteroaryl comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₄ is a monocyclic heterocycle. In some embodiments, R₄ is a 5-membered monocyclic heterocycle. In some embodiments, R₄ is

In some embodiments, R₄ is a 6-membered monocyclic heterocycle. In some embodiments, R₄ is

In some embodiments, R₅ is H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₅ is H.

In some embodiments, R₅ is halogen, —CN, C₁C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₅ is halogen. In some embodiments, R₅ is F, Cl, Br, or I. In some embodiments, R₅ is F, Cl, or Br. In some embodiments, R₅ is F. In some embodiments, R₅ is C₁.

In some embodiments, R₅ is Br. In some embodiments, R₅ is I.

In some embodiments, R₅ is —CN.

In some embodiments, R₅ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₅ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₅ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₅ is C₁-C₆ alkyl (e.g. linear or branched).

In some embodiments, R₅ is methyl. In some embodiments, R₅ is ethyl. In some embodiments, R₅ is propyl. In some embodiments, R₅ is n-propyl. In some embodiments, R₅ is isopropyl. In some embodiments, R₅ is butyl. In some embodiments, R₅ is n-butyl. In some embodiments, R₅ is isobutyl. In some embodiments, R₅ is sec-butyl. In some embodiments, R₅ is tert-butyl. In some embodiments, R₅ is pentyl. In some embodiments, R₅ is hexyl.

In some embodiments, R₅ is C₂-C₆ alkenyl.

In some embodiments, R₅ is C₂ alkenyl. In some embodiments, R₅ is C₃ alkenyl. In some embodiments, R₅ is C₄ alkenyl. In some embodiments, R₅ is C_(S) alkenyl. In some embodiments, R₅ is C₆ alkenyl.

In some embodiments, R₅ is C₂-C₆ alkynyl.

In some embodiments, R₅ is C₂ alkynyl. In some embodiments, R₅ is C₃ alkynyl. In some embodiments, R₅ is C₄ alkynyl. In some embodiments, R₅ is C₅ alkynyl. In some embodiments, R₅ is C₆ alkynyl.

In some embodiments, R₅ is C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₅ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₅ is C₁-C₆ haloalkyl.

In some embodiments, R₅ is halomethyl. In some embodiments, R₅ is haloethyl. In some embodiments, R₅ is halopropyl. In some embodiments, R₅ is halobutyl. In some embodiments, R₅ is halopentyl. In some embodiments, R₅ is halohexyl.

In some embodiments, R₅ is CH₂F. In some embodiments, R₅ is CHF₂. In some embodiments, R₅ is CF₃.

In some embodiments, R₅ is C₁-C₆ alkoxy.

In some embodiments, R₅ is C₁-C₆ alkoxy. In some embodiments, R₅ is methoxy. In some embodiments, R₅ is ethoxy. In some embodiments, R₅ is propoxy. In some embodiments, R₅ is butoxy. In some embodiments, R₅ is pentoxy. In some embodiments, one R₅ is hexoxy.

In some embodiments, R₅ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₅ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, or —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₅ is —(CH₂)_(m)—R₁₂. In some embodiments, R₅ is —(CH₂)_(m)—OR₁₂. In some embodiments, R₅ is —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₅ is —R₁₂. In some embodiments, R₅ is —CH₂—R₁₂. In some embodiments, R₅ is —CH₂CH₂—R₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂—R₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂CH₂—R₁₂.

In some embodiments, R₅ is —OR₁₂. In some embodiments, R₅ is —CH₂—OR₁₂. In some embodiments, R₅ is —CH₂CH₂—OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂—OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂CH₂—OR₁₂.

In some embodiments, R₅ is —OR₁₂, wherein R₁₂ is H. In some embodiments, R₅ is —OR₁₂, wherein R₁₂ is C₃₋₁₀ cycloalkyl. In some embodiments, R₅ is

In some embodiments, R₅ is —N(R₁₂)₂. In some embodiments, R₅ is —CH₂—N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂—N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂.

In some embodiments, R₅ is —N(CH₃)₂.

In some embodiments, R₅ is —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₅ is —(CH₂)_(m)—C(O)R₁₂. In some embodiments, R₅ is —(CH₂)_(m)—C(O)OR₁₂. In some embodiments, R₅ is —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₅ is —CH₂—C(O)R₁₂. In some embodiments, R₅ is —CH₂CH₂—C(O)R₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂.

In some embodiments, R₅ is —CH₂—C(O)OR₁₂. In some embodiments, R₅ is —CH₂CH₂—C(O)OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂.

In some embodiments, R₅ is —CH₂—C(O)N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂.

In some embodiments, R₅ is —CH₂—C(O)NH₂.

In some embodiments, R₅ is C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₅ is C₃-C₁₀ cycloalkyl or heterocycle.

In some embodiments, R₅ is aryl or heteroaryl.

In some embodiments, R₅ is C₃-C₁₀ cycloalkyl.

In some embodiments, R₅ is a monocyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₅ is a polycyclic C₃-C₁₀ cycloalkyl.

In some embodiments, R₅ is C₅-C₆ cycloalkyl.

In some embodiments, R₅ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, R₅ is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₅ is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₅ is a C₃-C₁₀ spirocycloalkyl.

In some embodiments, R₅ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₅ is a monocyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is a polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₅ is 3-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 4-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 5-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 7-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 8-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 9-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 10-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₅ is 3-membered heterocycle comprising one N heteroatom. In some embodiments, R₅ is 4-membered heterocycle comprising one N heteroatom. In some embodiments, R₅ is 5-membered heterocycle comprising one N heteroatom. In some embodiments, R₅ is 6-membered heterocycle comprising one N heteroatom. In some embodiments, R₅ is 7-membered heterocycle comprising one N heteroatom. In some embodiments, R₅ is 8-membered heterocycle comprising one N heteroatom. In some embodiments, R₅ is 9-membered heterocycle comprising one N heteroatom. In some embodiments, R₅ is 10-membered heterocycle comprising one N heteroatom.

In some embodiments, R₅ is heterocycle comprising one heteroatom selected from O, N, and S. In some embodiments, R₅ is heterocycle comprising two heteroatoms selected from O, N, and S. In some embodiments, R₅ is heterocycle comprising three heteroatoms selected from O, N, and S. In some embodiments, R₅ is heterocycle comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₅ is aryl. In some embodiments, R₅ is C₆ aryl (e.g., phenyl).

In some embodiments, R₅ is a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S

In some embodiments, R₅ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₅ is 5-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 7-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 8-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 9-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₅ is 10-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₅ is heteroaryl comprising one heteroatom selected from O, N, and S. In some embodiments, R₅ is heteroaryl comprising two heteroatoms selected from O, N, and S. In some embodiments, R₅ is heteroaryl comprising three heteroatoms selected from O, N, and S. In some embodiments, R₅ is heteroaryl comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₅ is a monocyclic heterocycle. In some embodiments, R₅ is a 5-membered monocyclic heterocycle. In some embodiments, R₅ is

In some embodiments, R₅ is a 6-membered monocyclic heterocycle. In some embodiments, R₅ is

In some embodiments, R₆ is H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₆ is H.

In some embodiments, R₆ is halogen, —CN, C₁C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₆ is halogen. In some embodiments, R₆ is F, Cl, Br, or I. In some embodiments, R₆ is F, Cl, or Br. In some embodiments, R₆ is F. In some embodiments, R₆ is C₁.

In some embodiments, R₆ is Br. In some embodiments, R₆ is I.

In some embodiments, R₆ is —CN.

In some embodiments, R₆ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₆ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₆ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₆ is C₁-C₆ alkyl (e.g. linear or branched).

In some embodiments, R₆ is methyl. In some embodiments, R₆ is ethyl. In some embodiments, R₆ is propyl. In some embodiments, R₆ is n-propyl. In some embodiments, R₆ is isopropyl. In some embodiments, R₆ is butyl. In some embodiments, R₆ is n-butyl. In some embodiments, R₆ is isobutyl. In some embodiments, R₆ is sec-butyl. In some embodiments, R₆ is tert-butyl. In some embodiments, R₆ is pentyl. In some embodiments, R₆ is hexyl.

In some embodiments, R₆ is C₂-C₆ alkenyl.

In some embodiments, R₆ is C₃-C₆ alkenyl. In some embodiments, R₆ is C₄-C₆ alkenyl. In some embodiments, R₆ is C₅-C₆ alkenyl. In some embodiments, R₆ is C₂-C₅ alkenyl. In some embodiments, R₆ is C₂-C₄ alkenyl. In some embodiments, R₆ is C₂-C₃ alkenyl. In some embodiments, R₆ is C₃-C₄ alkenyl. In some embodiments, R₆ is C₃-C₅ alkenyl. In some embodiments, R₆ is C₃-C₆ alkenyl. In some embodiments, R₆ is C₄-C₆ alkenyl. In some embodiments, R₆ is C₄-C₅ alkenyl. In some embodiments, R₆ is C₅-C₆ alkenyl.

In some embodiments, R₆ is C₂ alkenyl. In some embodiments, R₆ is C₃ alkenyl. In some embodiments, R₆ is C₄ alkenyl. In some embodiments, R₆ is C₅ alkenyl. In some embodiments, R₆ is C₆ alkenyl.

In some embodiments, R₆ is C₂-C₆ alkynyl.

In some embodiments, R₆ is C₃-C₆ alkynyl. In some embodiments, R₆ is C₄-C₆ alkynyl. In some embodiments, R₆ is C₅-C₆ alkynyl. In some embodiments, R₆ is C₂-C₅ alkynyl. In some embodiments, R₆ is C₂-C₄ alkynyl. In some embodiments, R₆ is C₂-C₃ alkynyl. In some embodiments, R₆ is C₃-C₄ alkynyl. In some embodiments, R₆ is C₃-C₅ alkynyl. In some embodiments, R₆ is C₃-C₆ alkynyl. In some embodiments, R₆ is C₄-C₆ alkynyl. In some embodiments, R₆ is C₄-C₅ alkynyl. In some embodiments, R₆ is C₅-C₆ alkynyl.

In some embodiments, R₆ is C₂ alkynyl. In some embodiments, R₆ is C₃ alkynyl. In some embodiments, R₆ is C₄ alkynyl. In some embodiments, R₆ is C₅ alkynyl. In some embodiments, R₆ is C₆ alkynyl.

In some embodiments, R₆ is C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₆ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₅ is C₁-C₆ haloalkyl.

In some embodiments, R₆ is halomethyl. In some embodiments, R₅ is haloethyl. In some embodiments, R is halopropyl. In some embodiments, R is halobutyl. In some embodiments, R₆ is halopentyl. In some embodiments, R₆ is halohexyl.

In some embodiments, R₆ is CH₂F. In some embodiments, R₅ is CHF₂. In some embodiments, R₅ is CF₃.

In some embodiments, R₆ is C₁-C₆ alkoxy.

In some embodiments, R₆ is C₁-C₆ alkoxy. In some embodiments, R₆ is methoxy. In some embodiments, R₆ is ethoxy. In some embodiments, R₆ is propoxy. In some embodiments, R₅ is butoxy. In some embodiments, R₅ is pentoxy. In some embodiments, one R₅ is hexoxy.

In some embodiments, R₆ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₆ is —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, or —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₅ is —(CH₂)_(m)—R₁₂. In some embodiments, R₅ is —(CH₂)_(m)—OR₁₂. In some embodiments, R₅ is —(CH₂)_(m)—N(R₁₂)₂.

In some embodiments, R₆ is —R₁₂. In some embodiments, R₆ is —CH₂—R₁₂. In some embodiments, R₆ is —CH₂CH₂—R₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂—R₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂CH₂—R₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂CH₂CH₂—R₁₂.

In some embodiments, R₆ is —OR₁₂. In some embodiments, R₅ is —CH₂—OR₁₂. In some embodiments, R₆ is —CH₂CH₂—OR₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂—OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R₅ is —CH₂CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, R is —CH₂CH₂CH₂CH₂CH₂CH₂—OR₁₂.

In some embodiments, R₆ is —OR₁₂, wherein R₁₂ is H. In some embodiments, R₆ is —OR₁₂, wherein R₁₂ is C₃₋₁₀ cycloalkyl. In some embodiments, R₆ is

In some embodiments, R₆ is —N(R₁₂)₂. In some embodiments, R₆ is —CH₂—N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂—N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂CH₂CH₂—N(R₁₂)₂.

In some embodiments, R₆ is —N(CH₃)₂.

In some embodiments, R₆ is —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, or —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₆ is —(CH₂)_(m)—C(O)R₁₂. In some embodiments, R₆ is —(CH₂)_(m)—C(O)OR₁₂. In some embodiments, R₆ is —(CH₂)_(m)—C(O)N(R₁₂)₂.

In some embodiments, R₆ is —CH₂—C(O)R₁₂. In some embodiments, R₆ is —CH₂CH₂—C(O)R₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, & is —CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂.

In some embodiments, R₆ is —CH₂—C(O)OR₁₂. In some embodiments, R₆ is —CH₂CH₂—C(O)OR₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, & is —CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂.

In some embodiments, R₆ is —CH₂—C(O)N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, R₆ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂.

In some embodiments, R₆ is —CH₂—C(O)NH₂.

In some embodiments, R₆ is C₃-C₁₀ cycloalkyl, heterocycle, aryl, or heteroaryl.

In some embodiments, R₆ is C₃-C₁₀ cycloalkyl or heterocycle.

In some embodiments, R₆ is aryl or heteroaryl.

In some embodiments, R₆ is C₃-C₁₀ cycloalkyl.

In some embodiments, R₆ is a monocyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₆ is a polycyclic C₃-C₁₀ cycloalkyl.

In some embodiments, R₆ is C₅-C₆ cycloalkyl.

In some embodiments, R₆ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, R₆ is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₆ is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₆ is a C₃-C₁₀ spirocycloalkyl.

In some embodiments, R₆ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₆ is a monocyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is a polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₆ is 3-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 4-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 5-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 7-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 8-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 9-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 10-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₆ is 3-membered heterocycle comprising one N heteroatom. In some embodiments, R₆ is 4-membered heterocycle comprising one N heteroatom. In some embodiments, R₆ is 5-membered heterocycle comprising one N heteroatom. In some embodiments, R₆ is 6-membered heterocycle comprising one N heteroatom. In some embodiments, R₆ is 7-membered heterocycle comprising one N heteroatom. In some embodiments, R₆ is 8-membered heterocycle comprising one N heteroatom. In some embodiments, R₆ is 9-membered heterocycle comprising one N heteroatom. In some embodiments, R₆ is 10-membered heterocycle comprising one N heteroatom.

In some embodiments, R₆ is heterocycle comprising one heteroatom selected from O, N, and S. In some embodiments, R₆ is heterocycle comprising two heteroatoms selected from O, N, and S. In some embodiments, R₆ is heterocycle comprising three heteroatoms selected from O, N, and S. In some embodiments, R₆ is heterocycle comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₆ is aryl. In some embodiments, R₆ is C₆ aryl (e.g., phenyl).

In some embodiments, R₆ is a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S

In some embodiments, R₆ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₆ is 5-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 7-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 8-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 9-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₆ is 10-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₆ is heteroaryl comprising one heteroatom selected from O, N, and S. In some embodiments, R₆ is heteroaryl comprising two heteroatoms selected from O, N, and S. In some embodiments, R₆ is heteroaryl comprising three heteroatoms selected from O, N, and S. In some embodiments, R₆ is heteroaryl comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₆ is a monocyclic heterocycle. In some embodiments, R₆ is a 5-membered monocyclic heterocycle. In some embodiments, R₆ is

In some embodiments, R₆ is a 6-membered monocyclic heterocycle. In some embodiments, R₆ is

In some embodiments, each R₇ and R₅ is independently H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, each R₇ and R₅ is independently H.

In some embodiments, each R₇ and R₅ is independently halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₇ is H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₇ is H.

In some embodiments, R₇ is halogen. In some embodiments, R₇ is F, Cl, Br, or I. In some embodiments, R₇ is F, Cl, or Br. In some embodiments, R₇ is F. In some embodiments, R₇ is C₁. In some embodiments, R₇ is Br. In some embodiments, R₇ is I.

In some embodiments, R₇ is —CN.

In some embodiments, R₇ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₇ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₇ is C₁-C₆ alkyl (e.g. linear or branched).

In some embodiments, R₇ is methyl. In some embodiments, R₇ is ethyl. In some embodiments, R₇ is propyl. In some embodiments, R₇ is n-propyl. In some embodiments, R₇ is isopropyl. In some embodiments, R₇ is butyl. In some embodiments, R₇ is n-butyl. In some embodiments, R₇ is isobutyl. In some embodiments, R₇ is sec-butyl. In some embodiments, R₇ is tert-butyl. In some embodiments, R₇ is pentyl. In some embodiments, R₇ is hexyl.

In some embodiments, R₇ is C₂-C₆ alkenyl.

In some embodiments, R₇ is C₂ alkenyl. In some embodiments, R₇ is C₃ alkenyl. In some embodiments, R₇ is C₄ alkenyl. In some embodiments, R₇ is C₅ alkenyl. In some embodiments, R₇ is C₆ alkenyl.

In some embodiments, R₇ is C₂-C₆ alkynyl.

In some embodiments, R₇ is C₂ alkynyl. In some embodiments, R₇ is C₃ alkynyl. In some embodiments, R₇ is C₄ alkynyl. In some embodiments, R₇ is C₅ alkynyl. In some embodiments, R₇ is C₆ alkynyl.

In some embodiments, R₇ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₇ is C₁-C₆ haloalkyl.

In some embodiments, R₇ is halomethyl. In some embodiments, R₇ is haloethyl. In some embodiments, R₇ is halopropyl. In some embodiments, R₇ is halobutyl. In some embodiments, R₇ is halopentyl. In some embodiments, R₇ is halohexyl.

In some embodiments, R₇ is CH₂F. In some embodiments, R₇ is CHF₂. In some embodiments, R₇ is CF₃.

In some embodiments, R₇ is C₁-C₆ alkoxy.

In some embodiments, R₇ is methoxy. In some embodiments, R₇ is ethoxy. In some embodiments, R₇ is propoxy. In some embodiments, R₇ is butoxy. In some embodiments, R₇ is pentoxy. In some embodiments, one R₇ is hexoxy.

In some embodiments, R₈ is H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₈ is H.

In some embodiments, R₈ is halogen. In some embodiments, R₈ is F, Cl, Br, or I. In some embodiments, R₈ is F, Cl, or Br. In some embodiments, R₈ is F. In some embodiments, R₈ is C₁.

In some embodiments, R₈ is Br. In some embodiments, R₈ is I.

In some embodiments, R₈ is —CN.

In some embodiments, R₈ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₈ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₈ is C₁-C₆ alkyl (e.g. linear or branched).

In some embodiments, R₈ is methyl. In some embodiments, R₈ is ethyl. In some embodiments, R₈ is propyl. In some embodiments, R₈ is n-propyl. In some embodiments, R₈ is isopropyl. In some embodiments, R₈ is butyl. In some embodiments, R₈ is n-butyl. In some embodiments, R₈ is isobutyl. In some embodiments, R₈ is sec-butyl. In some embodiments, R₈ is tert-butyl. In some embodiments, R₈ is pentyl. In some embodiments, R₈ is hexyl.

In some embodiments, R₈ is C₂-C₆ alkenyl.

In some embodiments, R₈ is C₂ alkenyl. In some embodiments, R₈ is C₃ alkenyl. In some embodiments, R₈ is C₄ alkenyl. In some embodiments, R₈ is C₈ alkenyl. In some embodiments, R₈ is C₆ alkenyl.

In some embodiments, R₈ is C₂-C₆ alkynyl.

In some embodiments, R₈ is C₂ alkynyl. In some embodiments, R₈ is C₃ alkynyl. In some embodiments, R₈ is C₄ alkynyl. In some embodiments, R₈ is C₈ alkynyl. In some embodiments, R₈ is C₆ alkynyl.

In some embodiments, R₈ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₈ is C₁-C₆ haloalkyl.

In some embodiments, R₈ is halomethyl. In some embodiments, R₈ is haloethyl. In some embodiments, R₈ is halopropyl. In some embodiments, R₈ is halobutyl. In some embodiments, R₈ is halopentyl. In some embodiments, R₈ is halohexyl.

In some embodiments, R₈ is CH₂F. In some embodiments, R₈ is CHF₂. In some embodiments, R₈ is CF₃.

In some embodiments, R₈ is C₁-C₆ alkoxy.

In some embodiments, R₈ is methoxy. In some embodiments, R₈ is ethoxy. In some embodiments, R₈ is propoxy. In some embodiments, R₈ is butoxy. In some embodiments, R₈ is pentoxy. In some embodiments, one R₈ is hexoxy.

In some embodiments, at least one R₉ is oxo, ═NR₁₁, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂—OR₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—CON(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₂)₂, —(CH₂)_(m)—P(O)(R₁₂)₂, —(CH₂)_(m)—B(OH)₂, —(CH₂)_(m)—B(R₁₂)₂, —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₂, —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₂, —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, at least one R₉ is oxo, ═NR₁₁, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂—OR₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—CON(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₂)₂, —(CH₂)_(m)—P(O)(R₁₂)₂, —(CH₂)_(m)—B(OH)₂, —(CH₂)_(m)—B(R₁₂)₂, —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₂, —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₂, —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₃-C₁₀ cycloalkyl, heterocycle, aryl, or 5- to 6-membered heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is oxo, ═NR₁₁, halogen, —CN, or —NO₂.

In some embodiments, at least one R₉ is oxo.

In some embodiments, at least one R₉ is ═NR₁₁.

In some embodiments, at least one R₉ is halogen. In some embodiments, at least one R₉ is F, Cl, Br, or I. In some embodiments, at least one R₉ is F, Cl, or Br. In some embodiments, R₉ is F. In some embodiments, R₉ is C₁. In some embodiments, R₉ is Br. In some embodiments, R₉ is I.

In some embodiments, at least one R₉ is —CN.

In some embodiments, at least one R₉ is NO₂.

In some embodiments, at least one R₉ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₉ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₉ is C₁-C₆ alkyl (e.g. linear or branched).

In some embodiments, R₉ is methyl. In some embodiments, R₉ is ethyl. In some embodiments, R₉ is propyl. In some embodiments, R₉ is n-propyl. In some embodiments, R₉ is isopropyl. In some embodiments, R₉ is butyl. In some embodiments, R₉ is n-butyl. In some embodiments, R₉ is isobutyl. In some embodiments, R₉ is sec-butyl. In some embodiments, R₉ is tert-butyl. In some embodiments, R₉ is pentyl. In some embodiments, R₉ is hexyl.

In some embodiments, R₉ is C₁-C₆ alkyl optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₉ is C₂-C₆ alkenyl.

In some embodiments, R₉ is C₂ alkenyl. In some embodiments, R₉ is C₃ alkenyl. In some embodiments, R₉ is C₄ alkenyl. In some embodiments, R₉ is C₅ alkenyl. In some embodiments, R₉ is C₆ alkenyl.

In some embodiments, R₉ is C₂-C₆ alkenyl optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₉ is C₂-C₆ alkynyl.

In some embodiments, R₉ is C₂ alkynyl. In some embodiments, R₉ is C₃ alkynyl. In some embodiments, R₉ is C₄ alkynyl. In some embodiments, R₉ is C_(S) alkynyl. In some embodiments, R₉ is C₆ alkynyl.

In some embodiments, R₉ is C₂-C₆ alkynyl optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₉ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₉ is C₁-C₆ haloalkyl.

In some embodiments, R₉ is halomethyl. In some embodiments, R₉ is haloethyl. In some embodiments, R₉ is halopropyl. In some embodiments, R₉ is halobutyl. In some embodiments, R₉ is halopentyl. In some embodiments, R₉ is halohexyl.

In some embodiments, R₉ is CH₂F. In some embodiments, R₉ is CHF₂. In some embodiments, R₉ is CF₃.

In some embodiments, R₉ is C₁-C₆ haloalkyl optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy

In some embodiments, R₉ is C₁-C₆ alkoxy.

In some embodiments, R₉ is methoxy. In some embodiments, R₉ is ethoxy. In some embodiments, R₉ is propoxy. In some embodiments, R₉ is butoxy. In some embodiments, R₉ is pentoxy. In some embodiments, one R₉ is hexoxy.

In some embodiments, R₉ is C₁-C₆ alkoxy optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂—OR₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—CON(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₂)₂, —(CH₂)_(m)—P(O)(R₁₂)₂, —(CH₂)_(m)—B(OH)₂, —(CH₂)_(m)—B(R₁₂)₂, —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₂, —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₂, —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, or —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃.

In some embodiments, at least one R₉ is —(CH₂)_(m)—N(R₁₂)₂ or —(CH₂)_(m)—OR₁₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—N(R₁₂)₂. In some embodiments, at least one R₉ is —(CH₂)_(m)—OR₁₂.

In some embodiments, at least one R₉ is-CH₂—N(R₁₂)₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, or —(CH₂)_(m)—CON(R₁₂)₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—C(O)R₁₂. In some embodiments, at least one R₉ is —(CH₂)_(m)—C(O)OR₁₂. In some embodiments, at least one R₉ is —(CH₂)_(m)—C(O)N(R₁₂)₂. In some embodiments, at least one R₉ is —(CH₂)_(m)—CON(R₁₂)₂.

In some embodiments, at least one R₉ is —C(O)R₁₂. In some embodiments, at least one R₉ is —CH₂—C(O)R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂—C(O)R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂.

In some embodiments, at least one R₉ is —C(O)OR₁₂. In some embodiments, at least one R₉ is —CH₂—C(O)OR₁₂. In some embodiments, at least one R₉ is —CH₂CH₂—C(O)OR₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—CON(R₁₂)₂.

In some embodiments, at least one R₉ is —C(O)N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂—CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂ CH₂CH₂CH₂—C(O)N(R₁₂)₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂—OR₁₂, or —(CH₂)_(m)—SO₂N(R₁₂)₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—SO₂R₁₂. In some embodiments, at least one R₉ is —(CH₂)_(m)—SO₂—OR₁₂. In some embodiments, at least one R₉ is —(CH₂)_(m)—SO₂N(R₁₂)₂.

In some embodiments, at least one R₉ is —SO₂R₁₂. In some embodiments, at least one R₉ is —CH₂—SO₂R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂—SO₂R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—SO₂R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—SO₂R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂—SO₂R₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂CH₂—SO₂R₁₂.

In some embodiments, at least one R₉ is —SO₂—OR₁₂. In some embodiments, at least one R₉ is —CH₂—SO₂—OR₁₂. In some embodiments, at least one R₉ is —CH₂CH₂—SO₂—OR₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—SO₂—OR₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—SO₂—OR₁₂. In some embodiments, at least one R₉ is —CH₂ CH₂CH₂CH₂CH₂—SO₂—OR₁₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂CH₂—SO₂R₁₂.

In some embodiments, at least one R₉ is —SO₂N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂—SO₂N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂—SO₂N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—SO₂N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—SO₂N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂—CH₂CH₂CH₂CH₂—SO₂N(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂CH₂—SO₂N(R₁₂)₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—P(O)(OR₁₂)₂, or —(CH₂)_(m)—P(O)(R₁₂)₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—P(O)(OR₁₂)₂. In some embodiments, at least one R₉ is —(CH₂)_(m)—P(O)(R₁₂)₂.

In some embodiments, at least one R₉ is —P(O)(OR₁₂)₂. In some embodiments, at least one R₉ is —CH₂—P(O)(OR₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂—P(O)(OR₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—P(O)(OR₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—P(O)(OR₁₂)₂. In some embodiments, at least one R₉ is —CH₂—CH₂CH₂CH₂CH₂—P(O)(OR₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂CH₂—P(O)(OR₁₂)₂.

In some embodiments, at least one R₉ is —P(O)(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂—P(O)(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂—P(O)(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—P(O)(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—P(O)(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂—CH₂CH₂CH₂CH₂—P(O)(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂CH₂—P(O)(R₁₂)₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—B(OH)₂, or —(CH₂)_(m)—B(R₁₂)₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—B(OH)₂. In some embodiments, at least one R₉ is —(CH₂)_(m)—B(R₁₂)₂.

In some embodiments, at least one R₉ is —B(OH)₂. In some embodiments, at least one R₉ is —CH₂—B(OH)₂. In some embodiments, at least one R₉ is —CH₂CH₂—B(OH)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—B(OH)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—B(OH)₂. In some embodiments, at least one R₉ is —CH₂— CH₂CH₂CH₂CH₂—B(OH)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂CH₂—B(OH)₂.

In some embodiments, at least one R₉ is —B(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂—B(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂—B(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂—B(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂—B(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂— CH₂CH₂CH₂CH₂—B(R₁₂)₂. In some embodiments, at least one R₉ is —CH₂CH₂CH₂CH₂CH₂CH₂.

In some embodiments, at least one R₉ is —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, or —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃.

In some embodiments, at least one R₉ is —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃. In some embodiments, at least one R₉ is —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃. In some embodiments, at least one R₉ is —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₃. In some embodiments, at least one R₉ is —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₃. In some embodiments, at least one R₉ is —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃. In some embodiments, at least one R₉ is —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃. In some embodiments, at least one R₉ is —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃. In some embodiments, at least one R₉ is —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃.

In some embodiments, at least one R₉ is —C(O)NR₁₂-R₁₃. In some embodiments, at least one R₉ is —C(O)NR₁₂—CH₂CH₂—OR₁₃. In some embodiments, at least one R₉ is —C(O)NR₁₂—(CH₂CH₂—O)₂R₁₃. In some embodiments, at least one R₉ is —C(O)NR₁₂—(CH₂CH₂—O)₃R₁₃. In some embodiments, at least one R₉ is —C(O)NR₁₂—(CH₂CH₂—O)₄R₁₃. In some embodiments, at least one R₉ is —C(O)NR₁₂—(CH₂CH₂—O)₅R₁₃. In some embodiments, at least one R₉ is —C(O)NR₁₂—(CH₂CH₂—O)₆R₁₃.

In some embodiments, at least one R₉ is —C(O)R₁₂-R₁₃. In some embodiments, at least one R₉ is —C(O)R₁₂—CH₂CH₂—OR₁₃. In some embodiments, at least one R₉ is —C(O)R₁₂—(CH₂CH₂—O)₂R₁₃. In some embodiments, at least one R₉ is —C(O)R₁₂—(CH₂CH₂—O)₃R₁₃. In some embodiments, at least one R₉ is —C(O)R₁₂—(CH₂CH₂—O)₄R₁₃. In some embodiments, at least one R₉ is —C(O)R₁₂—(CH₂CH₂—O)₅R₁₃. In some embodiments, at least one R₉ is —C(O)R₁₂—(CH₂CH₂—O)₆R₁₃.

In some embodiments, at least one R₉ is C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, Aryl, or 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the C₃-C₁₀ cycloalkyl, heterocycle, Aryl, or 5- to 6-membered heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is C₃-C₁₀ cycloalkyl, wherein the C₃-C₁₀ cycloalkyl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is aryl wherein the aryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the 5- to 6-membered heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl.

In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₉ is a monocyclic C₃-C₁₀ cycloalkyl. In some embodiments, at least one R₉ is a monocyclic C₃-C₁₀ cycloalkyl optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is a polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, at least one R₉ is a polycyclic C₃-C₁₀ cycloalkyl optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is C₅-C₆ cycloalkyl. In some embodiments, at least one R₉ is C₅-C₆ cycloalkyl optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl. In some embodiments, at least one R₉ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, at least one R₉ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, substituted with one substituent selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₉ is 5- to 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₉ is 5- to 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₉ is 5- to 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, substituted with one oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, substituted with two substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, substituted with three substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, substituted with four substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is heterocycle comprising three heteroatoms selected from N and S, optionally substituted with one or more oxo.

In some embodiments, at least one R₉ is 4-membered heterocycle comprising 1-3 heteroatoms selected from N, O, and S, optionally substituted with one or more oxo. In some embodiments, at least one R₉ is 5-membered heterocycle comprising 1-3 heteroatoms selected from N, O, and S, optionally substituted with one or more oxo. In some embodiments, at least one R₉ is 6-membered heterocycle comprising 1-3 heteroatoms selected from N, O, and S, optionally substituted with one or more oxo. In some embodiments, at least one R₉ is 7-membered heterocycle comprising 1-3 heteroatoms selected from N, O, and S, optionally substituted with one or more oxo. In some embodiments, at least one R₉ is 8-membered heterocycle comprising 1-3 heteroatoms selected from N, O, and S, optionally substituted with one or more oxo. In some embodiments, at least one R₉ is 9-membered heterocycle comprising 1-3 heteroatoms selected from N, O, and S, optionally substituted with one or more oxo. In some embodiments, at least one R₉ is 10-membered heterocycle comprising 1-3 heteroatoms selected from N, O, and S, optionally substituted with one or more oxo.

In some embodiments, at least one R₉ is

In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, wherein the heteroaryl is optionally substituted with one or more substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising one heteroatom selected from O, N, and S. In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising one heteroatom selected from O, N, and S, wherein the heteroaryl is optionally substituted with one or more substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising two heteroatoms selected from O, N, and S. In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising two heteroatoms selected from O, N, and S, wherein the heteroaryl is optionally substituted with one or more substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising three heteroatoms selected from O, N, and S. In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising three heteroatoms selected from O, N, and S, wherein the heteroaryl is optionally substituted with one or more substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, at least one R₉ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, wherein the heteroaryl is optionally substituted with one or more substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 5-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S. In some embodiments, at least one R₉ is 5-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the 5-membered heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 5-membered heteroaryl comprising one heteroatom selected from N, O, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is 5-membered heteroaryl comprising two heteroatoms selected from N, O, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is 5-membered heteroaryl comprising three heteroatoms selected from N, O, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is 5-membered heteroaryl comprising four heteroatoms selected from N, O, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 5-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, substituted with one oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 5-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, substituted with two substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 5-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, substituted with three substituents selected oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is

In some embodiments, at least one R₉ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S. In some embodiments, at least one R₉ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 6-membered heteroaryl comprising one heteroatom selected from N, O, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is 6-membered heteroaryl comprising two heteroatoms selected from N, O, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is 6-membered heteroaryl comprising three heteroatoms selected from N, O, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, at least one R₉ is 6-membered heteroaryl comprising four heteroatoms selected from N, O, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, substituted with one oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, substituted with two substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, substituted with three substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₉ is 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, substituted with four substituents selected from oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl or a 3- to 15-membered saturated or partially saturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl or a 3- to 15-membered saturated or partially saturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the cycloalkyl or heterocycle is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl.

In some embodiments, two R₉ together with the atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₅-C₆ cycloalkyl.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₅-C₆ cycloalkyl wherein the cycloalkyl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl substituted with one oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl substituted with two substituents selected from oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl substituted with three substituents selected from oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl substituted with four substituents selected from oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl is optionally substituted with four substituents selected from oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

some embodiments, two R₉ together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl wherein the cycloalkyl is optionally substituted with one or more oxo or ═NH.

In some embodiments, two R₉ together with the atoms to which they are attached form 3 to 15-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, two R₉ together with the atoms to which they are attached form heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form 3- to 15-membered saturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, two R₉ together with the atoms to which they are attached form 3-15-membered partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a heterocycle comprising one heteroatom selected from O, N, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, two R₉ together with the atoms to which they are attached form a heterocycle comprising two heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, two R₉ together with the atoms to which they are attached form a heterocycle comprising three heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy. In some embodiments, two R₉ together with the atoms to which they are attached form a heterocycle comprising four heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form heterocycle comprising 1-4 heteroatoms selected from O, N, and S, substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form a 5- to 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, two R₉ together with the atoms to which they are attached form a 5- to 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, two R₉ together with the atoms to which they are attached form heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more oxo or ═NH.

In some embodiments, two R₉ together with the atoms to which they are attached form 5-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, two R₉ together with the atoms to which they are attached form 5-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more oxo or ═NH. In some embodiments, two R₉ together with the atoms to which they are attached form 5-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more oxo. In some embodiments, two R₉ together with the atoms to which they are attached form 5-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more ═NH.

In some embodiments, two R₉ together with the atoms to which they are attached form 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, two R₉ together with the atoms to which they are attached form 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more oxo or ═NH. In some embodiments, two R₉ together with the atoms to which they are attached form 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more oxo. In some embodiments, two R₉ together with the atoms to which they are attached form 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the heterocycle is optionally substituted with one or more ═NH.

In some embodiments, two R₉ together with the atoms to which they are attached form

wherein “

” signifies the point at which the two R₉ attach to different atoms of ring A.

In some embodiments, two R₉ together with the atoms to which they are attached form

or wherein “

” signifies the point at which the two R₉ attach to different atoms of ring A.

In some embodiments, at least one R₁₀ is oxo, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂, C₃-C₁₀ cycloalkyl, heterocycle, aryl, and heteroaryl, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl is optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is oxo, halogen, or —CN.

In some embodiments, at least one R₁₀ is oxo.

In some embodiments, at least one R₁₀ is halogen. In some embodiments, at least one R₁₀ is F, Cl, Br, or I. In some embodiments, at least one R₁₀ is F, Cl, or Br. In some embodiments, at least one R₁₀ is F. In some embodiments, at least one R₁₀ is C₁. In some embodiments, at least one R₁₀ is Br. In some embodiments, at least one R₁₀ is I.

In some embodiments, at least one R₁₀ is —CN.

In some embodiments, at least one R₁₀ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, at least one R₁₀ is C₁-C₆ alkyl.

In some embodiments, at least one R₁₀ is methyl. In some embodiments, at least one R₁₀ is ethyl. In some embodiments, at least one R₁₀ is propyl. In some embodiments, at least one R₁₀ is n-propyl. In some embodiments, at least one R₁₀ is isopropyl. In some embodiments, at least one R₁₀ is butyl. In some embodiments, at least one R₁₀ is n-butyl. In some embodiments, at least one R₁₀ is isobutyl. In some embodiments, at least one R₁₀ is sec-butyl. In some embodiments, at least one R₁₀ is tert-butyl. In some embodiments, at least one R₁₀ is pentyl. In some embodiments, at least one R₁₀ is hexyl.

In some embodiments, at least one R₁₀ is C₂-C₆ alkenyl.

In some embodiments, at least one R₁₀ is C₂ alkenyl. In some embodiments, at least one R₁₀ is C₃ alkenyl. In some embodiments, at least one R₁₀ is C₄ alkenyl. In some embodiments, at least one R₁₀ is C_(S) alkenyl. In some embodiments, at least one R₁₀ is C₆ alkenyl.

In some embodiments, at least one R₁₀ is C₂-C₆ alkynyl.

In some embodiments, at least one R₁₀ is C₂ alkynyl. In some embodiments, at least one R₁₀ is C₃ alkynyl. In some embodiments, at least one R₁₀ is C₄ alkynyl. In some embodiments, at least one R₁₀ is C₅ alkynyl. In some embodiments, at least one R₁₀ is C₆ alkynyl.

In some embodiments, at least one R₁₀ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, at least one R₁₀ is C₁-C₆ haloalkyl.

In some embodiments, at least one R₁₀ is C₁-C₆ haloalkyl. In some embodiments, at least one R₁₀ is halomethyl. In some embodiments, at least one R₁₀ is haloethyl. In some embodiments, at least one R₁₀ is halopropyl. In some embodiments, at least one R₁₀ is halobutyl.

In some embodiments, at least one R₁₀ is halopentyl. In some embodiments, at least one R₁₀ is halohexyl.

In some embodiments, at least one R₁₀ is C₁-C₆ alkoxy.

In some embodiments, at least one R₁₀ is C₁-C₆ alkoxy. In some embodiments, at least one R₁₀ is methoxy. In some embodiments, at least one R₁₀ is ethoxy. In some embodiments, at least one R₁₀ is propoxy. In some embodiments, at least one R₁₀ is butoxy. In some embodiments, at least one R₁₀ is pentoxy. In some embodiments, at least one R₁₀ is hexoxy.

In some embodiments, at least one R₁₀ is —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, at least one R₁₀ is —(CH₂)_(n)—OR₁₂.

In some embodiments, at least one R₁₀ is —OR₁₂. In some embodiments, at least one R₁₀ is —CH₂—OR₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂—OR₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂—OR₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂—OR₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂—OR₁₂.

In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂CH₂—OR₁₂.

In some embodiments, at least one R₁₀ is —(CH₂)_(n)—N(R₁₂)₂.

In some embodiments, at least one R₁₀ is —N(R₁₂). In some embodiments, at least one R₁₀ is —CH₂—N(R₁₂). In some embodiments, at least one R₁₀ is —CH₂CH₂—N(R₁₂). In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂—N(R₁₂). In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂—N(R₁₂). In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂—N(R₁₂). In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂CH₂—N(R₁₂).

In some embodiments, at least one R₁₀ is —(CH₂)_(n)—C(O)R₁₂.

In some embodiments, at least one R₁₀ is —C(O)R₁₂. In some embodiments, at least one R₁₀ is —CH₂—C(O)R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂—C(O)R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)R₁₂.

In some embodiments, at least one R₁₀ is —(CH₂)_(n)—C(O)OR₁₂.

In some embodiments, at least one R₁₀ is —C(O)OR₁₂. In some embodiments, at least one R₁₀ is —CH₂—C(O)OR₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂—C(O)OR₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)OR₁₂.

In some embodiments, at least one R₁₀ is —(CH₂)_(n)—C(O)N(R₁₂)₂.

In some embodiments, at least one R₁₀ is —C(O)N(R₁₂)₂. In some embodiments, at least one R₁₀ is —CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₁₀ is —CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂CH₂—C(O)N(R₁₂)₂.

In some embodiments, at least one R₁₀ is —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, at least one R₁₀ is —SO₂R₁₂. In some embodiments, at least one R₁₀ is —CH₂—SO₂R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂—SO₂R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂—SO₂R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂—SO₂R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂—SO₂R₁₂. In some embodiments, at least one R₁₀ is —CH₂CH₂CH₂CH₂CH₂CH₂—SO₂R₁₂.

In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl, heterocycle, aryl, and heteroaryl.

In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl, heterocycle, Aryl, and heteroaryl, wherein the C₃-C₁₀ cycloalkyl, heterocycle, aryl, and heteroaryl is optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl. In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is a monocyclic C₃-C₁₀ cycloalkyl. In some embodiments, at least one R₁₀ is a monocyclic C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. In some embodiments, at least one R₁₀ is a polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, at least one R₁₀ is a polycyclic C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is C₅-C₆ cycloalkyl. In some embodiments, at least one R₁₀ is C₅-C₆ cycloalkyl optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl. In some embodiments, at least one R₁₀ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl is optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, at least one R₁₀ is a fused polycyclic C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, at least one R₁₀ is a bridged polycyclic C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. In some embodiments, at least one R₁₀ is a C₃-C₁₀ spirocycloalkyl. In some embodiments, at least one R₁₀ is a C₃-C₁₀ spirocycloalkyl optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ alkyl. In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl optionally substituted with C₂-C₆ alkenyl. In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl optionally substituted with C₂-C₆ alkynyl. In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ haloalkyl. In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ alkoxy. In some embodiments, at least one R₁₀ is C₃-C₁₀ cycloalkyl optionally substituted with C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, at least one R₁₀ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is a monocyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, at least one R₁₀ is a monocyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is a polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, at least one R₁₀ is a polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is 3-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. In some embodiments, at least one R₁₀ is 4-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. In some embodiments, at least one R₁₀ is 5-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. In some embodiments, at least one R₁₀ is 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. In some embodiments, at least one R₁₀ is 7-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. In some embodiments, at least one R₁₀ is 8-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. In some embodiments, at least one R₁₀ is 9-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy. In some embodiments, at least one R₁₀ is 10-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is 5- to 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, at least one R₁₀ is 5- to 6-membered heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is heterocycle comprising one, two, or three heteroatoms selected from N and O.

In some embodiments, at least one R₁₀ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl. In some embodiments, at least one R₁₀ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₂-C₆ alkenyl. In some embodiments, at least one R₁₀ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₂-C₆ alkynyl. In some embodiments, at least one R₁₀ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ haloalkyl. In some embodiments, at least one R₁₀ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkoxy.

In some embodiments, at least one R₁₀ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is aryl. In some embodiments, at least one R₁₀ is aryl optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is C₆ aryl (e.g., phenyl). In some embodiments, at least one R₁₀ is C₆ aryl (e.g., phenyl) optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is aryl optionally substituted with C₁-C₆ alkyl. In some embodiments, at least one R₁₀ is aryl optionally substituted with C₂-C₆ alkenyl. In some embodiments, at least one R₁₀ is aryl optionally substituted with C₂-C₆ alkynyl. In some embodiments, at least one R₁₀ is aryl optionally substituted with C₁-C₆ haloalkyl. In some embodiments, at least one R₁₀ is aryl optionally substituted with C₁-C₆ alkoxy. In some embodiments, at least one R₁₀ is aryl optionally substituted with C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, at least one R₁₀ is heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, at least one R₁₀ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is heteroaryl comprising 1-4 heteroatoms selected from O, N, and S optionally substituted with C₁-C₆ alkyl. In some embodiments, at least one R₁₀ is heteroaryl comprising 1-4 heteroatoms selected from O, N, and S optionally substituted with C₂-C₆ alkenyl. In some embodiments, at least one R₁₀ is heteroaryl comprising 1-4 heteroatoms selected from O, N, and S optionally substituted with C₂-C₆ alkynyl. In some embodiments, at least one R₁₀ is heteroaryl comprising 1-4 heteroatoms selected from O, N, and S optionally substituted with C₁-C₆ haloalkyl. In some embodiments, at least one R₁₀ is heteroaryl comprising 1-4 heteroatoms selected from O, N, and S optionally substituted with C₁-C₆ alkoxy. In some embodiments, at least one R₁₀ is heteroaryl comprising 1-4 heteroatoms selected from O, N, and S optionally substituted with C₁-C₆ haloalkoxy.

In some embodiments, at least one R₁₀ is

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a C₆₋₁₀ aryl or heteroaryl. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a C₆₋₁₀ aryl or heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl, wherein the aryl is optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a C₆ aryl (e.g., phenyl). In some embodiments, two R₁₀, together with the atoms to which they are attached, form a C₆ aryl (e.g., phenyl), wherein the aryl is optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl, wherein the aryl is substituted with one oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl, wherein the aryl is substituted with two substituents selected from oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl, wherein the aryl is substituted with three substituents selected from oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl, wherein the aryl is substituted with four substituents selected from oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, or —NO₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more oxo.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more ═NR₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more halogen. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more F.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl is optionally substituted with one or more C₁. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more Br. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more I.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl, wherein the aryl is optionally substituted with one or more —CN.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —NO₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more C₁-C₆ alkyl

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more C₂-C₆ alkenyl.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more C₂-C₆ alkynyl.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more C₁-C₆ haloalkyl.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more C₁-C₆ alkoxy.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —(CH₂)_(n)—OR₁₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —OR₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —(CH₂)_(n)—N(R₁₂)₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —N(R₁₂)₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —(CH₂)_(n)—C(O)R₁₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —C(O)R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —(CH₂)_(n)—C(O)OR₁₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —C(O)OR₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —(CH₂)_(n)—C(O)N(R₁₂)₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —C(O)N(R₁₂)₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —(CH₂)_(n)—SO₂R₁₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form aryl optionally substituted with one or more —SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, substituted with one oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, substituted with two substituents selected from oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, substituted with three substituents selected from oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, substituted with four substituents selected from oxo, ═NR₁₂, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more oxo, ═NR₁₂, halogen, —CN, or —NO₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more oxo.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more ═NR₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more halogen. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more F.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more C₁. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more Br. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more I.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —CN.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —NO₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more C₁-C₆ alkyl.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more C₂-C₆ alkenyl.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more C₂-C₆ alkynyl.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more C₁-C₆ haloalkyl.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more C₁-C₆ alkoxy.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —(CH₂)_(n)—OR₁₂, —(CH₂)_(n)—N(R₁₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₁₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)_(n)—SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —(CH₂)_(n)—OR₁₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —OR₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —(CH₂)_(n)—N(R₁₂)₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —N(R₁₂)₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —(CH₂)_(n)—C(O)R₁₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —C(O)R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —(CH₂)_(n)—C(O)OR₁₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —C(O)OR₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —(CH₂)_(n)—C(O)N(R₁₂)₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —C(O)N(R₁₂)₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —(CH₂)_(n)—SO₂R₁₂. In some embodiments, two R₁₀, together with the atoms to which they are attached, form a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S, optionally substituted with one or more —SO₂R₁₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form

wherein “

” signifies the point at which the two R₁₀ attach to the ring atoms of the heterocycle formed by R₁ and R₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form

wherein “

” signifies the point at which the two R₁₀ attach to the ring atoms of the heterocycle formed by R₁ and R₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form

wherein “

” signifies the point at which the two R₁₀ attach to the ring atoms of the heterocycle formed by R₁ and R₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form

wherein “

” signifies the point at which the two R₁₀ attach to the ring atoms of the heterocycle formed by R₁ and R₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form

wherein “

” signifies the point at which the two R₁₀ attach to the ring atoms of the heterocycle formed by R₁ and R₂.

In some embodiments, two R₁₀, together with the atoms to which they are attached, form,

wherein “

” signifies the point at which the two R₁₀ attach to the ring atoms of the heterocycle formed by R₁ and R₂.

In some embodiments, R₁₁ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₁₁ is H.

In some embodiments, R₁₁ is C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl.

In some embodiments, R₁₁ is C₁-C₆ alkyl.

In some embodiments, R₁₁ is methyl. In some embodiments, R₁₁ is ethyl. In some embodiments, R₁₁ is propyl. In some embodiments, R₁₁ is n-propyl. In some embodiments, R₁₁ is isopropyl. In some embodiments, R₁₁ is butyl. In some embodiments, R₁₁ is n-butyl. In some embodiments, R₁₁ is isobutyl. In some embodiments, R₁₁ is sec-butyl. In some embodiments, R₁₁ is tert-butyl. In some embodiments, R₁₁ is pentyl. In some embodiments, R₁₁ is hexyl.

In some embodiments, R₁₁ is C₂-C₆ alkenyl.

In some embodiments, R₁₁ is C₂-C₆ alkynyl.

In some embodiments, each R₁₂ and R₁₃ at each occurrence is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, each R₁₂ and R₁₃ at each occurrence is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, each R₁₂ and R₁₃ at each occurrence is independently H.

In some embodiments, R₁₂ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, R₁₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, R₁₂ is H.

In some embodiments, R₁₂ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₁₂ is C₁-C₆ alkyl.

In some embodiments, R₁₂ is methyl. In some embodiments, R₁₂ is ethyl. In some embodiments, R₁₂ is propyl. In some embodiments, R₁₂ is n-propyl. In some embodiments, R₁₂ is isopropyl. In some embodiments, R₁₂ is butyl. In some embodiments, R₁₂ is n-butyl. In some embodiments, R₁₂ is isobutyl. In some embodiments, R₁₂ is sec-butyl. In some embodiments, R₁₂ is tert-butyl. In some embodiments, R₁₂ is pentyl. In some embodiments, R₁₂ is hexyl.

In some embodiments, R₁₂ is C₂-C₆ alkenyl. In some embodiments, R₁₂ is C₂-C₆ alkynyl.

In some embodiments, R₁₂ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₁₂ is C₁-C₆ haloalkyl. In some embodiments, R₁₂ is halomethyl. In some embodiments, R₁₂ is haloethyl. In some embodiments, R₁₂ is halopropyl. In some embodiments, R₁₂ is halobutyl. In some embodiments, R₁₂ is halopentyl. In some embodiments, R₁₂ is halohexyl.

In some embodiments, R₁₂ is C₁-C₆ alkoxy. In some embodiments, R₁₂ is C₁-C₆ alkoxy. In some embodiments, R₁₂ is methoxy. In some embodiments, R₁₂ is ethoxy. In some embodiments, R₁₂ is propoxy. In some embodiments, R₁₂ is butoxy. In some embodiments, R₁₂ is pentoxy. In some embodiments, R₁₂ is hexoxy.

In some embodiments, R₁₂ is —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, or —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄.

In some embodiments, R₁₂ is —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —O—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —(CH₂)_(q)—O—C(O)—R₁₄.

In some embodiments, R₁₂ is —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —NH—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —(CH₂)_(q)—NH—C(O)—R₁₄.

In some embodiments, R₁₂ is —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₂ is —O—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —(CH₂)_(q)—O—C(O)—R₁₄.

In some embodiments, R₁₂ is —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₂ is —NH—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —(CH₂)_(q)—NH—R₁₄.

In some embodiments, R₁₂ is —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —O—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —(CH₂)_(q)—O—R₁₄.

In some embodiments, R₁₂ is —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —NH—(CH₂)_(r)—R₁₄. In some embodiments, R₁₂ is —(CH₂)_(q)—NH—R₁₄.

In some embodiments, R₁₂ is —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₂ is —O—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₂ is —(CH₂)_(q)—O—OR₁₄.

In some embodiments, R₁₂ is —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₂ is —NH—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₂ is —(CH₂)_(q)—NH—OR₁₄.

In some embodiments, R₁₂ is C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, R₁₂ is C₃-C₁₀ cycloalkyl or a heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₂ is C₃-C₁₀ cycloalkyl.

In some embodiments, R₁₂ is C₅-C₆ cycloalkyl.

In some embodiments, R₁₂ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, R₁₂ is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₁₂ is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₁₂ is a C₃-C₁₀ spirocycloalkyl.

In some embodiments, R₁₂ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₂ is a heterocycle comprising one heteroatom selected from O, N, and S. In some embodiments, R₁₂ is a heterocycle comprising one heteroatom which is N. In some embodiments, R₁₂ is a heterocycle comprising two heteroatoms selected from O, N, and S.

In some embodiments, R₁₂ is a heterocycle comprising three heteroatoms selected from O, N, and S. In some embodiments, R₁₂ is a heterocycle comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₁₂ is a 5- to 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₂ is a monocyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₁₂ is a polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₂ is a fused polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₁₂ is a bridged polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₁₂ is a spiroheterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₂ is aryl. In some embodiments, R₁₂ is C₆ aryl (e.g., phenyl).

In some embodiments, R₁₂ is a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S

In some embodiments, R₁₂ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₂ is heteroaryl comprising one heteroatom selected from O, N, and S. In some embodiments, R₁₂ is heteroaryl comprising two heteroatoms selected from O, N, and S. In some embodiments, R₁₂ is heteroaryl comprising three heteroatoms selected from O, N, and S. In some embodiments, R₁₂ is heteroaryl comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, R₁₃ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, R₁₃ is H.

In some embodiments, R₁₃ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy.

In some embodiments, R₁₃ is C₁-C₆ alkyl.

In some embodiments, R₁₃ is methyl. In some embodiments, R₁₃ is ethyl. In some embodiments, R₁₃ is propyl. In some embodiments, R₁₃ is n-propyl. In some embodiments, R₁₃ is isopropyl. In some embodiments, R₁₃ is butyl. In some embodiments, R₁₃ is n-butyl. In some embodiments, R₁₃ is isobutyl. In some embodiments, R₁₃ is sec-butyl. In some embodiments, R₁₃ is tert-butyl. In some embodiments, R₁₃ is pentyl. In some embodiments, R₁₃ is hexyl.

In some embodiments, R₁₃ is C₂-C₆ alkenyl. In some embodiments, R₁₃ is C₂-C₆ alkynyl.

In some embodiments, R₁₃ is C₁-C₆ haloalkyl or C₁-C₆ alkoxy.

In some embodiments, R₁₃ is C₁-C₆ haloalkyl. In some embodiments, R₁₃ is halomethyl. In some embodiments, R₁₃ is haloethyl. In some embodiments, R₁₃ is halopropyl. In some embodiments, R₁₃ is halobutyl. In some embodiments, R₁₃ is halopentyl. In some embodiments, R₁₃ is halohexyl.

In some embodiments, R₁₃ is C₁-C₆ alkoxy. In some embodiments, R₁₃ is C₁-C₆ alkoxy. In some embodiments, R₁₃ is methoxy. In some embodiments, R₁₃ is ethoxy. In some embodiments, R₁₃ is propoxy. In some embodiments, R₁₃ is butoxy. In some embodiments, R₁₃ is pentoxy. In some embodiments, R₁₃ is hexoxy.

In some embodiments, R₁₃ is —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, or —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄.

In some embodiments, R₁₃ is —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —O—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —(CH₂)_(q)—O—C(O)—R₁₄.

In some embodiments, R₁₃ is —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —NH—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —(CH₂)_(q)—NH—C(O)—R₁₄.

In some embodiments, R₁₃ is —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₃ is —O—C(O)—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —(CH₂)_(q)—O—C(O)—R₁₄.

In some embodiments, R₁₃ is —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₃ is —NH—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —(CH₂)_(q)—NH—R₁₄.

In some embodiments, R₁₃ is —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —O—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —(CH₂)_(q)—O—R₁₄.

In some embodiments, R₁₃ is —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —NH—(CH₂)_(r)—R₁₄. In some embodiments, R₁₃ is —(CH₂)_(q)—NH—R₁₄.

In some embodiments, R₁₃ is —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₃ is —O—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₃ is —(CH₂)_(q)—O—OR₁₄.

In some embodiments, R₁₃ is —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₃ is —NH—(CH₂)_(r)—OR₁₄. In some embodiments, R₁₃ is —(CH₂)_(q)—NH—OR₁₄.

In some embodiments, R₁₃ is C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, R₁₃ is C₃-C₁₀ cycloalkyl or a heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is C₃-C₁₀ cycloalkyl.

In some embodiments, R₁₃ is C₅-C₆ cycloalkyl.

In some embodiments, R₁₃ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, R₁₃ is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₁₃ is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, R₁₃ is a C₃-C₁₀ spirocycloalkyl.

In some embodiments, R₁₃ is heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is a heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is a heterocycle comprising one heteroatom selected from O, N, and S. In some embodiments, R₁₃ is a heterocycle comprising one heteroatom which is N. In some embodiments, R₁₃ is a heterocycle comprising two heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is a heterocycle comprising three heteroatoms selected from O, N, and S. In some embodiments, R₁₃ is a heterocycle comprising four heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is a 5- to 6-membered saturated or partially unsaturated heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is a monocyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₁₃ is a polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is a fused polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₁₃ is a bridged polycyclic heterocycle comprising 1-4 heteroatoms selected from O, N, and S. In some embodiments, R₁₃ is a spiroheterocycle comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is aryl. In some embodiments, R₁₃ is C₆ aryl (e.g., phenyl).

In some embodiments, R₁₃ is a heteroaryl comprising 1-4 heteroatoms selected from O, N, and S

In some embodiments, R₁₃ is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.

In some embodiments, R₁₃ is heteroaryl comprising one heteroatom selected from O, N, and S. In some embodiments, R₁₃ is heteroaryl comprising two heteroatoms selected from O, N, and S. In some embodiments, R₁₃ is heteroaryl comprising three heteroatoms selected from O, N, and S. In some embodiments, R₁₃ is heteroaryl comprising four heteroatoms selected from O, N, and S.

In some embodiments, Ring A is C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from N, O, and S, aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, Ring A is C₃-C₁₀ cycloalkyl or heterocycle comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, Ring A is C₃-C₁₀ cycloalkyl.

In some embodiments, Ring A is C₅-C₆ cycloalkyl. In some embodiments, Ring A is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl.

In some embodiments, Ring A is a fused polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, Ring A is a bridged polycyclic C₃-C₁₀ cycloalkyl. In some embodiments, Ring A is a C₃-C₁₀ spirocycloalkyl.

In some embodiments, Ring A is heterocycle comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, Ring A is a monocyclic heterocycle comprising 1-4 heteroatoms selected from N, O, and S. In some embodiments, Ring A is a polycyclic heterocycle comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, Ring A is 5- to 6-membered heterocycle comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, Ring A is heterocycle comprising one heteroatom selected from N, O, and S. In some embodiments, Ring A is heterocycle comprising two heteroatoms selected from N, O, and S. In some embodiments, Ring A is heterocycle comprising three heteroatoms selected from N, O, and S. In some embodiments, Ring A is heterocycle comprising four heteroatoms selected from N, O, and S.

In some embodiments, Ring A is aryl. In some embodiments, Ring A is C₆ aryl (e.g., phenyl). In some embodiments, Ring A is phenyl.

In some embodiments, Ring A is a heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, Ring A is 5- to 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O, and S.

In some embodiments, Ring A is heteroaryl comprising one heteroatom selected from N, O, and S. In some embodiments, Ring A is heteroaryl comprising two heteroatoms selected from N, O, and S. In some embodiments, Ring A is heteroaryl comprising three heteroatoms selected from N, O, and S. In some embodiments, Ring A is heteroaryl comprising four heteroatoms selected from N, O, and S.

In some embodiments, Ring A is

In some embodiments, Ring A is

In some embodiments, Ring A is

In some embodiments, Ring A is or

In some embodiments, Ring A is

In some embodiments, Ring A is or

In some embodiments, Ring A is

In some embodiments, Ring A is or

In some embodiments R₁₄ is

In some embodiments R₁₄ is

In some embodiments R₁₄ is

In some embodiments, each n, m, q, r, or s is independently at each occurrence 0, 1, 2, 3, 4, 5, or 6.

In some embodiments, n is 0, 1, 2, 3, 4, 5, or 6. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6.

In some embodiments, m is 0, 1, 2, 3, 4, 5, or 6. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6.

In some embodiments, q is 0, 1, 2, 3, 4, 5, or 6. In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4. In some embodiments, q is 5. In some embodiments, q is 6.

In some embodiments, r is 0, 1, 2, 3, 4, 5, or 6. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, r is 5. In some embodiments, r is 6.

In some embodiments, s is 0, 1, 2, 3, 4, 5, or 6. In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3. In some embodiments, s is 4. In some embodiments, s is 5. In some embodiments, s is 6.

In some embodiments, when R₁ and R₂ together with the nitrogen atom to which they are attached form a heterocycle, wherein if the heterocycle is morpholine and R₅ is —CH₃ then either (a) the morpholine is substituted or (b) Ring A is not phenyl.

In some embodiments, when R₁ and R₂ together with the nitrogen atom to which they are attached form a heterocycle, wherein if the heterocycle is morpholine and R₅ is —CH₃, then the morpholine is substituted.

In some embodiments, when R₁ and R₂ together with the nitrogen atom to which they are attached form a heterocycle, wherein if the heterocycle is morpholine and R % is —CH₃, then Ring A is not phenyl.

In some embodiments, the compound is of Formula (II′):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Y, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, Ring A, and s are as described herein.

In some embodiments, the compound is of Formula (II′) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIa):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein W, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, Ring A, and s are as described herein.

In some embodiments, the compound is of Formula (IIa) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIa′):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, Ring A, and s are as described herein.

In some embodiments, the compound is of Formula (IIa′) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIb):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₃, R₄, R₅, R₆, R₇, R₈, R₉, Ring A, and s are as described herein and t is 1, 2, 3, or 4.

In some embodiments, the compound is of Formula (IIb) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIc):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein W, R₁, R₂, R₃, R₄, R₅, R₇, R₈, and R₉ are as described herein.

In some embodiments, the compound is of Formula (IIc) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIc′):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₃, R₄, R₅, R₇, R₈, and R₉ are as described herein.

In some embodiments, the compound is of Formula (IIc′) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IId):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein W, R₁, R₂, R₃, R₄, R₅, R₆, R₉, Ring A, and s are as described herein.

In some embodiments, the compound is of Formula (IId) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IId′):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₃, R₄, R₅, R₆, R₉, Ring A, and s are as described herein.

In some embodiments, the compound is of Formula (IId′) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IId-1):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein W, R₁, R₂, R₃, R₄, R₅, R₆, R₉, Ring A, and s are as described herein.

In some embodiments, the compound is of Formula (IId-1) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IId′-1):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₃, R₄, R₅, R₆, R₉, Ring A, and s are as described herein.

In some embodiments, the compound is of Formula (IId′-1) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIe):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₃, R₄, R₅, R₆, R₉, Ring A, and s are as described herein and t is 1, 2, 3, or 4.

In some embodiments, the compound is of Formula (IIe) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIe-1):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₃, R₄, R₅, R₆, R₉, Ring A, and s are as described herein and t is 1, 2, 3, or 4.

In some embodiments, the compound is of Formula (IIe-1) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIf):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein W, R₁, R₂, R₃, R₄, R₅, and R₉ are as described herein.

In some embodiments, the compound is of Formula (IIf) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIf′):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₃, R₄, R₅, and R₉ are as described herein.

In some embodiments, the compound is of Formula (IIf) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIf-1):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein W, R₁, R₂, R₃, R₄, R₅, and R₉ are as described herein.

In some embodiments, the compound is of Formula (IIf-1) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIf′-1):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₁, R₂, R₃, R₄, R₅, and R₉ are as described herein.

In some embodiments, the compound is of Formula (IIf′-1) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIg):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₃, R₄, R₅, R₇, R₈, R₉, and R₁₀ are as described herein and t is 1, 2, 3, or 4.

In some embodiments, the compound is of Formula (IIg) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIh):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₃, R₄, R₅, R₉, and R₁₀ are as described herein and t is 1, 2, 3, or 4.

In some embodiments, the compound is of Formula (IIh) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIh-1):

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₃, R₄, R₅, R₉, and R₁₀ are as described herein and t is 1, 2, 3, or 4.

In some embodiments, the compound is of Formula (IIh-1) or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIa), (IIc), (IId), or (IIf), or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIb), (IIe), (IIg), or (IIh), or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is of Formula (IIc), (IIf), (IIg), or (IIh), or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

In some embodiments, the compound is selected from the compounds described in Table 1 and prodrugs and pharmaceutically acceptable salts thereof.

In some embodiments, the compound is selected from the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

In some embodiments, the compound is selected from the prodrugs of the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

In some embodiments, the compound is selected from the compounds described in Table 1.

TABLE 1 Compound Name (2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phenyl)boronic acid 5-borono-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-(4,4-dimethylpiperidin-1-yl)-6-methyl-8-(1-((1-methyl-1H-pyrazol-5-yl)amino)ethyl)-4H- chromen-4-one 1-(8-(1-((2-carboxyphenyl)amino)ethyl)-6-methyl-4-oxo-4H-chromen-2-yl)-3-methylazetidine- 3-carboxylic acid 2-((1-(6-methyl-4-oxo-2-(3-oxo-2,7-diazaspiro[4.5]decan-7-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-5- (trifluoromethyl)benzoic acid 2-((1-(2-(3-carbamoyl-3-methylazetidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-((S)-3-methoxypiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(1-oxo-2,8-diazaspiro[4.5]decan-8-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(4-isobutyl-4-methylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(4-cyano-4-methylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-2-(2-(4-(methylsulfonyl)phenyl)morpholino)-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(9-acetyl-3,9-diazaspiro[5.5]undecan-3-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(4-isobutyrylpiperazin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid (S)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-3,6-dimethyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid (R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-3,6-dimethyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(3-chloroazetidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(6-azaspiro[2.5]octan-6-yl)-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(3,3-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(4-ethyl-4-methylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(5-oxo-4,5-dihydro-3H-spiro[benzo[f][1,4]oxazepine-2,4′-piperidin]- 1′-yl)-4H-chromen-8-yl)ethyl)amino)benzoic acid 6-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzo[d][1,3]dioxole-5-carboxylic acid N-((2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phenyl)sulfonyl)acetamide 2-((1-(2-(isoindolin-2-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-5- ethylbenzoic acid 2-((1-(2-(3-(dimethylamino)azetidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(3-fluoroazetidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(3,3-dimethylazetidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(4-isopropyl-4-methylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(2-oxa-8-azaspiro[4.5]decan-8-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(4-(methoxymethyl)-4-methylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(4-(trifluoromethyl)piperidin-1-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(6,6-dimethyl-3-azabicyclo[3.1.0]hexan-3-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 6-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-3-fluoro- 2-methylbenzoic acid 2-((1-(6-methyl-4-oxo-2-(9-oxa-2-azaspiro[5.5]undecan-2-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzenesulfonic acid (S)-2-((1-(2-(isoindolin-2-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)(methyl)amino)benzoic acid 5-cyano-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 5-bromo-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(isobutylamino)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(dimethylamino)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-2-(3-methylpiperidin-1-yl)-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(3-ethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-(4,4-dimethylpiperidin-1-yl)-8-(1-((5-fluoro-2-nitrophenyl)amino)ethyl)-6-methyl-4H- chromen-4-one 4-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-1,3- dihydro-2H-benzo[d]imidazol-2-one 2-(4,4-dimethylpiperidin-1-yl)-6-methyl-8-(1-((2-(2,2,2-trifluoro-1- hydroxyethyl)phenyl)amino)ethyl)-4H-chromen-4-one 2-(4,4-dimethylpiperidin-1-yl)-6-methyl-8-(1-((2-(2,2,2-trifluoroacetyl)phenyl)amino)ethyl)- 4H-chromen-4-one 2-((1-(6-methyl-4-oxo-2-(2-azaspiro[3.5]nonan-2-yl)-4H-chromen-8-yl)ethyl)amino)benzoic acid (S)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(3,9-diazaspiro[5.5]undecan-3-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(piperazin-1-yl)-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-2-(4-methylpiperazin-1-yl)-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(1-oxa-9-azaspiro[5.5]undecan-9-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(3-oxa-9-azaspiro[5.5]undecan-9-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(ethylamino)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(pyrrolidin-1-yl)-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-4-fluoro- 5-methoxybenzoic acid 4-chloro-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 3-chloro-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-4,5- dimethylbenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-4,5- difluorobenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-4- fluorobenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-5- methylbenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-5- fluorobenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-5- methoxybenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-4,5- dimethoxybenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-3- methylbenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-4-fluoro- 5-methylbenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-N- methoxybenzamide 2-(((2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)methyl)amino)benzoic acid 8-(1-((2-(1H-tetrazol-5-yl)phenyl)amino)ethyl)-2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4H- chromen-4-one 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzenesulfonamide 8-(1-((2,3-dihydro-1H-inden-4-yl)amino)ethyl)-2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4H- chromen-4-one 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-6- fluorobenzoic acid 2-chloro-6-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(8-azaspiro[4.5]decan-8-yl)-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(3-carbamoylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-2-(4-methylpiperidin-1-yl)-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-2-(4-(methylcarbamoyl)piperidin-1-yl)-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(piperidin-1-yl)-4H-chromen-8-yl)ethyl)amino)benzamide 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-6- methylbenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-3- methoxybenzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)-4- methylbenzoic acid 5-chloro-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 7-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)isoindolin-1-one 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzonitrile methyl 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoate 2-((1-(2-(4-methoxypiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(4-cyanopiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(2-(4,4-dimethylpiperidin-1-yl)-3,6-dimethyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid 4-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)isoindoline-1,3-dione 2-((1-(2-(azetidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-(2-methoxyethoxy)ethyl (R)-2-((1-(6-methyl-4-oxo-2-(piperidin-1-yl)-4H-chromen-8- yl)ethyl)amino)benzoate 2-((1-(2-(4-acetylpiperazin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-4-oxo-2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid methyl (R)-2-((1-(6-methyl-4-oxo-2-(piperidin-1-yl)-4H-chromen-8-yl)ethyl)amino)benzoate 2-((1-(6-methyl-2-(3-methyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)-4-oxo-4H-chromen- 8-yl)ethyl)amino)benzoic acid 2-((1-(6-methyl-2-(2-methyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid (R)-N-(2-(2-methoxyethoxy)ethyl)-2-((1-(6-methyl-4-oxo-2-(piperidin-1-yl)-4H-chromen-8- yl)ethyl)amino)benzamide 2-((1-(2-(4-chloropiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid (R)-2-((1-(2-(isoindolin-2-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethyl)amino)benzoic acid (R)-2-((1-(2-(4,4-difluoropiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid (R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid (R)-2-((1-(6-methyl-4-oxo-2-thiomorpholino-4H-chromen-8-yl)ethyl)amino)benzoic acid 2-(((R)-1-(2-((2S,6R)-2,6-dimethylmorpholino)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid (R)-2-((1-(6-methyl-4-oxo-2-(piperidin-1-yl)-4H-chromen-8-yl)ethyl)amino)benzoic acid (R)-2-(4,4-dimethylpiperidin-1-yl)-6-methyl-8-(1-(phenylamino)ethyl)-4H-chromen-4-one 2-((2S,6R)-2,6-dimethylmorpholino)-6-methyl-8-((R)-1-(phenylamino)ethyl)-4H-chromen-4- one (R)-6-methyl-8-(1-(phenylamino)ethyl)-2-(piperidin-1-yl)-4H-chromen-4-one (R)-6-methyl-8-(1-(phenylamino)ethyl)-2-thiomorpholino-4H-chromen-4-one

In some embodiments, the compound is selected from the compounds described in Table 2.

TABLE 2 Compound Structure Compound Name

(R)-6-methyl-8-(1-(phenylamino)ethyl)-2- (piperidin-1-yl)-4H-thiochromen-4-one

(R)-6-methyl-8-(1-(phenylamino)ethyl)-2- (piperidin-1-yl)quinolin-4(1H)-one

(R)-3,6-dimethyl-2-morpholino-8-(1- (phenylamino)ethyl)-4H-chromen-4-one

(R)-2-morpholino-8-(1- (phenylamino)ethyl)-6-(pyrrolidin-1-yl)- 4H-chromen-4-one

(R)-5-isopropyl-2-morpholino-8-(1- (phenylamino)ethyl)-4H-chromen-4-one

(R)-6-methyl-2-morpholino-8-(1- (pyridazin-4-ylamino)ethyl)-4H-chromen- 4-one

(R)-6-(dimethylamino)-2-morpholino-8- (1-(phenylamino)ethyl)-4H-chromen-4- one

(R)-6-hydroxy-2-morpholino-8-(1- (phenylamino)ethyl)-4H-chromen-4-one

(R)-5-cyclopropoxy-2-morpholino-8-(1- (phenylamino)ethyl)-4H-chromen-4-one

(R)-2-((1-(2-(1,1-dioxidothiomorpholino)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

2-(((R)-1-(6-methyl-4-oxo-2-((S)-8-oxo- 2,9-diazaspiro[5.5]undecan-2-yl)-4H- chromen-8-yl)ethyl)amino)benzoic acid

(R)-2-((1-(6-methyl-4-oxo-2-(8- azaspiro[4.5]decan-8-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-8-(1-((2- ((difluoromethyl)sulfonyl)phenyl)amino)- ethyl)-2-(4,4-dimethylpiperidin-1-yl)-6- methyl-4H-chromen-4-one

2-(4,4-dimethylpiperidin-1-yl)-6-methyl- 8-((1R)-1-((2-(S- methylsulfonimidoyl)phenyl)amino)ethyl)- 4H-chromen-4-one

(R)-2-chloro-6-((1-(2-(4,4- dimethylpiperidin-1-yl)-6-methyl-4-oxo- 4H-chromen-8-yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-6-fluorobenzoic acid

2-(((1R)-1-(2-(3-cyanopiperidin-1-yl)-6- methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(3-cyanoazetidin-1-yl)-6- methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(3-cyano-3-methylazetidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(diethylamino)-6-methyl-4- oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-((2-amino-2- oxoethyl)amino)-6-methyl-4-oxo-4H- chromen-8-yl)ethyl)amino)benzoic acid

(R)-3-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)thiophene-2-carboxylic acid

(R)-4-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1-methyl-1H-pyrazole-5- carboxylic acid

(R)-4-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1-methyl-1H-pyrazole-3- carboxylic acid

(R)-5-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1-methyl-1H-pyrazole-4- carboxylic acid

(R)-3-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1-methyl-1H-pyrazole-4- carboxylic acid

(R)-5-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)isoxazole-4-carboxylic acid

(R)-4-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)isoxazole-5-carboxylic acid

(R)-4-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1-methyl-1H-imidazole- 5-carboxylic acid

(R)-4-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1H-imidazole-5- carboxylic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-6,7-dihydro-5H- pyrrolo[1,2-a]imidazole-3-carboxylic acid

(S)-2-((cyano(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)methyl)amino)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)propyl)amino)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-5- (methylsulfonyl)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-5-ethynylbenzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-5- (hydroxymethyl)benzoic acid

(R)-2-(2-((1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phenyl)acetic acid

(R)-6-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-2,3-difluorobenzoic acid

(R)-3-chloro-6-((1-(2-(4,4- dimethylpiperidin-1-yl)-6-methyl-4-oxo- 4H-chromen-8-yl)ethyl)amino)-2- fluorobenzoic acid

(R)-3-bromo-6-((1-(2-(4,4- dimethylpiperidin-1-yl)-6-methyl-4-oxo- 4H-chromen-8-yl)ethyl)amino)-2- fluorobenzoic acid

(R)-6-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1H-indazole-7-carboxylic acid

(R)-2-(4,4-dimethylpiperidin-1-yl)-8-(1- ((2-(3-hydroxy-4- (trifluoromethyl)isoxazol-5- yl)phenyl)amino)ethyl)-6-methyl-4H- chromen-4-one

(R)-2-(4,4-dimethylpiperidin-1-yl)-8-(1- ((2-(3-hydroxy-4-methylisoxazol-5- yl)phenyl)amino)ethyl)-6-methyl-4H- chromen-4-one

(R)-2-(2-((1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phenyl)-1,2,4- oxadiazolidine-3,5-dione

(R)-5-(2-(((R)-1-(2-(4,4- dimethylpiperidin-1-yl)-6-methyl-4-oxo- 4H-chromen-8- yl)ethyl)amino)phenyl)thiazolidine-2,4- dione

(S)-5-(2-(((R)-1-(2-(4,4- dimethylpiperidin-1-yl)-6-methyl-4-oxo- 4H-chromen-8- yl)ethyl)amino)phenyl)thiazolidine-2,4- dione

(R)-2-(4,4-dimethylpiperidin-1-yl)-6- methyl-8-(1-((2- (trifluoromethyl)phenyl)amino)ethyl)-4H- chromen-4-one

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-N- (methylsulfonyl)benzamide

(R)-2-(4,4-dimethylpiperidin-1-yl)-8-(1- ((2-(3-hydroxyisoxazol-5- yl)phenyl)amino)ethyl)-6-methyl-4H- chromen-4-one

1-(2-(((R)-1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phenyl)-4,5-dihydro-3H- 1l6,2,5-thiadiazol-3-one 1-oxide

(S)-4-(((R)-1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1-imino-2-methyl-1,2- dihydro-3H-1l4-benzo[d]isothiazol-3-one 1-oxide

(R)-4-(((R)-1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1-imino-2-methyl-1,2- dihydro-3H-1l4-benzo[d]isothiazol-3-one 1-oxide

(S)-7-(((R)-1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1-imino-2-methyl-1,2- dihydro-3H-1l4-benzo[d]isothiazol-3-one 1-oxide

(R)-7-(((R)-1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1-imino-2-methyl-1,2- dihydro-3H-1l4-benzo[d]isothiazol-3-one 1-oxide

(S)-1-(((R)-1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-3H-1l4- benzo[d]isothiazol-3-one 1-oxide

(R)-1-(((R)-1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-3H-1l4- benzo[d]isothiazol-3-one 1-oxide

(R)-2-(4,4-dimethylpiperidin-1-yl)-8-(1- ((1,1-dioxidobenzo[d]isothiazol-3- yl)amino)ethyl)-6-methyl-4H-chromen-4- one

(R)-(2-((1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phenyl)phosphonic acid

(2-(((R)-1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phenyl)(methyl)phosphinic acid

(R)-2-(1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethoxy)benzoic acid

(R)-3-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)furan-2-carboxylic acid

(R)-3-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phthalic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)isophthalic acid

(R)-3-(2-((1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phenyl)-1,2,4-oxadiazol- 5(4H)-one

(R)-5-(2-((1-(2-(4,4-dimethylpiperidin-1- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)phenyl)-1,2,4-oxadiazol- 3(2H)-one

(R)-4-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-7-fluoroisoindoline-1,3- dione

(R)-4-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)pyrimidine-5-carboxylic acid

(R)-4-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)pyridazine-3-carboxylic acid

(R)-5-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)pyrimidine-4-carboxylic acid

(R)-5-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)pyridazine-4-carboxylic acid

(R)-3-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)pyridazine-4-carboxylic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)nicotinic acid

(R)-2-((1-(2-(5,7-dihydro-6H-pyrrolo[3,4- b]pyridin-6-yl)-6-methyl-4-oxo-4H- chromen-8-yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(1,3-dihydro-2H-pyrrolo[3,4- c]pyridin-2-yl)-6-methyl-4-oxo-4H- chromen-8-yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidin-6-yl)-6-methyl-4-oxo-4H- chromen-8-yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(5,7-dihydro-6H-pyrrolo[3,4- b]pyrazin-6-yl)-6-methyl-4-oxo-4H- chromen-8-yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(6,8-dihydro-7H- [1,3]dioxolo[4,5-e]isoindol-7-yl)-6- methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(6-methyl-4-oxo-2-(4- (trifluoromethyl)isoindolin-2-yl)-4H- chromen-8-yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(5-cyanoisoindolin-2-yl)-6- methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(4-fluoroisoindolin-2-yl)-6- methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(5-fluoroisoindolin-2-yl)-6- methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(2,4-dioxo-1,2,3,4,5,7- hexahydro-6H-pyrrolo[3,4-d]pyrimidin-6- yl)-6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-(4,4-dimethylpiperidin-1-yl)-6- methyl-8-(1-(pyridazin-4-ylamino)ethyl)- 4H-chromen-4-one

(R)-2-((1-(6-methyl-4-oxo-2-(2- oxomorpholino)-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 4-oxo-6-(pyrrolidin-1-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 5-isopropyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 7-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(6-(dimethylamino)-2-(4,4- dimethylpiperidin-1-yl)-4-oxo-4H- chromen-8-yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-hydroxy-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(5-cyclopropoxy-2-(4,4- dimethylpiperidin-1-yl)-4-oxo-4H- chromen-8-yl)ethyl)amino)benzoic acid

(R)-4-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1H-indene-1,3-(2H)-dione

(R)-5-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-1H-benzo[d]imidazole-6- carboxylic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)-4-fluoro-5-nitrobenzoic acid

(R)-1-acetyl-3-((1-(2-(4,4- dimethylpiperidin-1-yl)-6-methyl-4-oxo- 4H-chromen-8-yl)ethyl)amino)-1H- pyrazole-4-carboxylic acid

(R)-1-acrylol-3-((1-(2-(4,4- dimethylpiperidin-1-yl)-6-methyl-4-oxo- 4H-chromen-8-yl)ethyl)amino)-1H- pyrazole-4-carboxylic acid

2-((2-(2-(4,4-dimethylpiperidin-1-yl)-6- methyl-4-oxo-4H-chromen-8-yl)propan-2- yl)amino)benzoic acid

2-(((R)-1-(2-((R)-2-(4- (difluoromethoxy)phenyl)morpholino)-6- methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

2-(((R)-1-(6-methyl-4-oxo-2-((R)-2-(4- (trifluoromethyl)phenyl)morpholino)-4H- chromen-8-yl)ethyl)amino)benzoic acid

2-(((R)-1-(6-methyl-2-((R)-2-(1-methyl- 1H-pyrazol-5-yl)morpholino)-4-oxo-4H- chromen-8-yl)ethyl)amino)benzoic acide

(R)-2-((1-(2-(2′-(dimethylcarbamoyl)- 4′H,7′H-spiro[piperidine-4,6′- pyrazolo[5,1-c][1,4]oxazin]-1-yl)-6- methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiepridin-1-yl)- 4-oxo-6-(trifluoromethyl)-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-((1-(2-(4,4-dimethylpiperidin-1-yl)- 6-fluoro-4-oxo-4H-chromen-8- yl)ethyl)amino)benzoic acid

(R)-2-(methyl(1-(6-methyl-4-oxo-2- (piperidin-1-yl)-4H-chromen-8- yl)ethyl)amino)benzoic acid

In some embodiments, the compound is selected from the compounds described in Table 3.

TABLE 3 Compound Structure Compound Name

2-chloro-5-[[(1R)-1-(2-isoindolin-2-yl-6-methyl-4- oxo-chromen-8-yl)ethyl]amino]thiazole-4- carboxylic acid

2-[[(1R)-1-[2-(6-azaspiro[2.5]octan-6-yl)-6-fluoro- 4-oxo-chromen-8-yl]ethyl]amino]benzoic acid

3-[[(1R)-1-[2-(6-azaspiro[2.5]octan-6-yl)-6-fluoro- 4-oxo-chromen-8-yl]ethyl]amino]-6-chloro- pyridine-2-carboxlic acid

6-chloro-3-[[(1R)-1-[6-fluoro-2-(5-fluoroisoindolin- 2-yl)-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2- carboxylic acid

3-hydroxy-5-[[(1R)-1-(2-isoindolin-2-yl-6-methyl- 4-oxo-chromen-8-yl)ethyl]amino]quinazolin-4-one

2-[[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo- chromen-8-yl]-2,2,2-trifluoro-ethyl]amino]benzoic acid

2-[[(1R)-1-[2-isoindolin-2-yl-6-methyl-4-oxo-3- (trifluoromethyl)chromen-8-yl]ethyl]amino]benzoic acid

2-[[(1R)-1-[2-(6-azaspiro[2.5]octan-6-yl)-4-oxo-6- (trifluoromethyl)chromen-8-yl]ethyl]amino]benzoic acid

3-[[(1R)-1-[2-(6-azaspiro[2.5]octan-6-yl)-4-oxo-6- (trifluoromethyl)chromen-8-yl]ethyl]amino]-6- chloro-pyridine-2-carboxylic acid

6-chloro-3-[[(1R)-1-[2-(5-fluoroisoindolin-2-yl)-4- oxo-6-(trifluoromethyl)chromen-8- yl]ethyl]amino]pyridine-2-carboxylic acid

6-chloro-3-[[(1R)-1-[2-isoindolin-2-yl-4-oxo-6- (trifluoromethyl)chromen-8- yl]ethyl]amino]pyridine-2-carboxylic acid

2-[[(1R)-1-[2-(11-azatricyclo[6.2.1.02,7]undeca- 2(7),3,5-trien-11-yl)-4-oxo-6- (trifluoromethyl)chromen-8-yl]ethyl]amino]benzoic acid

2-[[(1R)-1-(3-cyano-2-isoindolin-2-yl-6-methyl-4- oxo-chromen-8-yl)ethyl]amino]benzoic acid

2-[[(1R)-1-[2-isoindolin-2-yl-6-methyl-3-(1,3,4- oxadiazol-2-yl)-4-oxo-chromen-8- yl]ethyl]amino]benzoic acid

5-[[(1R)-1-(2-isoindolin-2-yl-6-methyl-4-oxo- chromen-8-yl)ethyl]amino]-2- (trifluoromethyl)pyrimidine-4-carboxylic acid

5-[[(1R)-1-(2-isoindolin-2-yl-6-methyl-4-oxo- chromen-8-yl)ethyl]amino]-2- (trifluoromethyl)thiazole-4-carboxylic acid

In some embodiments, the compound is a pharmaceutically acceptable salt of any one of the compounds described in Table 1, Table 2, or Table 3.

In some embodiments, the compound is a lithium salt, sodium salt, potassium salt, calcium salt, or magnesium salt of any one of the compounds described in Table 1, Table 2, or Table 3.

In some embodiments, the compound is a sodium salt or potassium salt of any one of the compounds described in Table 1, Table 2, or Table 3.

In some embodiments, the compound is a sodium salt of any one of the compounds described in Table 1, Table 2, or Table 3.

In some embodiments, the compound is a potassium salt of any one of the compounds described in Table 1, Table 2, or Table 3.

In some aspects, the present disclosure provides a compound being an isotopic derivative (e.g., isotopically labeled compound) of any one of the compounds of the Formulae disclosed herein.

In some embodiments, the compound is an isotopic derivative of any one of the compounds described in Table 1, Table 2, or Table 3 and prodrugs and pharmaceutically acceptable salts thereof.

In some embodiments, the compound is an isotopic derivative of any one of the compounds described in Table 1, Table 2, or Table 3 and pharmaceutically acceptable salts thereof.

In some embodiments, the compound is an isotopic derivative of any one of prodrugs of the compounds described in Table 1, Table 2, or Table 3 and pharmaceutically acceptable salts thereof.

In some embodiments, the compound is an isotopic derivative of any one of the compounds described in Table 1, Table 2, or Table 3.

It is understood that the isotopic derivative can be prepared using any of a variety of art-recognized techniques. For example, the isotopic derivative can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

In some embodiments, the isotopic derivative is a deuterium labeled compound.

In some embodiments, the isotopic derivative is a deuterium labeled compound of any one of the compounds of the Formulae disclosed herein.

The term “isotopic derivative”, as used herein, refers to a derivative of a compound in which one or more atoms are isotopically enriched or labelled. For example, an isotopic derivative of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) is isotopically enriched with regard to, or labelled with, one or more isotopes as compared to the corresponding compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II). In some embodiments, the isotopic derivative is enriched with regard to, or labelled with, one or more atoms selected from ²H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ²⁹Si, ³¹P, and ³⁴S. In some embodiments, the isotopic derivative is a deuterium labeled compound (i.e., being enriched with ²H with regard to one or more atoms thereof).

In some embodiments, the compound is a deuterium labeled compound of any one of the compounds described in Table 1, Table 2, or Table 3 and prodrugs and pharmaceutically acceptable salts thereof.

In some embodiments, the compound is a deuterium labeled compound of any one of the compounds described in Table 1, Table 2, or Table 3 and pharmaceutically acceptable salts thereof.

In some embodiments, the compound is a deuterium labeled compound of any one of the prodrugs of the compounds described in Table 1, Table 2, or Table 3 and pharmaceutically acceptable salts thereof.

In some embodiments, the compound is a deuterium labeled compound of any one of the compounds described in Table 1, Table 2, or Table 3.

It is understood that the deuterium labeled compound comprises a deuterium atom having an abundance of deuterium that is substantially greater than the natural abundance of deuterium, which is 0.015%.

In some embodiments, the deuterium labeled compound has a deuterium enrichment factor for each deuterium atom of at least 3500 (52.5% deuterium incorporation at each deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). As used herein, the term “deuterium enrichment factor” means the ratio between the deuterium abundance and the natural abundance of a deuterium.

It is understood that the deuterium labeled compound can be prepared using any of a variety of art-recognized techniques. For example, the deuterium labeled compound can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples described herein, by substituting a deuterium labeled reagent for a non-deuterium labeled reagent.

A compound of the disclosure or a pharmaceutically acceptable salt or solvate thereof that contains the aforementioned deuterium atom(s) is within the scope of the disclosure. Further, substitution with deuterium (i.e., ²H) may afford certain therapeutic advantages resulting from greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements.

In some embodiments, the compound is a ¹⁸F labeled compound.

In some embodiments, the compound is a ¹²³I labeled compound, a ¹²⁴I labeled compound, a ¹²⁵I labeled compound, a ¹²⁹I labeled compound, a ¹³¹I labeled compound, a ¹³⁵I labeled compound, or any combination thereof.

In some embodiments, the compound is a ³³S labeled compound, a ³⁴S labeled compound, a ³⁵S labeled compound, a ¹⁶S labeled compound, or any combination thereof.

It is understood that the ¹⁸F, ¹²³I, ¹²⁴I, ¹²⁵I, ¹²⁹I, ¹³¹I, ¹³⁵I, ³S, ³⁴S ³⁵S, and/or ³⁶S labeled compound, can be prepared using any of a variety of art-recognized techniques. For example, the deuterium labeled compound can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples described herein, by substituting a ¹⁸F, ¹²³I, ¹²⁴I, ¹²⁵I, ¹²⁹I, ¹³¹I, ¹³⁵I, ³S, ³⁴S ³⁵S, and/or ³⁶S labeled reagent for a non-isotope labeled reagent.

A compound of the disclosure or a pharmaceutically acceptable salt or solvate thereof that contains one or more of the aforementioned ¹⁸F, ¹²³I, ¹²⁴I, ¹²⁵I, ¹²⁹I, ¹³¹I, ¹³⁵I, ³S, ³⁴S, ³⁵S, and ³⁶S atom(s) is within the scope of the disclosure. Further, substitution with isotope (e.g., ¹⁸F, ¹²³I, ¹²⁴I, ¹²⁵I, ¹²⁹I, ¹³¹I, ¹³⁵I, ³S, ³⁴S, ³⁵S, and/or ³⁶S) may afford certain therapeutic advantages resulting from greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements.

For the avoidance of doubt it is to be understood that, where in this specification a group is qualified by “described herein”, the said group encompasses the first occurring and broadest definition as well as each and all of the particular definitions for that group.

The various functional groups and substituents making up the compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) are typically chosen such that the molecular weight of the compound does not exceed 1000 daltons. More usually, the molecular weight of the compound will be less than 900, for example less than 800, or less than 750, or less than 700, or less than 650 daltons. More conveniently, the molecular weight is less than 600 and, for example, is 550 daltons or less.

A suitable pharmaceutically acceptable salt of a compound of the disclosure is, for example, an acid-addition salt of a compound of the disclosure, which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid. In addition, a suitable pharmaceutically acceptable salt of a compound of the disclosure which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

It will be understood that the compounds of any one of the Formulae disclosed herein and any pharmaceutically acceptable salts thereof, comprise stereoisomers, mixtures of stereoisomers, polymorphs of all isomeric forms of said compounds.

As used herein, the term “isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture.”

As used herein, the term “chiral center” refers to a carbon atom bonded to four nonidentical substituents.

As used herein, the term “chiral isomer” means a compound with at least one chiral center. Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture.” When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).

As used herein, the term “geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds or a cycloalkyl linker (e.g., 1,3-cyclobutyl).

These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.

The compounds of the present disclosure may be depicted as different chiral isomers or geometric isomers. When compounds have chiral isomeric or geometric isomeric forms, all isomeric forms are intended to be included in the scope of the present disclosure, and the naming of the compounds does not exclude any isomeric forms, it being understood that not all isomers may have the same level of activity.

The structures and other compounds discussed in this disclosure include all atropic isomers thereof. Not all atropic isomers may have the same level of activity.

As used herein, the term “atropic isomers” are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques, it has been possible to separate mixtures of two atropic isomers in select cases.

As used herein, the term “tautomer” is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertible by tautomerizations is called tautomerism. Of the various types of tautomerism that are possible, two are commonly observed. In keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs. Ring-chain tautomerism arises as a result of the aldehyde group (—CHO) in a sugar chain molecule reacting with one of the hydroxy groups (—OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.

The compounds of the present disclosure may be depicted as different tautomers. It should also be understood that when compounds have tautomeric forms, all tautomeric forms are intended to be included in the scope of the present disclosure, and the naming of the compounds does not exclude any tautomer form. It will be understood that certain tautomers may have a higher level of activity than others.

Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterised by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (−)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.

The compounds of this disclosure may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of “Advanced Organic Chemistry”, 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of a racemic form. The designations “Isomer 1” and “Isomer 2” refer to the separated stereoisomers that elute from chiral chromatography separations under the stated conditions as specified in the examples. Some of the compounds of the disclosure may have geometric isomeric centers (E- and Z-isomers). It is to be understood that the present disclosure encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof.

The present disclosure also encompasses compounds of the disclosure as defined herein which comprise one or more isotopic substitutions.

It is to be understood that the compounds of any Formula described herein include the compounds themselves, as well as their salts, and their solvates, if applicable. A salt, for example, can be formed between an anion and a positively charged group (e.g., amino) on a substituted compound disclosed herein. Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).

As used herein, the term “pharmaceutically acceptable anion” refers to an anion suitable for forming a pharmaceutically acceptable salt. Likewise, a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a substituted compound disclosed herein. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion or diethylamine ion. The substituted compounds disclosed herein also include those salts containing quaternary nitrogen atoms.

The compounds of the present disclosure, for example, the salts of the compounds, can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules. Nonlimiting examples of hydrates include monohydrates, dihydrates, etc. Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.

As used herein, the term “solvate” means solvent addition forms that contain either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H₂O.

As used herein, the term “analog” refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group). Thus, an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.

As used herein, the term “derivative” refers to compounds that have a common core structure and are substituted with various groups as described herein.

It is also to be understood that certain compounds of any one of the Formulae disclosed herein may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. A suitable pharmaceutically acceptable solvate is, for example, a hydrate such as hemi-hydrate, a mono-hydrate, a di-hydrate or a tri-hydrate. It is to be understood that the disclosure encompasses all such solvated forms that possess inflammasome inhibitory activity.

It is also to be understood that certain compounds of any one of the Formulae disclosed herein may exhibit polymorphism, and that the disclosure encompasses all such forms, or mixtures thereof, which possess inflammasome inhibitory activity. It is generally known that crystalline materials may be analysed using conventional techniques such as X-Ray Powder Diffraction analysis, Differential Scanning Calorimetry, Thermal Gravimetric Analysis, Diffuse Reflectance Infrared Fourier Transform (DRIFT) spectroscopy, Near Infrared (NIR) spectroscopy, solution and/or solid state nuclear magnetic resonance spectroscopy. The water content of such crystalline materials may be determined by Karl Fischer analysis.

Compounds of any one of the Formulae disclosed herein may exist in a number of different tautomeric forms and references to compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) include all such forms. For the avoidance of doubt, where a compound can exist in one of several tautomeric forms, and only one is specifically described or shown, all others are nevertheless embraced by Formula (I). Examples of tautomeric forms include keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, and nitro/aci-nitro.

Compounds of any one of the Formulae disclosed herein containing an amine function may also form N-oxides. A reference herein to a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) that contains an amine function also includes the N-oxide. Where a compound contains several amine functions, one or more than one nitrogen atom may be oxidized to form an N-oxide. Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle. N-oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience. More particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with meta-chloroperoxybenzoic acid (mCPBA), for example, in an inert solvent such as dichloromethane.

The compounds of any one of the Formulae disclosed herein may be administered in the form of a prodrug which is broken down in the human or animal body to release a compound of the disclosure. A prodrug may be used to alter the physical properties and/or the pharmacokinetic properties of a compound of the disclosure. A prodrug can be formed when the compound of the disclosure contains a suitable group or substituent to which a property-modifying group can be attached. Examples of prodrugs include derivatives containing in vivo cleavable alkyl or acyl substituents at the ester or amide group in any one of the Formulae disclosed herein.

Accordingly, the present disclosure includes those compounds of any one of the Formulae disclosed herein as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a prodrug thereof. Accordingly, the present disclosure includes those compounds of any one of the Formulae disclosed herein that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of any one of the Formulae disclosed herein may be a synthetically-produced compound or a metabolically-produced compound.

A suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein is one that is based on reasonable medical judgment as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity. Various forms of prodrug have been described, for example in the following documents: a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, A.C.S. Symposium Series, Volume 14; and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.

A suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof. Suitable pharmaceutically acceptable amides from an amino group include, for example an amide formed with C₁-C₁₀ alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C₁-C₄ alkyl)piperazin-1-ylmethyl.

The in vivo effects of a compound of any one of the Formulae disclosed herein may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of any one of the Formulae disclosed herein. As stated hereinbefore, the in vivo effects of a compound of any one of the Formulae disclosed herein may also be exerted by way of metabolism of a precursor compound (a prodrug).

The compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below. Compounds of the present invention can be synthesized by following the steps outlined in General Schemes 1 and 2 which comprise different sequences of assembling intermediates or compounds. Starting materials are either commercially available or made by known procedures in the reported literature or as illustrated below.

Scheme 1 depicts the preparation of compounds of Formula (I), where W is N, X is NH, Y is O, R₇ is methyl, and R₈ is H. A person of ordinary skill in the art will recognize that acylation of substituted phenol (1) may provide ester (2). Ester (2) may undergo rearrangement under Lewis acid conditions to the hydroxy aryl ketone (3). Basic deprotonation of ketone (3) in the presence of carbon disulfide gives the bicyclic chromene-2-thione (4). Alkylation of thione (4) under basic conditions affords thiolether (5).

Oxidation of thiolether (5) with an oxidant such as m-CPBA may give sulfone (6). Substitution of sulfone (6) with various primary and secondary amines may then produce amino substituted chromen-4-one (7). Palladium-catalyzed acylation of bromide (7) may give the acyl chromen-4-one (10).

Alternatively, phenyl bromide (5) can be acylated via palladium catalysis to produce acyl chromen-4-one (8). This thiolether (8) can be oxidized with an oxidant such as m-CPBA to produce sulfone (9). Substitution of sulfone (9) with various primary and secondary amines may then produce amino substituted chromen-4-one (10). The ketone (10) can be reduced to hydroxy chromen-4-one (11) with a reducing agent such as sodium borohydride. Use of a halogenating agent such as phosphorus tribromide can be used to convert hydroxy compound (11) to the halo compound (12).

Alternatively, ketone (8) can be reduced to hydroxy compound (13) with a reagent such as sodium borohydride. This hydroxy compound (13) can be converted to halo compound (14) in a similar manner to the synthesis of bromide (12).

Substitution of bromide (12) with a substituted amine (15) produces compounds of Formula (I). Alternatively, bromide (14) can be substituted with amine (15) to produce thiolether (16). This thiolether can be oxidized to sulfoxide (17) followed by substitution with a primary or secondary amine to also produce compounds of Formula (I).

Scheme 2 depicts additional preparation of compounds of Formula (I), where W is N, X is NH, Y is O, R₇ is methyl, and R₈ is H. Condensation of ketone (10) with tert-butanesulfinamide using a Lewis acidic dehydrating agent such as a titanium(IV) alkoxide may afford ketimine (18). Asymmetric reduction of sulfinimine (18) may be effected with a borohydride reagent in the presence of a transition metal catalyst such as cerium (III) chloride to yield chirally enriched sulfinamide (19). Removal of the sulfinyl group under acidic conditions may be used to transform sulfinamide (19) to benzylamine (20) which can be alkylated with aryl halide (24) under Finkelstein or Ullmann-type conditions to give compounds of Formula (I).

A similar synthetic route allowing for access to different intermediates may also achieved. For instance, ketone (8) may be converted to benzylamine (23), using conditions previously described for the metal-catalyzed condensation, stereoselective reduction, and acid hydrolysis. Alkylation of benzylamine (23) with aryl halide (24) may be used to provide thiolether (25). This thiolether (25) can be oxidized to sulfoxide (26) followed by substitution with a primary or secondary amine to also produce compounds of Formula (I).

Biological Assays

Compounds designed, selected and/or optimized by methods described above, once produced, can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity. For example, the molecules can be characterized by conventional assays, including but not limited to those assays described below, to determine whether they have a predicted activity, binding activity and/or binding specificity.

Furthermore, high-throughput screening can be used to speed up analysis using such assays. As a result, it can be possible to rapidly screen the molecules described herein for activity, using techniques known in the art. General methodologies for performing high-throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Pat. No. 5,763,263. High-throughput assays can use one or more different assay techniques including, but not limited to, those described below.

Various in vitro or in vivo biological assays may be suitable for detecting the effect of the compounds of the present disclosure. These in vitro or in vivo biological assays can include, but are not limited to, enzymatic activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and the assays described herein.

Pharmaceutical Compositions

In some aspects, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) as an active ingredient. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the present disclosure provides a pharmaceutical composition comprising at least one compound selected from Table 1, Table 2, or Table 3.

As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

The compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) can be formulated for oral administration in forms such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. The compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) can also be formulated for intravenous (bolus or in-fusion), intraperitoneal, topical, subcutaneous, intramuscular or transdermal (e.g., patch) administration, all using forms well known to those of ordinary skill in the pharmaceutical arts.

The formulation of the present disclosure may be in the form of an aqueous solution comprising an aqueous vehicle. The aqueous vehicle component may comprise water and at least one pharmaceutically acceptable excipient. Suitable acceptable excipients include those selected from the group consisting of a solubility enhancing agent, chelating agent, preservative, tonicity agent, viscosity/suspending agent, buffer, and pH modifying agent, and a mixture thereof.

Any suitable solubility enhancing agent can be used. Examples of a solubility enhancing agent include cyclodextrin, such as those selected from the group consisting of hydroxypropyl-p-cyclodextrin, methyl-β-cyclodextrin, randomly methylated-p-cyclodextrin, ethylated-p-cyclodextrin, triacetyl-β-cyclodextrin, peracetylated-β-cyclodextrin, carboxymethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, 2-hydroxy-3-(trimethylammonio)propyl-β-cyclodextrin, glucosyl-β-cyclodextrin, sulfated β-cyclodextrin (S-β-CD), maltosyl-β-cyclodextrin, β-cyclodextrin sulfobutyl ether, branched-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, randomly methylated-γ-cyclodextrin, and trimethyl-γ-cyclodextrin, and mixtures thereof.

Any suitable chelating agent can be used. Examples of a suitable chelating agent include those selected from the group consisting of ethylenediaminetetraacetic acid and metal salts thereof, disodium edetate, trisodium edetate, and tetrasodium edetate, and mixtures thereof.

Any suitable preservative can be used. Examples of a preservative include those selected from the group consisting of quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetyl pyridinium chloride, benzyl bromide, phenylmercury nitrate, phenylmercury acetate, phenylmercury neodecanoate, merthiolate, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p-hydroxybenzoate, propylaminopropyl biguanide, butyl-p-hydroxybenzoate, and sorbic acid, and mixtures thereof.

In some embodiments, examples of a preservative include those selected from the group consisting of quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetyl pyridinium chloride, benzyl bromide, phenylmercury nitrate, merthiolate, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p-hydroxybenzoate, propylaminopropyl biguanide, butyl-p-hydroxybenzoate, and sorbic acid, and mixtures thereof.

The aqueous vehicle may also include a tonicity agent to adjust the tonicity (osmotic pressure). The tonicity agent can be selected from the group consisting of a glycol (such as propylene glycol, diethylene glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and sodium chloride, and a mixture thereof. In some embodiments, the tonicity agent is selected from the group consisting of a glycol (such as propylene glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and sodium chloride, and a mixture thereof.

The aqueous vehicle may also contain a viscosity/suspending agent. Suitable viscosity/suspending agents include those selected from the group consisting of cellulose derivatives, such as methyl cellulose, ethyl cellulose, hydroxyethylcellulose, polyethylene glycols (such as polyethylene glycol 300, polyethylene glycol 400), carboxymethyl cellulose, hydroxypropylmethyl cellulose, and cross-linked acrylic acid polymers (carbomers), such as polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol (Carbopols—such as Carbopol 934, Carbopol 934P, Carbopol 971, Carbopol 974 and Carbopol 974P), and a mixture thereof.

In order to adjust the formulation to an acceptable pH (typically a pH range of about 5.0 to about 9.0, more preferably about 5.5 to about 8.5, particularly about 6.0 to about 8.5, about 7.0 to about 8.5, about 7.2 to about 7.7, about 7.1 to about 7.9, or about 7.5 to about 8.0), the formulation may contain a pH modifying agent. The pH modifying agent is typically a mineral acid or metal hydroxide base, selected from the group of potassium hydroxide, sodium hydroxide, and hydrochloric acid, and mixtures thereof, and preferably sodium hydroxide and/or hydrochloric acid. These acidic and/or basic pH modifying agents are added to adjust the formulation to the target acceptable pH range. Hence it may not be necessary to use both acid and base—depending on the formulation, the addition of one of the acid or base may be sufficient to bring the mixture to the desired pH range.

The aqueous vehicle may also contain a buffering agent to stabilize the pH. When used, the buffer is selected from the group consisting of a phosphate buffer (such as sodium dihydrogen phosphate and disodium hydrogen phosphate), a borate buffer (such as boric acid, or salts thereof including disodium tetraborate), a citrate buffer (such as citric acid, or salts thereof including sodium citrate), and ε-aminocaproic acid, and mixtures thereof.

The formulation may further comprise a wetting agent. Suitable classes of wetting agents include those selected from the group consisting of polyoxypropylene-polyoxyethylene block copolymers (poloxamers), polyethoxylated ethers of castor oils, polyoxyethylenated sorbitan esters (polysorbates), polymers of oxyethylated octyl phenol (Tyloxapol), polyoxyl 40 stearate, fatty acid glycol esters, fatty acid glyceryl esters, sucrose fatty esters, and polyoxyethylene fatty esters, and mixtures thereof.

Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotex; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

According to a further aspect of the disclosure there is provided a pharmaceutical composition which comprises a compound any one of the Formulae disclosed herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.

The compositions of the disclosure may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the disclosure may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and/or preservative agents.

A therapeutically effective amount of a compound of any one of the Formulae disclosed herein for use in therapy is an amount sufficient to treat or prevent a PI3K related condition referred to herein, slow its progression and/or reduce the symptoms associated with the condition.

A therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) for use in therapy is an amount sufficient to treat an PI3K related condition referred to herein, slow its progression and/or reduce the symptoms associated with the condition.

The size of the dose for therapeutic or prophylactic purposes of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.

Methods of Use

In some aspects, the present disclosure provides a method of modulating PI3K (e.g., PI3Kα) activity (e.g., in vitro or in vivo), comprising contacting a cell with a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof.

In some aspects, the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some aspects, the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some embodiments, the disease or disorder is associated with an implicated PI3K activity. In some embodiments, the disease or disorder is a disease or disorder in which PI3K activity is implicated.

In some embodiments, the disease or disorder is a cancer.

In some embodiments, the cancer is selected from acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, aids-related cancers, aids-related lymphoma, anal cancer, astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, osteosarcoma, malignant fibrous histiocytoma, brain tumors, breast cancer, bronchial tumors, Burkitt lymphoma, carcinoid tumor, cancer of unknown primary, cardiac (heart) tumors, atypical teratoid/rhabdoid tumor, primary CNS lymphoma, cervical cancer, cholangiocarcinoma, chordoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), colorectal cancer, craniopharyngioma, cutaneous t-cell lymphoma, mycosis fungoides, Sezary syndrome, ductal carcinoma in situ (DCIS), embryonal tumors, medulloblastoma, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, fallopian tube cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, malignant gastrointestinal stromal tumors (GIST), germ cell tumors, gestational trophoblastic disease, hairy cell leukemia, head and neck cancer, hepatocellular cancer, Langerhans cell histiocytosis, Hodgkin lymphoma, islet cell tumors, pancreatic neuroendocrine tumors, Kaposi sarcoma, kidney cancer, laryngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, male breast cancer, intraocular melanoma, Merkel cell carcinoma, malignant mesothelioma, metastatic cancer, metastatic squamous neck cancer, midline tract carcinoma with nut gene changes, mouth cancer, multiple endocrine neoplasia syndromes, multiple myeloma/plasma cell neoplasms, myelodysplastic syndromes, myelodysplastic neoplasms, myeloproliferative neoplasms, chronic myeloproliferative neoplasm, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, lip and oral cavity cancer, oropharyngeal cancer, malignant fibrous histiocytoma of bone, ovarian cancer, pancreatic cancer, pancreatic neuroendocrine tumors (islet cell tumors), papillomatosis, paraganglioma, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary tumor, plasma cell neoplasm, multiple myeloma, pleuropulmonary blastoma, primary central nervous system (CNS) lymphoma, primary peritoneal cancer, prostate cancer, rectal cancer, recurrent cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, childhood vascular tumors, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma of the skin, testicular cancer, oropharyngeal cancer, hypopharyngeal cancer, thymoma, thymic carcinoma, thyroid cancer, tracheobronchial tumors, transitional cell cancer of the renal pelvis and ureter, urethral cancer, uterine sarcoma, vaginal cancer, vascular tumors, vulvar cancer, and Wilms tumor.

In some embodiments, the cancer is Endometrial cancer, Breast cancer, Oesophageal squamous-cell cancer, Cervical squamous-cell carcinoma, Cervical adenocarcinoma, Colorectal adenocarcinoma, Bladder Urothelial Carcinoma, Glioblastoma, Ovarian cancer, Non-small-cell Lung cancer, Esophagogastric cancer, Nerve-sheath tumor, Head and neck squamous-cell carcinoma, Melanoma, Esophagogastric adenocarcinoma, Soft-tissue sarcoma, Prostate cancer, Fibrolamellar carcinoma, Hepatocellular carcinoma, Diffuse glioma, Colorectal cancer, Pancreatic cancer, Cholangiocarcinoma, B-cell lymphoma, Mesothelioma, Adrenocortical carcinoma, Renal non-clear-cell carcinoma, Renal clear-cell carcinoma, Germ-cell carcinoma, Thymic tumor, Pheochromocytoma, Miscellaneous neuroepithelial tumor, thyroid cancer, leukemia, or encapsulated glioma.

In some embodiments, the cancer is a breast cancer, a prostate cancer, or a brain cancer.

In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a brain cancer.

In some embodiments, the breast cancer is metastatic breast cancer. In some embodiments, the breast cancer is ductal carcinoma in situ (DCIS). In some embodiments, the breast cancer is invasive ductal carcinoma. In some embodiments, the breast cancer is triple negative breast cancer. In some embodiments, the breast cancer is medullary carcinoma. In some embodiments, the breast cancer is tubular carcinoma. In some embodiments, the breast cancer is mucinous carcinoma. In some embodiments, the breast cancer is Paget disease of the breast or nipple. In some embodiments, the breast cancer is inflammatory breast cancer (IBC).

In some embodiments, the prostate cancer is an adenocarcinoma. In some embodiments, the prostate cancer is a small cell carcinoma. In some embodiments, the prostate cancer is a neuroendocrine tumor. In some embodiments, the prostate cancer is a transitional cell carcinoma.

In some embodiments, the prostate cancer is a sarcoma.

In some embodiments, the brain cancer is an acoustic neuroma. In some embodiments, the brain cancer is an astrocytoma. In some embodiments, the brain cancer is a brain metastasis. In some embodiments, the brain cancer is choroid plexus carcinoma. In some embodiments, the brain cancer is craniopharyngioma. In some embodiments, the brain cancer is an embryonal tumor. In some embodiments, the brain cancer is an ependymoma. In some embodiments, the brain cancer is a glioblastoma. In some embodiments, the brain cancer is a glioma. In some embodiments, the brain cancer is a medulloblastoma. In some embodiments, the brain cancer is a meningioma. In some embodiments, the brain cancer is an oligodendroglioma. In some embodiments, the brain cancer is a pediatric brain tumor. In some embodiments, the brain cancer is a pineoblastoma. In some embodiments, the brain cancer is a pituitary tumor.

In some embodiments, the disease or disorder associated with PI3K includes, but is not limited to, CLOVES syndrome (congenial lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome), PIK3CA-related overgrowth syndrome (PROS), breast cancer, brain cancer, prostate cancer, endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, or head and neck cancer.

In some embodiments, the diseases or disorder associated with PI3K is CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome).

In some embodiments, the disease or disorder associated with PI3K is PIK3CA-related overgrowth syndrome (PROS).

In some embodiments, the disease or disorder associated with PI3K is breast cancer, brain cancer, prostate cancer, endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, or head and neck cancer.

In some embodiments, the disease or disorder associated with PI3K is breast cancer, brain cancer, prostate cancer, endometrial cancer, gastric cancer, colorectal cancer, lung cancer, ovarian cancer, skin cancer, or head and neck cancer.

In some embodiments, the disease or disorder associated with PI3K is leukemia, lymphoma, or sarcoma.

In some embodiments, the cancer is endometrial cancer, head and neck cancer, or a sarcoma.

In some embodiments, the cancer is endometrial cancer. In some embodiments the cancer is head and neck cancer. In some embodiments, the cancer is a sarcoma.

In some embodiments, the sarcoma is soft tissue sarcoma, osteosarcoma, chondrosarcoma, Ewing sarcoma, hemangioendothelioma, angiosarcoma, fibrosarcoma, myofibrosarcoma, chordoma, adamantinoma, liposarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor, rhabdomyosarcoma, synovial sarcoma, or malignant solitary fibrous tumor.

In some embodiments, the sarcoma is soft tissue sarcoma. In some embodiments the soft tissue sarcoma is liposarcoma, atypical lipomatous tumor, dermatofibrosarcoma protuberans, malignant solitary fibrous tumor, inflammatory myofibroblastic tumor, low-grade myofibroblastic sarcoma, fibrosarcoma, myxofibrosarcoma, low-grade fibromyxoid sarcoma, giant cell tumor of soft tissues, leiomyosarcoma, malignant glomus tumor, rhabdomyosarcoma, hemangioendothelioma, angiosarcoma of soft tissue, extraskeletal osteosarcoma, gastrointestinal stromal tumor, malignant gastrointestinal stromal tumor (GIST), malignant peripheral nerve sheath tumor, malignant Triton tumor, malignant granular cell tumor, malignant ossifying fibromyxoid tumor, stromal sarcoma, myoepithelial carcinoma, malignant phosphaturic mesenchymal tumor, synovial sarcoma, epithelioid sarcoma, alveolar soft part sarcoma, clear cell sarcoma of soft tissue, extraskeletal myxoid chondrosarcoma, extraskeletal Ewing sarcoma, desmoplastic small round cell tumor, extrarenal rhabdoid tumor, perivascular epithelioid cell tumor, intimal sarcoma, undifferentiated spindle cell sarcoma, undifferentiated pleomorphic sarcoma, undifferentiated round cell sarcoma, undifferentiated epithelioid sarcoma, or undifferentiated sarcoma, not otherwise specified.

In some aspects, the present disclosure provides a method of treating or preventing a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some aspects, the present disclosure provides a method of treating a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some aspects, the present disclosure provides a method of treating or preventing a breast cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some aspects, the present disclosure provides a method of treating a breast cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some aspects, the present disclosure provides a method of treating or preventing a prostate cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some aspects, the present disclosure provides a method of treating a prostate cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some aspects, the present disclosure provides a method of treating or preventing a brain cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some aspects, the present disclosure provides a method of treating a brain cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in modulating PI3K (e.g., PI3Kα) activity (e.g., in vitro or in vivo).

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease or disorder disclosed herein.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder disclosed herein.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating or preventing a cancer in a subject in need thereof.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating a cancer in a subject in need thereof.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating or preventing a breast cancer in a subject in need thereof.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating a breast cancer in a subject in need thereof.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating or preventing a prostate cancer in a subject in need thereof.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating a prostate cancer in a subject in need thereof.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating or preventing a brain cancer in a subject in need thereof.

In some aspects, the present disclosure provides a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof for use in treating a brain cancer in a subject in need thereof.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for modulating PI3K (e.g., PI3Kα) activity (e.g., in vitro or in vivo).

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or disorder disclosed herein.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a cancer in a subject in need thereof.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a cancer in a subject in need thereof.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a breast cancer in a subject in need thereof.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a breast cancer in a subject in need thereof.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a prostate cancer in a subject in need thereof.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a prostate cancer in a subject in need thereof.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a brain cancer in a subject in need thereof.

In some aspects, the present disclosure provides use of a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a brain cancer in a subject in need thereof.

The present disclosure provides compounds that function as modulators of PI3K activity.

The present disclosure therefore provides a method of modulating PI3K activity in vitro or in vivo, said method comprising contacting a cell with a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, as defined herein.

In some embodiments, PI3K is modulation is inhibition of PI3K.

In some embodiments, the PI3K inhibitor is a compound of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II), or a pharmaceutically acceptable salt thereof. In some embodiments, the PI3K inhibitor is a PI3Kα inhibitor. In some embodiments, the PI3K inhibitor is a PI3KA H1047R mutant inhibitor. In some embodiments, the PI3K inhibitor is alpha/beta non-selective. In some embodiments, the PI3K inhibitor is alpha selective. In some embodiments, the PI3K inhibitor is beta selective.

Effectiveness of compounds of the disclosure can be determined by industry-accepted assays/disease models according to standard practices of elucidating the same as described in the art and are found in the current general knowledge.

The present disclosure also provides a method of treating a disease or disorder in which PI3K activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.

The disclosure provides a method of modulating the activity of the PI3Kα allosteric active site, wherein the modulation is induced through peripheral site targeting. In some embodiments, the peripheral site is targeted with an agent selected from a small molecule, a peptide, a peptidomimetic, a protein, a protein mimetic, a nucleic acid, an antibody, an antibody-drug conjugate, a nucleoprotein complex, an immunotherapy, or a combination thereof.

In some embodiments, the agent binds an epitope of the peripheral site selected from: (a) a) an epitope that comprises at least two contiguous or non-contiguous residues of SEQ ID NO: 1 or (b) an epitope that comprises at least two contiguous or non-contiguous residues of SEQ ID NO: 2.

In some embodiments, the agent binds an epitope of the peripheral site selected from: (a) an epitope that comprises at least one residue of SEQ ID NO: 1 wherein the at least one residue is: Cys901, Cys905, Thr908, Phe909, Phe954, Thr957, Phe960, Leu961, Ile964, Phe977, Phe980, Gln981, Cys984, Met1043, Ala1046, or His1047; or (b) an epitope that comprises at least one residue of SEQ ID NO: 2 wherein the at least one residue is: Cys901, Cys905, Thr908, Phe909, Phe954, Thr957, Phe960, Leu961, Ile964, Phe977, Phe980, Gln981, Cys984, Met1043, Ala1046, or Arg1047.

Routes of Administration

The compounds of Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), or (II) or pharmaceutical compositions comprising these compounds may be administered to a subject by any convenient route of administration, whether systemically/peripherally or topically (i.e., at the site of desired action).

Routes of administration include, but are not limited to, oral (e.g. by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intra-arterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot or reservoir, for example, subcutaneously or intramuscularly.

EXAMPLES

Exemplary compounds of Formula (I) are synthesized and tested in the examples. It is understood that compounds of Formula (I) may be converted to the corresponding pharmaceutically acceptable salts of the compounds using routine techniques in the art (e.g., by saponification of an ester to the carboxylic acid salt, or by hydrolyzing an amide to form a corresponding carboxylic acid and then converting the carboxylic acid to a carboxylic acid salt).

Nuclear magnetic resonance (NMR) spectra were recorded at 400 MHz or 300 MHz as stated and at 300.3 K unless otherwise stated; the chemical shifts (δ) are reported in parts per million (ppm). Spectra were recorded using a Bruker or Varian instrument with 8, 16 or 32 scans.

LC-MS chromatograms and spectra were recorded using an Agilent 1200 or Shimadzu LC-20 AD&MS 2020 instrument using a C-18 column such as a Luna-C18 2.0×30 mm or Xbridge Shield RPC18 2.1×50 mm. Injection volumes were 0.7-8.0 μl and the flow rates were typically 0.8 or 1.2 ml/min. Detection methods were diode array (DAD) or evaporative light scattering (ELSD) as well as positive ion electrospray ionization. MS range was 100-1000 Da. Solvents were gradients of water and acetonitrile both containing a modifier (typically 0.01-0.04%) such as trifluoroacetic acid or ammonium carbonate.

Abbreviations

-   -   4A MS 4 angstrom molecular sieves     -   ACN Acetonitrile     -   AcOH or (OAc) Acetic Acid     -   aq. Aqueous     -   ADP Adenosine diphosphate     -   ATP Adenosine triphosphate     -   CDCl₃ Chloroform-d     -   CHCl₃ Chloroform     -   CO Carbon monoxide     -   CuI Copper(I) iodide     -   DCE 1,2-Dichloroethane     -   DCM Dichloromethane     -   DIPEA, DIEA N,N-Diisopropylethylamine     -   DMAP 4-Dimethylaminopyridine     -   DMF N,N-dimethylformamide     -   DMSO Dimethylsulfoxide     -   DMSO-d₆ Hexadeuterodimethylsulfoxide     -   DPPF or dppf 1,1′-bis(diphenylphosphino)ferrocene     -   EDCI N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide     -   ee Enantiomeric excess     -   eq. Equivalents     -   ES/MS Electrospray mass spectrometry     -   EtI Ethyl iodide     -   EtOAc Ethyl acetate     -   EtOH Ethanol     -   FA Formic acid     -   h, hr(s) Hour(s)     -   HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid     -   ¹H NMR Proton nuclear magnetic resonance spectroscopy     -   HPLC High performance liquid chromatography     -   LC-MS Liquid chromatography-mass spectrometry     -   LiHMDS Lithium bis(trimethylsilyl)amide     -   m-CPBA meta-Chloroperoxybenzoic acid     -   MeCN Acetonitrile     -   MeOH Methanol     -   min(s) Minute(s)     -   n-BuLi n-Butyllithium     -   NaOAc Sodium acetate     -   NaHMDS Sodium bis(trimethylsilyl)amide     -   pet. ether or PE Petroleum ether     -   PIP2 Phosphatidylinositol 4,5-bisphosphate     -   PPh₃ Triphenylphosphine     -   ppm Parts per million     -   RM Reaction mixture     -   rt Room temperature     -   sat. Saturated     -   SFC Supercritical fluid chromatography     -   t-BuOK Potassium tert-butoxide     -   TEA Triethylamine     -   Tf₂O Trifluoromethanesulfonic anhydride     -   TFA Trifluoroacetic acid     -   THf Tetrahydrofuran     -   Ti(i-PrO)₄ Titanium(IV) isopropoxide     -   TLC Thin layer chromatography

Tables 4 & 5—Columns & Eluents for Chiral SFC Purifications

TABLE 4 Chiral SFC Columns Column Description A Daicel Chiracel OD-H, 21 × 250 mm, 5 um B Daicel Chiralcel OD-H, 21 × 150 mm, 5 um C Daicel Chiralcel OJ-H, 21 × 150 mm, 5 um D Daicel Chiralpak AD-H, 21 × 150 mm, 5 um E Daicel Chiralpak AS-H, 21 × 150 mm, 5 um F Daicel Chiralpak IH, 20 × 250 mm, 5 um G Lux Cellulose-2 AD-H, 21 × 250 mm H Lux Cellulose-2, 21 × 250 mm I Daicel Chiralpak AD-H, 20 × 250 mm, 5 um J Daicel Chiralpak AD-H, 30 × 250 mm, 5 um K Daicel Chiralpak AS-H, 20 × 250 mm, 5 um L Daicel Chiralpak IA, 20 × 250 mm, 5 um M Daicel Chiralpak IC, 20 × 250 mm, 5 um N Daicel Chiralpak ID, 20 × 250 mm, 5 um O Daicel Chiralpak IG, 30 × 250 mm, 5 um P Daicel Chiralpak OD-H, 20 × 250 mm, 5 um Q Daicel Chiralpak OJ-H, 20 × 250 mm, 5 um R Daicel Chiralpak AD, 50 × 250 mm, 10 um S Daicel Chiralpak AS, 50 × 250 mm, 10 um T Regis(S,S)Whelk-O1, 25 × 250 mm, 10 um U Daicel Chiralpak AS, 30 × 250 mm, 10 um V Daicel Chiralpak AD-H, 30 × 250 mm, 5 um W Daicel Chiralpak OD-H, 30 × 250 mm, 5 um X Daicel Chiralpak AD, 30 × 250 mm, 10 um Y Daicel ChiralCel OD, 30 × 250 mm, 10 um Z Daicel ChiralCel OD-H, 30 × 250 mm, 5 um AA Daicel ChiralCel OJ, 30 × 250 mm; 10 um AB Daicel ChiralCel OJ-H, 30 × 250 mm; 5 um AC Daicel Chiralpak IC, 30 × 250 mm, 10 um AD Daicel Chiralpak OJ, 30 × 250 mm, 10 um AE Daicel ChiralCel AS, 30 × 250 mm, 10 um AF Daicel Chiralpak OD, 30 × 250 mm, 10 um AG (s,s) WHELK-O1 (250 × 30 mm, 5 um)

TABLE 5 SFC Eluents Chromatography Eluent 1 15% MeOH:85% CO2 2 20% MeOH:80% CO2 3 25% MeOH:75% CO2 4 30% MeOH:70% CO2 5 40% MeOH:60% CO2 6 5-50% MeOH (w/0.1% aq NH3) in CO2 7 35% MeOH (w/0.1% aq NH3):65% CO2 8 50% MeOH (w/0.1% aq NH3):50% CO2 9 55% MeOH (w/0.1% aq NH3):45% CO2 10 25% MeOH (w/0.2% DMEA):75% CO2 11 30% MeOH (w/0.2% DMEA):70% CO2 12 35% MeOH (w/0.2% DMEA):65% CO2 13 40% MeOH (w/0.2% DMEA):60% CO2 14 15% MeOH (w/0.5% DMEA):85% CO2 15 20% MeOH (w/0.5% DMEA):80% CO2 16 25% MeOH (w/0.5% DMEA):75% CO2 17 30% MeOH (w/0.5% DMEA):70% CO2 18 35% MeOH (w/0.5% DMEA):65% CO2 19 40% MeOH (w/0.5% DMEA):60% CO2 20 50% MeOH (w/0.5% DMEA):50% CO2 21 20% EtOH (w/0.1% aq NH3):80% CO2 22 25% EtOH (w/0.1% aq NH3):75% CO2 23 30% EtOH (w/0.1% aq NH3):70% CO2 24 35% EtOH (w/0.1% aq NH3):65% CO2 25 40% EtOH (w/0.1% aq NH3):60% CO2 26 45% EtOH (w/0.1% aq NH3):55% CO2 27 55% EtOH (w/0.1% aq NH3):45% CO2 28 60% EtOH (w/0.1% aq NH3):40% CO2 29 10% EtOH (w/0.2% DMEA):90% CO2 30 35% EtOH (w/0.2% DMEA):65% CO2 31 30% EtOH (w/0.5% DMEA):70% CO2 32 40% EtOH (w/0.5% DMEA):60% CO2 33 35% IPA (w/0.2% DMEA):65% CO2 34 40% IPA (w/0.2% DMEA):60% CO2 35 30% IPA (w/0.5% DMEA):70% CO2 36 35% IPA (w/0.5% DMEA):65% CO2 37 55% IPA (w/0.1% aq NH3):45% CO2 38 40% MeOH (w/0.1% aq NH3):60% CO2

Intermediate 1: 8-Bromo-2-ethylsulfanyl-6-methyl-chromen-4-one

Step 1: 2-bromo-4-methylphenyl acetate. A mixture of 2-bromo-4-methyl-phenol (300 g, 1.60 mol) and pyridine (152 g, 1.92 mol) in DCM (2.4 L) was added acetyl chloride (151 g, 1.92 mol) at 0° C., and stirred at 25° C. for 16 h. The mixture was diluted with water (1500 mL) and adjusted to pH=5 with HCl (2 M), then extracted with DCM (500 mL×3). The combined extract was washed with brine (250 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as oil (400 g, crude). ¹H NMR (400 MHz, CDCl₃) δ ppm 2.24 (s, 3H), 2.25 (s, 3H), 6.91 (d, J=8.4 Hz, 2H), 7.01-7.02 (m, 2H), 7.33 (s, 1H).

Step 2: 1-(3-bromo-2-hydroxy-5-methyl-phenyl)ethanone. A mixture of (2-bromo-4-methyl-phenyl) acetate (50 g, 218 mmol) and AlCl₃ (102 g, 764 mmol) was degassed and purged with N₂ for 3 times and stirred at 140° C. for 1 h. When cooled to rt the reaction was diluted with DCM (30 mL), dropped in H₂O (150 mL) at 0° C. The mixture was filtered, aqueous phase was extracted with DCM (150 mL×2). The combined extract was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was triturated with petroleum ether (150 mL×2) to give the product as a solid (30 g, 52%). ¹H NMR (400 MHz, CDCl₃) δ ppm 2.30 (s, 3H), 2.68 (s, 3H), 7.73 (s, 1H), 7.33 (s, 1H), 12.64 (s, 1H).

Step 3: 8-bromo-4-hydroxy-6-methyl-chromene-2-thione. A solution of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)ethanone (65 g, 284 mmol) in THE (800 mL) was added NaHMDS (851 mL, 1 M) at −50° C. over 30 min, warmed to −5 to 0° C. and stirred for 1 h. To the mixture was added CS₂ (64.8 g, 851 mmol) at −20° C. dropwise over 1 h, warmed to 25° C. and stirred for another 16 h. The reaction was quenched with H₂SO₄ (800 mL, 15%) at −50° C. over 1 h, warmed to rt and extracted with EtOAc (1 L×2). The combined extract was washed with brine (1 L), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was triturated with EtOAc (0.5 L) to give the product as a solid (210 g crude, yield: 64%, purity: 76%).

Step 4: 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one. A mixture of 8-bromo-4-hydroxy-6-methyl-chromene-2-thione (20.0 g, 73.8 mmol), EtI (46.0 g, 295 mmol) and K₂CO₃ (12.2 g, 88.5 mmol) in acetone (200 mL) was stirred at 60° C. for 3 h. When cooled to rt the mixture was diluted with water (200 mL), extracted with DCM (200 mL×2). The combined extract was concentrated and purified by silica gel chromatography eluted with 20%-40% EtOAc in petroleum ether to give 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one (14.6 g, 66%) as gum. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.51 (t, J=7.2 Hz, 3H), 2.45 (s, 3H), 3.22 (q, J=7.2 Hz, 2H), 6.32 (s, 1H), 7.70 (s, 1H), 7.93 (s, 1H). MS ES+ m/z 301 [M+H]⁺.

Intermediate 2: 8-Bromo-2-ethylsulfonyl-6-methyl-chromen-4-one

A mixture of 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one (9.5 g, 31.7 mmol) in DCM (150 mL) was added m-CPBA (13.7 g, 63.5 mmol, 80% purity) in portions at 10° C., then warmed to 25° C. and stirred for 16 h. The mixture and another batch (5.1 g) were cooled to −15° C. and filtered. The filter cake was washed with cold DCM (20 mL×3). The filtrate was washed with sat.Na₂S₂O₄ (300 mL×2), sat.NaHCO₃ (300 mL×2) and concentrated to give 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (16.1 g, crude) as a solid. MS ES+ m/z 333 [M+H]⁺.

Intermediate 3: 8-(1-Bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one

Step 1: 8-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (11.0 g, crude) and 4,4-dimethylpiperidine (7.46 g, 49.8 mmol, HCl salt) in DCM (200 mL) was added DIPEA (17.2 g, 133 mmol) dropwise at 5-10° C. and stirred at 20° C. for 16 h. The mixture was combined with another batch (5 g) and washed with water (300 mL×2), followed by brine (250 mL×2). The extract was dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 25%-80% EtOAc in pet. ether to give the product as gum (14.2 g, 84%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.06 (s, 6H), 1.50-1.55 (m, 4H), 2.42 (s, 3H), 3.55-3.64 (m, 4H), 5.53 (s, 1H), 7.58 (d, J=1.6 Hz, 1H), 7.90 (d, J=1.6 Hz, 1H).

Step 2: 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (9.0 g, 25.7 mmol), Pd(PPh₃)₂CL₂ (902 mg, 1.28 mmol) and tributyl(1-ethoxyvinyl)stannane (11.1 g, 30.8 mmol) in dioxane (100 mL) was stirred at 95° C. under N₂ atmosphere for 16 h. HCl (12 mL, 2 M) was added into the mixture and stirred at 50° C. for 0.5 h. The mixture was combined with another batch (5 g), added sat. KF (200 mL) and stirred at 20° C. for 0.5 h. The gray suspension was filtered. The filter cake was washed with EtOAc (50 mL×3). The aqueous phase was extracted with EtOAc (200 mL×2).

The combined organic layer was washed with brine (250 mL), filtered, concentrated and triturated with PE/EtOAc (200 mL/15 mL) to give the product (8.2 g). The mother liquor was concentrated and triturated with PE/EtOAc (100 mL/5 mL) to give the product (3.53 g), combined to provide a total product (11.73 g, 92%). ¹H NMR (400 MHz, DMSO-d₄) δ ppm 0.99 (s, 6H), 1.40-1.45 (m, 4H), 2.43 (s, 3H), 2.67 (s, 3H), 3.52-3.60 (m, 4H), 5.54 (s, 1H), 7.89-7.95 (m, 2H). MS ES+ m/z 314 [M+H]⁺.

Step 3: 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-6-methyl-chromen-4-one. A mixture of 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (8.2 g, 26.2 mmol) in DCM (50 mL) and MeOH (50 mL) was added NaBH₄ (1.19 g, 31.4 mmol) in portions at −10° C., then stirred at 20° C. for 16 h. The mixture was quenched with sat.NH₄Cl (120 mL) and extracted with DCM (150 mL×2). The combined extract was washed with brine (150 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was triturated with PE/EtOAc (120 mL/10 mL) to give the product as a solid (8.2 g, 99%). ¹H NMR (400 MHz, DMSO-d₄) δ ppm 0.99 (s, 6H), 1.30-1.45 (m, 7H), 2.38 (s, 3H), 3.46-3.54 (m, 4H), 5.10-5.20 (m, 1H), 5.35 (d, J=4.4 Hz, 1H), 5.48 (s, 1H), 7.55 (d, J=2.0 Hz, 1H), 7.58 (d, J=2.0 Hz, 1H). MS ES+ m/z 316 [M+H]⁺.

Step 4: 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-6-methyl-chromen-4-one (7.60 g, 24.1 mmol) in DCM (150 mL) was added PBr₃ (9.78 g, 36.1 mmol) dropwise at 0° C., and stirred at 25° C. for 16 h. The mixture was adjusted to pH=8 with sat.NaHCO₃ slowly and stirred for 0.5 h. The mixture was filtered. The filter cake was washed with DCM (20 mL×2). The filtrate was extracted with DCM (200 mL×2). The combined extract was washed with brine (300 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and triturated with PE/EtOAc (200 mL/15 mL) to give the product as a solid (6.85 g). The mother liquor was combined with another batch (4 g) and purified by silica gel chromatography eluted with 50%-100% EtOAc in pet. ether to give the product as a solid (1.5 g). Total amount of 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (8.35 g, 89%). ¹H NMR (400 MHz, DMSO-d₄) δ ppm 1.00 (s, 6H), 1.40-1.49 (m, 4H), 2.11 (d, J=6.8 Hz, 3H), 2.40 (s, 3H), 3.54-3.65 (m, 4H), 5.53 (s, 1H), 5.80-5.88 (m, 1H), 7.60-7.71 (m, 2H). MS ES+ m/z 380 [M+H]⁺.

Intermediate 4: 8-(1-Bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one

Step 1: (2-bromo-4-methyl-phenyl) propanoate. A mixture of 2-bromo-4-methyl-phenol (10.0 g, 53.5 mmol) and pyridine (6.34 g, 80.2 mmol) in DCM (100 mL) was added propanoyl chloride (5.44 g, 58.8 mmol) at 0° C., and stirred at 25° C. for 16 h. Then the mixture was diluted with water (100 mL), adjusted to pH=5 with HCl (2 M) and extracted with DCM (100 mL×2). The combined extract was washed with brine (150 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as oil (13 g, crude). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.17 (t, J=7.6 Hz, 3H), 2.30 (s, 3H), 2.62 (q, J=7.6 Hz, 2H), 7.11-7.18 (m, 1H), 7.19-7.26 (m, 1H), 7.50-7.55 (m, 1H).

Step 2: 1-(3-bromo-2-hydroxy-5-methyl-phenyl)propan-1-one. A mixture of (2-bromo-4-methyl-phenyl) propanoate (12.5 g, 51.4 mmol) and AlCl₃ (24.0 g, 180 mmol) was stirred at 140° C. for 1 h. When cooled to rt the mixture was quenched with water (80 mL) dropwise and stirred for 30 min. Then the mixture was extracted with EtOAc (100 mL×3). The combined extract was washed with brine (200 mL×2), dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated and triturated with petroleum ether (20 mL) to give the product as a solid (9.82 g, 79%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.10 (t, J=7.2 Hz, 3H), 2.28 (s, 3H), 3.15 (q, J=7.2 Hz, 2H), 7.66-7.73 (m, 1H), 7.77-7.83 (m, 1H), 12.66 (s, 1H).

Step 3: 8-bromo-4-hydroxy-3,6-dimethyl-chromene-2-thione. A mixture of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)propan-1-one (5.0 g, 21 mmol) in THE (80 mL) was added NaHMDS (1 M, 72 mL) at −50° C. dropwise, then warmed to −5-0° C. and stirred for 1 h, then added CS₂ (2.51 g, 32.9 mmol) at −20° C., and stirred at 25° C. for another 16 h. When cooled to −50° C. the mixture was quenched with 15% H₂SO₄ (50 mL) and extracted with DCM (100 mL×3). The combined extract was washed with brine (150 mL×2), dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated and triturated with DCM (10 mL) to give the product as a solid (4.1 g, 70%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.24 (s, 3H), 2.39 (s, 3H), 7.80 (s, 2H).

Step 4: 8-bromo-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one. A mixture of 9-bromo-2-hydroxy-7-methyl-pyrido[1,2-a]pyrimidin-4-one (4.1 g, 14 mmol), EtI (9.0 g, 58 mmol) and K₂CO₃ (2.38 g, 17.2 mmol) in acetone (80 mL) was stirred at 60° C. for 2 h. When cooled to rt the mixture was quenched with water (100 mL), extracted with DCM (150 mL×3), dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated and purified on a silica gel column eluted with 0-20% EtOAc in petroleum ether to give the product as a solid (3.25 g, 71%). MS ES+ m/z 315 [M+H]⁺.

Step 5: 8-bromo-2-ethylsulfonyl-3,6-dimethyl-chromen-4-one. A mixture of 8-bromo-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one (1.5 g, 4.8 mmol) in DCM (15 mL) was added m-CPBA (2.92 g, 14.4 mmol, 85% purity) at 10° C., and stirred at 20° C. for 16 h. The mixture was diluted with sat.aq.Na₂SO₃ (40 mL), extracted with DCM (40 mL×3). The combined extract was washed with sat.aq.NaHCO₃ (60 mL×2), dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated and purified on a silica gel column eluted with 0-20% EtOAc in petroleum ether to give the product as a solid (1.5 g, 91%). MS ES+ m/z 347 [M+H]⁺.

Step 6: 8-bromo-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one. A mixture of 8-bromo-2-ethylsulfonyl-3,6-dimethyl-chromen-4-one (1.5 g, 4.3 mmol) in DCM (15 mL) was added 4,4-dimethylpiperidine (1.95 g, 13.0 mmol, HCl) and DIPEA (4.49 g, 34.8 mmol) at 10° C., stirred at 20° C. for 15 h. The mixture was diluted with water (30 mL), extracted with DCM (40 mL×3), washed with brine (50 mL×2), dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated and purified on a silica gel column eluted with 0-15% EtOAc in petroleum ether to give the product as a solid (1.4 g, 88%). MS ES+ m/z 364 [M+H]⁺.

Step 7: 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one. A mixture of 8-bromo-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one (1.4 g, 3.8 mmol), Pd(PPh₃)₂Cl₂ (270 mg, 0.384 mmol) and tributyl(1-ethoxyvinyl)stannane (1.67 g, 4.61 mmol) in dioxane (15 mL) was stirred at 95° C. under N₂ for 16 h. To the mixture was added HCl (2 mL, 1 M) and stirred for 0.5 h. When cooled to rt the mixture was added sat.aq. KF (30 mL) and stirred for 1 h, filtered and the filter cake was rinsed with DCM (20 mL). The aqueous phase was extracted with DCM (50 mL×3). The combined extract was dried over anhydrous Na₂SO₄, filtered, concentrated and triturated with PE/EtOAc (5/1, 12 mL) to give the product as a solid (1.2 g, crude). MS ES+ m/z 328 [M+H]⁺.

Step 8: 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-3,6-dimethyl-chromen-4-one. A mixture of 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one (1.2 g, 3.7 mmol) in DCM (6 mL) and MeOH (6 mL) was added NaBH₄ (166.38 mg, 4.40 mmol) at −10° C., and stirred at −10° C. for 1.5 h. The reaction mixture was quenched with water (30 mL), extracted with DCM/MeOH (40 mL×3, 10/1). The combined extract was washed with brine (50 mL×2), dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated to give the product as a solid (1.2 g, crude). MS ES+ m/z 330 [M+H]⁺.

Step 9: 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one. A mixture of 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-3,6-dimethyl-chromen-4-one (1.2 g, 3.6 mmol) in DCM (12 mL) was added PBr₃ (1.48 g, 5.46 mmol) at 0° C., and stirred at 20° C. for 2 h. The reaction mixture was quenched with sat.aq.NaHCO₃(50 mL), extracted with DCM (60 mL×3). The combined extract was washed with brine (80 mL×2), dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated and purified on a silica gel column eluted with 0-25% EtOAc in petroleum ether to give 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one as a solid (930 mg, 65%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.01 (s, 6H), 1.46-1.51 (m, 4H), 1.91 (s, 3H), 2.11 (d, J=6.8 Hz, 3H), 2.40 (s, 3H), 3.42-3.51 (m, 4H), 5.84 (q, J=6.8 Hz, 1H), 7.72 (d, J=7.2 Hz, 2H).

Intermediate 5: 8-(1-Bromoethyl)-6-methyl-2-(1-piperidyl)chromen-4-one

Step 1: 8-bromo-6-methyl-2-(1-piperidyl)chromen-4-one. A mixture of piperidine (340 mg, 3.99 mmol) and DIPEA (937 mg, 7.25 mmol) in DCM (5 mL) was added dropwise to a solution of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (600 mg, 1.81 mmol) in DCM (10 mL) at 10° C. and stirred at 20° C. for 2 h. The mixture was diluted with H₂O (20 mL), quenched with HCl (2M, 1 mL), then extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a solid (550 mg, 96%). MS ES+ m/z 324 [M+H]⁺.

Step 2: 8-acetyl-6-methyl-2-(1-piperidyl)chromen-4-one. A mixture of 8-bromo-6-methyl-2-(1-piperidyl)chromen-4-one (550 mg, 1.71 mmol), Pd(PPh₃)₂CL₂ (240 mg, 0.341 mmol) and tributyl(1-ethoxyvinyl)stannane (863 mg, 2.39 mmol) in dioxane (10 mL) was stirred at 95° C. for 16 h under N₂ atmosphere. Then HCl (1 M, 1.71 mL) was added into the mixture and stirred at 50° C. for 4 h. When cooled to rt the mixture was added aq. KF (10 mL) and stirred at 25° C. for 0.5 h, then filtered. The filtrate was extracted with DCM (30 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a solid (480 mg, crude). MS ES+ m/z 286 [M+H]⁺.

Step 3: 8-(1-hydroxyethyl)-6-methyl-2-(1-piperidyl)chromen-4-one. A mixture of 8-acetyl-6-methyl-2-(1-piperidyl)chromen-4-one (480 mg, 1.68 mmol) in DCM (3 mL) and MeOH (3 mL) was added NaBH₄ (76.4 mg, 2.02 mmol) at −10° C., and stirred at −10° C. for 1 h. The reaction mixture was quenched with water (15 mL), the aqueous layer was extracted with DCM/MeOH (20 mL×2, 10/1). The combined extract was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-10% MeOH in DCM to give the product as a solid (360 mg, 75%). MS ES+ m/z 288 [M+H]⁺.

Step 4: 8-(1-bromoethyl)-6-methyl-2-(1-piperidyl)chromen-4-one. A mixture of 8-(1-hydroxyethyl)-6-methyl-2-(1-piperidyl)chromen-4-one (300 mg, 1.04 mmol) in DCM (5 mL) was added PBr₃ (283 mg, 1.04 mmol) dropwise at 0° C. and stirred at 20° C. for 2 h. The reaction mixture was quenched with sat. aq. NaHCO₃(20 mL), the aqueous phase was extracted with DCM (20 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give 8-(1-bromoethyl)-6-methyl-2-(1-piperidyl)chromen-4-one as a solid (300 mg, crude). MS ES+ m/z 352 [M+H]⁺.

Intermediate 6: Methyl 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate

Step 1: 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one. A mixture of 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one (9.00 g, 30.0 mmol), tributyl(1-ethoxyvinyl)tin (13.3 g, 36.8 mmol) and Pd(PPh₃)₂Cl₂ (2.11 g, 3.01 mmol) in dioxane (90 mL) was stirred at 95° C. for 16 h. HCl (30 mL, 1 M) was added to the mixture and stirred at 50° C. for 0.5 h. When cooled to rt the mixture and added sat. KF (100 mL) and stirred for 0.5 h, then filtered. The filter cake was washed with EtOAc (40 mL×3). The filtrate was extracted with EtOAc (80 mL×2). The combined extract was concentrated and purified on a silica gel column eluted with 0-60% EtOAc in petroleum ether to give the product as a solid (5.8 g, 60%). MS ES+ m/z 263 [M+H]⁺.

Step 2: 2-ethylsulfanyl-8-(1-hydroxyethyl)-6-methyl-chromen-4-one. A solution of 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one (8.30 g, 31.6 mmol) in DCM (30 mL) and MeOH (30 mL) was added NaBH₄ (1.32 g, 34.8 mmol) in portions at 0° C., and stirred at 15° C. for 1 h. The mixture was diluted with water (50 mL), then extracted with DCM (100 mL×2). The combined extract was washed with brine (80 mL), dried over anhydrous Na₂SO₄, filtered, concentrated. The residue was purified on a silica gel column eluted with 0-4% MeOH in DCM to give the product as a solid (6.0 g, 60%). MS ES+ m/z 265 [M+H]⁺.

Step 3: 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one. A mixture of 2-ethylsulfanyl-8-(1-hydroxyethyl)-6-methyl-chromen-4-one (5.50 g, 20.8 mmol) in DCM (50 mL) was added PBr₃ (16.9 g, 62.4 mmol) dropwise at 0° C., then stirred at 30° C. for 4 h. The reaction mixture was added water (20 mL) at 0° C., and then adjusted with sat.NaHCO₃ to pH=8. The mixture was extracted with DCM (80 mL×2). The combined extract was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as oil (4.7 g, 61%). MS ES+ m/z 329 [M+2+H]⁺.

Step 4: methyl 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate. A mixture of 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one (4.00 g, 12.2 mmol) and methyl 2-aminobenzoate (3.70 g, 24.5 mmol) in DMF (30 mL) was stirred at 80° C. for 8 h. When cooled to rt the mixture was diluted with water (100 mL), extracted with EtOAc (80 mL×3). The combined extract was washed with brine (100 mL×3), dried over anhydrous Na₂SO₄, filtered, concentrated. The residue was purified by silica gel chromatography eluted with 0%-27% EtOAc in petroleum ether to give methyl 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate (4.5 g, 84%) as a solid. MS ES+ m/z 398 [M+H]⁺.

Intermediate 7: Methyl 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate

A mixture of methyl 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate (4.80 g, 12.1 mmol) in DCM (50 mL) was added m-CPBA (3.39 g, 15.7 mmol, 80% purity) in portions at 0° C., and stirred at 15° C. for 2 h. The mixture was filtered, the filter cake was washed with DCM (10 mL×3). The filtrate was washed with sat. Na₂S₂O₄ (100 mL) and followed by sat.NaHCO₃(100 mL). The organic phase was concentrated and purified by silica gel chromatography eluted with 0%-68% EtOAc in petroleum ether to give methyl 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate (3.7 g, 70%) as a solid. MS ES+ m/z 414 [M+H]⁺.

Intermediate 8: 2-[1-(2-Ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid

Step 1: 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid. A mixture of 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one (200 mg, 611 μmol) and 2-aminobenzoic acid (167 mg, 1.22 mmol) in DMF (2 mL) was stirred at 80° C. for 14 h. When cooled to rt the mixture was diluted with water (20 mL), extracted with EtOAc (20 mL×3). The combined extract was washed with brine (40 mL×3), dried over anhydrous Na₂SO₄, filtered, concentrated. The residue was purified on a silica gel column eluted with 0-2% MeOH in DCM to give the product as a solid (160 mg, 57%). MS ES+ m/z 384 [M+H]⁺.

Step 2: 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid. A mixture of 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (160 mg, 350 μmol) in DCM (5 mL) was added m-CPBA (98.0 mg, 456 μmol, 80% purity) in portions at 0° C., then stirred at 15° C. for 2 h. The mixture was diluted with DCM (20 mL), and washed with sat.Na₂S₂O₄ (15 mL). The organic phase was concentrated and purified on a silica gel column eluted with 0-2% MeOH in DCM to give 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid as oil (100 mg, 64%). MS ES+ m/z 400 [M+H]⁺.

Intermediate 9: 2-[1-(2-Ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 1

Step 1: 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 1. The mixture of 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one (10 g, 31 mmol) and 2-aminobenzoic acid (8.38 g, 61.1 mmol) in DMF (70 mL) was stirred at 80° C. for 2 h. The reaction mixture was diluted with DCM (200 mL) and water (500 mL), then adjusted to pH=11 with aq. NaOH (2 M). The aqueous layer was washed with MTBE (200 mL×2) and adjusted to pH=3 with aq. HCl (2 M) to give a solid. After stirring 0.5 h, the mixture was filtered and the filter cake was purified by chiral SFC (AB, 6; See Tables 4 and 5 for chiral columns and eluents) to give the product as a solid (4.7 g, yield: 47%, ee: 93%). MS ES+ m/z 383 [M+H]⁺.

Step 2: 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 1. To a mixture of 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 1 (850 mg, 2.22 mmol) and DCM (10 mL) was added m-CPBA (585 mg, 2.88 mmol, 85% purity) under N₂ at 0° C., and stirred at 25° C. for 2 h. The mixture was quenched with sat.Na₂S₂O₃ (10 mL) at 0° C., the aqueous layer was extracted with EtOAc (20 mL×2). The combined organic layer was washed with brine (20 mL×3), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=1/0 to 1/4) to give 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 1 as a solid. (410 mg, yield: 42%). MS ES+ m/z 400 [M+H]⁺.

Intermediate 10: 8-Acetyl-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one

Prepared in the same manner as 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one to give 8-acetyl-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one as a solid (yield: 57%). MS ES+ m/z 277 [M+H]⁺.

Intermediate 11: 8-(1-Bromoethyl)-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one

Step 1: 2-ethylsulfanyl-8-(1-hydroxyethyl)-3,6-dimethyl-chromen-4-one. Prepared in the same manner as 2-ethylsulfanyl-8-(1-hydroxyethyl)-6-methyl-chromen-4-one to give the product as a solid (yield: 61%). MS ES+ m/z 278 [M+H]⁺.

Step 2: 8-(1-bromoethyl)-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one. Prepared in the same manner as 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one to give 8-(1-bromoethyl)-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one as a solid (yield: 95%). MS ES+ m/z 342 [M+H]⁺.

Intermediate 12: 2-[1-(2-Ethylsulfonyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid

To a solution of 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (199 g, 519 mmol) in DCM (3 L) was added m-CPBA (142 g, 701 mmol, 85% purity) at 0° C., and stirred at rt for 2 h. The mixture was added sat.Na₂S₂O₃ (1000 mL) and extracted with DCM (600 mL×3). The combined organic phase was washed with brine (1000 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (PE to PE:EtOAc=1:1 to DCM:EtOAc=2:1) to give 2-[1-(2-ethylsulfonyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid as a solid (70 g, crude). MS ES+ m/z 438 [M+Na].

Intermediate 13: Methyl 2-[1-(2-ethylsulfonyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate

To a solution of methyl 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate (1.0 g, 2.5 mmol) in DCM (10 mL) was added m-CPBA (1.3 g, 6.4 mmol, 85% purity) at 0° C., and stirred at rt for 16 h. The mixture was quenched with sat.Na₂S₂O₃ (10 mL), the aqueous layer was extracted with DCM (20 mL×3). The combined organic phase was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (PE:EtOAc=1:0 to 1:1, then DCM:EtOAc=2:1) to give methyl 2-[1-(2-ethylsulfonyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate as a solid (650 mg, yield: 65%).

Intermediate 14: 8-[(1R)-1-Aminoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one

Step 1: 8-acetyl-2-ethylsulfonyl-6-methyl-chromen-4-one. To a mixture of 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one (10.0 g, 38.1 mmol) in DCM (100 mL) was added m-CPBA (23.2 g, 114 mmol, 85% purity) at 0° C., and stirred at 25° C. for 16 h. The mixture was cooled to −10° C. and filtrated, the filter cake was washed with DCM (100 mL×2). The filtrate was diluted with sat.Na₂S₂O₃ (150 mL), the aqueous layer was extracted with DCM (100 mL×3). The combined extracts were washed with sat.NaHCO₃(100 mL×3), brine (200 mL), dried over anhydrous Na₂SO₄, filtrated and concentrated to give the product as a solid (11.3 g, crude). MS ES+ m/z 295 [M+H]⁺.

Step 2: 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. To a mixture of 8-acetyl-2-ethylsulfonyl-6-methyl-chromen-4-one (10.3 g, 35.0 mmol) and 4,4-dimethylpiperidine (6.28 g, 42.0 mmol, HCl salt) in DCM (100 mL) was added DIEA (22.6 g, 175 mmol) at 0° C., and stirred at rt for 16 h. The reaction mixture was diluted with H₂O (100 mL), the aqueous layer was extracted with DCM (100 mL×3). The combined extracts were washed with HCl (1 M, 100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄, filtrated and concentrated to give the product as a solid (11 g, crude). MS ES+ m/z 314 [M+H]⁺.

Step 3: (NE,R)—N-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylidene]-2-methyl-propane-2-sulfinamide. To a mixture of 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (11.0 g, 35.1 mmol) and (R)-2-methylpropane-2-sulfinamide (8.51 g, 70.2 mmol) in THE (100 mL) was added Ti(i-PrO)₄ (39.9 g, 140 mmol), and stirred at 75° C. for 16 h. When cooled to rt, the mixture was quenched with brine (200 mL), stirred for 0.5 h and filtered. The filter cake was washed with EtOAc (300 mL). The aqueous layer was extracted with EtOAc (300 mL×2). The combined extracts were washed with brine (200 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a solid (13 g, crude). MS ES+ m/z 417 [M+H]⁺.

Step 4: (R)—N-[(1R)-1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide. To a mixture of (NE,R)—N-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylidene]-2-methyl-propane-2-sulfinamide (13.0 g, 31.2 mmol) and CeCl₃·7H₂O (5.81 g, 15.6 mmol) in MeOH (120 mL) was added NaBH₄ (2.36 g, 62.4 mmol) in portions at −78° C., and stirred at 20° C. for 16 h. The reaction mixture was quenched with sat.NH₄Cl (200 mL) and filtered. The filter cake was washed with DCM (500 mL). The aqueous layer was extracted with DCM (300 mL×2). The combined extracts were washed with brine (300 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by preparative HPLC to give the product as a solid (3.8 g, yield: 27%). MS ES+ m/z 419 [M+H]⁺.

Step 5: 8-[(1R)-1-aminoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. To a mixture of (R)—N-[(1R)-1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide (3.8 g, 9.08 mmol) in EtOAc (30 mL) was added HCl (8.65 mL, 4 M in EtOAc), and stirred at rt for 16 h. The reaction mixture was diluted with H₂O (50 mL) and washed with EtOAc (50 mL×2). The aqueous phase was adjusted to pH=12 with aq.NH₃H₂O (25%) and extracted with DCM (50 mL×2). The combined extracts were washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give 8-[(1R)-1-aminoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one as a solid (2.2 g, yield: 76%). MS ES+ m/z 315 [M+H]⁺.

Intermediate 15: 8-[(1R)-1-Aminoethyl]-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one

Step 1: 8-acetyl-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one. Prepared in the same manner as 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one to give the product as a solid (yield: 87%). MS ES+ m/z 338 [M+H]⁺.

Step 2: (NE,R)—N-[1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylidene]-2-methyl-propane-2-sulfinamide. Prepared in the same manner as (NE,R)—N-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylidene]-2-methyl-propane-2-sulfinamide to give the product as oil (crude). MS ES+ m/z 441 [M+H]⁺.

Step 3: (R)—N-[(1R)-1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide. Prepared in the same manner as (R)—N-[(1R)-1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide to give the product as a solid (yield: 31%). MS ES+ m/z 443 [M+H]⁺.

Step 4: 8-[(1R)-1-aminoethyl]-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one. Prepared in the same manner as 8-[(1R)-1-aminoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one to give 8-[(1R)-1-aminoethyl]-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one as yellow oil (crude). MS ES+ m/z 339 [M+H]⁺.

Intermediate 16: Methyl 2-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoate

Step 1: methyl 2-[1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoate. To a mixture of 8-(1-bromoethyl)-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one (780 mg, 2.29 mmol) in DMF (10 mL) was added methyl 2-aminobenzoate (691 mg, 4.57 mmol), and stirred at 80° C. for 16 h. The reaction mixture was diluted with H₂O (30 mL), extracted with EtOAc (40 mL×3), washed with brine (40 mL×3), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by flash silica gel chromatography eluent of 0˜15% EtOAc in petroleum ether to give the product as a solid (940 mg, yield: 93%). MS ES+ m/z 412 [M+H]⁺.

Step 2: methyl 2-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoate. To a mixture of methyl 2-[1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoate (940 mg, 2.28 mmol) in DCM (10 mL) was added m-CPBA (557 mg, 2.74 mmol, 85% purity) at 0° C., and stirred at 25° C. for 15 h. The mixture was quenched with sat.Na₂SO₃ (30 mL), extracted with DCM (30 mL×3), washed with sat.NaHCO₃(50 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-35% EtOAc in petroleum ether to give methyl 2-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoate as a solid (760 mg, yield: 78%). MS ES+ m/z 428 [M+H]⁺.

Intermediate 17: 2-[1-(2-Ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid

Step 1: 2-[1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid. A mixture of 8-(1-bromoethyl)-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one (37.0 g, 108 mmol) and 2-aminobenzoic acid (29.7 g, 216 mmol) in DMF (300 mL) was stirred at 80° C. for 16 h. The mixture was diluted with H₂O (400 mL), adjusted to pH=12 with NaOH (2 M) and washed with MTBE (200 mL×2). The aqueous layer was adjusted to pH=2 with HCl (2 M) to give a white solid and filtered. The filter cake was dried in vacuum to give the product as a solid (51 g, crude). MS ES+ m/z 398 [M+H]⁺.

Step 2: 2-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid. To a mixture of 2-[1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (46.0 g, 116 mmol) in DCM (300 mL) was added m-CPBA (58.7 g, 289 mmol, 85% purity) at 0° C., and stirred at 25° C. for 2 h. The mixture was quenched with sat.Na₂S₂O₃(400 mL) and extracted with DCM (300 mL×3). The combined organic phase was washed with brine (300 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-3% MeOH in DCM to give 2-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid as oil (24 g, crude). MS ES+ m/z 414 [M+H]⁺.

Intermediate 18: 2-[[(1R)-1-(2-Ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]benzoic acid

Step 1: (NE,R)—N-[1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylidene]-2-methyl-propane-2-sulfinamide. Prepared in the same manner as (NE,R)—N-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylidene]-2-methyl-propane-2-sulfinamide to give the product as a yellow oil (crude). MS ES+ m/z 380 [M+H]⁺.

Step 2: (R)—N-[(1R)-1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]-2-methyl-propane-2-sulfinamide. To a mixture of (NE,R)—N-[1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylidene]-2-methyl-propane-2-sulfinamide (100 g, 179 mmol) and CeCl₃·7H₂O (33.3 g, 89.5 mmol) in MeOH (500 mL) was added NaBH₄ (13.5 g, 358. mmol) at −70° C. under N₂, then the mixture was warmed up to 25° C. slowly and stirred for 16 h. The residue was triturated with EtOAc (400 mL). The mixture was filtered, the filtrate was concentrated under reduced pressure to give a residue. This was recrystallized by adding 200 mL EtOAc to obtain a filtrate, which was concentrated to give the product as yellow oil (30 g, yield: 33%). MS ES+ m/z 382 [M+H]⁺.

Step 3: 8-[(1R)-1-aminoethyl]-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one. Prepared in the same manner as 8-[(1R)-1-aminoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one to give the product as a yellow solid (7.8 g, yield: 78%, ee: 97.57%). MS ES+ m/z 278 [M+H]⁺.

Step 4: 2-[[(1R)-1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]benzoic acid. The mixture of 8-[(1R)-1-aminoethyl]-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one (6.44 g, 23.2 mmol), 2-iodobenzoic acid (8.64 g, 34.8 mmol), N,N-diethylethanamine (4.70 g, 46.4 mmol) and copper (885 mg, 13.9 mmol) in dimethylacetamide (120 mL) was stirred at 110° C. for 3 h. The mixture was added H₂O (400 mL) and adjusted pH to 12 with NaOH (aq., 2M), let stand for 10 minutes to filter and wash the filtrate with EtOAc (200 mL), the mixture was adjusted pH to 2 with HCl (aq., 2M), the mixture was filtered and concentrated to give the product as yellow oil (8 g, crude). MS ES+ m/z 398 [M+H]⁺.

Step 5: 2-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]benzoic acid. To a mixture of 2-[[(1R)-1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]benzoic acid (8.00 g, 14.8 mmol) in DCM (80 mL) was added m-CPBA (3.02 g, 14.8 mmol) at 0° C., then the mixture was stirred at 25° C. for 1 h. The mixture was added with sat.Na₂S₂O₃ (100 mL) and extracted with DCM (100 mL×3). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na₂SO₄, filtered and concentrated in vacuum to give 2-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]benzoic acid as yellow oil (9 g, crude). MS ES+ m/z 414 [M+H]⁺.

Intermediate 19: 8-(1-Bromoethyl)-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one

Step 1: 8-bromo-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one. A mixture of 5-fluoroisoindoline;hydrochloride (2.00 g, 9.52 mmol, HCl salt) and DIPEA (3.28 g, 25.4 mmol, 4.42 mL) in DCM (10 mL) was added dropwise to a stirred solution of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (2 g, 6.35 mmol) in DCM (10 mL) at 10° C. under N₂ atmosphere. The resulting solution was stirred at 45° C. for 16 h. The reaction mixture was diluted with water (40 mL) and extracted with DCM (50 mL×2). The combined organic layer was washed with brine (50 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was triturated with 20% EtOAc in petroleum ether (60 mL) to give the product as a solid (2.37 g, crude). MS ES+ m/z 374 [M+H]⁺.

Step 2: 8-acetyl-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one. A mixture of 8-bromo-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one (1.67 g, 4.46 mmol) in dioxane (30 mL) was added Pd(PPh₃)₂CL₂ (313 mg, 0.446 mmol) and tributyl(1-ethoxyvinyl)stannane (1.93 g, 5.36 mmol) under N₂ atmosphere, and stirred at 95° C. for 16 h. The reaction was added HCl (1 M, 2.23 mL) and stirred at 50° C. for 0.5 h. When cooled to rt, the mixture was added sat. KF (50 mL), stirred for 0.5 h and filtered. The filtrate was extracted with DCM (50 mL×2). The combined organic layer was washed with brine (7 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by a silica gel chromatography eluted with 0-5% MeOH in DCM to give the product as a solid (2 g, crude). MS ES+ m/z 337.9 [M+H]⁺.

Step 3: 2-(5-fluoroisoindolin-2-yl)-8-(1-hydroxyethyl)-6-methyl-chromen-4-one. A mixture of 8-acetyl-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one (1.50 g, 4.45 mmol) in DCM (15 mL) and MeOH (10 mL) was added NaBH₄ (185 mg, 4.89 mmol) at 0° C., and stirred at 25° C. for 1 h. The mixture was diluted with water (40 mL), extracted with a DCM/MeOH=10:1 (100 mL×4). The combined extracts were washed with brine (200 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel column eluted with 0-4% MeOH in DCM to give the product as a solid (1.3 g, yield: 86%). MS ES+ m/z 340 [M+H]⁺.

Step 4: 8-(1-bromoethyl)-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one. To a mixture of 2-(5-fluoroisoindolin-2-yl)-8-(1-hydroxyethyl)-6-methyl-chromen-4-one (1.10 g, 3.24 mmol) in DCM (30 mL) was added PBr₃ (2.63 g, 9.72 mmol) dropwise at 0° C., then warmed to 25° C. and stirred for 14 h. The reaction mixture was added water (20 mL) at 0° C. and adjusted to pH=8 with sat.NaHCO₃. The mixture was extracted with a DCM/MeOH=10:1 (110 mL×2). The combined organic layer was washed with brine (60 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give 8-(1-bromoethyl)-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one as a solid (1 g, yield: 67%). MS ES+ m/z 402 [M+H]⁺.

Intermediate 20: 6-Chloro-3-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid

Step 1: (NE,R)—N-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylidene]-2-methyl-propane-2-sulfinamide. To a mixture of 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one (9.49 g, 36.2 mmol) and (R)-2-methylpropane-2-sulfinamide (8.77 g, 72.4 mmol) in THE (100 mL) was added Ti(i-PrO)₄ (41.1 g, 145 mmol), and stirred at 75° C. for 16 h. The reaction was added (R)-2-methylpropane-2-sulfinamide (6.58 g, 54.3 mmol) and Ti(i-PrO)₄ (30.9 g, 109 mmol) and stirred at 75° C. for another 16 h. The mixture was added brine (200 mL), stirred for 0.5 h and filtered. The filter cake was washed with EtOAc (300 mL). The aqueous layer was extracted with EtOAc (300 mL×2). The combined extracts were washed with brine (200 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a solid (13 g, curde). MS ES+ m/z 366 [M+H]⁺.

Step 2: (R)—N-[(1R)-1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethyl]-2-methyl-propane-2-sulfinamide. To a mixture of (NE,R)—N-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylidene]-2-methyl-propane-2-sulfinamide (12.0 g, 32.8 mmol) in DCM (100 mL) and MeOH (100 mL) was added AcOH (15.8 g, 262 mmol) and NaBH₃CN (6.19 g, 98.5 mmol) at −10° C., and stirred at 25° C. for 16 h. The mixture was quenched with NH₃H₂O (250 mL), extracted with DCM (200 mL×3). The combined extracts were washed with brine (300 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a solid (11 g, isomer ratio: 3/2, crude). MS ES+ m/z 368 [M+H]⁺.

Step 3: 8-(1-aminoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one. To a mixture of (R)—N-[(1R)-1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]-2-methyl-propane-2-sulfinamide (6.00 g, 16.3 mmol) in EtOAc (40 mL) was added HCl (82 mL, 4 M in EtOAc), and stirred at 25° C. for 16 h. The mixture was concentrated, diluted with H₂O (100 mL) and washed with EtOAc (100 mL). The aqueous phase was adjusted to pH=8 with NH₃H₂O (25%) and extracted with DCM (100 mL×3). The combined organic phase was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as oil (2.4 g, crude). MS ES+m/z 264 [M+H]⁺.

Step 4: 6-chloro-3-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid. A mixture of 8-(1-aminoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one (2.70 g, 10.3 mmol) and 6-chloro-3-fluoro-pyridine-2-carboxylic acid (3.60 g, 20.5 mmol) in DMSO (10 mL) was stirred at 120° C. for 17 h. The mixture was added 6-chloro-3-fluoro-pyridine-2-carboxylic acid (900 mg, 5.13 mmol) and stirred at 120° C. for another 3 h. When cooled to rt, the mixture was poured into water (30 mL), adjusted to pH=2 with HCl (1M) and extracted with DCM (30 mL×3). The combined organic layer was washed with brine (40 mL×3), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-87% EtOAc:DCM=2:1 in petroleum ether to give the product as a gum (710 mg, yield: 12%). MS ES+ m/z 419 [M+H]⁺.

Step 5: 6-chloro-3-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid. A mixture of 6-chloro-3-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid (710 mg, 1.69 mmol) in DCM (10 mL) was added m-CPBA (475 mg, 2.20 mmol) at 0° C., and stirred at 25° C. for 2 h. The mixture was added m-CPBA (110 mg, 0.508 mmol) and stirred at 25° C. for another 2 h. The reaction mixture was quenched with sat.Na₂S₂O₃ (40 mL) and extracted with DCM (40 mL×3). The combined organic phase was washed with brine (40 mL), dried over anhydrous Na₂SO₄, filtered and concentrated.

The residue was purified by silica gel chromatography eluted with 0%-6% MeOH in dichloromethane to give 6-chloro-3-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid as a solid (620 mg, yield: 54%). MS ES+ m/z 319 [M+H]⁺.

Intermediate 21: Methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate

Step 1: (R)—N-[(1R)-1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethyl]-2-methyl-propane-2-sulfinamide. Prepared in the same manner as (R)—N-[(1R)-1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethyl]-2-methyl-propane-2-sulfinamide (Intermediate 20, Step 2) to give the product as brown gum (18.8 g, isomer ratio: 3/2, crude). The crude product was purified by preparative HPLC to give the product as oil (5.33 g, yield: 17%). MS ES+ m/z 368 [M+H]⁺.

Step 2: 8-[(1R)-1-aminoethyl]-2-ethylsulfanyl-6-methyl-chromen-4-one. Prepared in the same manner as 8-(1-aminoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 87%). MS ES+ m/z 264 [M+H]⁺.

Step 3: methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate. A mixture of 8-[(1R)-1-aminoethyl]-2-ethylsulfanyl-6-methyl-chromen-4-one (880 mg, 3.34 mmol), methyl 6-chloro-3-fluoro-pyridine-2-carboxylate (950 mg, 5.01 mmol) and DIEA (2.16 g, 16.7 mmol) in DMF (10 mL) was stirred at 100° C. for 21 h. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL×2). The combined extracts were washed with brine (10 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-35% EtOAc in petroleum ether to give the product as a solid (1.08 g, yield: 75%). MS ES+ m/z 433 [M+H]⁺.

Step 4: methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate. A mixture of methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate (0.98 g, 2.26 mmol) in DCM (10 mL) was added m-CPBA (597 mg, 2.94 mmol, 85% purity) at 0° C., and stirred at 10° C. for 2 h. The mixture was added m-CPBA (46.0 mg, 0.226 mmol, 85% purity) and stirred at 25° C. for another 18 h. The mixture was added m-CPBA (46.0 mg, 0.226 mmol, 85% purity) and stirred at 25° C. for another 1 h. The mixture was quenched with sat.Na₂S₂O₃ (50 mL) and extracted with DCM (40 mL×3). The combined organic phase was washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-60% EtOAc in petroleum ether to give methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate as a solid (600 mg, yield: 59%). MS ES+ m/z 449 [M+H]⁺.

Intermediate 22: 6-Chloro-3-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid

Step 1: (NE,R)—N-[1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylidene]-2-methyl-propane-2-sulfinamide. Prepared in the same manner as (NE,R)—N-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylidene]-2-methyl-propane-2-sulfinamide to give the product as a solid (crude).

Step 2: (R)—N—[(I R)-1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]-2-methyl-propane-2-sulfinamide. Prepared in the same manner as (R)—N-[(1R)-1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethyl]-2-methyl-propane-2-sulfinamide to give the product as a solid (crude, isomer ratio: 3/1). MS ES+ m/z 398 [M+H]⁺.

Step 3: 8-(1-aminoethyl)-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one. Prepared in the same manner as 8-(1-aminoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 69%). MS ES+ m/z 294 [M+H]⁺.

Step 4: 6-chloro-3-[1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid. Prepared in the same manner as 6-chloro-3-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid to give the product as a solid (yield: 39%). MS ES+ m/z 433 [M+H]⁺.

Step 5: 6-chloro-3-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid. Prepared in the same manner as 6-chloro-3-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid to give 6-chloro-3-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid as a solid (yield: 89%). MS ES+ m/z 449 [M+H]⁺.

Intermediate 23: Methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate

Step 1: (R)—N-[(1R)-1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]-2-methyl-propane-2-sulfinamide. Prepared in the same manner as (R)—N-[(1R)-1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethyl]-2-methyl-propane-2-sulfinamide to give the product as a yellow solid (crude, isomer ratio: 3/1). The crude product (6 g) was purified by preparative HPLC to give the product as a solid (yield: 63%, de: 94.8%). MS ES+ m/z 382 [M+H]⁺.

Step 2: 8-[(1R)-1-aminoethyl]-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one. Prepared in the same manner as 8-(1-aminoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 99%, ee: 98%). MS ES+ m/z 278 [M+H]⁺.

Step 3: methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfanyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate. Prepared in the same manner as methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate to give the product as a solid (3 g, yield: 96%, ee: 97%). MS ES+ m/z 447 [M+H]⁺.

Step 4: methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate. Prepared in the same manner as methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate to give methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate as a solid (yield: 90%). MS ES+ m/z 463 [M+H]⁺.

Intermediate 24: 2-[1-(2-Ethylsulfinyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid

Step 1: (2-bromo-4-fluoro-phenyl) acetate. Prepared in the same manner as 2-bromo-4-methylphenyl acetate to give the product as oil (crude).

Step 2: 1-(3-bromo-5-fluoro-2-hydroxy-phenyl)ethanone. Prepared in the same manner as 1-(3-bromo-2-hydroxy-5-methyl-phenyl)ethanone to give the product as a solid (yield: 79%).

Step 3: 8-bromo-6-fluoro-4-hydroxy-chromene-2-thione. Prepared in the same manner as 8-bromo-4-hydroxy-6-methyl-chromene-2-thione to give the product as a solid (yield: 43%).

Step 4: 8-bromo-2-ethylsulfanyl-6-fluoro-chromen-4-one. Prepared in the same manner as 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 45%). MS ES+ m/z 305 [M+H]⁺.

Step 5: 8-acetyl-2-ethylsulfanyl-6-fluoro-chromen-4-one. Prepared in the same manner as 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 36%). MS ES+ m/z 267 [M+H]⁺.

Step 6: 2-ethylsulfanyl-6-fluoro-8-(1-hydroxyethyl)chromen-4-one. Prepared in the same manner as 2-ethylsulfanyl-8-(1-hydroxyethyl)-6-methyl-chromen-4-one to give the product as a solid (crude). MS ES+ m/z 269 [M+H]⁺.

Step 7: 8-(1-bromoethyl)-2-ethylsulfanyl-6-fluoro-chromen-4-one. Prepared in the same manner as 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 35%). MS ES+ m/z 333 [M+H]⁺.

Step 8: 2-[1-(2-ethylsulfanyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give the product as a solid (yield: 73%). MS ES+ m/z 388 [M+H]⁺.

Step 9: 2-[1-(2-ethylsulfinyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid. A mixture of 2-[1-(2-ethylsulfanyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid (2.80 g, 7.23 mmol) in DCM (30 mL) was added m-CPBA (2.03 g, 9.40 mmol, 85% purity) at 0° C., and stirred at 25° C. for 2 h. The mixture was quenched with sat.Na₂S₂O₃ (50 mL), extracted with DCM (50 ml×3), washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered, concentrated. The residue was purified by silica gel chromatography eluted with 0%-70% EtOAc in petroleum ether to give 2-[1-(2-ethylsulfinyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid as a solid (600 mg, yield: 19%). MS ES+ m/z 404 [M+H]⁺.

Intermediate 25: 2-[1-(2-Ethylsulfinyl-6-fluoro-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid

Step 1: (2-bromo-4-fluoro-phenyl) propanoate. Prepared in the same manner as 2-bromo-4-methylphenyl acetate to give the product as oil (crude).

Step 2: 1-(3-bromo-5-fluoro-2-hydroxy-phenyl)propan-1-one. Prepared in the same manner as 1-(3-bromo-2-hydroxy-5-methyl-phenyl)ethanone to give the product as a solid (crude).

Step 3: 8-bromo-6-fluoro-4-hydroxy-3-methyl-chromene-2-thione. Prepared in the same manner as 8-bromo-4-hydroxy-6-methyl-chromene-2-thione to give the product as a solid (yield: 64%).

Step 4: 8-bromo-2-ethylsulfanyl-6-fluoro-3-methyl-chromen-4-one. Prepared in the same manner as 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 45%). MS ES+ m/z 319 [M+H]⁺.

Step 5: 8-acetyl-2-ethylsulfanyl-6-fluoro-3-methyl-chromen-4-one. Prepared in the same manner as 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 59%). MS ES+ m/z 281 [M+H]⁺.

Step 6: 2-ethylsulfanyl-6-fluoro-8-(1-hydroxyethyl)-3-methyl-chromen-4-one. Prepared in the same manner as 2-ethylsulfanyl-8-(1-hydroxyethyl)-6-methyl-chromen-4-one to give the product as a solid (crude). MS ES+ m/z 283 [M+H]⁺.

Step 7: 8-(1-bromoethyl)-2-ethylsulfanyl-6-fluoro-3-methyl-chromen-4-one. Prepared in the same manner as 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 81%). MS ES+ m/z 347 [M+H]⁺.

Step 8: 2-[1-(2-ethylsulfanyl-6-fluoro-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give the product as a solid (yield: 31%). MS ES+ m/z 402 [M+H]⁺.

Step 9: 2-[1-(2-ethylsulfinyl-6-fluoro-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfinyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give 2-[1-(2-ethylsulfinyl-6-fluoro-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid as a solid (yield: 66%). MS ES+ m/z 418 [M+H]⁺.

Intermediate 26: 2-[1-(2-Ethylsulfinyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid

Step 1: 8-bromo-4-hydroxy-chromene-2-thione. A mixture of 1-(3-bromo-2-hydroxy-phenyl) ethanone (19.6 g, 91.1 mmol) and CS₂ (8.33 g, 109 mmol) in THE (100 mL) was slowly added to a stirred mixture of t-BuOK (30.7 g, 273 mmol) in THE (100 mL) at 0° C., then stirred at 25° C. under N₂ for 16 h. The mixture was diluted with water (100 mL) and EtOAc (80 mL) and adjusted to pH=3 with HCl (2 M). The aqueous layer was extracted with EtOAc (80 mL×2). The combined extracts were washed with brine (80 mL), dried over Na₂SO₄, filtered and concentrated. The residue was triturated with DCM (40 mL) to give the product as a solid (15.5 g, yield: 66%).

Step 2: 8-bromo-2-ethylsulfanyl-chromen-4-one. Prepared in the same manner as 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (12 g, yield: 62%). MS ES+m/z 285 [M+H]⁺.

Step 3: 8-acetyl-2-ethylsulfanyl-chromen-4-one. Prepared in the same manner as 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (8.7 g, yield: 83%). MS ES+ m/z 249 [M+H]⁺.

Step 4: 2-ethylsulfanyl-8-(1-hydroxyethyl)chromen-4-one. Prepared in the same manner as 2-ethylsulfanyl-8-(1-hydroxyethyl)-6-methyl-chromen-4-one to give the product as a solid (5.48 g, crude). MS ES+ m/z 251 [M+H]⁺.

Step 5: 8-(1-bromoethyl)-2-ethylsulfanyl-chromen-4-one. Prepared in the same manner as 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as oil (4.1 g, 60%, purity: 100%). MS ES+ m/z 315 [M+H]⁺.

Step 6: 2-[1-(2-ethylsulfanyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give the product as a solid (crude). MS ES+ m/z 370 [M+H]⁺.

Step 7: 2-[1-(2-ethylsulfinyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfinyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give 2-[1-(2-ethylsulfinyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid as a solid (yield: 51%). MS ES+ m/z 386 [M+H]⁺.

Intermediate 27: 2-[1-[2-Ethylsulfinyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid

Step 1: 1-[2-hydroxy-5-(trifluoromethyl)phenyl]ethanone. To a mixture of 2-bromo-4-(trifluoromethyl)phenol (50.0 g, 207 mmol) in dioxane (400 mL) was added Pd(PPh₃)₂Cl₂ (7.28 g, 10.37 mmol) and tributyl(1-ethoxyvinyl)stannane (90.0 g, 249 mmol) under N₂ atmosphere, and stirred at 95° C. for 16 h. To the reaction was added HCl (1 M, 207 mL) and stirred at 50° C. for 1 h. When cooled to rt, to the mixture was added sat. KF (200 mL), stirred for 0.5 h and filtered. The aqueous layer was extracted with DCM (100 mL×2). The combined organic layer was washed with brine (150 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as light yellow oil (31 g, crude).

Step 2: 1-[3-bromo-2-hydroxy-5-(trifluoromethyl)phenyl]ethanone. A mixture of Br₂ (29.0 g, 182 mmol) in AcOH (50 mL) was added to a mixture of 1-[2-hydroxy-5-(trifluoromethyl)phenyl]ethanone (31.0 g, 152 mmol) and NaOAc (15.0 g, 182 mmol) in AcOH (250 mL) dropwise at 0° C., and stirred at 20° C. for 16 h. The reaction mixture was poured into ice and water (500 mL) and filtered. The filter cake was dried in vacuum to give the product as solid (31 g, yield: 72%).

Step 3: 8-bromo-4-hydroxy-6-(trifluoromethyl)chromene-2-thione. Prepared in the same manner as 8-bromo-4-hydroxy-chromene-2-thione to give the product as a solid (yield: 64%). MS ES+m/z 326 [M+H]⁺.

Step 4: 8-bromo-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one. Prepared in the same manner as 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 70.7%). MS ES+ m/z 354 [M+H]⁺.

Step 5: 8-acetyl-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one. Prepared in the same manner as 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product (crude) as a solid. MS ES+ m/z 317 [M+H]⁺.

Step 6: 2-ethylsulfanyl-8-(1-hydroxyethyl)-6-(trifluoromethyl)chromen-4-one. Prepared in the same manner as 2-ethylsulfanyl-8-(1-hydroxyethyl)-6-methyl-chromen-4-one to give the product as a gum (yield: 78%). MS ES+ m/z 319 [M+H]⁺.

Step 7: 8-(1-bromoethyl)-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one. Prepared in the same manner as 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 99%). MS ES+ m/z 382 [M+H]⁺.

Step 8: 2-[1-[2-ethylsulfanyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give the product as a solid (yield: 93%). MS ES+ m/z 438 [M+H]⁺.

Step 9: 2-[1-[2-ethylsulfinyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfinyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give 2-[1-[2-ethylsulfinyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid as a solid (yield: 89%). MS ES+ m/z 454 [M+H]⁺.

Intermediate 28: 2-[1-[2-Ethylsulfinyl-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid

Step 1: 2-[4-(trifluoromethyl)phenoxy]tetrahydropyran. A mixture of 4-(trifluoromethyl)phenol (50 g, 308 mmol), 3,4-dihydro-2H-pyran (64.9 g, 771 mmol) and 4-methylbenzenesulfonic acid;pyridine (77.5 g, 308 mmol) in DCM (500 mL) was stirred at rt for 4 h. The reaction mixture was diluted with H₂O (500 mL) and extracted with DCM (500 mL×3). The combined organic phase was washed with brine (500 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel column eluted with 0-10% EtOAc in petroleum ether to give the product as oil (62 g, yield: 82%).

Step 2: 1-[2-tetrahydropyran-2-yloxy-5-(trifluoromethyl)phenyl]propan-1-one. n-BuLi (2.5 M in hexane, 151 mL) was placed in a 1000 mL round-bottomed flask and while stirring tetramethylethylenediamine (TMEDA) (43.9 g, 378 mmol) was added dropwise at −10° C. After stirring 0.25 h, 2-[4-(trifluoromethyl)phenoxy]tetrahydropyran (62.0 g, 252 mmol) was added dropwise at −10° C., whereupon the lithium complex precipitated. After stirring 1 h, N-methoxy-N-methyl-propanamide (44.3 g, 378 mmol) was added, then the mixture was stirred at −10° C. for 1 h. To the mixture was added H₂O (300 mL) dropwise and extracted with EtOAc (200 mL×2). The combined organic phase was washed with brine (200 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by a silica gel column eluted with 0-10% EtOAc in petroleum ether to give the product as oil (15.5 g, yield: 20%).

Step 3: 1-[2-hydroxy-5-(trifluoromethyl)phenyl]propan-1-one. To a solution of 1-[2-tetrahydropyran-2-yloxy-5-(trifluoromethyl)phenyl]propan-1-one (14.5 g, 48.0 mmol) in MeOH (50 mL) was added HCl (10 mL, 12 M), and stirred at 20° C. for 16 h. The mixture was adjusted to pH=7 with sat.NaHCO₃, extracted with EtOAc (40 mL×3). The combined extracts were washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as oil (9.70 g, crude).

Step 4: 1-[3-bromo-2-hydroxy-5-(trifluoromethyl)phenyl]propan-1-one. A mixture of Br₂ (8.53 g, 53.3 mmol) in HOAc (18 mL) was added to a mixture of 1-[2-hydroxy-5-(trifluoromethyl)phenyl]propan-1-one (9.70 g, 44.5 mmol), NaOAc (4.38 g, 53.3 mmol) in HOAc (80 mL) dropwise at 0° C., and stirred at 20° C. for 16 h. The mixture was poured into ice and water (140 mL) and filtered. The filter cake was dried in vacuum to give the product as oil (7.81 g, crude).

Step 5: 8-bromo-4-hydroxy-3-methyl-6-(trifluoromethyl)chromene-2-thione. Prepared in the same manner as 8-bromo-4-hydroxy-chromene-2-thione to give the product as a solid (crude). MS ES+ m/z 340 [M+H]⁺.

Step 6: 8-bromo-2-ethylsulfanyl-3-methyl-6-(trifluoromethyl)chromen-4-one. Prepared in the same manner as 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 54%). MS ES+ m/z 368 [M+H]⁺.

Step 7: 8-acetyl-2-ethylsulfanyl-3-methyl-6-(trifluoromethyl)chromen-4-one. Prepared in the same manner as 8-acetyl-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 78%). MS ES+ m/z 331 [M+H]⁺.

Step 8: 2-ethylsulfanyl-8-(1-hydroxyethyl)-3-methyl-6-(trifluoromethyl)chromen-4-one. Prepared in the same manner as 2-ethylsulfanyl-8-(1-hydroxyethyl)-6-methyl-chromen-4-one to give the product as a solid (crude). MS ES+ m/z 333 [M+H]⁺.

Step 9: 8-(1-bromoethyl)-2-ethylsulfanyl-3-methyl-6-(trifluoromethyl)chromen-4-one. Prepared in the same manner as 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product as a solid (yield: 53%). MS ES+ m/z 396 [M+H]⁺.

Step 10: 2-[1-[2-ethylsulfanyl-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give the product as a solid (crude). MS ES+ m/z 452 [M+H]⁺.

Step 11: 2-[1-[2-ethylsulfinyl-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfinyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give 2-[1-[2-ethylsulfinyl-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid (yield: 55%) as a solid. MS ES+ m/z 468 [M+H]⁺.

Intermediate 29: 2-[1-(2-Ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]-5-fluoro-benzoic acid

Step 1: 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]-5-fluoro-benzoic acid. Prepared in the same manner as 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give the product as a solid (1.5 g, yield: 76%). MS ES+ m/z 402 [M+H]⁺.

Step 2: 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]-5-fluoro-benzoic acid Prepared in the same manner as 2-[1-(2-ethylsulfinyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid to give 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]-5-fluoro-benzoic acid as a solid (700 mg, yield: 45%). MS ES+ m/z 418 [M+H]⁺.

Intermediate 30: 8-(1-Bromopropyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one

Step 1: 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxypropyl)-6-methyl-chromen-4-one. To a solution of 8-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (370.0 mg, 1 eq., 1.056 mmol) in THE (25 mL) at −78° C. was added n-butyllithium (74.44 mg, 464.8 μL, 2.5 molar in hexanes, 1.1 eq., 1.162 mmol) dropwise and the resulting mixture was stirred for 20 minutes.

After that propionaldehyde (92.03 mg, 1.5 eq., 1.585 mmol) in THE (1 mL) was added dropwise to the reaction mixture and the resulting mixture was allowed to warm at room temperature and stirred for 1 hour. The reaction was quenched with sat. NH₄Cl solution (10 mL) and extracted with ethyl acetate (2×50 mL). The organic layer was dried over sodium sulfate and concentrated and purified using silica column (10-100% ethyl acetate in heptane) to give the product (65.0 mg, 197 μmol, 18.7%). MS ES+ m/z 330.4 [M+H]⁺.

Step 2: 8-(1-bromopropyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. To a mixture of 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxypropyl)-6-methyl-chromen-4-one (65.0 mg, 1 eq., 197 μmol) in DCM (6 mL) was added PBr₃ (80.1 mg, 27.9 μL, 1.5 eq., 296 μmol) at 0° C., and stirred at 20° C. for 2 h. The reaction mixture was quenched with aq. NaHCO₃(50 mL), extracted with DCM (60 mL×3). The combined extract was washed with brine (50 mL), dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated and purified on a silica gel column eluted with 0-50% ethyl acetate in heptane to give 8-(1-bromopropyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (26 mg, 66 μmol, 34%). MS ES+ m/z 394.2 [M+2H]⁺.

Intermediate 31: tert-Butyl 6-chloro-3-[1-[2-ethylsulfanyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]pyridine-2-carboxylate

Step 1: 8-(1-azidoethyl)-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one. Sodium azide (0.36 mg, 3 eq., 5.6 μmol) was added to a stirred solution of 8-(1-bromoethyl)-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one (0.71 mg, 1 eq., 1.9 μmol) in DMF (20 mL) at 25° C., and then heated to 80° C. for 1.25 hours. The reaction was diluted with water (220 ml) and EtOAc (75 ml). The aqueous layer was extracted with EtOAc (2×75 ml) and then washed the combined organic with brine (50 ml). The organic layer was dried over Na₂SO₄, filtered, and concentrated to give the product (0.63 g, 99% yield) as an amber oil. MS ES+ m/z 344 [M+H]⁺.

Step 2: 8-(1-aminoethyl)-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one. Triphenylphosphine-polymer bound (963 mg, 2 eq., 3.67 mmol) (resin bound ˜3 mmol/g, 2 eq. added 1.4 g) was added to a solution of 8-(1-azidoethyl)-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one (630 mg, 1 eq., 1.84 mmol) in THE (18 mL) and water (4.25 mL) and stirred at 25° C. for 3 days. The reaction mixture was filtered, and resin washed with THF/water (1/1, 10 ml) and then MeOH (10 ml). The filtrate was concentrated to give the product (0.39 g, 67% yield). MS ES+ m/z 318 [M+H]⁺.

Step 3: tert-butyl 6-chloro-3-fluoropicolinate. 6-Chloro-3-fluoropicolinic acid (2.0 g, 1 eq., 11 mmol), DCC (2.8 g, 1.2 eq., 14 mmol), DMAP (0.35 g, 0.25 eq., 2.8 mmol), and tBuOH (1.7 g, 2.2 mL, 2 eq., 23 mmol) in DCM (15 mL) were stirred at 25° C. for 30 minutes. The reaction mixture was filtered, concentrated, and purified using a silica column (0-50% ethyl acetate in heptane) to give the product (2.4 g, 91% yield) as an off white solid. MS ES+ m/z 254.2 [M+Na]⁺.

Step 4: tert-butyl 6-chloro-3-[1-[2-ethylsulfanyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]pyridine-2-carboxylate. 8-(1-aminoethyl)-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one (390 mg, 1 eq., 1.24 mmol), tert-butyl 6-chloro-3-fluoropicolinate (288 mg, 1 eq., 1.24 mmol), and DIEA (322 mg, 434 μL, 2 eq., 2.49 mmol) in DMSO (5 mL) were heated at 100° C. for 12 hours. The reaction was diluted with water (200 ml) and extracted with EtOAc (3×75 ml). The combined organic layers were washed with brine (50 ml), dried over Na₂SO₄, filtered, concentrated and purified by silica chromatography (10-75% EtOAc/Heptanes) to give tert-butyl 6-chloro-3-[1-[2-ethylsulfanyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]pyridine-2-carboxylate (180 mg, 28% yield) MS ES+m/z 529 [M+H]⁺.

Intermediate 32: tert-Butyl 6-chloro-3-[1-(2-ethylsulfanyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylate

Step 1: 8-(1-azidoethyl)-2-ethylsulfanyl-6-fluoro-chromen-4-one. Prepared in the same manner as 8-(1-azidoethyl)-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one to give the product (0.33 g, yield: 93%). MS ES+ m/z 294 [M+H]⁺.

Step 2: 8-(1-aminoethyl)-2-ethylsulfanyl-6-fluoro-chromen-4-one. Prepared in the same manner as 8-(1-aminoethyl)-2-ethylsulfanyl-6-(trifluoromethyl)chromen-4-one to give the product (0.13 g, yield: 44%). MS ES+ m/z 268 [M+H]⁺.

Step 3: tert-butyl 6-chloro-3-[1-(2-ethylsulfanyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylate. Prepared in the same manner as tert-butyl 6-chloro-3-[1-[2-ethylsulfanyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]pyridine-2-carboxylate to give tert-butyl 6-chloro-3-[1-(2-ethylsulfanyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylate (0.13 g, yield: 56%). MS ES+ m/z 479 [M+H]⁺.

Intermediate 33: Methyl 5-amino-2-(trifluoromethyl)pyrimidine-4-carboxylate

Step 1: 4-bromo-2-(trifluoromethyl)pyrimidin-5-amine. To a solution of 2-(trifluoromethyl)pyrimidin-5-amine (3 g, 1 eq., 18.4 mmol) in acetonitrile (30 mL) was added 1-bromopyrrolidine-2,5-dione (3.93 g, 1.2 eq., 22.1 mmol). The mixture was stirred at room temperature for 16 h. Acetonitrile was evaporated, the residue was partitioned in water and ethyl acetate (100 mL), the layers separated, and the aqueous layer was extracted (2×50 mL) with ethyl acetate. The combined organic layers were washed with brine (50 mL), dried over anhydrous Na₂SO₄, and concentrated. The reaction was repeated at 2 g scale (13.7 mmol). The resulting crude materials from both experiments were combined and purified by silica gel chromatography eluted with 0-30% ethyl acetate in heptane to give the product (4.42 g, 54%) as a yellow solid. MS ES+ m/z 242.0, 244.0 [M+H]⁺.

Step 2: methyl 5-amino-2-(trifluoromethyl)pyrimidine-4-carboxylate. A solution of 4-bromo-2-(trifluoromethyl)pyrimidin-5-amine (2 g, 1 eq., 8.26 mmol) in triethylamine (16 mL) was treated with methanol (7.94 g, 10.0 mL, 30 eq., 247.9 mmol). The mixture was degassed and flushed with argon, the process was repeated three times. Xantphos (286.9 mg, 0.06 eq., 495.9 μmol) and Pd(OAc)₂ (55.66 mg, 0.03 eq., 247.9 μmol) was added. The mixture was degassed and flushed with argon (3×) followed with carbon monoxide (3×). The mixture was stirred at 70° C. under CO atmosphere (balloon) for 16 h. After cooling down to room temperature, the mixture was diluted with ethyl acetate (50 mL) and water (50 mL) and filtered over a pad of celite. The filtrate was separated, the aqueous layer was extracted with ethyl acetate (2×50 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by silica gel chromatography and eluted with 0-30% ethyl acetate in heptane to give methyl 5-amino-2-(trifluoromethyl)pyrimidine-4-carboxylate (1.12 g, 61%) as an off-white solid. MS ES+ m/z 222.0 [M+H]⁺.

Intermediate 34: 8-(1-Bromoethyl)-6-chloro-2-isoindolin-2-yl-chromen-4-one

Step 1: 8-bromo-6-chloro-4-hydroxy-chromene-2-thione. Prepared in the same manner as 8-bromo-4-hydroxy-6-methyl-chromene-2-thione to give the product (0.80 g). MS ES+ m/z 291, 293 [M+H]⁺.

Step 2: 8-bromo-6-chloro-2-ethylsulfanyl-chromen-4-one. Prepared in the same manner as 8-bromo-2-ethylsulfanyl-6-methyl-chromen-4-one to give the product (0.50 g). MS ES+ m/z 319, 321 [M+H]⁺.

Step 3: 8-bromo-6-chloro-2-ethylsulfonyl-chromen-4-one. Prepared in the same manner as 8-bromo-2-ethylsulfonyl-3,6-dimethyl-chromen-4-one to give the product.

Step 4: 8-bromo-6-chloro-2-isoindolin-2-yl-chromen-4-one. Prepared in the same manner as 8-bromo-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one to give the product (0.35 g). MS ES+ m/z 376, 378 [M+H]⁺.

Step 5: 8-acetyl-6-chloro-2-isoindolin-2-yl-chromen-4-one. Prepared in the same manner as 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one to give the product. MS ES+m/z 340 [M+H]⁺.

Step 6: 6-chloro-8-(1-hydroxyethyl)-2-isoindolin-2-yl-chromen-4-one. Prepared in the same manner as 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-3,6-dimethyl-chromen-4-one to give the product. MS ES+ m/z 342 [M+H]⁺.

Step 7: 8-(1-bromoethyl)-6-chloro-2-isoindolin-2-yl-chromen-4-one. Prepared in the same manner as 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one to give 8-(1-bromoethyl)-6-chloro-2-isoindolin-2-yl-chromen-4-one (0.12 g). MS ES+ m/z 404, 406 [M+H]⁺.

Intermediate 35: 8-(1-Bromoethyl)-3-cyclopropyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one

Step 1: 8-acetyl-3-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (3.00 g, 9.57 mmol) and NBS (1.70 g, 9.57 mmol) in DCM (30 mL) was stirred at 25° C. for 0.5 h. The mixture was concentrated and purified on a silica gel column eluted with 0-100% EtOAc in petroleum ether and 0-50% (EtOAc/DCM (3/1)) in petroleum ether. The impure product was diluted with DCM (80 mL), washed with aq. NaOH (0.1 M, 100 mL×4), dried over Na₂SO₄, filtered and concentrated to give the product as a solid (2.98 g, 79%). MS ES+ m/z 392 [M+H]⁺.

Step 2: 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-3-vinyl-chromen-4-one. A mixture of 8-acetyl-3-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (1.00 g, 2.55 mmol), tributyl(vinyl)stannane (1.21 g, 3.82 mmol), Pd(PPh₃)₄ (295 mg, 0.255 mmol), CuI (146 mg, 0.765 mmol) and CsF (1.16 g, 7.65 mmol) in toluene (10 mL) was stirred at 130° C. under N₂ for 16 h. When cooled to rt the mixture was quenched with sat. aq. KF (30 mL) and stirred for 1 h, then filtered and the filter cake was rinsed with DCM (50 mL). The filtrate was extracted with DCM (50 mL×3), washed with brine (80 mL), dried over Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0-40% EtOAc in petroleum ether to give the product as a solid (670 mg, 77%). MS ES+ m/z 340 [M+H]⁺.

Step 3: 8-acetyl-3-cyclopropyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-3-vinyl-chromen-4-one (300 mg, 0.884 mmol) in DCM (6 mL) was added ZnEt₂ (1 M, 4.42 mmol) and CH₂I₂ (2.37 g, 8.84 mmol) dropwise at 0° C. under N₂, and stirred at 25° C. for 16 h. The mixture was quenched with sat.aq.NH₄Cl (10 mL), extracted with DCM (20 mL×3), washed with brine (30 mL), dried over Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0-35% EtOAc in petroleum ether to give the product as gum (320 mg, crude). MS ES+ m/z 354 [M+H]⁺.

Step 4: 3-cyclopropyl-2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-6-methyl-chromen-4-one. Prepared in the same manner as 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-3,6-dimethyl-chromen-4-one to give the product. MS ES+ m/z 356 [M+H]⁺.

Step 5: 8-(1-bromoethyl)-3-cyclopropyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. Prepared in the same manner as 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one to give 8-(1-bromoethyl)-3-cyclopropyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one as a solid. MS ES+ m/z 417, 419 [M+H]⁺.

Intermediate 36: 8-(1-Bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3-isoxazol-4-yl-6-methyl-chromen-4-one

Step 1: 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-3-isoxazol-4-yl-6-methyl-chromen-4-one. A mixture of 8-acetyl-3-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (300 mg, 0.765 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (224 mg, 1.15 mmol), ditertbutyl(cyclopentyl)phosphane;dichloropalladium;iron (50 mg, 0.76 mmol), and TEA (232 mg, 2.29 mmol) in H₂O (2 mL) and THE (10 mL) was stirred at 25° C. under N₂ for 40 h. The mixture was quenched with H₂O (20 mL), extracted with EtOAc (100 mL×3), washed with brine (100 mL×2), dried with Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-28% EtOAc in petroleum ether to give 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-3-isoxazol-4-yl-6-methyl-chromen-4-one as a solid (220 mg, 76%). MS ES+ m/z 381 [M+H]⁺.

Step 2: 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-3-isoxazol-4-yl-6-methyl-chromen-4-one. Prepared in the same manner as 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-3,6-dimethyl-chromen-4-one to give the product. MS ES+ m/z 383 [M+H]⁺.

Step 3: 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3-isoxazol-4-yl-6-methyl-chromen-4-one. Prepared in the same manner as 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one to give 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3-isoxazol-4-yl-6-methyl-chromen-4-one as a solid. MS ES+ m/z 444, 446 [M+H]⁺.

The following compounds in Table 6 were prepared essentially as described for 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one, Steps 1-9.

TABLE 6 ES/MS Intermediate m/z # Chemical Name Structure (M + H) 37 8-(1-bromoethyl)-2-(4,4-dimethyl-1- piperidyl)-3-ethyl-6-methyl- chromen-4-one

406 38 8-(1-bromoethyl)-2-(4,4-dimethyl-1- piperidyl)-6-fluoro-chromen-4-one

382 39 8-(1-bromoethyl)-2-(4,4-dimethyl-1- piperidyl)-6- (trifluoromethyl)chromen-4-one

432 40 8-(1-bromoethyl)-2-(4,4-dimethyl-1- piperidyl)-6-methoxy-chromen-4- one

394

Example 1: 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-4-fluoro-5-methoxy-benzoic acid

A mixture of 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (40 mg, 0.11 mmol) and 2-amino-4-fluoro-5-methoxy-benzoic acid (39 mg, 0.21 mmol) in DMF (1 mL) was stirred at 80° C. for 12 h. When cooled to rt the mixture was adjusted to pH=12 with NaOH (aq 2M), diluted with H₂O (15 mL) and washed with EtOAc (20 mL×2). The aqueous phase was adjusted to pH=2 with HCl (aq 1M) and extracted with EtOAc (20 mL×2). The combined extract was washed with brine (10 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by preparative HPLC to give 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-4-fluoro-5-methoxy-benzoic acid as a solid (11.6 mg, 22%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.98 (s, 6H), 1.38-1.43 (m, 4H), 1.56 (d, J=6.8 Hz, 3H), 2.31 (s, 3H), 3.54 (dd, J=6.8, 4.4 Hz, 4H), 3.72 (s, 3H), 5.01 (s, 1H), 5.52 (s, 1H), 6.37 (d, J=14.0 Hz, 1H), 7.35 (d, J=2.0 Hz, 1H), 7.51 (d, J=10.0 Hz, 1H), 7.60 (d, J=1.6 Hz, 1H), 8.26 (s, 1H). MS ES+ m/z 483 [M+H]⁺.

The following compounds in Table 7 were prepared essentially as described for 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-4-fluoro-5-methoxy-benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 7 ES/MS m/z (M + H) Example & Chiral # Chemical Name Structure Method 2 2-(4,4-Dimethyl-1-piperidyl)-6-methyl- 8-[1-[(2-methylpyrazol-3- yl)amino]ethyl]chromen-4-one

395 3 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-5- (trifluoromethyl)benzoic acid

503 4 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzenesulfonic acid

471 5 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8-yl]ethyl- methyl-amino]benzoic acid

449 6 5-Cyano-2-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

460 7 5-Bromo-2-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

513 8 2-(4,4-Dimethyl-1-piperidyl)-8-[1-(5- fluoro-2-nitro-anilino)ethyl]-6-methyl- chromen-4-one

454 9 4-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-1,3- dihydrobenzimidazol-2-one

447 10 4-Chloro-2-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

469 11 3-Chloro-2-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

469 12 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-4,5-dimethyl-benzoic acid

463 13 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-4,5-difluoro-benzoic acid

470 14 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-5-fluoro-benzoic acid

453 15 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-5-methoxy-benzoic acid

465 16 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-4,5-dimethoxy-benzoic acid

495 17 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-3-methyl-benzoic acid

467 18 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-4-fluoro-5-methyl- benzoic acid

467 19 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-N-methoxy-benzamide

464 20 2-(4,4-Dimethyl-1-piperidyl)-6-methyl- 8-[1-[2-(1H-tetrazol-5- yl)anilino]ethyl]chromen-4-one

459 21 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzenesulfonamide

470 22 2-(4,4-Dimethyl-1-piperidyl)-8-[1- (indan-4-ylamino)ethyl]-6-methyl- chromen-4-one

431 23 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-6-fluoro-benzoic acid

453 24 2-Chloro-6-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

469 25 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-6-methyl-benzoic acid

349 26 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-3-methoxy-benzoic acid

465 27 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-4-methyl-benzoic acid

467 28 5-Chloro-2-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

469 29 7-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]isoindolin-1-one

446 30 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzonitrile

416 31 Methyl 2-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoate

449 32 4-((1-(2-(4,4-Dimethylpiperidin-1-yl)- 6-methyl-4-oxo-4H-chromen-8- yl)ethyl)amino)isoindoline-1,3-dione

460 33 6-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-1,3-benzodioxole-5- carboxylic acid

479 34 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-5-ethyl-benzoic acid

463 35 6-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-3-fluoro-2-methyl- benzoic acid

467 36 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-4-fluoro-benzoic acid

453 37 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-6-methyl-benzoic acid

449 38 8-[1-[2- (Difluoromethylsulfonyl)anilino]ethyl]- 2-(4,4-dimethyl-1-piperidyl)-6-methyl- chromen-4-one

505 39 3-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]thiophene-2-carboxylic acid

441 40 4-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-1-methyl-pyrazole-3- carboxylic acid

439 41 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-5-ethynyl-benzoic acid

459 42 6-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-2,3-difluoro-benzoic acid

471 43 3-Chloro-6-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]-2-fluoro-benzoic acid

487 44 3-Bromo-6-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]-2-fluoro-benzoic acid

531 45 3-[2-[1-[2-(4,4-Dimethyl-1-piperidyl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]phenyl]-4H-1,2,4- oxadiazol-5-one

475 46 7-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzothiophene-2- carboxylic acid

491 47 4-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-1,3-benzoxazole-2- carboxylic acid

476 48 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-4,6-difluoro-benzoic acid

504 49 3-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-6-methyl-pyridine-2- carboxylic acid

450 50 6-Cyclopropyl-3-[1-[2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]pyridine-2-carboxylic acid

476 51 2-[1-[3-Cyclopropyl-2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethyalmino]benzoic acid, Isomer 1

475 R, 14 52 2-[1-[3-Cyclopropyl-2-(4,4-dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 2

475 R, 14 53 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6- isoxazol-4-yl-6-methyl-4-oxo- chromen-8-yl]ethylamino]benzoic acid, Isomer 1

502 W, 24 54 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-3- isoxazol-4-yl-6-methyl-4-oxo- chromen-8-yl]ethylamino]benzoic acid, Isomer 2

502 W, 24 55 2-[1-[2-(4,4-dimethyl-1-piperidyl)-3- ethyl-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

463 56 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6- fluoro-4-oxo-chromen-8- yl]ethylamino]benzoic acid

439 57 2-[1-[2-(4,4-dimethyl-1-piperidyl)-4- oxo-6-(trifluoromethyl)chromen-8- yl]ethylamino]benzoic acid

489 58 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6- methoxy-4-oxo-chromen-8- yl]ethylamino]benzoic acid

451

Example 59: 2-[1-[2-[(3S)-3-Methoxy-1-piperidyl]-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1. A mixture of methyl 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate (50 mg, 0.12 mmol), (3S)-3-methoxypiperidine (37 mg, 0.24 mmol, HCl salt) and DIPEA (156 mg, 1.21 mmol) in DCM (1.5 mL) was stirred at 40° C. for 46 h. The mixture was diluted with water (15 mL) and extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by silica gel chromatography eluted with 0-5% MeOH in DCM to give methyl 2-[1-[2-[(3S)-3-methoxy-1-piperidyl]-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate as gum (40 mg, 73%). MS ES+ m/z 451 [M+H]⁺.

Step 2. A mixture of methyl 2-[1-[2-[(3S)-3-methoxy-1-piperidyl]-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate (40 mg, 0.089 mmol) and NaOH (14 mg, 0.36 mmol) in MeOH (2 mL) and H₂O (2 mL) was stirred at 40° C. for 16 h. The mixture was concentrated and purified by preparative HPLC to give 2-[1-[2-[(3S)-3-methoxy-1-piperidyl]-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (14.82 mg, 38%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.45-1.58 (m, 1H), 1.58 (d, J=6.8 Hz, 3H), 1.57-1.69 (m, 1H), 1.69-1.80 (m, 1H), 1.80-1.92 (m, 1H), 2.30 (s, 3H), 3.28 (d, J=5.6 Hz, 3H), 3.45-3.60 (m, 4H), 3.65-3.75 (m, 1H), 5.00-5.12 (m, 1H), 5.56 (s, 1H), 6.38 (t, J=9.2 Hz, 1H), 6.53 (t, J=7.2 Hz, 1H), 7.19 (t, J=8.0 Hz, 1H), 7.36 (d, J=2.0 Hz, 1H), 7.60 (d, J=2.0 Hz, 1H), 7.81 (dd, J=8.0, 1.6 Hz, 1H), 8.65 (brs, 1H). MS ES+ m/z 437 [M+H]⁺.

The following compounds in Table 8 were prepared essentially as described for 2-[1-[2-[(3S)-3-methoxy-1-piperidyl]-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 8 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method  60 1-[8-[1-(2-Carboxyanilino)ethyl]-6- methyl-4-oxo-chromen-2-yl]-3- methyl-azetidine-3-carboxylic acid

437  61 2-[1-[6-Methyl-4-oxo-2-(3-oxo-2,7- diazaspiro[4.5]decan-7-yl)chromen- 8-yl]ethylamino]benzoic acid

476  62 2-[1-[2-(3-Carbamoyl-3-methyl- azetidin-1-yl)-6-methyl-4-oxo- chromen-8-yl]ethylamino]benzoic acid

436  63 2-[1-[2-(3-Chloroazetidin-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

413  64 2-[1-[2-(6-Azaspiro[2.5]octan-6-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

433  65 2-[1-[2-(3,3-Dimethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

435  66 2-[1-[2-(4-Ethyl-4-methyl-1- piperidyl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid

449  67 2-[1-[6-Methyl-4-oxo-2-(5- oxospiro[3,4-dihydro-1,4- benzoxazepine-2,4′-piperidine]-1′- yl)chromen-8-yl]ethylamino]benzoic acid

554  68 2-[1-[2-[3-(Dimethylamino)azetidin- 1-yl]-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

422  69 2-[1-[2-(3-Fluoroazetidin-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

397  70 2-[1-[2-(3,3-Dimethylazetidin-1-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

407  71 2-[1-[2-(4-Isopropyl-4-methyl-1- piperidyl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid

463  72 2-[1-[6-Methyl-2-(2-oxa-8- azaspiro[4.5]decan-8-yl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid

463  73 2-[1-[2-[4-(Methoxymethyl)-4- methyl-1-piperidyl]-6-methyl-4-oxo- chromen-8-yl]ethylamino]benzoic acid

465  74 2-[1-[6-Methyl-4-oxo-2-[4- (trifluoromethyl)-1- piperidyl]chromen-8- yl]ethylamino]benzoic acid

475  75 2-[1-[2-(6,6-Dimethyl-3- azabicyclo[3.1.0]hexan-3-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

433  76 2-[1-[6-Methyl-2-(9-oxa-2- azaspiro[5.5]undecan-2-yl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid

477  77 2-[1-[2-(Isobutylamino)-6-methyl-4- oxo-chromen-8- yl]ethylamino]benzoic acid

395  78 2-[1-[2-(Dimethylamino)-6-methyl- 4-oxo-chromen-8- yl]ethylamino]benzoic acid

367  79 2-[1-[6-Methyl-2-(3-methyl-1- piperidyl)-4-oxo-chromen-8- yl]ethylamino]benzoic acid

421  80 2-[1-[2-(3-Ethyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

435  81 2-[1-[6-Methyl-4-oxo-2-(1-oxo-2,8- diazaspiro[4.5]decan-8-yl)chromen- 8-yl]ethylamino]benzoic acid

476  82 2-[1-[6-Methyl-2-(8-oxa-3- azabicyclo[3.2.1]octan-3-yl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid

435  83 2-[1-[2-(4-Isobutyl-4-methyl-1- piperidyl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid

477  84 2-[1-[2-(4-Cyano-4-methyl-1- piperidyl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid^(a)

446  85 2-[1-[6-Methyl-2-[2-(4- methylsulfonylphenyl)morpholin-4- yl]-4-oxo-chromen-8- yl]ethylamino]benzoic acid

563  86 2-[1-[2-(3-Acetyl-3,9- diazaspiro[5.5]undecan-9-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

518  87 2-[1-[6-Methyl-2-[4-(2- methylpropanoyl)piperazin-1-yl]-4- oxo-chromen-8- yl]ethylamino]benzoic acid

478  88 2-[1-[2-(2-Azaspiro[3.5]nonan-2-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

447  89 2-[1-[2-(3,9-Diazaspiro[5.5]undecan- 3-yl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

476  90 2-[1-[2-(4-tert- Butoxycarbonylpiperazin-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

508  91 2-[1-(6-Methyl-4-oxo-2-piperazin-1- yl-chromen-8-yl)ethylamino]benzoic acid

408  92 2-[1-[6-Methyl-2-(4- methylpiperazin-1-yl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid

422  93 2-[1-[6-Methyl-2-(1-oxa-9- azaspiro[5.5]undecan-9-yl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid

477  94 2-[1-[6-Methyl-2-(3-oxa-9- azaspiro[5.5]undecan-9-yl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid

477  95 2-[1-[6-Methyl-4-oxo-2-(1-oxo-2,9- diazaspiro[4.5]decan-9-yl)chromen- 8-yl]ethylamino]benzoic acid

476  96 2-[1-[2-(8-Azaspiro[4.5]decan-8-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

461  97 2-[1-[2-(3-Carbamoyl-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

450  98 2-[1-[6-Methyl-2-(2-oxa-7- azaspiro[3.5]nonan-7-yl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid

449  99 2-[1-[2-(Diethylamino)-6-methyl-4- oxo-chromen-8- yl]ethylamino]benzoic acid

395 100 2-[1-[2-(5,7-Dihydropyrrolo[3,4- b]pyridin-6-yl)-6-methyl-4-oxo- chromen-8-yl]ethylamino]benzoic acid

442 101 2-[1-[2-(1,3-Dihydropyrrolo[3,4- c]pyridin-2-yl)-6-methyl-4-oxo- chromen-8-yl]ethylamino]benzoic acid

442 102 2-[1-[2-(5,7-Dihydropyrrolo[3,4- d]pyrimidin-6-yl)-6-methyl-4-oxo- chromen-8-yl]ethylamino]benzoic acid

443 103 2-[l-[6-Methyl-4-oxo-2-[4- (trifluoromethyl)isoindolin-2- yl]chromen-8-yl]ethylamino]benzoic acid

509 104 2-[1-[2-(4-Fluoroisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

459 105 2-[1-[2-(5-Fluoroisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

459 106 2-[1-[2-[2-[4- (Difluoromethoxy)phenyl]morpholin- 4-yl]-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

551 107 2-[1-[2-[2- (Dimethylcarbamoyl)spiro[4,7- dihydropyrazolo[5,1-c][1,4]oxazine- 6,4′-piperidine]-1′-yl]-6-methyl-4- oxo-chromen-8- yl]ethylamino]benzoic acid

586 108 2-[1-[6-Methyl-2-[(1R,5R)-1-methyl- 2-azabicyclo[3.2.0]heptan-2-yl]-4- oxo-chromen-8- yl]ethylamino]benzoic acid

433 109 2-[1-[6-Methyl-2-(6-oxa-2- azaspiro[4.5]decan-2-yl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid

463 110 2-[1-[2-(3-Cyano-1-piperidyl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

432 111 2-[1-[2-(4-Methoxy-2- azabicyclo[2.1.1]hexan-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

435 X, 38 112 2-[1-[2-(4-Methoxy-2- azabicyclo[2.1.1]hexan-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 2

435 X, 38 113 2-[1-[2-[(3aS,7aS)-3,3a,4,6,7,7a- Hexahydro-2H-furo[3,2-c]pyridin-5- yl]-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

449 114 2-[1-[2-(2-Isopropylmorpholin-4-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

451 115 2-[1-[2-[4-[(6-Methoxypyrimidin-4- yl)amino]-1-piperidyl]-6-methyl-4- oxo-chromen-8- yl]ethylamino]benzoic acid

530 116 2-[1-[6-Methyl-2-(4-methyl-4- morpholino-1-piperidyl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid

506 117 2-[1-[2-(1,1-Dioxo-1,4-thiazinan-4- yl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

457 118 2-[1-[6-Methyl-4-oxo-2-(1-oxo-1,4- thiazinan-4-yl)chromen-8- yl]ethylamino]benzoic acid

441 119 2-[1-[2-(5-Cyanoisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

466 J, 18 120 2-[1-[2-(5-Cyanoisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 2

466 J, 18 121 2-[1-[6-Methyl-4-oxo-2-[2-[4- (trifluoromethyl)phenyl]morpholin-4- yl]chromen-8-yl]ethylamino]benzoic acid

553 122 2-[1-[6-Methyl-2-[2-(2- methylpyrazol-3-yl)morpholin-4-yl]- 4-oxo-chromen-8- yl]ethylamino]benzoic acid

489 123 2-[1-[2-(5-Fluoroisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

459 124 2-[1-[2-(5-Fluoroisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 2

459 125 2-[1-[2-(5-Cyanoisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

466 ^(a)Used LiOH—H₂O instead of NaOH as the base.

Example 126: 2-[1-[2-(Ethylamino)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (30 mg, 0.075 mmol), ethanamine (25 mg, 0.30 mmol, HCl) and DIPEA (68 mg, 0.53 mmol) in DCM (2 mL) was stirred at 35° C. for 20 h. The mixture was diluted with water (10 mL) and DCM (20 mL), adjusted to pH=4 with HCl (aq 1 M), and extracted with DCM (20 mL). The extract was dried over anhydrous Na₂SO₄, filtered, concentrated and purified by preparative HPLC to give 2-[1-[2-(ethylamino)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (11 mg, 40%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.21 (t, J=7.2 Hz, 3H), 1.56 (d, J=6.8 Hz, 3H), 2.28 (s, 3H), 3.26-3.29 (m, 2H), 5.10-5.13 (m, 1H), 5.25 (s, 1H), 6.43 (d, J=8.8 Hz, 1H), 6.54 (t, J=7.6 Hz, 1H), 7.22-7.26 (m, 1H), 7.32 (d, J=2.0 Hz, 1H), 7.58 (d, J=1.2 Hz, 1H), 7.80 (dd, J=8.0, 1.6 Hz, 1H), 8.08 (s, 1H), 8.37 (d, J=6.4 Hz, 1H), 12.77 (br s, 1H). MS ES+ m/z 367 [M+H]⁺.

The following compounds in Table 9 were prepared essentially as described for 2-[1-[2-(ethylamino)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 9 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method 127 2-[1-[2-(4- Methoxycarbonylpiperazin-1- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid, Isomer 1

466 T, 35 128 2-[1-[2-(4- Methoxycarbonylpiperazin-1- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid, Isomer 2

466 T, 35 129 2-[1-[2-(4,4-Difluoro-1- piperidyl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 1

443 U, 5 130 2-[1-[2-(4,4-Difluoro-1- piperidyl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 2

443 U, 5 131 2-[1-[2-(3-Cyanoazetidin-1- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid

404 132 2-[1-[2-(6,8-Dihydro- [1,3]dioxolo[4,5-e]isoindol-7- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid, Isomer 1

485 J, 35 133 2-[1-[2-(6,8-Dihydro- [1,3]dioxolo[4,5-e]isoindol-7- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid, Isomer 2

485 J, 35 134 2-[1-[2-(3,3-Dimethyl- 3a,4,6,6a-tetrahydro-2H- furo[3,4-b]pyrrol-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

463 AF, 38 then AG, 36 135 2-[1-[2-(3,3-Dimethyl- 3a,4,6,6a-tetrahydro-2H- furo[3,4-b]pyrrol-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 2

463 AF, 38 then AG, 36 136 2-[1-[2-(3,3-Dimethyl- 3a,4,6,6a-tetrahydro-2H- furo[3,4-b]pyrrol-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 3

463 AF, 38 then AG, 36 137 2-[1-[2-(3,3-Dimethyl- 3a,4,6,6a-tetrahydro-2H- furo[3,4-b]pyrrol-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 4

463 AF, 38 then AG, 36 138 2-[1-(6-Methyl-4-oxo-2- spiro[3a,4,6,6a-tetrahydro-2H- furo[3,4-b]pyrrole-3,1′- cyclobutane]-1-yl-chromen-8- yl)ethylamino]benzoic acid, Isomer 1

475 U, 28 then Y, 36 139 2-[1-(6-Methyl-4-oxo-2- spiro[3a,4,6,6a-tetrahydro-2H- furo[3,4-b]pyrrole-3,1′- cyclobutane]-1-yl-chromen-8- yl)ethylamino]benzoic acid, Isomer 2

475 U, 28 then Y, 36 140 2-[1-(6-Methyl-4-oxo-2- spiro[3a,4,6,6a-tetrahydro-2H- furo[3,4-b]pyrrole-3,1′- cyclobutane]-1-yl-chromen-8- yl)ethylamino]benzoic acid, Isomer 3

475 U, 28 then Y, 36 141 2-[1-(6-Methyl-4-oxo-2- spiro[3a,4,6,6a-tetrahydro-2H- furo[3,4-b]pyrrole-3,1′- cyclobutane]-1-yl-chromen-8- yl)ethylamino]benzoic acid, Isomer 4

475 U, 28 then Y, 36 142 2-[1-[2-(2- Azabicyclo[4.2.0]octan-2-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

433 J, 18 143 2-[1-[2-(2- Azabicyclo[4.2.0]octan-2-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 2

433 J, 18 144 2-[1-[2-(3,3-Difluoroazetidin- 1-yl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid

415 145 2-[1-[6-Methyl-2-[4-methyl-4- (trifluoromethyl)-1-piperidyl]- 4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

489 Y, 35 146 2-[1-[6-Methyl-2-[4-methyl-4- (trifluoromethyl)-1-piperidyl]- 4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 2

489 Y, 35 147 2-[1-[2-[4-Methoxy-4- (trifluoromethyl)-1-piperidyl]- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

505 Y, 5 148 2-[1-[2-[4-Methoxy-4- (trifluoromethyl)-1-piperidyl]- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 2

505 Y, 5 149 2-[1-[2-(3,4-Dihydro-1H- isoquinolin-2-yl)-6-methyl-4- oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

455 W, 28 150 2-[1-[2-(3,4-Dihydro-1H- isoquinolin-2-yl)-6-methyl-4- oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 2

455 W, 28 151 2-[1-[6-Methyl-2-(1,4- oxazepan-4-yl)-4-oxo- chromen-8- yl]ethylamino]benzoic acid

423 152 2-[1-[2-[4-(Cyclobutoxy)-1- piperidyl]-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 1

477 X, 35 153 2-[1-[2-[4-(Cyclobutoxy)-1- piperidyl]-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 2

477 X, 35 154 2-[1-[6-Methyl-4-oxo-2-(4- phenoxy-1-piperidyl)chromen- 8-yl]ethylamino]benzoic acid

499 155 2-[1-[6-Methyl-4-oxo-2-(2- oxo-1,7-diazaspiro[3.5]nonan- 7-yl)chromen-8- yl]ethylamino]benzoic acid

462 156 2-[1-[2-(3-Methoxycarbonyl- 3,9-diazaspiro[5.5]undecan-9- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid

534 157 2-[1-[6-Methyl-4-oxo-2-(2- oxospiro[1H-pyrido[2,3- d][1,3]oxazine-4,4′- piperidine]-1′-yl)chromen-8- yl]ethylamino]benzoic acid

541 158 2-[1-[6-Methyl-4-oxo-2-[4- (1H-pyrrolo[2,3-b]pyridin-3- yl)-1-piperidyl]chromen-8- yl]ethylamino]benzoic acid

523 159 2-[1-(6-Methyl-4-oxo-2- spiro[4,5-dihydro-2H-1,5- benzoxazepine-3,4′- piperidine]-1′-yl-chromen-8- yl)ethylamino]benzoic acid

540 160 2-[1-[2-(6,8-Dihydro-5H- imidazo[1,2-a]pyrazin-7-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

445 161 2-[1-[2-(3,4-Dihydro-1H- benzofuro[3,2-c]pyridin-2-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

495 162 2-[1-[2-(6,7-Dihydro-4H- furo[3,2-c]pyridin-5-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

445 163 2-[1-[2-(6,8-Dihydro-5H- [1,2,4]triazolo[4,3-a]pyrazin- 7-yl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid

446 164 2-[1-[6-Methyl-2-(3-methyl- 6,8-dihydro-5H- [1,2,4]triazolo[4,3-a]pyrazin- 7-yl)-4-oxo-chromen-8- yl]ethylamino]benzoic acid

460 165 2-[1-[2-(3-Cyclopropyl-6,8- dihydro-5H- [1,2,4]triazolo[4,3-a]pyrazin- 7-yl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid

486 166 2-[1-[2-(3,3- Dimethylpyrrolidin-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

421 167 2-[1-[2-(4-Chloro-1- piperidyl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 1

441 168 2-[1-[2-(4-Chloro-1- piperidyl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 2

441 169 2-[1-[24[3-(Hydroxymethyl)- 1-adamantyl]amino]-6-methyl- 4-oxo-chromen-8- yl]ethylamino]benzoic acid

503 170 2-[1-[2-(4-Cyano-4-ethyl-1- piperidyl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid

460 171 2-[1-[2-(3,4-Dihydro-1H- pyrrolo[1,2-a]pyrazin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

444 172 2-[1-[6-Methyl-2-(3-methyl-3- phenyl-azetidin-1-yl)-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

469 173 2-[1-[2-[3-(Methoxymethyl)- 3-phenyl-azetidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

499 174 2-[1-[2-(3-Benzyl-3-methyl- azetidin-1-yl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid

483 175 2-[1-[2-(1H-Indol-3- ylmethylamino)-6-methyl-4- oxo-chromen-8- yl]ethylamino]benzoic acid

468 176 2-[1-[2-(1H-Indol-2- ylmethylamino)-6-methyl-4- oxo-chromen-8- yl]ethylamino]benzoic acid

468 177 2-[1-[2-(3- Azabicyclo[3.1.1]heptan-3-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

419 178 2-[1-[2-(3-Carbamoyl-3- phenyl-azetidin-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

498 179 2-[1-[6-Methyl-4-oxo-2-[(3S)- 3-phenylpyrrolidin-1- yl]chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

469 180 2-[1-[6-Methyl-4-oxo-2-[(3R)- 3-phenylpyrrolidin-1- yl]chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

469 181 2-[1-[2-(6,6-Difluoro-3- azabicyclo[3.1.1]heptan-3-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

455 182 2-[1-[2-(6- Azabicyclo[3.1.1]heptan-6-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

419 183 2-[1-[2-[(3R,4S)-3,4- Difluoropyrrolidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

429 184 2-[1-[2-[(3S)-3-Fluoro-1- piperidyl]-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

425 185 2-[1-[2-[(3R)-3-Fluoro-1- piperidyl]-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

425 186 2-[1-[2-[(3R,4R)-3,4- Difluoropyrrolidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

429 187 2-[1-[6-Methyl-4-oxo-2-[(3R)- 3-(trifluoromethyl)pyrrolidin- 1-yl]chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

461 188 2-[1-[6-Methyl-4-oxo-2-[(3S)- 3-(trifluoromethyl)-1- piperidyl]chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

475 189 2-[1-[2-[3-(1,1- Difluoroethyl)azetidin-l-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

443 190 2-[1-[2-(11- Azatricyclo[6.2.1.02,7]undeca- 2(7),3,5-trien-11-yl)-6-methyl- 4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

467 191 2-[1-[2-[3-(4- Methoxyphenyl)azetidin-1-yl]- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

485 192 2-[1-[2-[3-[(6-Methoxy-3- pyridyl)amino]-3-methyl- azetidin-1-yl]-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

515 193 2-[1-[2-(3-Anilino-3-methyl- azetidin-1-yl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

484 194 2-[1-[6-Methyl-4-oxo-2-[3-(4- pyridyl)pyrrolidin-1- yl]chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

470 195 2-[1-[6-Methyl-4-oxo-2-[3-(4- pyridyl)azetidin-1-yl]chromen- 8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

456 196 2-[1-[2-[3-(6- Methoxypyridazin-3-yl)oxy-3- methyl-azetidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

517 197 2-[1-[6-Methyl-2-(3-methyl-3- phenoxy-azetidin-1-yl)-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

485 198 2-[1-[2-(3-Methoxy-3-phenyl- azetidin-1-yl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

485 199 2-[1-[2-[3-(Hydroxymethyl)-3- phenyl-pyrrolidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

499 200 2-[1-[2-[4-(Hydroxymethyl)-4- phenyl-1-piperidyl-6-methyl- 4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

513 201 2-[1-[2-(4-Hydroxy-4-phenyl- 1-piperidyl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

496 202 2-[1-[2-(3-Hydroxy-3-phenyl- azetidin-1-yl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

471 203 2-[1-[6-Methyl-4-oxo-2-(1- phenyl-1,6- diazaspiro[3.3]heptan-6- yl)chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

496 204 2-[1-[2-[4-(Hydroxymethyl)-4- methyl-1-piperidyl]-6-methyl- 4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

451 205 2-[1-[6-Methyl-4-oxo-2-[3-(2- pyridyl)pyrrolidin-1- yl]chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

470 206 2-[1-[2-[4-Cyano-4-(4- fluorophenyl)-1-piperidyl]-4- oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifuoroacetic acid, Isomer 1

526 207 2-[1-[2-(4-Cyano-4-phenyl-1- piperidyl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

508 208 2-[1-[6-Methyl-4-oxo-2-(6- phenyl-3,6- diazabicyclo[3.1.1]heptan-3- yl)chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

496 209 2-[1-[6-Methyl-2-[3-(1- methylpyrazol-3-yl)pyrrolidin- 1-yl]-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

473 210 2-[1-[6-Methyl-2-[3-(2- methylpyrazol-3-yl)pyrrolidin- 1-yl]-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

473 211 2-[1-[2-[3-(2-Fluorophenyl)-3- methyl-azetidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

487 212 2-[1-[2-(3-Ethyl-3-phenyl- azetidin-1-yl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

483 213 2-[1-[2-[3-(4-Fluorophenyl)-3- methyl-azetidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

487 214 2-[1-[2-(3-Isopropyl-3-phenyl- azetidin-1-yl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

497 215 2-[1-[2-[3-(2,2-Difluoroethyl)- 3-phenyl-azetidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

519 216 2-[1-[6-Methyl-4-oxo-2-[3-(2- pyridyl)azetidin-1-yl]chromen- 8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

456 217 2-[1-[2-[3-Fluoro-3-(3- pyridyl)azetidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

474 218 2-[1-[6-Methyl-2-(4-methyl-4- phenyl-1-piperidyl)-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

497 219 2-[1-[2-[3-(Hydroxymethyl)-3- phenyl-azetidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

485 220 2-[1-[2-(7,7-Difluoro-2- azaspiro[3.3]heptan-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

455 221 2-[1-[6-Methyl-4-oxo-2-[6- (trifluoromethyl)-2- azaspiro[3.3]heptan-2- yl]chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

487 222 2-[1[2-(6,6-Difluoro-2- azaspiro[3.3]heptan-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

455 223 2-[1-[2-[(3R)-3- Fluoropyrrolidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

411 224 2-[1-[2-[(3S)-3- Fluoropyrrolidin-1-yl]-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

411 225 2-[1-[2-[3-Fluoro-3- (trifluoromethyl)azetidin-1- yl]-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

465 226 2-[1-[2-(3,3- Difluoropyrrolidin-1-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

429 227 2-[1-[2-(3,3-Difluoro-1- piperidyl)-6-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

443 228 2-[1-[2-(1-Fluoro-3- azabicyclo[3.1.1]heptan-3-yl)- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid, Isomer 1

437 229 2-[1-[6-Methyl-4-oxo-2-[(3R)- 3-phenylpyrrolidin-1- yl]chromen-8- yl]ethylamino]benzoic acid, Isomer 1

469 230 2-[1-[6-Methyl-2-(4- methylisoindolin-2-yl)-4-oxo- chromen-8- yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

455 231 2-[1-[2-(4-Chloroisoindolin-2- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

475 232 2-[1-[2-(5-Chloroisoindolin-2- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

475 233 2-[1-[2-(3,4-Dihydro-1H- isoquinolin-2-yl)-6-methyl-4- oxo-chromen-8- yl]ethylamino]benzoic acid

455 234 2-[1-[2-[(1R,6S)-2- Azabicyclo[4.2.0]octan-2-yl]- 6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

433 235 2-[1-[2-(6,8-Dihydro- [1,3]dioxolo[4,5-e]isoindol-7- yl)-6-methyl-4-oxo-chromen- 8-ylethylamino]benzoic acid

485

Example 236: 2-[1-[6-Methyl-4-oxo-2-(3-phenylazetidin-1-yl)chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

A mixture of 3-phenylazetidine hydrochloride (46 mg, 1.1 eq., 0.27 mmol), 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 1 (98 mg, 1 eq., 0.25 mmol) and DIPEA (0.13 g, 0.17 mL, 4 eq., 0.98 mmol) in acetonitrile (10 mL) was stirred at 80° C. for 16 h. After cooling to room temperature, the solvent was removed under reduced pressure. The residue was then purified by preparative HPLC (5-95% ACN[0.1% TFA]/Water[0.1% TFA]) to give 2-[1-[6-methyl-4-oxo-2-(3-phenylazetidin-1-yl)chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1 (93 mg, 0.16 mmol, 66%). MS ES+ m/z 455.2 [M+H]⁺.

Example 237: 3-[1-(2-Isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]-6-methoxy-pyridine-2-carboxylic acid

Step 1. A mixture of 8-(1-bromoethyl)-2-ethylsulfanyl-6-methyl-chromen-4-one (150 mg, 458 umol, 1 eq) and 3-amino-6-methoxy-pyridine-2-carboxylic acid (92 mg, 550 umol, 1.2 eq) in DMF (3 mL) was stirred at 80° C. for 5 h to give a brown solution. The mixture was diluted with water (20 mL), extracted with ethyl acetate (3×20 mL), washed with brine (2×40 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0˜3% methanol in dichloromethane).

Step 2. The product from Step 1 (100 mg, 241 umol, 1 eq) in dichloromethane (2 mL) was treated with m-CPBA (88. mg, 434 umol, 85% purity, 1.8 eq) at 0° C., and stirred at 20° C. for 3 h. The mixture was quenched with sat. Na₂S₂O₃ (10 mL), extracted with dichloromethane (2×20 mL), dried over sodium sulfate, filtered, and concentrated.

Step 3. The product from Step 2 (70 mg, 162 umol, 1 eq), isoindoline-HCl (38 mg, 244 umol, 36 uL, 1.5 eq), and DIEA (105 mg, 813 umol, 141 uL, 5 eq) in dichloromethane (2 mL) were stirred at 45° C. for 14 h to give a brown solution. The mixture was diluted with water (15 mL), extracted with DCM (2×15 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by reverse phase HPLC (C18 column, water:acetonitrile gradient, with 0.05% ammonium hydroxide) to give 3-[1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]-6-methoxy-pyridine-2-carboxylic acid. MS ES+ m/z 472.3 [M+H]⁺.

The following compounds in Table 10 were prepared essentially as described for 3-[1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]-6-methoxy-pyridine-2-carboxylic acid. In some instances, Steps 2 and 3 were combined in a two-step one-pot manner.

TABLE 10 ES/MS Example m/z # Chemical Name Structure (M + H) 238 2-Fluoro-6-[1-[2-(5-fluoroisoindolin- 2-yl)-6-methyl-4-oxo-chromen-8- yl]ethylamino]benzoic acid

477 239 2-Isoindolin-2-yl-8-[1-(2-isoxazol-5- ylanilino)ethyl]-6-methyl-chromen-4- one 2,2,2-trifluoroacetic acid

464 240 2-Isoindolin-2-yl-6-methyl-8-[1-[2- (tetrazol-1-yl)anilino]ethyl]chromen- 4-one

465 241 2-[1-(2-Isoindolin-2-yl-6-methyl-4- oxo-chromen-8- yl)ethylamino] benzenecarbohydroxamic acid 2,2,2-trifluoroacetic acid

456 242 2-[1-(2-Isoindolin-2-yl-6-methyl-4- oxo-chromen-8- yl)ethylamino]benzenesulfonamide 2,2,2-trifluoroacetic acid

476

Example 243 (Isomer 1) and Example 244 (Isomer 2): 2-Fluoro-6-[1-[2-(5-fluoroisoindolin-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1. A mixture of 8-(1-bromoethyl)-2-ethylsulfanyl-3,6-dimethyl-chromen-4-one (1 g, 2.9 mmol, 1 eq) and methyl 2-amino-6-fluoro-benzoate (1.49 g, 8.79 mmol, 3 eq) in DMF (10 mL) was stirred at 80° C. for 16 h to give a yellow solution. The mixture was concentrated and purified by silica gel chromatography (0-10% ethyl acetate/petroleum ether).

Step 2. The product from Step 1 (1.24 g, 2.89 mmol, 1 eq) in dichloromethane (15 mL) was treated with m-CPBA (935 mg, 4.3 mmol, 80% purity, 1.5 eq) at 0° C. and stirred at 25° C. for 2 h. The mixture was quenched with saturated aq. Na₂SO₃ (20 mL), extracted with DCM (3×50 mL), dried over sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography (0-40% ethyl acetate/petroleum ether).

Step 3. A mixture of the product from Step 2 (500 mg, 1.12 mmol, 1 eq), 5-fluoroisoindoline-HCl (292 mg, 1.7 mmol, 1.5 eq), and DIEA (725 mg, 5.6 mmol, 977 uL, 5 eq) in chloroform (3 mL) were stirred at 60° C. for 32 h to give a dark solution. The mixture was concentrated and purified by silica gel chromatography (0-46% ethyl acetate/petroleum ether).

Step 4. A mixture of the product from Step 3 (772 mg, 1.5 mmol, 1 eq), NaOH (244 mg, 6.1 mmol, 4 eq), water (1 mL) and methanol (10 mL) was stirred at 60° C. for 16 h. The mixture was concentrated and purified by reverse phase HPLC (C18 column, water:acetonitrile gradient, with 0.05% ammonium hydroxide as an additive). The racemic product was purified by chiral SFC (U, 28; See Tables 4 and 5 for chiral column and eluent) to give 2-fluoro-6-[1-[2-(5-fluoroisoindolin-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 and 2-fluoro-6-[1-[2-(5-fluoroisoindolin-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2. For both products: ee>99%; MS ES+ m/z 491.4 [M+H]⁺.

The following compounds in Table 11 were prepared essentially as described for 2-fluoro-6-[1-[2-(5-fluoroisoindolin-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. Ester hydrolysis may alternatively have been achieved with boron tribromide in dichloromethane.

TABLE 11 ES/MS Example m/z # Chemical Name Structure (M + H) 245 2-Chloro-5-[1-(2-isoindolin-2-yl- 6-methyl-4-oxo-chromen-8- yl)ethylamino]thiazole-4- carboxylic acid 2,2,2- trifluoroacetic acid

482 246 5-[1-(2-Isoindolin-2-yl-6-methyl- 4-oxo-chromen-8-yl)ethylamino]- 2-(trifluoromethyl)pyrimidine-4- carboxylic acid 2,2,2- trifluoroacetic acid

511

Example 247: 2-[1-[6-Methyl-4-oxo-2-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfonyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (50 mg, 120 umol, 1 eq), 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (46 mg, 241 umol, 2 eq), and DIEA (78 mg, 602 umol, 105 uL, 5 eq) in chloroform (2.5 mL) was stirred at 60° C. for 16 h. The mixture was diluted with water, adjusted to pH 6 with HCl (1M. aq.), and extracted with dichloromethane (3×10 mL). The combined organic phase was dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase HPLC (C18 column, water:acetonitrile gradient, with 0.225% formic acid as an additive) to give 2-[1-[6-methyl-4-oxo-2-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]chromen-8-yl]ethylamino]benzoic acid. MS ES+ m/z 514.4 [M+H]⁺.

Example 248: 1-[8-[1-(2-Carboxyanilino)ethyl]-6-methyl-4-oxo-chromen-2-yl]azetidine-3-carboxylic acid

Step 1. A mixture of methyl 2-[1-(2-ethylsulfonyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate (0.05 g, 116 umol, 1 eq), azetidine-3-carbonitrile-HCl (27 mg, 233 umol, 2 eq), and DIEA (150 mg, 1.16 mmol, 203 uL, 10 eq) in dichloromethane (1 mL) was stirred at 45° C. for 4 h. The mixture was extracted with dichloromethane (2×15 mL), washed with brine (15 mL), and concentrated in vacuo.

Step 2. The product from Step 1 (0.04 g, 96 umol, 1 eq) was dissolved in a mixture of methanol (1 mL) and water (1 mL) and treated with LiOH·H₂O (16 mg, 383 umol, 4 eq). The mixture was stirred at 45° C. for 16 hr and concentrated in vacuo. The residue was purified by reverse phase HPLC (C18 column, water:acetonitrile gradient, with 0.225% formic acid as an additive) to give 1-[8-[1-(2-carboxyanilino)ethyl]-6-methyl-4-oxo-chromen-2-yl]azetidine-3-carboxylic acid. MS ES+ m/z 423.1 [M+H]⁺.

Example 249: 6-Bromo-3-[[(1R)-1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid

Step 1. A mixture of 8-[(1R)-1-aminoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (50 mg, 159 umol, 1 eq), methyl 6-bromo-3-fluoro-pyridine-2-carboxylate (74 mg, 318 umol, 2 eq), and DIEA (62 mg, 477 umol, 83 uL, 3 eq) in DMF (1 mL) was stirred at 100° C. under nitrogen for 16 h. The mixture was quenched with water (10 mL) and extracted with ethyl acetate (2×10 mL). The combined organic layer was washed with brine (3×10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.

Step 2. The product from Step 1 (20 mg, 37.85 umol, 1 eq) was dissolved in a mixture of methanol (0.5 mL) and water (0.05 mL) and treated with NaOH (3 mg, 76 umol, 2 eq). The mixture was stirred at 25° C. for 16 hr and concentrated. The residue was purified by reverse phase HPLC (Column: Xtimate C18 100×30 mm, 10 um; Mobile phase: [A: Water (0.225% FA); B: ACN]; B %: 45%-75% in 10 min) to give 6-bromo-3-[[(1R)-1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid. MS ES+ m/z 514.3, 516.0 [M+H]⁺.

The following compounds in Table 12 were prepared essentially as described for 6-bromo-3-[[(1R)-1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid.

TABLE 12 ES/MS Example m/z # Chemical Name Structure (M + H) 250 2-[[(1R)-1-[2-(4,4-Dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen- 8-yl]ethyl]amino]-5-methylsulfonyl- benzoic acid

513 251 4-[[(1R)-1[2-(4,4-Dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen- 8-yl]lethyl]amino]pyridazine-3- carboxylic acid

437 252 2-[[(1R)-1-[2-(4,4-Dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen- 8-yl]lethyl]amino]pyridine-3- carboxylic acid

436 253 3-[[(1R)-1-[2-(4,4-Dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen- 8-yl]ethyl]amino]-5-fluoro-pyridine- 2-carboxylic acid

454 254 5-Chloro-3-[[(1R)-1-[2-(4,4- dimethyl-1-piperidyl)-6-methyl-4- oxo-chromen-8- yl]lethyl]amino]pyridine-2- carboxylic acid

470 255 3-[[(1R)-1[2-(4,4-Dimethyl-1- piperidyl)-6-methyl-4-oxo-chromen- 8-yl]ethyl]amino]-6- (trifluoromethyppyridine-2- carboxylic acid

504 256 6-Chloro-3-[[(1R)-1-[2-(4,4- dimethyl-1-piperidyl)-6-methyl-4- oxo-chromen-8- yl]lethyl]amino]pyridine-2- carboxylic acid

470 257 2-Cyano-6-[[(1R)-1-[2-(4,4- dimethyl-1-piperidyl)-6-methyl-4- oxo-chromen-8- yl]lethyl]amino]benzoic acid

460

Example 258 (Isomer 1) and Example 259 (Isomer 2): 2-[1-[3,6-Dimethyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethylamino]benzoic acid

Step 1. A mixture of methyl 2-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoate (680 mg, 1.59 mmol, 1 eq) in chloroform (8 mL), piperidine (271 mg, 3.2 mmol, 314 uL, 2 eq), and DIEA (1.23 g, 9.5 mmol, 1.7 mL, 6 eq) was stirred at 60° C. for 48 hr to give a yellow solution. The mixture was diluted with water (30 mL) and extracted with dichloromethane (2×30 mL). The combined extracts were washed with brine (2×30 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (0-30% ethyl acetate/petroleum ether).

Step 2. The product from Step 1 was dissolved in a mixture of methanol (2 mL) and water (0.5 mL) and treated with NaOH (28 mg, 690 umol, 3 eq). The mixture was stirred at 45° C. for 16 h and concentrated. The residue was purified by reverse phase HPLC (C18 column, water:acetonitrile gradient, with 0.225% formic acid as an additive). The resulting racemic mixture was purified by chiral SFC (U, 24; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[3,6-dimethyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 1 and 2-[1-[3,6-dimethyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 2; both >97%; MS ES+ m/z 435.4 [M+H]⁺.

The following compounds in Table 13 were prepared essentially as described for 2-[1-[3,6-dimethyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 13 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method 260 Methyl 2-[1-[3,6-dimethyl-4-oxo-2- (1-piperidyl)chromen-8- yl]ethylamino]benzoate, Isomer 1

435 U, 24 261 Methyl 2-[1-[3,6-dimethyl-4-oxo-2- (1-piperidyl)chromen-8- yl]ethylamino]benzoate, Isomer 2

435 U, 24 262 2-[1-[3,6-Dimethyl-4-oxo-2-(1- piperidyl)chromen-8- yl]ethylamino]benzoic acid

421

Example 263 (Isomer 1) and Example 264 (Isomer 2): 2-[1-[2-(6,8-Dihydro-[1,3]dioxolo[4,5-e]isoindol-7-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (100 mg, 242 umol, 1 eq), 7,8-dihydro-6H-[1,3]dioxolo[4,5-e]isoindole-HCl (72.42 mg, 362.77 umol, 1.5 eq), and DIEA (156 mg, 1.2 mmol, 211 uL, 5 eq) in DMSO (2 mL) was stirred at 80° C. for 16 h to give a dark solution. The mixture was diluted with water (30 mL) and extracted with DCM (3×50). The combined organic phase was washed with brine (2×30 mL), dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by trituration with acetonitrile (2 mL). This racemic mixture was purified by chiral SFC (J, 5; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[2-(6,8-dihydro-[1,3]dioxolo[4,5-e]isoindol-7-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 and 2-[1-[2-(6,8-dihydro-[1,3]dioxolo[4,5-e]isoindol-7-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2. For each enantiomer: ee>96%; MS ES+ m/z 499.3 [M+H]⁺.

The following compounds in Table 14 were prepared essentially as described for 2-[1-[2-(6,8-dihydro-[1,3]dioxolo[4,5-e]isoindol-7-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 14 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method 265 2-[1-(2-Isoindolin-2-yl-3,6- dimethyl-4-oxo-chromen-8- yl)ethylamino]benzoic acid, Isomer 1

455 W, 5 then AD, 37 266 2-[1-(2-Isoindolin-2-yl-3,6- dimethyl-4-oxo-chromen-8- yl)ethylamino]benzoic acid, Isomer 2

455 W, 5 then AD, 37 267 2-[1-[2-(5-Carbamoylisoindolin- 2-yl)-3,6-dimethyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 1

498 J, 5 268 2-[1-[2-(5-Carbamoylisoindolin- 2-yl)-3,6-dimethyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 2

498 J, 5 269 2-[1-[2-(5-Cyanoisoindolin-2- yl)-3,6-dimethyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 1

480 Y, 35 270 2-[1-[2-(5-Cyanoisoindolin-2- yl)-3,6-dimethyl-4-oxo- chromen-8-yl] ethylamino]benzoic acid, Isomer 2

480 Y, 35 271 2-[1-(2-Isoindolin-2-yl-3,6- dimethyl-4-oxo-chromen-8- yl)ethylamino]benzoic acid

455

Example 272 (Isomer 1) and Example 273 (Isomer 2): 2-[1-[2-(5-Fluoroisoindolin-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (500 mg, 1.2 mmol, 1 eq), 5-fluoroisoindoline-HCl (315 mg, 1.8 mmol, 1.5 eq), and DIEA (625 mg, 4.8 mmol, 842 uL, 4 eq) in chloroform (10 mL) was stirred at 60° C. for 120 hours. The mixture was treated with water (30 mL) and extracted with dichloromethane (3×50 mL). The combined organic phase was dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo. This racemic mixture was purified by chiral SFC (J, 5; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[2-(5-fluoroisoindolin-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 (>96% ee) and 2-[1-[2-(5-fluoroisoindolin-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 (>99% ee). For both enantiomers: MS ES+ m/z 473.3 [M+H]⁺.

Example 274: 2-[[(1R)-1-[3,6-Dimethyl-2-(3-methyl-3-phenyl-azetidin-1-yl)-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid

A mixture of 2-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]benzoic acid (50 mg, 121 umol, 1 eq), 3-methyl-3-phenyl-azetidine-HCl (33 mg, 181 umol, 1.5 eq), and DIEA (78 mg, 605 umol, 105 uL, 5 eq) in DMSO (1.5 mL) was stirred at 80° C. for 16 h to give a dark solution. The mixture was filtered and purified by reverse phase HPLC (C18 column, water:acetonitrile gradient, with 0.225% formic acid as an additive) to give 2-[[(1R)-1-[3,6-dimethyl-2-(3-methyl-3-phenyl-azetidin-1-yl)-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid. MS ES+ m/z 483.3 [M+H]⁺.

The following compounds in Table 15 were prepared essentially as described for 2-[[(1R)-1-[3,6-dimethyl-2-(3-methyl-3-phenyl-azetidin-1-yl)-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid.

TABLE 15 ES/MS Example m/z # Chemical Name Structure (M + H) 275 2-[[(1R)-1-[2-[3-(1,1- Difluoroethyl)azetidin-l-yl]-3,6- dimethyl-4-oxo-chromen-8- yl]ethyl]amino]benzoic acid

457 276 2-[[(1R)-1-[2-(6,6-Difluoro-2- azaspiro[3.3]heptan-2-yl)-3,6- dimethyl-4-oxo-chromen-8- yl]ethyl]amino]benzoic acid

469 277 2-[[(1R)-1-[2-[3-(2-Fluorophenyl)-3- methyl-azetidin-1-yl]-3,6-dimethyl-4- oxo-chromen-8- yl]ethyl]amino]benzoic acid

501 278 2-[[(1R)-1-[3,6-Dimethyl-4-oxo-2-[3- (2-pyridyl)azetidin-1-yl]chromen-8- yl]ethyl]amino]benzoic acid

470 279 2-[[(1R)-1-[3,6-Dimethyl-4-oxo-2-[6- (trifluoromethyl)-2- azaspiro[3.3]heptan-2-yl]chromen-8- yl]ethyl]amino]benzoic acid

501 280 2-[[(1R)-1-[2-[3-(4-Fluorophenyl)-3- methyl-azetidin-1-yl]-3,6-dimethyl-4- oxo-chromen-8- yl]ethyl]amino]benzoic acid

501 281 2-[[(1R)-1-[2-(3,3- Difluoropyrrolidin-l-yl)-3,6- dimethyl-4-oxo-chromen-8- yl]ethyl]amino]benzoic acid

443 282 2-[[(1R)-1-[2-(4,4-Difluoro-1- piperidyl)-3,6-dimethyl-4-oxo- chromen-8-yl]ethyl]amino]benzoic acid

457 283 2-[[(1R)-1-[2-(4-Fluoro-1-piperidyl)- 3,6-dimethyl-4-oxo-chromen-8- yl]ethyl]amino]benzoic acid

439 284 2-[[(1R)-1-[2-[(3S,4R)-3,4- Difluoropyrrolidin-l-yl]-3,6- dimethyl-4-oxo-chromen-8- yl]ethyl]amino]benzoic acid

443 285 2- [[(1R)-1- [2-(6-Azaspiro[2.5]octan- 6-yl)-3,6-dimethyl-4-oxo-chromen-8- yl]ethyl]amino]benzoicacid

447 286 2- [[(1R)-1-[3,6-dimethyl-4-oxo-2- [(3R)-3-phenylpyrrolidin-1- yl]chromen-8-yl]ethyl]amino]benzoic acid

483 287 2-[[(1R)-1-[3,6-dimethyl-4-oxo-2- [(3S)-3-phenylpyrrolidin-1- yl]chromen-8-yl]ethyl]amino]benzoic acid

483

Example 288: 2-[[(1R)-1-[2-(4-Cyano-4-phenyl-1-piperidyl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid

A mixture of 2-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]benzoic acid (50 mg, 121 umol, 1 eq), 4-phenylpiperidine-4-carbonitrile (34 mg, 181 umol, 1.5 eq), and DIEA (78 mg, 605 umol, 105 uL, 5 eq) in DMSO (1 mL) was stirred at 80° C. for 3 d. The mixture was filtered and the filtrate was purified by reverse phase HPLC (C18 column, water:acetonitrile gradient with 0.22500 formic acid as an additive) to give 2-[[(1R)-1-[2-(4-cyano-4-phenyl-1-piperidyl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid. MS ES+ m/z 522.3 [M+H]⁺.

Example 289: 2-[[(1R)-1-[2-(7,7-Difluoro-2-azaspiro[3.3]heptan-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid

A mixture of 2-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]benzoic acid (50 mg, 121 umol, 1 eq), 7,7-difluoro-2-azaspiro[3.3]heptane-HCl (31 mg, 181 umol, 1.5 eq), and DIEA (78 mg, 605 umol, 105 uL, 5 eq) in DMSO (1 mL) was stirred at 80° C. for 16 h.

The mixture was filtered, and the filtrate was purified by reverse phase HPLC (C18 column, water:acetonitrile gradient with 0.225% formic acid as an additive) to give 2-[[(1R)-1-[2-(7,7-difluoro-2-azaspiro[3.3]heptan-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid as an off-white solid. MS ES+ m/z 469.3 [M+H]⁺.

Example 290: 2-[1-[2-(5-Fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzamide

A mixture of 8-(1-bromoethyl)-2-(5-fluoroisoindolin-2-yl)-6-methyl-chromen-4-one (40 mg, 99 umol, 1 eq) and 2-amino-N-methyl-benzamide (27 mg, 199 umol, 2 eq) in DMF (1 mL) was stirred at 80° C. for 14 h and purified by reverse phase HPLC (C18 column, water:acetonitrile gradient, with 0.225% formic acid as an additive) to give 2-[1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzamide as a white solid. MS ES+ m/z 458.4 [M+H]⁺.

The following compounds in Table 16 were prepared essentially as described for 2-[1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzamide.

TABLE 16 ES/MS Example m/z # Chemical Name Structure (M + H) 291 2-[1-[2-(5-Fluoroisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-N-methyl- benzamide

472 292 2-[1-[2-(5-Fluoroisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-N,N-dimethyl- benzamide

486 293 2-[1-[2-(5-Fluoroisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-6-methoxy-benzoic acid, Isomer 1

489 294 2-[1-[2-(5-Fluoroisoindolin-2-yl)-6- methyl-4-oxo-chromen-8- yl]ethylamino]-6-methoxy-benzoic acid, Isomer 2

489

Example 295: 3-[l-[2-(5-Carbamoylisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-6-chloro-pyridine-2-carboxylic acid

A mixture of 6-chloro-3-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid (150 mg, 344.9 mmol, 1 eq), isoindoline-5-carboxamide (102.8 mg, 517.37 umol, 1.5 eq, HCl), and DIEA (222.9 mg, 1.7 mmol, 300 uL, 5 eq) in DMSO (1 mL) was stirred at 80° C. for 16 hours to give a dark suspension. The mixture was poured into water (20 mL) and EtOAc (20 mL) was added. The aqueous phase was adjusted pH to 2 with HCl (aq 1M), and then the solid crude product was collected by filtration. The crude product was treated with DMF (3 mL) and aqueous ammonia (0.25 mL), and the mixture was purified by reverse phase HPLC (C-18 column, Water-acetonitrile gradient with 0.2% ammonium hydroxide) to give 3-[1-[2-(5-carbamoylisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-6-chloro-pyridine-2-carboxylic acid. MS ES+ m/z 519 [M+H]⁺.

The following compounds in Table 17 were prepared essentially as described for 3-[1-[2-(5-carbamoylisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-6-chloro-pyridine-2-carboxylic acid.

TABLE 17 ES/MS Example m/z # Chemical Name Structure (M + H) 296 6-Chloro-3-[1-(2-isoindolin-2-yl-6- methyl-4-oxo-chromen-8- yl)ethylamino]pyridine-2-carboxylic acid

476

Example 297: 6-Chloro-3-[1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]pyridine-2-carboxylic acid

A mixture of 6-chloro-3-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid (150 mg, 345 umol, 1 eq), 5-fluoroisoindoline-HCl (120 mg, 690 umol, 2 eq), and DIEA (223 mg, 1.7 mmol, 300 uL, 5 eq) in chloroform (2 mL) was stirred at 60° C. for 16 hours to give a brown suspension. The mixture was concentrated, and the residue was triturated with DMF (3 mL) and aqueous ammonium hydroxide (0.5 mL). 6-Chloro-3-[1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]pyridine-2-carboxylic acid was collected by filtration. MS ES+ m/z 494.1 [M+H]⁺.

Example 298: 3-[1-[2-(6-Azaspiro[2.5]octan-6-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-6-chloro-pyridine-2-carboxylic acid

A mixture of 6-chloro-3-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid (100 mg, 230 umol, 1 eq) and 6-azaspiro[2.5]octane-HCl (68 mg, 460 umol, 2 eq), and DIEA (149 mg, 1.15 mmol, 200 uL, 5 eq) in chloroform (2 mL) was stirred at 60° C. for 16 h to give a dark suspension. The mixture was diluted with water (20 mL), then extracted with dichloromethane (2×20 mL), washed with brine (20 mL×2), dried over sodium sulfate, filtered, and concentrated. The residue was triturated with acetonitrile (1.5 mL) and purified by reverse phase HPLC (C-18 column, water-acetonitrile gradient, 36-76% acetonitrile, with 0.225% formic acid as an additive) to give 3-[1-[2-(6-azaspiro[2.5]octan-6-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-6-chloro-pyridine-2-carboxylic acid. MS ES+ m/z 468.3 [M+H]⁺.

Example 299: 6-Chloro-3-[1-[2-(6,8-dihydro-[1,3]dioxolo[4,5-e]isoindol-7-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]pyridine-2-carboxylic acid

A mixture of 6-chloro-3-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid (100 mg, 223 umol, 1 eq), 7,8-dihydro-6H-[1,3]dioxolo[4,5-e]isoindole-HCl (69 mg, 345 umol, 1.50 eq), and DIEA (149 mg, 1.15 mmol, 200 uL, 5 eq) in chloroform (2 mL) was stirred at 60° C. for 16 h to give a dark suspension. The mixture was diluted with water (10 mL), extracted with dichloromethane (3×10 mL), dried over sodium sulfate, filtered, and concentrated. The residue was triturated with acetonitrile (3 mL) and purified by reverse phase HPLC (C-18 column, water-acetonitrile gradient with 0.225% formic acid) to give 6-chloro-3-[1-[2-(6,8-dihydro-[1,3]dioxolo[4,5-e]isoindol-7-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]pyridine-2-carboxylic acid. MS ES+ m/z 520.3 [M+H]⁺.

Example 300: 6-Chloro-3-[[(1R)-1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylic acid

Step 1: A mixture of methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate (200 mg, 445.5 umol, 1 eq), isoindoline-HCl (139 mg, 891 umol, 132 uL, 2 eq), and DIEA (288 mg, 2.2 mmol, 388 uL, 5 eq) in chloroform (2 mL) was stirred at 60° C. for 16 hours to give a brown solution. The mixture was poured into water (10 mL) and DCM (10 mL), the aqueous phase was adjusted pH to 2 with HCl (1M), the layers were separated, and the aqueous layer was extracted again with DCM (3×10 mL). The combined organic layer was washed with brine (20 mL), dried over anhydrous sodium sulfate, and concentrated in vacuum.

Step 2: The crude material (200 mg, ˜408.21 umol, 1 eq) was treated with a solution of NaOH (33 mg, 816 umol, 2 eq) and H₂O (0.2 mL) in MeOH (2 mL). The mixture was stirred at 50° C. for 1 hour to give a brown solution. The mixture was poured into water (20 mL), adjusted to pH 2 with HCl (1M), and extracted with DCM (3×20 mL). The combined organic layer was washed with brine (30 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was dissolved in a mixture of MeOH (2 mL), DMF (2 mL) and ammonia water (0.5 mL) and purified by HPLC (Column: YMC Triart C18, 7 um, 250×50 mm; mobile phase: [A: Water with 0.05% ammonia hydroxide v/v)-B: Acetonitrile]; B %: 0%-40%, 9 min) to give 6-chloro-3-[[(1R)-1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylic acid. MS ES+ m/z 476.1 [M+H]⁺.

Example 301: 6-Chloro-3-[[(1R)-1-[2-(6,8-dihydro-[1,3]dioxolo[4,5-e]isoindol-7-yl)-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid

Step 1: A mixture of methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate (276 mg, 615 umol, 1 eq), 7,8-dihydro-6H-[1,3]dioxolo[4,5-e]isoindole-HCl (196 mg, 982 umol, 1.6 eq), and DIEA (397 mg, 3.1 mmol, 536 uL, 5 eq) in CHCl₃ (4 mL) was stirred at 60° C. for 16 hours to give a black-brown solution. The mixture was concentrated in vacuo to give a crude residue.

Step 2: The crude material was treated with a solution of NaOH (90 mg) and H₂O (0.6 mL) in MeOH (6 mL). The mixture was stirred at 50° C. for 1.5 hours to give a black-brown solution. The mixture was poured into water (20 mL), adjusted to pH 2 with HCl (1M), and extracted with DCM (3×20 mL). The combined organic layer was washed with brine (30 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was triturated from DMF (4 mL) and 6-chloro-3-[[(1R)-1-[2-(6,8-dihydro-[1,3]dioxolo[4,5-e]isoindol-7-yl)-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid was collected by filtration. MS ES+ m/z 520 [M+H]⁺.

Example 302: 3-[1-[2-(6-Azaspiro[2.5]octan-6-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]-6-chloro-pyridine-2-carboxylic acid

A mixture of 6-chloro-3-[1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid (150.00 mg, 334.14 umol, 1 eq), 6-azaspiro[2.5]octane-HCl (74 mg, 501 umol, 1.5 eq), and DIEA (216 mg, 1.67 mmol, 291 uL, 5 eq) in chloroform (2 mL) was stirred at 60° C. for 16 h to give a black solution. To complete the reaction, the mixture was treated with additional 6-azaspiro[2.5]octane-HCl (74 mg, 501 umol, 1.5 eq). The mixture was stirred for 16 h at 60° C. then concentrated and purified by reverse phase HPLC (water-acetonitrile gradient, 0.2% formic acid or ammonium hydroxide as additive) to give 3-[1-[2-(6-azaspiro[2.5]octan-6-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]-6-chloro-pyridine-2-carboxylic acid. MS ES+ m/z 482.2 [M+H]⁺.

The following compounds in Table 18 were prepared essentially as described for 3-[1-[2-(6-azaspiro[2.5]octan-6-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]-6-chloro-pyridine-2-carboxylic acid.

TABLE 18 ES/MS Example m/z # Chemical Name Structure (M + H) 303 6-Chloro-3-[1-(2-isoindolin-2- yl-3,6-dimethyl-4-oxo-chromen- 8-yl)ethylamino]pyridine-2- carboxylic acid

490 304 3-[1-[2-(5-Carbamoylisoindolin- 2-yl)-3,6-dimethyl-4-oxo- chromen-8-yl]ethylamino]-6- chloro-pyridine-2-carboxylic acid

533 305 6-Chloro-3-[1-[3,6-dimethyl-4- oxo-2-(1-piperidyl)chromen-8- yl]ethylamino]pyridine-2- carboxylic acid

456

Example 306: 3-[[(1R)-1-[2-(6-Azaspiro[2.5]octan-6-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]-6-chloro-pyridine-2-carboxylic acid

Step 1. A mixture of methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate (350 mg, 756 umol, 1 eq), 6-azaspiro[2.5]octane-HCl (134 mg, 907 umol, 1.2 eq), and DIEA (489 mg, 3.8 mmol, 658 uL, 5 eq) in DMSO (10 mL) was stirred at 80° C. for 54 h to give a dark solution. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (2×50 mL). The combined organic phase was washed with brine (50 mL), dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo.

Step 2. The product from Step 1 (˜400 mg, 807 umol, 1 eq), NaOH (161 mg, 4.0 mmol, 5 eq), methanol (15 mL) and water (3 mL) were stirred at 45° C. for 1 h. The mixture was treated with HCl (20 mL, 1M, aq) and extracted with dichloromethane (2×50 mL). The combined organic phase was washed with brine (30 mL), dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase HPLC (C18 column; water-acetonitrile gradient, with 0.225% formic acid as an additive) to give 3-[[(1R)-1-[2-(6-azaspiro[2.5]octan-6-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]-6-chloro-pyridine-2-carboxylic acid as a yellow solid. MS ES+ m/z 482.1 [M+H]⁺.

The following compounds in Table 19 were prepared essentially as described for 3-[[(1R)-1-[2-(6-azaspiro[2.5]octan-6-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]-6-chloro-pyridine-2-carboxylic acid.

TABLE 19 ES/MS Example m/z # Chemical Name Structure (M + H) 307 6-Chloro-3-[[(1R)-1-[2-(4,4- dimethyl-1-piperidyl)-3,6-dimethyl- 4-oxo-chromen-8- yl]ethyl]amino]pyridine-2- carboxylic acid

484

Example 308: 6-Chloro-3-[[(1R)-1-[2-(5-fluoroisoindolin-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid

Step 1. A mixture of methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate (350 mg, 756 umol, 1 eq), 5-fluoroisoindoline-HCl (158 mg, 907 umol, 1.2 eq), and DIEA (489 mg, 3.78 mmol, 658 uL, 5 eq) in DMSO (10 mL) was stirred at 80° C. for 54 h to give a dark solution. The mixture was treated with water (30 mL) and extracted with ethyl acetate (2×50 mL). The combined organic phase was washed with brine (50 mL), dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo.

Step 2. The product from Step 1 (400 mg, 766 umol, 1 eq) was dissolved in a mixture of methanol (15 mL) and water (3 mL) and treated with NaOH (153 mg, 3.8 mmol, 5 eq). The mixture was stirred at 45° C. for 1 h., treated with HCl (20 mL, 1M, aq), and extracted with dichloromethane (2×50 mL). The combined organic phase was washed with brine (30 mL), dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase HPLC (Column: Boston Prime C18 150×30 mm, Sum; Mobile phase: [A: Water (with 0.225% formic acid), B: Acetonitrile]; B %: 43%-73% in 9 min) to give 6-chloro-3-[[(1R)-1-[2-(5-fluoroisoindolin-2-yl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid as a yellow solid. ES+ m/z 508.1 [M+H]⁺.

Example 309: 6-Chloro-3-[[(1R)-1-[3,6-dimethyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid

Step 1. A mixture of methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate (200 mg, 432 umol, 2.4 mL, 1 eq), piperidine-HCl (63 mg, 518 umol, 73 uL, 1.2 eq), and DIEA (279 mg, 2.2 mmol, 376 uL, 5 eq) in DMSO (5 mL) was stirred at 80° C. for 16 hr. The reaction mixture was treated with brine (30 mL) and extracted with ethyl acetate (3×20 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.

Step 2. The product from Step 1 (˜200 mg, 425 umol, 2.4 mL, 1 eq) and NaOH (85 mg, 2.1 mmol, 5 eq) in a mixture of methanol (10 mL) and water (4 mL) was stirred at 45° C. for 1 hr. The mixture was treated with HCl (1 M, 5 mL, aq) and extracted with dichloromethane (2×40 mL). The combined organic layer was washed with brine (40 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase HPLC (Column: Phenomenex Luna C18 100×30 mm, 3 um; mobile phase: [A: water (with 0.225% formic acid); B: acetonitrile]; B %: 50%-80% in 8 min. to give 6-chloro-3-[[(1R)-1-[3,6-dimethyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid as a white solid. MS ES+ m/z 456.0 [M+H]⁺.

Example 310: 6-Chloro-3-[[(1R)-1-[2-(4,4-difluoro-1-piperidyl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid

Step 1. A mixture of methyl 6-chloro-3-[[(1R)-1-(2-ethylsulfinyl-3,6-dimethyl-4-oxo-chromen-8-yl)ethyl]amino]pyridine-2-carboxylate (75 mg, 162 umol, 1 eq), 4,4-difluoropiperidine (39 mg, 324 umol, 2 eq), and DIEA (104 mg, 810 umol, 141 uL, 5 eq) in DMSO (1.5 mL) was stirred at 80° C. for 3 d. The mixture was diluted with water (20 mL) and extracted with ethyl acetate (3×20 mL). The combined organic phase was washed with brine (2×20 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (0-50% ethyl acetate in petroleum ether).

Step 2. The product from Step 1 (˜40 mg, 79 umol, 1 eq) was dissolved in a mixture of methanol (1 mL) and water (0.1 mL), treated with NaOH (9 mg, 237 umol, 3 eq), and stirred at 45° C. for 1 h. The mixture was concentrated and purified by reverse phase HPLC (C18 column, water:acetonitrile gradient with 0.1% ammonium hydroxide as an additive) to give 6-chloro-3-[[(1R)-1-[2-(4,4-difluoro-1-piperidyl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethyl]amino]pyridine-2-carboxylic acid. MS ES+ m/z 492.3 [M+H]⁺.

Example 311 (Isomer 1) and Example 312 (Isomer 2): 2-[1-[6-Fluoro-2-(5-fluoroisoindolin-2-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid (150 mg, 372 umol, 1 eq), DIEA (240 mg, 1.86 mmol, 324 uL, 5 eq) and 5-fluoroisoindoline-HCl (97 mg, 558 umol, 1.5 eq) in chloroform (2 mL) was stirred at 60° C. for 16 hours to give a yellow solution. The mixture was diluted with water (20 mL) and extracted with dichloromethane (3×20 mL). The combined extracts were dried with sodium sulfate, filtered, and concentrated. The residue was triturated with acetonitrile (1 mL) to yield a solid. This was purified by SFC (Y, 36; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[6-fluoro-2-(5-fluoroisoindolin-2-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 and 2-[1-[6-fluoro-2-(5-fluoroisoindolin-2-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2; both >96% ee. Each enantiomer: MS ES+ m/z 463.3 [M+H]⁺.

The following compounds in Table 20 were prepared essentially as described for 2-[1-[6-fluoro-2-(5-fluoroisoindolin-2-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 20 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method 313 2-[1-[2-(5-Cyanoisoindolin- 2-yl)-6-fluoro-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 1

470 J, 5 314 2-[1-[2-(5-Cyanoisoindolin- 2-yl)-6-fluoro-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 2

470 J, 5 315 2-[1-(6-fluoro-2-isoindolin- 2-yl-4-oxo-chromen-8- yl)ethylamino]benzoic acid, Isomer 1

445 AA, 38 316 2-[1-(6-fluoro-2-isoindolin- 2-yl-4-oxo-chromen-8- yl)ethylamino]benzoic acid, Isomer 2

445 AA, 38 317 2-[1-[2-(4,4-dimethyl-1- piperidyl)-6-fluoro-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 1

439 Y, 5 318 2-[1-[2-(4,4-dimethyl-1- piperidyl)-6-fluoro-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 2

439 Y, 5

Example 319 (Isomer 1) and Example 320 (Isomer 2): 2-[1-[6-Fluoro-2-(5-fluoroisoindolin-2-yl)-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-6-fluoro-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (400 mg, 958 umol, 1 eq), 5-fluoroisoindoline-HCl (299 mg, 1.72 mmol, 1.8 eq, HCl), and DIEA (619 mg, 4.8 mmol, 834 uL, 5 eq) in DMSO (8 mL) was stirred at 80° C. for 20 h to give a dark solution. The mixture was diluted with water (40 mL) and EtOAc (40 mL), adjusted to pH 3 with aqueous HCl (2 M), and extracted with ethyl acetate (3×50 mL). The combined organic phase was washed with brine (2×100 mL), dried over sodium sulfate, filtered, and concentrated to a solid. This was purified by SFC (X, 34; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[6-fluoro-2-(5-fluoroisoindolin-2-yl)-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 and 2-[1-[6-fluoro-2-(5-fluoroisoindolin-2-yl)-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2; both >98% ee. For both: MS ES+ m/z 477.1 [M+H]⁺.

The following compounds in Table 21 were prepared essentially as described for 2-[1-[6-fluoro-2-(5-fluoroisoindolin-2-yl)-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 21 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method 321 2-[1-[2-(5-Cyanoisoindolin-2- yl)-6-fluoro-3-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 1

484 Y, 36 322 2-[1-[2-(5-Cyanoisoindolin-2- yl)-6-fluoro-3-methyl-4-oxo- chromen-8- yl]ethylamino]benzoic acid, Isomer 2

484 Y, 36

Example 323 (Isomer 1) and Example 324 (Isomer 2): 2-[1-(6-Fluoro-2-isoindolin-2-yl-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-6-fluoro-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (150 mg, 359 umol, 1 eq), isoindoline-HCl (84 mg, 539 umol, 80 uL, 1.5 eq), and DIEA (232 mg, 1.8 mmol, 313 uL, 5 eq) in chloroform (3 mL) was stirred at 60° C. for 16 h under a nitrogen atmosphere. The mixture was diluted with water (20 mL) and extracted with dichloromethane (2×20 mL). The combined organic phase was washed with brine (2×20 mL), dried over sodium sulfate, filtered, concentrated in vacuo, and triturated with acetonitrile (1 mL) to give a solid. This racemic mixture was purified by SFC (U, 5; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-(6-fluoro-2-isoindolin-2-yl-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 1 (9900 ee) and 2-[1-(6-fluoro-2-isoindolin-2-yl-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 2 (98% ee). For each enantiomer: MS ES+m/z 459.3 [M+H]⁺.

Example 325 (Isomer 1) and Example 326 (Isomer 2): 2-[1-[2-(4,4-Difluoro-1-piperidyl)-6-fluoro-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-6-fluoro-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (150 mg, 359 umol, 1 eq), 4,4-difluoropiperidine (65 mg, 539 umol, 1.5 eq), and DIEA (232 mg, 1.8 mmol, 313 uL, 5 eq) in DMSO (1 mL) was stirred at 80° C. for 18 h. The mixture was purified by reverse phase HPLC (Column: Boston Prime C18 150×30 mm, 5 um; Mobile phase: [A: Water with 0.05% ammonium hydroxide; B: Acetonitrile]; B %: 14%-44% in 9 min). The racemic product was purified by SFC (W, 31; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[2-(4,4-difluoro-1-piperidyl)-6-fluoro-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 (100% ee) and 2-[1-[2-(4,4-difluoro-1-piperidyl)-6-fluoro-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 (97% ee). For both enantiomers MS ES+ m/z 461.2 [M+H]⁺.

Example 327 (Isomer 1) and Example 328 (Isomer 2): 2-[1-[2-(6-Azaspiro[2.5]octan-6-yl)-6-fluoro-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-6-fluoro-3-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (151 mg, 363 umol, 1 eq) and 6-azaspiro[2.5]octane-HCl (100 mg, 544 umol, 1.5 eq), DIEA (234 mg, 1.8 mmol, 316 uL, 5 eq) in DMSO (2 mL) was stirred at 80° C. for 16 h. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (3×10 mL). The combined organic phase was dried over sodium sulfate and concentrated in vacuo. The residue was purified by reverse phase HPLC (Column: Boston Prime C18 150×30 mm, 5 um; Mobile phase: [A: Water (with 0.225% formic acid); B: Acetonitrile] B %: 49%-79% in 9 min). The racemic mixture was purified by SFC (W, 14; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[2-(6-azaspiro[2.5]octan-6-yl)-6-fluoro-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 (100% ee) and 2-[1-[2-(6-azaspiro[2.5]octan-6-yl)-6-fluoro-3-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 (100% ee). For both enantiomers MS ES+ m/z 451.3 [M+H]⁺.

Example 329 (Isomer 1) and Example 330 (Isomer 2): 2-[1-[2-(5-Fluoroisoindolin-2-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid (100 mg, 259 umol, 1 eq), 5-fluoroisoindoline-HCl (81 mg, 467 umol, 1.80 eq), and DIEA (168 mg, 1.30 mmol, 226 uL, 5 eq) in CHCl₃ (2 mL) was stirred at 60° C. for 15 h to give an orange suspension. The mixture was diluted with water (20 mL), adjusted to pH 2 with aqueous 1 M HCl, extracted with dichloromethane (3×20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was triturated with acetonitrile (2 mL) to yield a pink solid.

This solid was purified by SFC (Y, 21; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[2-(5-fluoroisoindolin-2-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 and 2-[1-[2-(5-fluoroisoindolin-2-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2; both >98% ee. For both: MS ES+ m/z 445.0 [M+H]⁺.

The following compounds in Table 22 were prepared essentially as described for 2-[1-[2-(5-fluoroisoindolin-2-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 22 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method 331 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-4- oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1

421 W, 24 332 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-4- oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2

421 W, 24 333 2-[1-[4-Oxo-2-(1-piperidyl)chromen- 8-yl]ethylamino]benzoic acid, Isomer 1

393 Y, 15 334 2-[1-[4-Oxo-2-(1-piperidyl)chromen- 8-yl]ethylamino]benzoic acid, Isomer 2

393 Y, 15

Example 335 (Isomer 1) and Example 336 (Isomer 2): 2-[1-[2-(5-Fluoroisoindolin-2-yl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-[2-ethylsulfinyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid (600 mg, 1.18 mmol, 1 eq), DIEA (763 mg, 5.9 mmol, 1.0 mL, 5 eq), and 5-fluoroisoindoline-HCl (410.10 mg, 2.36 mmol, 2 eq) in chloroform (6 mL) was stirred at 60° C. for 16 hours to give a yellow solution. The mixture was diluted with water (20 mL), adjusted to pH 3 with 1 M HCl, and extracted with DCM (3×20 mL). The combined organic phase was dried over sodium sulfate, filtered, and concentrated to give a solid residue. This was purified by SFC (Z, 35; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[2-(5-fluoroisoindolin-2-yl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 1 and 2-[1-[2-(5-fluoroisoindolin-2-yl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 2; both >95% ee. For both enantiomers: MS ES+ m/z 513.1 [M+H]⁺.

The following compounds in Table 23 were prepared essentially as described for 2-[1-[2-(5-fluoroisoindolin-2-yl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 23 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method 337 2-[1-[2-(5-Cyanoisoindolin-2- yl)-4-oxo-6- (trifluoromethyl)chromen-8- yl]ethylamino]benzoic acid, Isomer 1

520 AA, 5 338 2-[1-[2-(5-Cyanoisoindolin-2- yl)-4-oxo-6- (trifluoromethyl)chromen-8- yl]ethylamino]benzoic acid, Isomer 2

520 AA, 5 339 2-[1-[2-(4,4-dimethyl-1- piperidyl)-4-oxo-6- (trifluoromethyl)chromen-8- yl]ethylamino]benzoic acid, Isomer 1

489 340 2-[1-[2-(4,4-dimethyl-1- piperidyl)-4-oxo-6- (trifluoromethyl)chromen-8- yl]ethylamino]benzoic acid, Isomer 2

489

Example 341 (Isomer 1) and Example 342 (Isomer 2): 2-[1-[2-Isoindolin-2-yl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-[2-ethylsulfinyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid (600 mg, 1.18 mmol, 1 eq), DIEA (763 mg, 5.9 mmol, 1.0 mL, 5 eq), and isoindoline-HCl (367 mg, 2.36 mmol, 2 eq) in chloroform (6 mL) was stirred at 60° C. for 16 hours. The mixture was diluted with water (20 mL), and extracted with dichloromethane (3×20 mL). The combined organic phase was dried over sodium sulfate, filtered, concentrated in vacuo, and triturated with acetonitrile (5 mL) to give a solid residue. This was purified by SFC (Z, 34; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[2-isoindolin-2-yl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 1 (ee=100%) and 2-[1-[2-isoindolin-2-yl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 2 (ee=100%). For both enantiomers MS ES+ m/z 495.1 [M+H]⁺.

Example 343 (Isomer 1) and Example 344 (Isomer 2): 2-[1-[2-(5-Fluoroisoindolin-2-yl)-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-[2-ethylsulfinyl-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid (100 mg, 214 umol, 1 eq), 5-fluoroisoindoline-HCl (56 mg, 321 umol, 1.5 eq), and DIEA (138 mg, 1.07 mmol, 186 uL, 5 eq) in DMSO (5 mL) was stirred at 80° C. for 16 h. The mixture was diluted with water (15 mL) and extracted with EtOAc (3×20 mL). The combined organic layer was washed with brine (3×30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by prep-HPLC: Column: Phenomenex Luna C18 100×30 mm, 3 um; Mobile phase: [A: Water (0.225% FA); B: ACN]; B %₀: 500%-80% in 8 min., then purified by SFC (X, 5; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[2-(5-fluoroisoindolin-2-yl)-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 1 and 2-[1-[2-(5-fluoroisoindolin-2-yl)-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 2; both >99 ee. For both enantiomers: MS ES+ m/z 527.3 [M+H]⁺.

The following compounds in Table 24 were prepared essentially as described for 2-[1-[2-(5-fluoroisoindolin-2-yl)-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 24 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method 345 2-[1-[2-(5-Cyanoisoindolin-2- yl)-3-methyl-4-oxo-6- (trifluoromethyl)chromen-8- yl]ethylamino]benzoic acid, Isomer 1

534 AE, 5 346 2-[1-[2-(5-Cyanoisoindolin-2- yl)-3-methyl-4-oxo-6- (trifluoromethyl)chromen-8- yl]ethylamino]benzoic acid, Isomer 2

534 AE, 5

Example 347 (Isomer 1) and Example 348 (Isomer 2): 2-[1-[2-Isoindolin-2-yl-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-[2-ethylsulfinyl-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid (100 mg, 214 umol, 1 eq), isoindoline-HCl (50 mg, 321 umol, 1.5 eq), and DIEA (138 mg, 1.07 mmol, 186 uL, 5 eq) in DMSO (5 mL) was stirred at 80° C. for 16 h. The mixture was diluted with water (15 mL) and extracted with EtOAc (3×20 mL). The combined organic layer was washed with brine (3×30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse phase HPLC (Column: Phenomenex Luna C18 100×30 mm, 3 um; Mobile phase: [A: Water (0.225% FA); B: ACN]; B %: 50%-80% in 8 min., then purified by SFC (AB, 21; See Tables 4 and 5 for chiral columns and eluents) to give 2-[1-[2-isoindolin-2-yl-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 1 (ee=100%) and 2-[1-[2-isoindolin-2-yl-3-methyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid, Isomer 2 (ee=100%). For both enantiomers: MS ES+ m/z 509.3 [M+H]⁺.

Example 349 (Isomer 1) and Example 350 (Isomer 2): 5-Fluoro-2-[1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]-5-fluoro-benzoic acid (150 mg, 359 umol, 1 eq), DIEA (232 mg, 1.80 mmol, 312.94 uL, 5 eq), and 5-fluoroisoindoline (74 mg, 539 umol, 1.5 eq) in chloroform (2 mL) was stirred at 60° C. for 16 hours. The mixture was diluted with water (20 mL) and extracted with DCM (3×20 mL). The combined organic phase was dried over sodium sulfate, filtered, and concentrated to give a residue that was triturated with acetonitrile (1 mL) to yield the racemic product as a solid. This was purified by SFC (Z, 5; See Tables 4 and 5 for chiral columns and eluents) to give 5-fluoro-2-[1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 and 5-fluoro-2-[1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2; both >9800 ee. For both enantiomers: MS ES+ m/z 477.3 [M+H]⁺.

The following compounds in Table 25 were prepared essentially as described for 5-fluoro-2-[1-[2-(5-fluoroisoindolin-2-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. If the Example was purified with chiral SFC, the chiral column and eluent are listed in the final column (see Tables 4 and 5).

TABLE 25 ES/MS m/z (M + H) & Example Chiral # Chemical Name Structure Method 351 2-[1-[2-(5-Cyanoisoindolin-2- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]-5-fluoro- benzoic acid, Isomer 1

484 Z, 35 352 2-[1-[2-(5-Cyanoisoindolin-2- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]-5-fluoro- benzoic acid, Isomer 2

484 Z, 35 353 5-Fluoro-2-[1-[2-(4- methoxycarbonylpiperazin-1- yl)-6-methyl-4-oxo-chromen- 8-yl]ethylamino]benzoic acid

484 354 5-Fluoro-2-[1-(2-isoindolin-2- yl-6-methyl-4-oxo-chromen-8- yl)ethylamino]benzoic acid, Isomer 1

459 AD, 28 355 5-Fluoro-2-[1-(2-isoindolin-2- yl-6-methyl-4-oxo-chromen-8- yl)ethylamino]benzoic acid, Isomer 2

459 AD, 28

Example 356: [2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]phenyl]boronic acid

A mixture of 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (200 mg, 0.529 mmol) and (2-aminophenyl)boronic acid (145 mg, 1.06 mmol) in DMF (4 mL) was stirred at 80° C. for 16 h. When cooled to rt the mixture was filtered, the filtrate was purified by preparative HPLC to give [2-[l-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]phenyl]boronic acid as a solid (59 mg, 250%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.98 (s, 6H), 1.41-1.45 (m, 4H), 1.51 (d, J=6.8 Hz, 3H), 2.29 (s, 3H), 3.52-3.56 (m, 4H), 4.87-4.97 (m, 1H), 5.51 (s, 1H), 6.18 (d, J=8.4 Hz, 1H), 6.43-6.51 (m, 1H), 6.98-7.07 (m, 2H), 7.37 (d, J=2.0 Hz, 1H), 7.55-7.61 (m, 2H), 8.28 (s, 2H). MS ES+ m/z 435 [M+H]⁺.

Example 357: 5-Borono-2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1: methyl 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate. A mixture of methyl 2-amino-5-bromo-benzoate (500 mg, 2.17 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (828 mg, 3.26 mmol), Pd(dppf)Cl₂ (159 mg, 0.22 mmol), KOAc (640 mg, 6.52 mmol) in dioxane (10 mL) was stirred at 100° C. for 16 h under N₂. When cooled to rt the mixture was filtered, the filtrate was concentrated and purified on a silica gel column eluted with 0-15% EtOAc in petroleum ether to give the product as a solid (490 mg, 81%). ¹H NMR (400 MHz, CDCl₃-d) δ ppm 1.21-1.37 (m, 12H), 3.81-3.96 (m, 3H), 5.97 (s, 2H), 6.64 (d, J=8.4 Hz, 1H), 7.68 (dd, J=8.4, 1.2 Hz, 1H), 8.34 (d, J=1.2 Hz, 1H).

Step 2: 5-borono-2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. A mixture of 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (60.0 mg, 0.16 mmol) and methyl 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (87.9 mg, 0.32 mmol) in DMF (1 mL) was stirred in 80° C. for 12 h. When cooled to rt the mixture was added H₂O (10 mL) and extracted with EtOAc (20 mL×3). The combined extract was washed with brine (15 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0-10% MeOH in DCM to give methyl 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate as a solid (100 mg, crude). A mixture of methyl 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (100 mg, 0.17 mmol) and NaOH (28 mg, 0.70 mmol) in MeOH (1 mL) and H₂O (0.4 mL) was stirred at 25° C. for 16 h, then stirred at 35° C. for 7 h. The mixture was added NaOH (14 mg, 0.35 mmol) and stirred at 35° C. for another 16 h. The mixture was added H₂O (15 mL) and washed with EtOAc (20 mL×2). The aqueous phase was adjusted to pH=2 with HCl (1 M), extracted with DCM (20 mL×2). The combined extract was dried over anhydrous Na₂SO₄, filtered, concentrated and purified by preparative HPLC to give 5-borono-2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (8.6 mg, 17%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.98 (s, 6H), 1.39-1.44 (m, 4H), 1.59 (d, J=6.8 Hz, 3H), 2.30 (s, 3H), 3.51-3.57 (m, 4H), 5.09 (d, J=7.6 Hz, 1H), 5.52 (s, 1H), 6.43 (d, J=8.4 Hz, 1H), 7.35 (s, 1H), 7.59-7.66 (m, 2H), 7.71 (s, 1H), 8.32 (d, J=1.6 Hz, 1H), 8.49 (d, J=6.4 Hz, 1H), 12.51-12.79 (m, 1H). MS ES+ m/z 479 [M+H]⁺.

Example 358, Example 359 (Isomer 1), and Example 360 (Isomer 2): 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-chromen-4-one (300 mg, 0.765 mmol) and 2-aminobenzoic acid (210 mg, 1.53 mmol) in DMF (6 mL) was stirred at 25° C. for 16 h and at 35° C. for 6 h. The mixture was diluted with EtOAc (20 mL), water (20 mL) and adjusted to pH=11 with NaOH (2 M). The aqueous layer was washed with EtOAc (40 mL×2), then adjusted to pH 4 with HCl (2 M), white solid was precipitated out and filtered. The filter cake was triturated with MeCN (2 mL) to give 2-[1-[2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (150 mg, 43%). MS ES+ m/z 449 [M+H]⁺.

2-[1-[2-(4,4-Dimethyl-1-piperidyl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid was purified by chiral SFC (W, 14; See Tables 4 and 5 for chiral column and eluent) to give 2-[1-[2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 as a solid (61.8 mg, 41%, ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.98 (s, 6H), 1.41-1.50 (m, 4H), 1.60 (d, J=6.8 Hz, 3H), 1.92 (s, 3H), 2.31 (s, 3H), 3.37-3.45 (m, 4H), 5.03-5.15 (m, 1H), 6.48 (d, J=8.4 Hz, 1H), 6.54 (t, J=7.6 Hz, 1H), 7.20-7.28 (m, 1H), 7.40 (d, J=2.0 Hz, 1H), 7.64 (d, J=1.2 Hz, 1H), 7.80 (dd, J=8.0, 1.6 Hz, 1H), 8.35 (d, J=5.6 Hz, 1H), 12.73 (brs, 1H), MS ES+ m/z 449 [M+H]⁺) and 2-[1-[2-(4,4-dimethyl-1-piperidyl)-3,6-dimethyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 as a solid (61.2 mg, 40%, ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.98 (s, 6H), 1.42-1.50 (m, 4H), 1.60 (d, J=6.4 Hz, 3H), 1.92 (s, 3H), 2.31 (s, 3H), 3.37-3.45 (m, 4H), 5.03-5.14 (m, 1H), 6.48 (d, J=8.4 Hz, 1H), 6.54 (t, J=7.6 Hz, 1H), 7.18-7.29 (m, 1H), 7.40 (d, J=2.0 Hz, 1H), 7.64 (d, J=1.2 Hz, 1H), 7.80 (dd, J=8.0, 1.6 Hz, 1H), 8.35 (d, J=5.6 Hz, 1H), 12.72 (s, 1H), MS ES+ m/z 449 [M+H]⁺).

Example 361: N-[2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]phenyl]sulfonylacetamide

Step 1: N-(2-aminophenyl)sulfonylacetamide. A mixture of 2-aminobenzenesulfonamide (200 mg, 1.16 mmol) and DMAP (284 mg, 2.32 mmol) in THE (4 mL) was added Ac₂O (130 mg, 1.28 mmol) at 0° C. under N₂, and stirred at 20° C. for 1 h. The mixture was diluted with water (20 mL), extracted with EtOAc (30 mL×3), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0-50% EtOAc in petroleum ether to give the product as gum (120 mg, 48%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.92 (s, 3H), 6.02 (brs, 2H), 6.58-6.67 (m, 1H), 6.76-6.84 (m, 1H), 7.25-7.33 (m, 1H), 7.56 (dd, J=8.0, 1.6 Hz, 1H), 11.86 (brs, 1H). MS ES+ m/z 215 [M+H]⁺.

Step 2: N-[2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]phenyl]sulfonylacetamide. A mixture of 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (50 mg, 0.13 mmol) and N-(2-aminophenyl)sulfonylacetamide (57 mg, 0.26 mmol) in DMF (1 mL) was stirred at 80° C. for 16 h. When cooled to rt the mixture was filtered. The filtrate was combined with another batch (50 mg) and purified by preparative HPLC to give N-[2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]phenyl]sulfonylacetamide as a solid (9.12 mg, 7%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.98 (s, 6H), 1.38-1.46 (m, 4H), 1.57 (d, J=6.4 Hz, 3H), 1.92 (s, 3H), 2.28 (s, 3H), 3.48-3.57 (m, 4H), 5.10 (q, J=6.4 Hz, 1H), 5.51 (s, 1H), 6.42 (d, J=8.4 Hz, 1H), 6.54 (d, J=5.6 Hz, 1H), 6.63 (t, J=7.6 Hz, 1H), 6.77-7.38 (m, 2H), 7.45 (d, J=2.0 Hz, 1H), 7.59 (d, J=2.0 Hz, 1H), 7.64 (dd, J=8.0, 1.6 Hz, 1H). MS ES+ m/z 512 [M+H]⁺.

Example 362 (Isomer 1) and Example 363 (Isomer 2): 2-[1-(2-Isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid

A mixture of methyl 2-[1-(2-ethylsulfinyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate (500 mg, 1.21 mmol) in DCM (10 mL) was added isoindoline (753 mg, 4.84 mmol, HCl) and DIPEA (1.56 g, 12.1 mmol) at 10° C., then stirred at 40° C. for 20 h. The mixture was diluted with water (20 mL), extracted with DCM (40 mL×3). The combined extract was washed with brine (60 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give methyl 2-[1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate as gum (500 mg).

A mixture of methyl 2-[1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate (500 mg, 1.10 mmol) and NaOH (176 mg, 4.40 mmol) in MeOH (3 mL), H₂O (5 mL) and THE (4 mL) was stirred at 40° C. for 16 h. The mixture was diluted with EtOAc (50 mL) and water (50 mL), some pink solid was precipitated out and filtered. The filter cake was diluted with DCM (50 mL) and water (50 mL), adjusted to pH=4 with HCl (2 M), pink solid was precipitated out and filtered. The filter cake was purified by preparative HPLC and then by chiral SFC (U, 5; See Tables 4 and 5 for chiral column and eluent) to give 2-[1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 1 as a solid (48.9 mg, 20%, ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.67 (d, J=6.8 Hz, 3H), 2.32 (s, 3H), 4.50-5.12 (m, 4H), 5.14-5.23 (m, 1H), 5.31 (s, 1H), 6.52-6.62 (m, 2H), 7.23-7.29 (m, 1H), 7.33-7.39 (m, 2H), 7.39-7.46 (m, 3H), 7.65 (d, J=1.6 Hz, 1H), 7.81 (dd, J=8.0, 1.6 Hz, 1H), 8.42 (d, J=6.0 Hz, 1H), 12.74 (brs, 1H), MS ES+ m/z 441 [M+H]⁺) and 2-[1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 2 as a solid (39.7 mg, 17%, ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.67 (d, J=6.4 Hz, 3H), 2.32 (s, 3H), 4.61-5.09 (m, 4H), 5.16-5.26 (m, 1H), 5.31 (s, 1H), 6.51-6.62 (m, 2H), 7.23-7.30 (m, 1H), 7.32-7.39 (m, 2H), 7.39-7.47 (m, 3H), 7.65 (s, 1H), 7.81 (dd, J=8.0, 1.6 Hz, 1H), 8.41 (d, J=6.4 Hz, 1H), 12.73 (brs, 1H), MS ES+ m/z 441 [M+H]⁺).

Example 364: 2-(4,4-Dimethyl-1-piperidyl)-6-methyl-8-[1-[2-(2,2,2-trifluoro-1-hydroxy-ethyl)anilino]ethyl]chromen-4-one

A mixture of 2-(4,4-dimethyl-1-piperidyl)-6-methyl-8-[1-[2-(2,2,2-trifluoroacetyl)anilino]ethyl]chromen-4-one (20 mg, 0.041 mmol) and NaBH₄ (2.0 mg, 0.049 mmol) in MeOH (3 mL) was stirred at 15° C. for 2 h. The mixture was added water (0.3 mL), concentrated and purified by preparative HPLC to give 2-(4,4-dimethyl-1-piperidyl)-6-methyl-8-[1-[2-(2,2,2-trifluoro-1-hydroxy-ethyl)anilino]ethyl]chromen-4-one as a solid (8.5 mg, 42%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.98-0.99 (m, 6H), 1.41-1.46 (m, 4H), 1.52 (d, J=6.4 Hz, 3H), 2.27 (d, J=8.8 Hz, 3H), 3.53-3.55 (m, 4H), 4.96-5.01 (m, 1H), 5.52 (s, 1H), 5.53-5.55 (m, 1H), 6.01 (d, J=6.0 Hz, 0.5H), 6.08 (d, J=6.8 Hz, 0.5H), 6.26 (d, J=8.0 Hz, 1H), 6.56 (t, J=7.2 Hz, 1H), 6.98-7.02 (m, 2H), 7.26 (d, J=7.6 Hz, 1H), 7.34 (d, J=2.0 Hz, 0.5H), 7.41 (d, J=2.4 Hz, 0.5H), 7.57 (s, 1H). MS ES+ m/z 489 [M+H]⁺.

Example 365: 2-(4,4-Dimethyl-1-piperidyl)-6-methyl-8-[1-[2-(2,2,2-trifluoroacetyl)anilino]ethyl]chromen-4-one

Step 1: 2,2,2-trifluoro-1-(2-nitrophenyl)ethanol. A mixture of 2-nitrobenzaldehyde (1.00 g, 6.62 mmol), K₂CO₃ (2.74 g, 19.9 mmol) and TMSCF₃ (1.88 g, 13.2 mmol) in DMF (20 mL) was stirred at 20° C. for 12 h. The mixture was added 2 N HCl (30 mL), and stirred for 2 h. The mixture was extracted with EtOAc (20 mL×3). The combined extract was washed with sat. NaHCO₃(30 mL) and brine (15 mL×3), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product (1.4 g, 96%) as oil. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 5.85-5.92 (m, 1H), 7.34 (d, J=6.0 Hz, 1H), 7.66-7.74 (m, 1H), 7.83-7.87 (m, 1H), 7.92-7.92 (m, 1H), 8.05 (dd, J=8.0, 1.2 Hz, 1H).

Step 2: 2,2,2-trifluoro-1-(2-nitrophenyl)ethanone. A mixture of 2,2,2-trifluoro-1-(2-nitrophenyl)ethanol (700 mg, 3.17 mmol) and 2-iodoxybenzoic acid (1.77 g, 6.33 mmol) in EtOAc (20 mL) was stirred at 77° C. for 14 h. When cooled to rt the mixture was filtered, and filter cake was washed with EtOAc (20 mL). The filtrate was washed with sat. Na₂S₂O₃ (30 mL), sat.NaHCO₃(30 mL) and brine (30 mL×3), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by silica gel chromatography eluted with 0%-10% EtOAc in petroleum ether to give the product (500 mg, 72%) as oil. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.92 (dd, J=7.2, 1.2 Hz, 1H), 8.00-8.04 (m, 1H), 8.08-8.10 (m, 1H), 8.43 (dd, J=8.4, 1.2 Hz, 1H).

Step 3: 1-(2-aminophenyl)-2,2,2-trifluoro-ethanone. A mixture of 2,2,2-trifluoro-1-(2-nitrophenyl)ethanone (200 mg, 0.913 mmol), NH₄Cl (391 mg, 7.30 mmol) and Fe (408 mg, 7.30 mmol) in EtOH (8 mL) and H₂O (2 mL) was stirred at 80° C. for 6 h. The mixture was filtered, the filter cake was washed with EtOH (10 mL). The filtrate was concentrated. The residue was diluted with water (15 mL), extracted with DCM (15 mL×3). The combined extract was washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by silica gel chromatography eluted with 0%-22% EtOAc in petroleum ether to give the product (100 mg, 56%) as a solid. MS ES+ m/z 190 [M+H]⁺.

Step 4: 2-(4,4-dimethyl-1-piperidyl)-6-methyl-8-[1-[2-(2,2,2-trifluoroacetyl)anilino]ethyl]chromen-4-one. A mixture of 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (60 mg, 0.16 mmol) and 1-(2-aminophenyl)-2,2,2-trifluoro-ethanone (45 mg, 0.24 mmol) in DMF (1 mL) was stirred at 80° C. for 34 h. When cooled to rt the reaction mixture was purified by preparative HPLC to give 2-(4,4-dimethyl-1-piperidyl)-6-methyl-8-[1-[2-(2,2,2-trifluoroacetyl)anilino]ethyl]chromen-4-one as a solid (25.79 mg, 33%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.97 (s, 6H), 1.36-1.39 (m, 4H), 1.65 (d, J=6.8 Hz, 3H), 2.32 (s, 3H), 3.50-3.53 (m, 4H), 5.22-5.29 (m, 1H), 5.52 (s, 1H), 6.72-6.77 (m, 2H), 7.43 (d, J=2.0 Hz, 1H), 7.50 (t, J=8.0 Hz, 1H), 7.63-7.64 (m, 1H), 7.73 (d, J=8.4 Hz, 1H), 9.02 (d, J=6.0 Hz, 1H). MS ES+ m/z 487 [M+H]⁺.

Example 366 (Isomer 1) and Example 367 (Isomer 2): 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

A mixture of 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (4.00 g, 10.6 mmol) and 2-aminobenzoic acid (2.90 g, 21.1 mmol) in DMF (40 mL) was stirred at 80° C. for 16 h. When cooled to rt the mixture was diluted with EtOAc (120 mL), water (120 mL) and adjusted to pH=11 with NaOH (2 M). The aqueous layer was washed with EtOAc (200 mL×2), adjusted to pH=4 with HCl (2 M), white solid was precipitated out and filtered. The filter cake was diluted with DCM/MeOH (10/1, 400 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by SFC to give 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 as a solid (1.73 g, 39%, ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.97 (s, 6H), 1.37-1.45 (m, 4H), 1.57 (d, J=6.4 Hz, 3H), 2.30 (s, 3H), 3.49-3.60 (m, 4H), 5.00-5.10 (m, 1H), 5.52 (s, 1H), 6.43 (d, J=8.4 Hz, 1H), 6.54 (t, J=7.6 Hz, 1H), 7.17-7.27 (m, 1H), 7.36 (d, J=2.0 Hz, 1H), 7.60 (d, J=1.6 Hz, 1H), 7.81 (dd, J=8.0, 1.6 Hz, 1 H), 8.44 (brs, 1H), MS ES+ m/z 435 [M+H]⁺) and 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 as a solid (1.76 g, 39%, ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.98 (s, 6H), 1.36-1.47 (m, 4H), 1.58 (d, J=6.4 Hz, 3H), 2.30 (s, 3H), 3.47-3.61 (m, 4H), 5.00-5.11 (m, 1H), 5.51 (s, 1H), 6.45 (d, J=8.4 Hz, 1H), 6.55 (t, J=7.6 Hz, 1H), 7.19-7.29 (m, 1H), 7.36 (d, J=2.0 Hz, 1H), 7.60 (d, J=1.6 Hz, 1H), 7.81 (dd, J=8.0, 1.6 Hz, 1H), 8.35 (d, J=5.6 Hz, 1H), 12.59 (brs, 1H), MS ES+ m/z 435 [M+H]⁺).

Example 368: 2-[1-(6-Methyl-4-oxo-2-pyrrolidin-1-yl-chromen-8-yl)ethylamino]benzoic acid

A mixture of methyl 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoate (30 mg, 0.075 mmol) and pyrrolidine (16 mg, 0.23 mmol) in EtOH (3 mL) was stirred at 78° C. for 32 h. When cooled to rt the mixture was concentrated to give methyl 2-[1-(6-methyl-4-oxo-2-pyrrolidin-1-yl-chromen-8-yl)ethylamino]benzoate as a solid (30 mg, crude). MS ES+ m/z 407 [M+H]⁺. A mixture of methyl 2-[1-(6-methyl-4-oxo-2-pyrrolidin-1-yl-chromen-8-yl)ethylamino]benzoate (30 mg, 0.074 mmol) and LiOH·H₂O (9.3 mg, 0.22 mmol) in MeOH (2 mL) and H₂O (0.2 mL) was stirred at 30° C. for 20 h. The mixture was added NaOH (24 mg, 0.59 mmol) and stirred at 30° C. for another 40 h. The mixture was adjusted to pH=4 with HCl (1 M), concentrated and purified by preparative HPLC to give 2-[1-(6-methyl-4-oxo-2-pyrrolidin-1-yl-chromen-8-yl)ethylamino]benzoic acid as a solid (16.07 mg, 55%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.60 (d, J=6.4 Hz, 3H), 1.97-2.00 (m, 4H), 2.30 (s, 3H), 3.55-3.75 (m, 4H), 5.06-5.09 (m, 1H), 5.22 (s, 1H), 6.46 (d, J=8.8 Hz, 1H), 6.55 (t, J=7.2 Hz, 1H), 7.22-7.25 (m, 1H), 7.35 (d, J=2.4 Hz, 1H), 7.61 (d, J=1.6 Hz, 1H), 7.80 (dd, J=8.0, 1.6 Hz, 1H), 8.36 (br, J=6.0 Hz, 1H), 12.78 (br s, 1H). MS ES+ m/z 393 [M+H]⁺.

Example 369: 2-[[2-(4,4-Dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]methylamino]benzoic acid

Step 1: 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]-N-methoxy-benzamide. A mixture of 8-bromo-2-(4,4-dimethylpiperidin-1-yl)-6-methyl-4H-chromen-4-one (220 mg, 0.628 mmol), DPPF (35 mg, 0.063 mmol), TEA (953 mg, 9.42 mmol) and Pd(OAc)₂ (21 mg, 0.094 mmol) in DMF (5 mL) and MeOH (8 mL) was stirred at 80° C. under CO atmosphere (50 psi) for 5 h. When cooled to rt the mixture was concentrated, diluted with water (20 mL), extracted with EtOAc (20 mL×3). The combined extract was washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a solid (200 mg, crude). MS ES+ m/z 330 [M+H]⁺.

Step 2: 2-(4,4-dimethyl-1-piperidyl)-8-(hydroxymethyl)-6-methyl-chromen-4-one. A mixture of methyl 2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromene-8-carboxylate (200 mg, 0.607 mmol) in THE (3 mL) was added LiAlH₄ (23 mg, 0.61 mmol) in portions at 0° C. and stirred at 20° C. for 2 h. The reaction mixture was quenched with sat.NH₄Cl (15 mL) and extracted with EtOAc (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 30-100% EtOAc in petroleum ether to give the product as a solid (140 mg, 77%). MS ES+ m/z 302 [M+H]⁺.

Step 3: 8-(bromomethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 2-(4,4-dimethyl-1-piperidyl)-8-(hydroxymethyl)-6-methyl-chromen-4-one (140 mg, 0.465 mmol) in DCM (4 mL) was added PBr₃ (251 mg, 0.929 mmol) at 0° C., then stirred at 20° C. for 16 h.

The mixture was quenched with sat. NaHCO₃(10 mL). The aqueous layer was extracted with DCM (15 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel chromatography eluted with 30-70% EtOAc in petroleum ether to give the product as a solid (90 mg, 53%). MS ES+ m/z 366 [M+H]⁺.

Step 4: 2-[[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]methylamino]benzoic acid. A mixture of 8-(bromomethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (70 mg, 0.19 mmol) and 2-aminobenzoic acid (53 mg, 0.38 mmol) in DMF (1 mL) was at 80° C. under N₂ for 16 h. When cooled to rt the mixture was diluted with H₂O (5 mL) and adjusted to pH=10 with aq. NaOH (1 M), then washed with DCM (10 mL×2). The aqueous phase was adjusted to pH=5 with aq. HCl (2 M) and extracted with DCM (10 mL×2). The combined extract was dried over anhydrous Na₂SO₄, filtered, concentrated and purified by preparative HPLC to give 2-[[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]methylamino]benzoic acid as a solid (18.1 mg, 22%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.96 (s, 6H), 1.35-1.38 (m, 4H), 2.07 (s, 3H), 3.47-3.50 (m, 4H), 4.63-4.64 (m, 2H), 5.50 (s, 1H), 6.59 (t, J=6.4 Hz, 1H), 6.74 (d, J=6.8 Hz, 1H), 7.32 (t, J=5.6 Hz, 1H), 6.35 (d, J=1.6 Hz, 1H), 7.35 (d, J=1.6 Hz, 1H), 7.81 (d, J=6.4 Hz, 1H), 8.26 (brs, 1H). MS ES+ m/z 421 [M+H]⁺.

Example 370: 2-[1-[6-Methyl-2-(4-methyl-1-piperidyl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1: 8-bromo-6-methyl-2-(4-methyl-1-piperidyl)chromen-4-one. A mixture of 4-methylpiperidine (72 mg, 0.72 mmol) and DIPEA (312 mg, 2.42 mmol) in DCM (3 mL) was added dropwise to a solution of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (200 mg, 0.604 mmol) in DCM (3 mL) at 10° C. under N₂ atmosphere, and stirred at 25° C. for 4 h. The mixture was diluted with water (20 mL), extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a solid (203 mg, 80%). MS ES+ m/z 338 [M+2+H]⁺.

Step 2: 8-acetyl-6-methyl-2-(4-methyl-1-piperidyl)chromen-4-one. A mixture of 8-bromo-6-methyl-2-(4-methyl-1-piperidyl)chromen-4-one (200 mg, 0.595 mmol), tributyl(1-ethoxyvinyl)stannane (430 mg, 1.19 mmol) and Pd(PPh₃)₂Cl₂ (42 mg, 0.059 mmol) in dioxane (10 mL) was stirred at 95° C. under N₂ for 16 h. The mixture was added aq. HCl (2 mL, 2 M) and stirred at 50° C. for 1 h. When cooled to rt the mixture was added sat. KF (30 mL), stirred for 1 h, extracted with EtOAc (30 mL×3). The combined extract was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-10% MeOH in DCM to give the product (178 mg, 97%) as a solid. MS ES+ m/z 300 [M+H]⁺.

Step 3: 8-(1-hydroxyethyl)-6-methyl-2-(4-methyl-1-piperidyl)chromen-4-one. A mixture of 8-acetyl-6-methyl-2-(4-methyl-1-piperidyl)chromen-4-one (170 mg, 0.568 mmol) in DCM (2 mL) and MeOH (2 mL) was added NaBH₄ (26 mg, 0.68 mmol) at 0° C., then stirred at 15° C. for 1 h. The mixture was diluted with water (10 mL), extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-3% MeOH in DCM to give the product (160 mg, crude) as a solid. MS ES+ m/z 302 [M+H]⁺.

Step 4: 8-(1-bromoethyl)-6-methyl-2-(4-methyl-1-piperidyl)chromen-4-one. A mixture of 8-(1-hydroxyethyl)-6-methyl-2-(4-methyl-1-piperidyl)chromen-4-one (160 mg, 0.531 mmol) in DCM (3 mL) was added PBr₃ (287 mg, 1.06 mmol) at 0° C., stirred at 15° C. for 15 h. The mixture was adjusted with sat.NaHCO₃ to pH=9, extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-8% MeOH in DCM to give the product (160 mg, crude) as oil. MS ES+ m/z 364 [M+H]⁺.

Step 5: 2-[1-[6-methyl-2-(4-methyl-1-piperidyl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid. A mixture of 8-(1-bromoethyl)-6-methyl-2-(4-methyl-1-piperidyl)chromen-4-one (70.0 mg, 0.192 mmol) and 2-aminobenzoic acid (79.1 mg, 0.576 mmol) in DMF (1 mL) was stirred at 80° C. for 14 h. When cooled to rt the mixture was diluted with water (10 mL) and EtOAc (20 mL), then adjusted with aq. NaOH (1 M) to pH=12, the mixture was extracted with EtOAc (20 mL). The aqueous layer was adjusted with aq. HCl (1 M) to pH=4, then extracted with DCM (20 mL×3). The combined extract was dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by preparative HPLC to give 2-[1-[6-methyl-2-(4-methyl-1-piperidyl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (6.74 mg, 8%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.92 (d, J=6.4 Hz, 3H), 1.16-1.23 (m, 2H), 1.58 (d, J=6.4 Hz, 3H), 1.63-1.73 (m, 3H), 2.30 (s, 3H), 3.02 (t, J=12.4 Hz, 2H), 4.05-4.08 (m, 2H), 5.05-5.08 (m, 1H), 5.52 (s, 1H,), 6.45 (d, J=8.4 Hz, 1H), 6.55 (t, J=7.6 Hz, 1H), 7.24 (t, J=7.6 Hz, 1H), 7.36 (d, J=2.0 Hz, 1H), 7.60 (d, J=1.6 Hz, 1H), 7.81 (dd, J=8.0, 1.6 Hz, 1H), 8.37 (br s, 1H), 12.73 (s, 1H). MS ES+ m/z 421 [M+H]⁺. MS ES+ m/z 421 [M+H]⁺.

Example 371: 2-[1-[6-Methyl-2-[4-(methylcarbamoyl)-1-piperidyl]-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1: 1-(8-bromo-6-methyl-4-oxo-chromen-2-yl)-N-methyl-piperidine-4-carboxamide. A mixture of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (300 mg, 0.906 mmol) in DCM (6 mL) was added N-methylpiperidine-4-carboxamide (322 mg, 2.26 mmol) and DIPEA (702 mg, 5.44 mmol) at 10° C., and stirred at 25° C. for 3 h. The mixture was quenched with HCl (1M, 2 mL), extracted with DCM (20 mL×3). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as gum (400 mg, crude). MS ES+ m/z 381 [M+H]⁺.

Step 2: 1-(8-acetyl-6-methyl-4-oxo-chromen-2-yl)-N-methyl-piperidine-4-carboxamide. A mixture of 1-(8-bromo-6-methyl-4-oxo-chromen-2-yl)-N-methyl-piperidine-4-carboxamide (350 mg, 0.923 mmol), Pd(PPh₃)₂Cl₂ (65 mg, 0.092 mmol) and tributyl(1-ethoxyvinyl)stannane (400 mg, 1.11 mmol) in dioxane (7 mL) was stirred at 95° C. under N₂ for 16 h. The mixture was added HCl (1.5 mL, 2 M) and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was combined with another batch (50 mg), added sat. aq. KF (10 mL) and stirred for 1 h, filtered and the filter cake was rinsed with DCM (30 mL). The aqueous phase was extracted with DCM (30 mL×3). The combined extract was dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0-10% MeOH in DCM to give the product as a solid (130 mg, 36%). MS ES+ m/z 343 [M+H]⁺.

Step 3: 1-[8-(1-hydroxyethyl)-6-methyl-4-oxo-chromen-2-yl]-N-methyl-piperidine-4-carboxamide. A mixture of 1-(8-acetyl-6-methyl-4-oxo-chromen-2-yl)-N-methyl-piperidine-4-carboxamide (110 mg, 0.321 mmol) in DCM (1 mL) and MeOH (1 mL) was added NaBH₄ (15 mg, 0.39 mmol) at −10° C., and stirred at −10° C. for 1.5 h. The mixture was combined with another batch (20 mg), quenched with water (30 mL), extracted with DCM/MeOH (30 mL×3, 10/1). The combined extract was dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as gum (130 mg, crude). MS ES+ m/z 345 [M+H]⁺.

Step 4: 1-[8-(1-bromoethyl)-6-methyl-4-oxo-chromen-2-yl]-N-methyl-piperidine-4-carboxamide. A mixture of 1-[8-(1-hydroxyethyl)-6-methyl-4-oxo-chromen-2-yl]-N-methyl-piperidine-4-carboxamide (110 mg, 0.319 mmol) in DCM (3 mL) was added PBr₃ (173 mg, 0.639 mmol) at 0° C., and stirred at 20° C. for 16 h. The reaction mixture was quenched with sat.aq.NaHCO₃(10 mL), extracted with DCM (30 mL×3). The combined extract was washed with brine (50 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0-8% MeOH in DCM to give the product as a solid (45 mg, 35%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.59-1.67 (m, 2H), 1.77-1.83 (m, 2H), 2.10 (d, J=7.2 Hz, 3H), 2.39 (s, 3H), 2.54-2.60 (m, 4H), 3.09-3.18 (m, 2H), 4.10-4.21 (m, 2H), 5.55 (s, 1H), 5.85 (q, J=6.8 Hz, 1H), 7.66-7.71 (m, 2H), 7.76-7.82 (m, 1H). MS ES+ m/z 407 [M+H]⁺.

Step 5: 2-[1-[6-methyl-2-[4-(methylcarbamoyl)-1-piperidyl]-4-oxo-chromen-8-yl]ethylamino]benzoic acid. A mixture of 1-[8-(1-bromoethyl)-6-methyl-4-oxo-chromen-2-yl]-N-methyl-piperidine-4-carboxamide (40 mg, 0.098 mmol) and 2-aminobenzoic acid (27 mg, 0.20 mmol) in DMF (1 mL) was stirred at 80° C. for 16 h. When cooled to rt the mixture was filtered. The filtrate was purified by preparative HPLC to give 2-[1-[6-methyl-2-[4-(methylcarbamoyl)-1-piperidyl]-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (8.37 mg, 18%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.58 (d, J=6.4 Hz, 3H), 1.60-1.68 (m, 2H), 1.72-1.82 (m, 2H), 2.30 (s, 3H), 2.54-2.61 (m, 4H), 3.00-3.14 (m, 2H), 4.01-4.16 (m, 2H), 5.08 (q, J=6.4 Hz, 1H), 5.54 (s, 1H), 6.46 (d, J=8.4 Hz, 1H), 6.55 (t, J=7.6 Hz, 1H), 7.20-7.28 (m, 1H), 7.36 (d, J=2.4 Hz, 1 H), 7.60 (d, J=1.6 Hz, 1H), 7.74-7.85 (m, 2H), 8.34 (d, J=6.0 Hz, 1H), 12.68 (brs, 1H). MS ES+ m/z 464 [M+H]⁺.

Example 372: 2-[1-[6-Methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethylamino]benzamide

A mixture of 8-(1-bromoethyl)-6-methyl-2-(1-piperidyl)chromen-4-one (80 mg, 0.23 mmol) and 2-aminobenzamide (62 mg, 0.46 mmol) in DMF (1 mL) was stirred at 80° C. for 16 h. When cooled to rt the mixture was quenched with H₂O (20 mL), extracted with DCM (20 mL×2). The combined extracted was washed with brine (40 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by preparative HPLC to give 2-[1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethylamino]benzamide as a solid (90 mg, 97%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.53-1.62 (m, 9H), 2.33 (s, 3H), 3.54-3.56 (m, 4H), 5.00 (t, J=6.8 Hz, 1H), 5.51 (s, 1H), 6.38 (d, J=8.0 Hz, 1H), 6.52 (t, J=7.6 Hz, 1H), 7.13 (t, J=7.2 Hz, 1H), 7.14 (brs, 1H), 7.36 (d, J=2.0 Hz, 1H), 7.59-7.63 (m, 2H), 7.91 (brs, 1H), 8.72 (d, J=6.0 Hz, 1H). MS ES+ m/z 406 [M+H]⁺.

Example 373: 2-[1-[2-(4-Methoxy-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1: 8-bromo-2-(4-methoxy-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (200 mg, 0.604 mmol), DIPEA (312 mg, 2.42 mmol) and 4-methoxypiperidine (153 mg, 1.33 mmol) in DCM (25 mL) was stirred at 20° C. for 2 h. The mixture was quenched with HCl (1M, 2 mL), extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a solid (213 mg, crude). MS ES+ m/z 436 [M+H]⁺.

Step 2: 8-acetyl-2-(4-methoxy-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-bromo-2-(4-methoxy-1-piperidyl)-6-methyl-chromen-4-one (200 mg, 0.568 mmol), Pd(PPh₃)₂Cl₂ (40 mg, 0.057 mmol) and tributyl(1-ethoxyvinyl)stannane (246 mg, 0.681 mmol) in dioxane (20 mL) was stirred at 95° C. under N₂ for 16 h. HCl (2 M, 5.68 mL) was added to the mixture and stirred at 50° C. for 1 h. When cooled to rt the mixture was quenched with sat.aq. KF (10 mL) and stirred for 0.5 h, filtered, the filtrate was adjusted to pH=8 and extracted with DCM (30 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0-10% MeOH in DCM to give the product as a solid (179 mg, crude). MS ES+ m/z 316 [M+H]⁺.

Step 3: 8-(1-hydroxyethyl)-2-(4-methoxy-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-acetyl-2-(4-methoxy-1-piperidyl)-6-methyl-chromen-4-one (179 mg, 0.567 mmol) in DCM (2 mL) and MeOH (2 mL) was added NaBH₄ (32 mg, 0.85 mmol) in one portion at −10° C. under N₂ and stirred at −10° C. for 1 h. The reaction mixture was quenched with water (15 mL), extracted with DCM/MeOH (20 mL×2, 10/1). The combined extract was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel chromatography eluted with 0%-10% MeOH in DCM to give the product as a solid (190 mg, crude). MS ES+ m/z 318 [M+H]⁺.

Step 4: 8-(1-bromoethyl)-2-(4-methoxy-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-(1-hydroxyethyl)-2-(4-methoxy-1-piperidyl)-6-methyl-chromen-4-one (190 mg, 0.598 mmol) in DCM (5 mL) was added PBr₃ (162 mg, 0.598 mmol) dropwise at 0° C. and stirred at 20° C. for 2 h. The reaction mixture was quenched with sat.aq.NaHCO₃(20 mL), extracted with DCM (20 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous anhydrous Na₂SO₄ (30 mL), filtered and concentrated to give the product as a solid (200 mg, 88%). MS ES+ m/z 352 [M+H]⁺.

Step 5: 2-[1-[2-(4-methoxy-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. A mixture of 8-(1-bromoethyl)-2-(4-methoxy-1-piperidyl)-6-methyl-chromen-4-one (200 mg, 0.526 mmol) and methyl 2-aminobenzoate (159 mg, 1.05 mmol) in DMF (1 mL) was stirred at 80° C. for 16 h. When cooled to rt the mixture was quenched with H₂O (20 mL), extracted with DCM (20 mL×2). The combined extract was washed with brine (40 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel chromatography eluted with 0%-10% MeOH in DCM to give methyl 2-[1-[2-(4-methoxy-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate as a solid (100 mg, 42%). A mixture of methyl 2-[1-[2-(4-methoxy-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate (100 mg, 0.222 mmol) and LiOH·H₂O (19 mg, 0.44 mmol) in THE (2 mL), EtOH (1 mL) and H₂O (4 mL) was stirred at 20° C. for 18 h. Then the reaction mixture was added NaOH (17.8 mg, 0.444 mol) in H₂O (4 mL) and stirred at 20° C. for 4 h. The mixture was concentrated to remove most of EtOH and THF, then purified by preparative HPLC to give 2-[1-[2-(4-methoxy-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (20 mg, 21%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.52-1.57 (m, 5H), 1.90-1.91 (m, 2H), 2.29 (s, 3H), 3.27 (s, 3H), 3.45-3.48 (m, 3H), 3.74-3.77 (m, 2H), 5.01-5.05 (m, 1H), 5.54 (s, 1H), 6.37 (d, J=8.8 Hz, 1H), 6.49 (t, J=7.6 Hz, 1H), 7.12-7.16 (m, 1H), 7.37 (d, J=1.6 Hz, 1H), 7.59 (d, J=1.6 Hz, 1H), 7.79 (d, J=7.6 Hz, 1H), 8.83 (brs, 1H). MS ES+ m/z 437 [M+H]⁺.

Example 374: 2-[1-[2-(4-Cyano-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1: 1-(8-bromo-6-methyl-4-oxo-chromen-2-yl)piperidine-4-carbonitrile. A mixture of piperidine-4-carbonitrile (80 mg, 0.72 mmo) and DIPEA (312 mg, 2.42 mmol) in DCM (3 mL) was added dropwise to a solution of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (200 mg, 0.604 mmol) in DCM (3 mL) at 10° C. under N₂ atmosphere, and stirred at 20° C. for 14 h. The mixture was diluted with water (20 mL), extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as oil (209 mg, 100%). MS ES+ m/z 349 [M+2+H]⁺.

Step 2: 1-(8-acetyl-6-methyl-4-oxo-chromen-2-yl)piperidine-4-carbonitrile. A mixture of 1-(8-bromo-6-methyl-4-oxo-chromen-2-yl)piperidine-4-carbonitrile (200 mg, 0.576 mmol), tributyl(1-ethoxyvinyl)stannane (416 mg, 1.15 mmol) and Pd(PPh₃)₂Cl₂ (40 mg, 0.58 mmol) in dioxane (2 mL) was stirred at 95° C. under N₂ for 16 h. HCl (0.5 mL, 2 M) was added to the mixture and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was quenched with sat. aq. KF (10 mL) and stirred for 0.5 h, filtered, the filtrate was adjusted to pH=8 and extracted with DCM (30 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0%-2% MeOH in DCM to give the product as oil (222 mg, 93%). MS ES+ m/z 311 [M+H]⁺.

Step 3: 1-[8-(1-hydroxyethyl)-6-methyl-4-oxo-chromen-2-yl]piperidine-4-carbonitrile. A mixture of 1-(8-acetyl-6-methyl-4-oxo-chromen-2-yl)piperidine-4-carbonitrile (200 mg, 0.483 mmol) in DCM (3 mL) and MeOH (3 mL) was added NaBH₄ (22 mg, 0.58 mmol) at 0° C., and stirred at 20° C. for 1 h. The mixture was diluted with water (15 mL), extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0%-4% MeOH in DCM to give the product as a solid (140 mg, 88%). MS ES+ m/z 313 [M+H]⁺.

Step 4: 1-[8-(1-bromoethyl)-6-methyl-4-oxo-chromen-2-yl]piperidine-4-carbonitrile. A mixture of 1-[8-(1-hydroxyethyl)-6-methyl-4-oxo-chromen-2-yl]piperidine-4-carbonitrile (140 mg, 0.448 mmol) in DCM (3 mL) was added PBr₃ (182 mg, 0.672 mmol) at 0° C., and stirred at 15° C. for 3 h. The reaction mixture was adjusted to pH=9 with sat.NaHCO₃, extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0%-9% MeOH in DCM to give the product as a solid (100 mg, 54%). MS ES+ m/z 375 [M+H]⁺.

Step 5: 2-[1-[2-(4-cyano-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. A mixture of 1-[8-(1-bromoethyl)-6-methyl-4-oxo-chromen-2-yl]piperidine-4-carbonitrile (50 mg, 0.13 mmol) and 2-aminobenzoic acid (55 mg, 0.40 mmol) in DMF (1 mL) was stirred at 80° C. for 14 h. The mixture was diluted with water (10 mL), adjusted to pH=12 with aq. NaOH (1 M) and extracted with EtOAc (20 mL×2). The aqueous layer was adjusted to pH=4 with HCl (1 M), extracted with DCM (20 mL×3). The combined extract was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by preparative HPLC to give 2-[1-[2-(4-cyano-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (25.41 mg, 44%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.58 (d, J=6.8 Hz, 3H), 1.80-1.85 (m, 2H), 1.95-2.02 (m, 2H), 2.30 (s, 3H), 3.16-3.20 (m, 1H), 3.41-3.44 (m, 2H), 3.76-3.79 (m, 2H), 5.06-5.09 (m, 1H), 5.58 (s, 1H), 6.46 (d, J=8.8 Hz, 1H,), 6.55 (t, J=7.2 Hz, 1H), 7.24 (t, J=7.2 Hz, 1H), 7.37 (d, J=1.6 Hz, 1H), 7.60 (s, 1H), 7.81 (dd, J=8.0, 1.6 Hz, 1H), 8.38 (br s, 1H). MS ES+ m/z 432 [M+H]⁺.

Example 375: 2-[1-[2-(Azetidin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1: 2-(azetidin-1-yl)-8-bromo-6-methyl-chromen-4-one. A mixture of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (200 mg, 0.604 mmol), azetidine (85 mg, 0.91 mmol, HCl salt) and DIPEA (78 mg, 0.60 mmol) in DCM (10 mL) was stirred at 25° C. for 4 h. The reaction mixture was concentrated and purified on a silica gel column eluted with 0-10% MeOH in DCM to give the product as a solid (177 mg, 99%). MS ES+ m/z 294 [M+H]⁺.

Step 2: 8-acetyl-2-(azetidin-1-yl)-6-methyl-chromen-4-one. A mixture of 2-(azetidin-1-yl)-8-bromo-6-methyl-chromen-4-one (110 mg, 0.374 mmol), tributyl(1-ethoxyvinyl)stannane (270 mg, 0.748 mmol) and Pd(PPh₃)₂Cl₂ (26 mg, 0.037 mmol) in dioxane (5 mL) was stirred at 95° C. under N₂ for 16 h. HCl (4 mL, 1 M) was added and stirred at 50° C. for 1 h. The mixture was combined with another batch (50 mg), quenched with sat. KF (30 mL) and filtered. The filtrate was diluted with sat.NaHCO₃(30 mL), extracted with EtOAc (30 mL×3). The combined extract was washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0-10% MeOH in DCM to give the product as a solid (139 mg, 99%). MS ES+ m/z 258 [M+H]⁺.

Step 3: 2-(azetidin-1-yl)-8-(1-hydroxyethyl)-6-methyl-chromen-4-one. A mixture of 8-acetyl-2-(azetidin-1-yl)-6-methyl-chromen-4-one (139 mg, 0.540 mmol) in DCM (5 mL) and MeOH (5 mL) was added NaBH₄ (31 mg, 0.81 mmol) at −10° C. and stirred for 1 h. The reaction mixture was quenched with water (20 mL), extracted with DCM/MeOH (20 mL×2, 10/1). The combined extract was washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a solid (140 mg, crude). MS ES+ m/z 260 [M+H]⁺.

Step 4: 2-(azetidin-1-yl)-8-(1-bromoethyl)-6-methyl-chromen-4-one. A mixture of 2-(azetidin-1-yl)-8-(1-hydroxyethyl)-6-methyl-chromen-4-one (140 mg, 0.540 mmol) in DCM (5 mL) was added PBr₃ (219 mg, 0.810 mmol) at 0° C. and stirred at 20° C. for 2 h. The mixture was quenched with sat.NaHCO₃(30 mL), extracted with DCM (30 mL×3). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 0-10% MeOH in DCM to give the product as a solid (100 mg, 57%). MS ES+ m/z 322 [M+H]⁺.

Step 5: 2-[1-[2-(azetidin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. A mixture of 2-(azetidin-1-yl)-8-(1-bromoethyl)-6-methyl-chromen-4-one (75 mg, 0.23 mmol), methyl 2-aminobenzoate (70 mg, 0.46 mmol) and KI (42 mg, 0.26 mmol) in DCM (4 mL) and MeOH (1 mL) was stirred at 20° C. for 24 h. The reaction mixture was concentrated and purified by preparative TLC to give methyl 2-[1-[2-(azetidin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate as a solid (70 mg, 77%). A mixture of methyl 2-[1-[2-(azetidin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate (70 mg, 0.18 mmol) and LiOH·H₂O (26 mg, 0.16 mmol) in THE (3 mL) and H₂O (1 mL) was stirred at 25° C. for 16 h. The reaction mixture was concentrated and purified by preparative HPLC to give 2-[1-[2-(azetidin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (4.43 mg, 7%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.59 (d, J=6.8 Hz, 3H), 2.31 (s, 3H), 2.36-2.45 (m, 2H), 4.13-4.23 (m, 4H), 4.98-5.06 (m, 2H), 6.48-6.58 (m, 2H), 7.21-7.29 (m, 1H), 7.39 (d, J=2.0 Hz, 1H), 7.61 (d, J=1.2 Hz, 1H), 7.80 (dd, J=8.0, 1.2 Hz, 1H), 8.37 (d, J=6.8 Hz, 1H), 12.78 (brs, 1H). MS ES+ m/z 379 [M+H]⁺.

Example 376: 2-[[(1R)-1-[6-Methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzoic acid

A mixture of 8-[(1R)-1-aminoethyl]-6-methyl-2-(1-piperidyl)chromen-4-one (150 mg, 0.524 mmol), 2-iodobenzoic acid (234 mg, 0.943 mmol), CuI (10 mg, 0.052 mmol), 2-(methylamino)acetic acid (9.0 mg, 0.10 mmol) and K₂CO₃ (145 mg, 1.05 mmol) in DMSO (3 mL) was stirred at 45° C. under N₂ for 96 h. When cooled to rt the mixture was combined with another batch (50 mg), extracted with DCM (20 mL×3). The combined extract was dried over anhydrous Na₂SO₄, filtered, concentrated, purified by preparative HPLC and SFC to give 2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzoic acid as a solid (14.78 mg, 14%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.54-1.65 (m, 9H), 2.30 (s, 3H), 3.48-3.62 (m, 4H), 5.00-5.11 (m, 1H), 5.51 (s, 1H), 6.44 (d, J=8.4 Hz, 1H), 6.54 (t, J=7.2 Hz, 1H), 7.17-7.28 (m, 1H), 7.36 (d, J=1.6 Hz, 1H), 7.60 (d, J=1.2 Hz, 1H), 7.81 (dd, J=8.0, 1.6 Hz, 1H), 8.46 (brs, 1H). MS ES+ m/z 407 [M+H]⁺.

Example 377: 2-(2-Methoxyethoxy)ethyl 2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzoate

A mixture of 2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzoic acid (30 mg, 0.074 mmol) and K₂CO₃ (20 mg, 0.15 mmol) in DMF (2 mL) was added 1-(2-bromoethoxy)-2-methoxy-ethane (20 mg, 0.11 mmol) under N₂ and stirred at 20° C. for 48 h. The reaction mixture was filtered and purified by preparative HPLC to give 2-(2-methoxyethoxy)ethyl 2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzoate as a solid (10 mg, 27%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.59-1.60 (m, 9H), 2.30 (s, 3H), 3.23 (s, 3H), 3.44-3.47 (m, 2H), 2.54-3.55 (m, 4H), 3.59-3.61 (m, 2H), 3.75-3.76 (m, 2H), 4.38-4.39 (m, 2H), 5.07-5.13 (m, 1H), 5.52 (s, 1H), 6.50 (d, J=8.4 Hz, 1H), 6.60 (t, J=7.6 Hz, 1H), 7.29 (t, J=8.0 Hz, 1H), 7.37 (d, J=2.0 Hz, 1H), 7.60 (d, J=1.6 Hz, 1H), 7.84 (dd, J=8.0, 1.6 Hz, 1H), 8.08 (d, J=6.4 Hz, 1H). MS ES+ m/z 509 [M+H]⁺.

Example 378: 2-[1-[2-(4-Acetylpiperazin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1: 2-(4-acetylpiperazin-1-yl)-8-bromo-6-methyl-chromen-4-one. A mixture of 1-piperazin-1-ylethanone (348 mg, 2.72 mmol) and DIPEA (585 mg, 4.53 mmol) in DCM (3 mL) was added dropwise to a solution of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (300 mg, 906 μmol) in DCM (5 mL) at 10° C. under N₂ atmosphere, and stirred at 20° C. for 4 h. The mixture was quenched with HCl (1M, 2 mL), extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 1%-9% MeOH in DCM to give the product as a solid (250 mg, 76%). MS ES+ m/z 367 [M+2+H]⁺.

Step 2: 8-acetyl-2-(4-acetylpiperazin-1-yl)-6-methyl-chromen-4-one. A mixture of 2-(4-acetylpiperazin-1-yl)-8-bromo-6-methyl-chromen-4-one (200 mg, 0.548 mmol), tributyl(1-ethoxyvinyl)stannane (237 mg, 0.657 mmol) and Pd(PPh₃)₂Cl₂ (384 mg, 0.548 mmol) in dioxane (8 mL) was stirred at 95° C. under N₂ for 16 h. HCl (0.5 mL, 2 M) was added to the mixture and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was quenched with sat. aq. KF (10 mL) and stirred for 0.5 h, filtered, the filtrate was adjusted to pH=8 and extracted with DCM (30 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 1%-9% MeOH in DCM to give the product as a solid (180 mg, 92%). MS ES+ m/z 329 [M+H]⁺.

Step 3: 2-(4-acetylpiperazin-1-yl)-8-(1-hydroxyethyl)-6-methyl-chromen-4-one. A mixture of 8-acetyl-2-(4-acetylpiperazin-1-yl)-6-methyl-chromen-4-one (180 mg, 0.548 mmol) in DCM (2 mL) and MeOH (2 mL) was added NaBH₄ (25 mg, 0.66 mmol) at 0° C., and stirred at 25° C. for 2 h. The mixture was adjusted to pH=8 with sat.NaHCO₃, extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 1%-9% MeOH in DCM to give the product as a solid (80 mg, 42%). MS ES+ m/z 331 [M+H]⁺.

Step 4: 2-(4-acetylpiperazin-1-yl)-8-(1-bromoethyl)-6-methyl-chromen-4-one. A mixture of 2-(4-acetylpiperazin-1-yl)-8-(1-hydroxyethyl)-6-methyl-chromen-4-one (80 mg, 0.24 mmol) in DCM (2 mL) was added PBr₃ (98 mg, 0.36 mmol) at 0° C., and stirred at 25° C. for 16 h. The mixture was adjusted to pH=9 with sat.Na₂CO₃, extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated and purified on a silica gel column eluted with 1%-9% MeOH in DCM to give the product as a solid (73 mg, 63%). MS ES+ m/z 395 [M+2+H]⁺.

Step 5: 2-[1-[2-(4-acetylpiperazin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid. A mixture of 2-(4-acetylpiperazin-1-yl)-8-(1-bromoethyl)-6-methyl-chromen-4-one (35 mg, 0.089 mmol), methyl 2-aminobenzoate (27 mg, 0.18 mmol) and KI (19 mg, 0.12 mmol) in DCM/MeOH (4/1, 2.5 mL) was stirred at 25° C. for 48 h. The mixture was concentrated and purified on a silica gel column eluted with 1%-9% MeOH in DCM to give methyl 2-[1-[2-(4-acetylpiperazin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate as a solid (47 mg, 88%). MS ES+ m/z 464 [M+H]⁺. A mixture of methyl 2-[1-[2-(4-acetylpiperazin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate (50 mg, 0.11 mmol) and LiOH·H₂O (11 mg, 0.27 mmol) in EtOH (1 mL) and H₂O (1 mL) was stirred at 20° C. for 24 h. The mixture was concentrated and purified by preparative HPLC to give 2-[1-[2-(4-acetylpiperazin-1-yl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (6.3 mg, 13%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.60 (d, J=6.4 Hz, 3H), 2.05 (s, 3H), 2.31 (s, 3H), 3.56-3.62 (m, 8H), 5.10-5.13 (m, 1H), 5.56 (s, 1H), 6.47 (d, J=8.4 Hz, 1H), 6.57 (t, J=7.6 Hz, 1H), 7.24-7.28 (m, 1H), 7.39 (d, J=1.6 Hz, 1H), 7.62 (s, 1H), 7.82 (dd, J=8.0, 1.6 Hz, 1H), 8.36 (d, J=6.0 Hz, 1H). MS ES+ m/z 450 [M+H]⁺.

Example 379: Methyl 2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzoate

A mixture of 2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzoic acid (20 mg, 0.049 mmol), K₂CO₃ (10 mg, 0.074 mmol) and Mel (11 mg, 0.074 mmol) in DMF (2 mL) was stirred at 20° C. for 2 h. The reaction mixture was filtered. The filtrate was concentrated and purified by preparative HPLC to give methyl 2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzoate as a solid (5.4 mg, 26%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.58-1.60 (m, 9H), 2.29 (s, 3H), 3.53-3.54 (m, 4H), 3.83 (s, 3H), 5.07-5.10 (m, 1H), 5.51 (s, 1H), 6.50 (d, J=8.8 Hz, 1H), 6.58 (t, J=7.2 Hz, 1H), 7.28 (td, J=8.4, 1.6 Hz, 1H), 7.36 (d, J=2.0 Hz, 1H), 7.60 (d, J=1.6 Hz, 1H), 7.70 (dd, J=7.6, 1.6 Hz, 1H), 8.15 (d, J=6.0 Hz, 1H). MS ES+ m/z 421 [M+H]⁺.

Example 380: 2-[1-[6-Methyl-2-(3-methyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1: tert-butyl 4-(2-ethoxy-2-oxo-ethyl)-4-hydroxy-piperidine-1-carboxylate. A mixture of ethyl acetate (4.95 g, 56.2 mmol) in THE (60 mL) was added LiHMDS (55 mL, 1 M in THF) dropwise at −65° C. over 2 h, then stirred at −65° C. for 30 min. Then tert-butyl 4-(2-ethoxy-2-oxo-ethyl)-4-hydroxy-piperidine-1-carboxylate (10.0 g, 50.2 mmol) in THE (60 mL) was added dropwise at −65° C. and stirred for 1 h, then stirred at 0° C. for 14 h. The mixture was quenched with sat.NH₄Cl (100 mL) and extracted with EtOAc (150 mL×2). The combined extract was concentrated and purified by silica gel chromatography eluted with 10-25% EtOAc in petroleum ether to give the product as oil (8.8 g, 61%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.30 (t, J=7.2 Hz, 3H), 1.47 (s, 9H), 1.43-1.55 (m, 2H), 1.63-1.75 (m, 2H), 2.48 (s, 2H), 3.10-3.30 (m, 2H), 3.62 (brs, 1H), 3.75-3.86 (m, 2H), 4.20 (q, J=7.2 Hz, 2H).

Step 2: 2-(1-tert-butoxycarbonyl-4-hydroxy-4-piperidyl)acetic acid. A mixture of tert-butyl 4-(2-ethoxy-2-oxo-ethyl)-4-hydroxy-piperidine-1-carboxylate (8.80 g, 30.6 mmol) and LiOH·H₂O (1.54 g, 36.7 mmol) in MeOH (100 mL) and H₂O (50 mL) was stirred at 25° C. for 16 h. The mixture was concentrated, diluted with water (50 mL) and adjusted to pH=7 with HCl (3 M). The mixture was washed with DCM (100 mL×2). The aqueous phase was lyophilized to give the product as a solid (7.94 g, contained LiCl). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.15-1.30 (m, 2H), 1.38 (s, 9H), 1.35-1.55 (m, 2H), 1.98 (s, 2H), 2.95-3.20 (m, 2H), 3.50-3.70 (m, 2H), 6.80-8.00 (brs, 1H).

Step 3: tert-butyl 2-oxo-1-oxa-3,8-diazaspiro[4.5]decane-8-carboxylate. A mixture of 2-(1-tert-butoxycarbonyl-4-hydroxy-4-piperidyl)acetic acid (7.94 g, crude) (200 mL), DPPA (9.27 g, 33.7 mmol) and TEA (3.41 g, 33.7 mmol) in toluene was stirred at 120° C. for 16 h. When cooled to rt the mixture was diluted with water (100 mL) and extracted with EtOAc (80 mL×2). The combined extract was washed with brine (100 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 20-85% EtOAc in petroleum ether to give the product as an solid (3.8 g, yield for two steps: 48%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.48 (s, 9H), 1.60-1.75 (m, 2H), 1.90-2.00 (m, 2H), 3.20-3.38 (m, 4H), 3.79-3.92 (m, 2H), 5.23 (brs, 1H).

Step 4: 3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one. A mixture of tert-butyl 2-oxo-1-oxa-3,8-diazaspiro[4.5]decane-8-carboxylate (3.80 g, 14.8 mmol) in DMF (40 mL) was added NaH (890 mg, 22.2 mmol, 60% dispersed in mineral oil) in portions at 0° C. and stirred for 0.5 h, then added CH₃I (3.16 g, 22.2 mmol) dropwise at 0° C. and stirred at 25° C. for 16 h. The mixture was quenched with sat.NH₄Cl (60 mL) and extracted with EtOAc (60 mL×3). The combined extract was washed with brine (80 mL×3), dried over anhydrous Na₂SO₄, filtered and concentrated to give tert-butyl 3-methyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]decane-8-carboxylate (3.5 g, 87%) as a solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41 (s, 9H), 1.65-1.78 (m, 4H), 2.75 (s, 2H), 3.15-3.30 (m, 2H), 3.34 (s, 3H), 3.50-3.59 (m, 2H). A mixture of tert-butyl 3-methyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]decane-8-carboxylate (500 mg, 1.85 mmol) in FA (15 mL) was stirred at 100° C. for 1 h. The mixture was concentrated. Water (40 mL) was added and lyophilized to give the product as a solid (400 mg, FA salt). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.68-1.85 (m, 4H), 2.76 (s, 3H), 2.85-3.00 (m, 4H), 3.34 (s, 2H).

Step 5: 8-(8-bromo-6-methyl-4-oxo-chromen-2-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one. A mixture of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (350 mg, 1.06 mmol), 3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one (388 mg, 1.80 mmol, FA salt) and DIPEA (742 mg, 5.74 mmol) in DCM (14 mL) was stirred at 25° C. for 14 h. The mixture was quenched with HCl (1 M, 2 mL), extracted with DCM (40 mL×2). The combined extract was washed with brine (40 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0-10% MeOH in DCM to give the product as a solid (420 mg, 98%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.83-1.95 (4H, m), 2.38 (3H, s), 2.77 (3H, s), 3.37 (2H, s), 3.40-3.55 (2H, m), 3.80-3.91 (2H, m), 5.63 (1H, s), 7.70 (1H, d, J=2.0 Hz), 7.80 (1H, d, J=2.0 Hz). MS ES+ m/z 407 [M+H]⁺.

Step 6: 8-(8-acetyl-6-methyl-4-oxo-chromen-2-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one. A mixture of 8-(8-bromo-6-methyl-4-oxo-chromen-2-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one (420 mg, 1.03 mmol), Pd(PPh₃)₂Cl₂ (72 mg, 0.103 mmol) and tributyl(1-ethoxyvinyl)stannane (447 mg, 1.24 mmol) in dioxane (10 mL) was stirred at 95° C. under N₂ for 16 h. HCl (1 mL, 2 M) was added and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was added sat. KF (10 mL), stirred for 1 h, extracted with EtOAc (10 mL×3). The combined extract was washed with brine (10 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0-10% MeOH in DCM to give the product as a solid (350 mg, 92%). MS ES+ m/z 371 [M+H]⁺.

Step 7: 8-[8-(1-hydroxyethyl)-6-methyl-4-oxo-chromen-2-yl]-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one. A mixture of 8-(8-acetyl-6-methyl-4-oxo-chromen-2-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one (100 mg, 0.270 mmol) in MeOH (5 mL) and DCM (5 mL) was added NaBH₄ (12 mg, 0.32 mmol) at −10° C., then stirred at 0° C. for 2 h. The mixture was quenched with water (15 mL), extracted with DCM (15 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as gum (100 mg, crude). MS ES+ m/z 373 [M+H]⁺.

Step 8: 8-[8-(1-bromoethyl)-6-methyl-4-oxo-chromen-2-yl]-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one. A mixture of 8-[8-(1-hydroxyethyl)-6-methyl-4-oxo-chromen-2-yl]-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one (100 mg, 0.268 mmol) in DCM (5 mL) was added PBr₃ (109 mg, 0.403 mmol) dropwise at 0° C., then stirred at 25° C. for 2 h. The mixture was adjusted to pH=8 with sat.NaHCO₃, extracted with DCM (20 mL×2). The combined extract was concentrated and purified by silica gel chromatography eluted with 0-5% MeOH in DCM to give the product as a solid (75 mg, yield for two steps: 64%). MS ES+ m/z 435 [M+H]⁺.

Step 9: 2-[1-[6-methyl-2-(3-methyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid. A mixture of 8-[8-(1-bromoethyl)-6-methyl-4-oxo-chromen-2-yl]-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one (75 mg, 0.17 mmol), methyl 2-aminobenzoate (52 mg, 0.34 mmol) and KI (31 mg, 0.19 mmol) in DCM (4 mL) and MeOH (1 mL) was stirred at 25° C. for 16 h. The mixture was quenched with water (15 mL), extracted with DCM (20 mL×2). The combined extract was concentrated and purified by silica gel chromatography eluted with 0-10% MeOH in DCM to give methyl 2-[1-[6-methyl-2-(3-methyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoate (50 mg, 34%). A mixture of methyl 2-[1-[6-methyl-2-(3-methyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoate (30 mg, crude) and LiOH·H₂O (5 mg, 0.1 mmol) in EtOH (1 mL) and water (1 mL) was stirred at 25° C. for 16 h. The mixture was concentrated and adjusted to pH=5 with HCl (1 M) and filtered. The filter cake was purified by preparative HPLC to give 2-[1-[6-methyl-2-(3-methyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (7.0 mg, 24%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.59 (d, J=6.8 Hz, 3H), 1.81-1.98 (m, 4H), 2.33 (s, 3H), 2.77 (s, 3H), 3.36 (s, 2H), 3.40-3.55 (m, 2H), 3.80-3.91 (m, 2H), 5.00-5.13 (m, 1H), 5.62 (s, 1H), 6.47 (d, J=8.8 Hz, 1H), 6.56 (t, J=8.0 Hz, 1H), 7.23 (t, J=7.2 Hz, 1H), 7.39 (d, J=2.0 Hz, 1H), 7.62 (d, J=2.0 Hz, 1H), 7.81 (dd, J=8.0, 1.6 Hz, 1H), 8.37 (brs, 1H), 12.78 (brs, 1H). MS ES+ m/z 492 [M+H]⁺.

Example 381: 2-[1-[6-Methyl-2-(2-methyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid

Step 1: 2-methyl-2,8-diazaspiro[4.5]decan-1-one. A mixture of tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate (1.50 g, 5.90 mmol) in DMF (20 mL) was added NaH (354 mg, 8.85 mmol, 60% dispersed in mineral oil) in portions at 0° C. and stirred for 0.5 h, then added CH₃I (1.26 g, 8.85 mmol) dropwise at 0° C., then stirred at 25° C. for 16 h. The mixture was quenched with sat.NH₄Cl (40 mL) and extracted with DCM (40 mL×6). The combined extract was washed with brine (100 mL×3), dried over anhydrous Na₂SO₄, filtered and concentrated to give tert-butyl 2-methyl-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate as oil (1.58 g, crude). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.20-1.40 (m, 2H), 1.40 (s, 9H), 1.45-1.60 (m, 2H), 1.80-1.95 (m, 2H), 2.72 (s, 3H), 2.75-2.90 (m, 2H), 3.25-3.33 (m, 2H), 3.74-3.90 (m, 2H). A mixture of tert-butyl 2-methyl-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate (500 mg, crude) was added FA (3 mL) and stirred at 100° C. for 1 h. The mixture was concentrated and diluted with DCM/MeOH (10/1, 30 mL), then adjusted to pH=8 with NaHCO₃ solid. The mixture was filtered. The filtrate was concentrated to give the product as a pale yellow oil (520 mg, crude).

Step 2: 8-(8-bromo-6-methyl-4-oxo-chromen-2-yl)-2-methyl-2,8-diazaspiro[4.5]decan-1-one. A mixture of 8-bromo-2-ethylsulfonyl-6-methyl-chromen-4-one (200 mg, 0.604 mmol), 2-methyl-2,8-diazaspiro[4.5]decan-1-one (259 mg, crude), DIPEA (390 mg, 3.02 mmol) in DCM (12 mL) was stirred at 25° C. for 14 h. The mixture and another batch (100 mg) were diluted with water (25 mL), extracted with DCM (25 mL×2). The combined extract was concentrated and purified silica gel chromatography eluted with 0-10% MeOH in DCM to give the product as gum (300 mg, 82%). MS ES+ m/z 405 [M+H]⁺.

Step 3: 8-(8-acetyl-6-methyl-4-oxo-chromen-2-yl)-2-methyl-2,8-diazaspiro[4.5]decan-1-one. A mixture of 8-(8-bromo-6-methyl-4-oxo-chromen-2-yl)-2-methyl-2,8-diazaspiro[4.5]decan-1-one (300 mg, crude), Pd(PPh₃)₂Cl₂ (52 mg, 0.074 mmol) and tributyl(1-ethoxyvinyl)stannane (321 mg, 0.889 mmol) in dioxane (10 mL) was stirred at 95° C. under N₂ atmosphere for 16 h. HCl (1 mL, 2 M) was added and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was added sat. KF (10 mL), stirred for 1 h, extracted with EtOAc (10 mL×3), the combined extract was washed with brine (10 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0-10% MeOH in DCM to give the product as a solid (265 mg, 97%). MS ES+ m/z 369 [M+H]⁺.

Step 4: 8-[8-(1-hydroxyethyl)-6-methyl-4-oxo-chromen-2-yl]-2-methyl-2,8-diazaspiro[4.5]decan-1-one. A mixture of 8-(8-acetyl-6-methyl-4-oxo-chromen-2-yl)-2-methyl-2,8-diazaspiro[4.5]decan-1-one (150 mg, 0.407 mmol) in DCM (5 mL) and MeOH (5 mL) was added NaBH₄ (18 mg, 0.49 mmol) in portions at −10° C., then stirred at 0° C. for 2 h. The mixture was quenched with water (15 mL), extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0-10% MeOH in DCM to give the product as a solid (110 mg, 73%). MS ES+ m/z 371 [M+H]⁺.

Step 5: 8-[8-(1-bromoethyl)-6-methyl-4-oxo-chromen-2-yl]-2-methyl-2,8-diazaspiro[4.5]decan-1-one. A mixture of 8-[8-(1-hydroxyethyl)-6-methyl-4-oxo-chromen-2-yl]-2-methyl-2,8-diazaspiro[4.5]decan-1-one (110 mg, 0.297 mmol) in DCM (8 mL) was added PBr₃ (127 mg, 0.468 mmol) at 0° C., then stirred at 25° C. for 16 h. The mixture was adjusted to pH=8 with sat.NaHCO₃, extracted with DCM (20 mL×2) The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0-7% MeOH in DCM to give the product as gum (100 mg, 78%). MS ES+ m/z 433 [M+H]⁺.

Step 6: 2-[1-[6-methyl-2-(2-methyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid. A mixture of 8-[8-(1-bromoethyl)-6-methyl-4-oxo-chromen-2-yl]-2-methyl-2,8-diazaspiro[4.5]decan-1-one (100 mg, 0.231 mmol), methyl 2-aminobenzoate (70 mg, 0.46 mmol) and KI (57 mg, 0.35 mmol) in DCM (4 mL) and MeOH (0.5 mL) was stirred at 25° C. for 4 h. The mixture was diluted with water (15 mL) and extracted with DCM (20 mL×2). The combined extract was washed with brine (20 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0-10% MeOH in DCM to give methyl 2-[1-[6-methyl-2-(2-methyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoate as yellow gum (30 mg, 17%). A mixture of methyl 2-[1-[6-methyl-2-(2-methyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoate (30 mg, crude) and LiOH·H₂O (8 mg, 0.2 mmol) in THE (0.5 mL), EtOH (0.5 mL) and water (0.5 mL) was stirred at 25° C. for 16 h. The mixture was diluted with water (10 mL) and washed with EtOAc (15 mL×2). The aqueous phase was lyophilized and purified by preparative HPLC to give 2-[1-[6-methyl-2-(2-methyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid as a solid (2.1 mg, yield: 7%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.40-1.52 (m, 2H), 1.58 (d, J=6.8 Hz, 3H), 1.70-1.82 (m, 2H), 1.99 (t, J=6.8 Hz, 2H), 2.31 (s, 3H), 2.74 (s, 3H), 3.20-3.40 (m, 4H), 3.90-4.11 (m, 2H), 5.00-5.11 (m, 1H), 5.58 (s, 1H), 6.46 (d, J=8.4 Hz, 1H), 6.55 (t, J=7.6 Hz, 1H), 7.24 (t, J=7.2 Hz, 1H), 7.37 (d, J=2.0 Hz, 1H), 7.61 (d, J=2.0 Hz, 1H), 7.82 (d, J=7.6 Hz, 1H), 8.40 (brs, 1H), 12.50 (brs, 1H). MS ES+ m/z 490 [M+H]⁺.

Example 382: N-[2-(2-Methoxyethoxy)ethyl]-2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzamide

A mixture of 2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzoic acid (30 mg, 0.074 mmol), 2-(2-methoxyethoxy)ethanamine (13 mg, 0.11 mmol) and EDCI (28 mg, 0.15 mmol) in pyridine (1 mL) was stirred at 25° C. for 4 h. The reaction mixture was concentrated to remove most of pyridine and purified by preparative HPLC to give N-[2-(2-methoxyethoxy)ethyl]-2-[[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]amino]benzamide as a solid (3.6 mg, 9.4%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.53 (d, J=6.8 Hz, 3H), 1.61 (s, 6H), 2.28 (s, 3H), 3.23 (s, 3H), 2.43-3.46 (m, 4H), 3.52-3.55 (m, 8H), 4.99 (t, J=6.4 Hz, 1H), 5.50 (s, 1H), 6.39 (d, J=8.4 Hz, 1H), 6.54 (t, J=7.6 Hz, 1H), 7.14 (t, J=7.2 Hz, 1H), 7.35 (d, J=1.6 Hz, 1H), 7.55-7.57 (m, 2H), 8.42 (d, J=6.4 Hz, 2H). MS ES+m/z 508 [M+H]⁺.

Example 383: 2-[[(1R)-1-[2-(4-Chloro-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid

Step 1: 1-(3-bromo-2-hydroxy-5-methylphenyl)-3-(4-chloropiperidin-1-yl)propane-1,3-dione. A mixture of 4-chloropiperidine (1 g, 6 mmol, HCl), TEA (972 mg, 9.61 mmol) in DCM (10 mL) was added dropwise to a solution of triphosgene (950 mg, 3.20 mmol) in DCM (10 mL) at −10° C., and stirred at −10° C. for 1 h, then stirred at 0° C. for another 3 h. The mixture was concentrated, added EtOAc (20 mL) and stirred for 30 min, then filtered. The filter cake was washed with EtOAc (10 mL×2). The filtrate was concentrated and purified by silica gel chromatography eluted with 0%-25% EtOAc in petroleum ether to give 1-(3-bromo-2-hydroxy-5-methylphenyl)-3-(4-chloropiperidin-1-yl)propane-1,3-dione (1.07 g, 81%) as a solid. A mixture of 1-(3-bromo-2-hydroxy-5-methylphenyl)ethanone (1.12 g, 4.90 mmol) in THE (10 mL) was added LiHMDS (1 M, 17.14 mL) dropwise at −65° C., stirred at 0° C. for 2 h. The mixture was added a mixture of 4-chloropiperidine-1-carbonyl chloride (1.07 g, 5.88 mmol) in THF (5 mL) dropwise. The mixture was stirred at 25° C. for another 14 h, quenched with sat.NH₄Cl (40 mL) dropwise, then adjusted to pH=7 with HCl (2 M), extracted with EtOAc (20 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 16%-75% EtOAc in petroleum ether to give the product (1.44 g, 75%) as oil. MS ES+ m/z 374 [M+H]⁺.

Step 2: 8-bromo-2-(4-chloro-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 1-(3-bromo-2-hydroxy-5-methylphenyl)-3-(4-chloropiperidin-1-yl)propane-1,3-dione (800 mg, 2.41 mmol) and Tf₂O (2.41 g, 8.54 mmol) in DCE (20 mL) was stirred at 50° C. for 4 h. When cooled to rt the mixture was concentrated, diluted with DCM (20 mL), adjusted to pH=7 with sat.NaHCO₃, and extracted with DCM (30 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0%-33% EtOAc in petroleum ether to give the product (435 mg, 57%) as a solid. MS ES+ m/z 358 [M+2+H]⁺.

Step 3: 8-acetyl-2-(4-chloro-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-bromo-2-(4-chloro-1-piperidyl)-6-methyl-chromen-4-one (380 mg, 1.07 mmol), tributyl (1-ethoxyvinyl) stannane (770 mg, 2.13 mmol) and Pd(PPh₃)₂Cl₂ (74.8 mg, 0.107 mmol) in dioxane (10 mL) was stirred at 95° C. under N₂ for 16 h. HCl (0.5 mL, 2 M) was added to the mixture and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was added sat. KF (30 mL), stirred for 1 h, extracted with EtOAc (30 mL×3). The combined extract was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 66%-100% EtOAc in petroleum ether to give the product (300 mg, 85%) as a solid. MS ES+ m/z 320 [M+H]⁺.

Step 4: (R,E)-N-(1-(2-(4-chloropiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethylidene)-2-methylpropane-2-sulfinamide. A mixture of 8-acetyl-2-(4-chloro-1-piperidyl)-6-methyl-chromen-4-one (305 mg, 887 μmol), 2-methylpropane-2-sulfinamide (537 mg, 4.44 mmol) and tetraisopropoxytitanium (2.02 g, 7.10 mmol) in THE (8 mL) was stirred at 80° C. for 32 h. When cooled to rt the mixture was quenched with brine (20 mL) and stirred for 0.5 h, then filtered. The filter cake was washed with EtOAc (20 mL×3). The aqueous phase was extracted with EtOAc (30 mL×2). The combined extract was washed with brine (40 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a gum (375 mg, 100%). MS ES+ m/z 423 [M+H]⁺.

Step 5: N-[(1R)-1-[2-(4-chloro-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide. A mixture of (R,E)-N-(1-(2-(4-chloropiperidin-1-yl)-6-methyl-4-oxo-4H-chromen-8-yl)ethylidene)-2-methylpropane-2-sulfinamide (375 mg, 0.887 mmol) in MeOH (8 mL) and DCM (8 mL) was added NaBH₃CN (445 mg, 7.09 mmol) and AcOH (213 mg, 3.55 mmol) at 0° C., then stirred at 25° C. for 14 h. The mixture was adjusted to pH=8 with sat.NaHCO₃, then extracted with DCM (25 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by preparative HPLC to give the product as oil (250 mg, 64%). MS ES+ m/z 425 [M+H]⁺.

Step 6: 8-[(1S)-1-aminoethyl]-2-(4-chloro-1-piperidyl)-6-methyl-chromen-4-one. A mixture of N-[(1R)-1-[2-(4-chloro-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide (250 mg, 588 μmol) and HCl/dioxane (0.50 mL, 4M) in dioxane (2 mL) was stirred at 25° C. for 1 h. The mixture was concentrated, diluted with DCM/MeOH (1/1, 15 mL), added excess NaHCO₃ solid and stirred for 1 h to give an off-white suspension. The mixture was filtered, the filter cake was washed with DCM (10 mL×2). The filtrate was concentrated and purified by silica gel chromatography eluted with 1%-10% MeOH in DCM to give the product (150 mg, 72%) as oil. MS ES+ m/z 321 [M+H]⁺.

Step 7: 2-[[(1R)-1-[2-(4-chloro-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid. A mixture of 8-[(1R)-1-aminoethyl]-2-(4-chloro-1-piperidyl)-6-methyl-chromen-4-one (125 mg, 0.389 mmol), 2-iodobenzoic acid (289 mg, 1.17 mmol) and 2-(methylamino) acetic acid (6.94 mg, 0.0779 mmol), K₂CO₃ (134 mg, 0.974 mmol) and CuI (14.8 mg, 0.0779 mmol) in DMSO (1 mL) was stirred at 95° C. under N₂ for 16 h. When cooled to rt the mixture was filtered, the filter cake was washed with DCM (10 mL×2). The filtrate was diluted with water (20 mL) and extracted with DCM (30 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by preparative HPLC to give 2-[[(1R)-1-[2-(4-chloro-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid as a solid (18 mg, 10%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.59 (d, J=6.4 Hz, 3H), 1.79-1.88 (m, 2H), 2.08-2.20 (m, 2H), 2.31-2.34 (m, 3H), 3.45-3.53 (m, 2H), 3.80 (s, 2H), 4.48-4.53 (m, 1H), 5.06-5.12 (m, 1H), 5.61 (s, 1H), 6.48 (d, J=8.8 Hz, 1H), 6.57 (t, J=7.6 Hz, 1H), 7.26 (t, J=7.2 Hz, 1H), 7.39 (d, J=2.0 Hz, 1H), 7.62 (d, J=1.2 Hz, 1H), 7.82 (dd, J=7.6, 1.2 Hz, 1H), 8.34 (d, J=5.2 Hz, 1H), 12.78 (s, 1H). MS ES+m/z 441 [M+H]⁺.

Example 384: 2-[[(1R)-1-(6-Methyl-4-oxo-2-thiomorpholino-chromen-8-yl)ethyl]amino]benzoic acid

A mixture of 8-[(1R)-1-aminoethyl]-6-methyl-2-thiomorpholino-chromen-4-one (100 mg, 0.329 mmol), 2-iodobenzoic acid (163 mg, 0.657 mmol), CuI (6 mg, 0.03 mmol), K₂CO₃ (91 mg, 0.66 mmol) and 2-(methylamino) acetic acid (6 mg, 0.07 mmol) in DMSO (1.5 mL) was stirred at 45° C. under 02 atmosphere for 168 h. When cooled to rt the mixture was diluted with water (15 mL) and adjusted to pH=5 with HCl (2M). The mixture was extracted with DCM (20 mL×3), the combined extract was concentrated and purified by preparative HPLC, SFC to give 2-[[(1R)-1-(6-methyl-4-oxo-2-thiomorpholino-chromen-8-yl)ethyl]amino]benzoic acid as a solid (7.32 mg, 8%, ee>99%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.57 (d, J=6.8 Hz, 3H), 2.30 (s, 3H), 2.59-2.70 (m, 4H), 3.81-3.92 (m, 4H), 4.95-5.12 (m, 1H), 5.58 (s, 1H), 6.45 (d, J=8.4 Hz, 1H), 6.54 (t, J=7.6 Hz, 1H), 7.23 (td, J=8.8, 1.6 Hz, 1H), 7.37 (d, J=2.0 Hz, 1H), 7.61 (d, J=1.6 Hz, 1H), 7.81 (dd, J=8.4, 1.2 Hz, 1H), 8.35-8.55 (m, 1H). MS ES+ m/z 425 [M+H]⁺.

Example 385: 2-[[(1R)-1-[2-[(2S,6R)-2,6-Dimethylmorpholin-4-yl]-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid

A mixture of 8-[(1R)-1-aminoethyl]-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one (200 mg, 0.632 mmol), 2-iodobenzoic acid (282 mg, 1.14 mmol), CuI (12 mg, 0.06 mmol), K₂CO₃ (175 mg, 1.26 mmol) and 2-(methylamino) acetic acid (11 mg, 0.13 mmol) in DMSO (1.5 mL) was stirred at 45° C. under N₂ for 136 h. The mixture and another batch (200 mg) were diluted with water (30 mL), adjusted to pH=9 with NaOH (1 M). The mixture was washed with DCM (20 mL). The aqueous phase was adjusted to pH=5 with HCl (2 M) and extracted with DCM (20 mL×3), the combined extract was concentrated and purified by preparative HPLC, SFC to give 2-[[(1R)-1-[2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-4-oxo-chromen-8-yl]ethyl]amino]benzoic acid as a solid (43.81 mg, ee>99%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.00-1.20 (m, 6H), 1.58 (d, J=6.4 Hz, 3H), 2.31 (s, 3H), 2.52-2.71 (m, 2H), 3.55-3.70 (m, 2H), 3.89-4.01 (m, 2H), 5.05-5.15 (m, 1H), 5.58 (s, 1H), 6.48 (d, J=8.4 Hz, 1H), 6.56 (td, J=8.0, 0.8 Hz, 1H), 7.26 (td, J=8.8, 1.2 Hz, 1H), 7.39 (d, J=2.0 Hz, 1H), 7.62 (d, J=1.6 Hz, 1H), 7.82 (dd, J=8.0, 1.6 Hz, 1H), 8.34 (d, J=6.4 Hz, 1H), 12.76 (brs, 1H). MS ES+ m/z 437 [M+H]⁺.

Example 386: 8-[(1R)-1-Anilinoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one

Step 1: 1-(3-bromo-2-hydroxy-5-methyl-phenyl)-3-(4,4-dimethyl-1-piperidyl)propane-1,3-dione.

A solution of triphosgene (2.08 g, 7.02 mmol) in DCM (30 mL) was added dropwise a solution of TEA (3.55 g, 35.1 mmol) and 4,4-dimethylpiperidine (2.10 g, 14.0 mmol, HCl salt) in DCM (10 mL) at −10° C. and stirred for 1 h, then stirred at 0° C. for another 3 h. The mixture was concentrated, added EtOAc (50 mL) and filtered. The filter cake was washed with EtOAc (10 mL×3). The filtrate was concentrated and purified by silica gel chromatography eluted with 0-5% EtOAc in petroleum ether to give 4,4-dimethylpiperidine-1-carbonyl chloride as oil (1.20 g, 49%). A mixture of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)ethanone (2.00 g, 8.73 mmol) in THF (25 mL) was added LiHMDS (29.7 mL, 1 M in THF) dropwise at −65° C., and stirred at 0° C. for 2 h. Then cooled to −65° C. and added a solution of 4,4-dimethylpiperidine-1-carbonyl chloride (2.20 g, 12.5 mmol) in THE (5 mL) dropwise, and stirred at 25° C. for another 14 h. The mixture was quenched with water (15 mL), adjusted to pH=7 with HCl (2 M), extracted with EtOAc (30 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 10%-50% EtOAc in petroleum ether to the product as a brown solid (2.60 g, 81%). MS ES+ m/z 368 [M+H]⁺

Step 2: 8-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)-3-(4,4-dimethyl-1-piperidyl)propane-1,3-dione (2.60 g, 7.06 mmol) and Tf₂O (7.97 g, 28.2 mmol) in DCE (30 mL) was stirred at 50° C. for 4 h. When cooled to rt the mixture was quenched with MeOH (20 mL), adjusted to pH=7 with sat.NaHCO₃, extracted with EtOAc (30 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0-70% EtOAc in petroleum ether to give the product as a solid (1.83 g, 74%). ¹H NMR (400 MHz, CDCl₃) δ 1.04 (s, 6H), 1.49-1.54 (m, 4H), 2.40 (s, 3H), 3.56-3.60 (m, 4H), 5.52 (s, 1H), 7.56 (d, J=2.0 Hz, 1H), 7.88 (d, J=1.2 Hz, 1H)

Step 3: 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (800 mg, 2.28 mmol), tributyl(1-ethoxyvinyl)stannane (990 mg, 2.74 mmol) and Pd(dppf)Cl₂ (167 mg, 0.228 mmol) in dioxane (8 mL) was stirred at 95° C. under N₂ for 14 h. HCl (1 mL) was added into the mixture and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was added sat. KF (100 mL), stirred for 1 h, extracted with EtOAc (100 mL×3). The combined extract was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0-10% MeOH in DCM to give the product as a solid (450 mg, 63%). ¹H NMR (400 MHz, CDCl₃) 1.04 (s, 6H), 1.49-1.53 (m, 4H), 2.46 (s, 3H), 2.68 (s, 3H), 3.56-3.60 (m, 4H), 5.55 (s, 1H), 7.74 (d, J=2.0 Hz, 1H), 8.16 (d, J=1.6 Hz, 1H). MS ES+ m/z 314 [M+H]⁺.

Step 4: (NE)-N-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylidene]-2-methyl-propane-2-sulfinamide. A mixture of 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (450 mg, 1.44 mmol), (R)-2-tert-butyl-2-sulfinamide (348 mg, 2.87 mmol), titanium(IV) isopropoxide (2.04 g, 7.18 mmol) in THE (20 mL) was stirred at 70° C. for 32 h. When cooled to rt the mixture was quenched with brine (20 mL) and filtered. The filter cake was washed with EtOAc (20 mL×3). The aqueous phase was extracted with EtOAc (30 mL×2), the combined extract was washed with brine (40 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a gum (590 mg, crude).

Step 5: N-[(1R)-1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide. NaBH₃CN (267 mg, 4.25 mmol) and AcOH (680 mg, 11.3 mmol) was added into a solution of (NE)-N-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylidene]-2-methyl-propane-2-sulfinamide (590 mg, crude) in DCM (10 mL) and MeOH (10 mL) at 0° C., then stirred at 25° C. for 16 h. The mixture was adjusted to pH=8 with sat.NaHCO₃, extracted with DCM (25 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as gum (590 mg, crude).

Step 6: 8-[(1R)-1-aminoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of N-[(1R)-1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide (590 mg, 1.41 mmol) in EtOAc (10 mL) was added HCl/EtOAc (1 mL, 4 M) and stirred at 25° C. for 16 h. The mixture was concentrated, then diluted with DCM/MeOH (1/1, 15 mL), added excess NaHCO₃ solid and filtered. The filter cake was washed with DCM (10 mL×2). The filtrate was concentrated and purified by silica gel chromatography eluted with 0-10% MeOH in EtOAc (5% TEA) to give the product as a solid (400 mg, yield for three steps: 86%). MS ES+ m/z 315 [M+H]⁺.

Step 7: 8-[(1R)-1-anilinoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. A mixture of 8-[(1R)-1-aminoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (400 mg, 1.27 mmol), phenylboronic acid (388 mg, 3.18 mmol), Cu(OAc)₂ (254 mg, 1.40 mmol), 4A MS (100 mg) and pyridine (253 mg, 3.20 mmol) in DCE (20 mL) was stirred at 35° C. under 02 atmosphere (15 psi) for 16 h. The mixture was filtered, the filter cake was washed with DCM (10 mL×2). The filtrate was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 30%-100% EtOAc in petroleum ether, then 0-10% MeOH in DCM to give a crude product. The crude product was triturated with CH₃CN (10 mL) to give the product (230 mg, 44%, ee: 79.2%). Then further purified by SFC to give 8-[(1R)-1-anilinoethyl]-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one as a solid (134.88 mg, ee>99%). ¹H NMR (400 MHz, DMSO-d₆) δ 0.99 (s, 6H), 1.39-1.45 (m, 4H), 1.49 (d, J=6.8 Hz, 3H), 2.29 (s, 3H), 3.51-3.60 (m, 4H), 4.85-4.95 (m, 1H), 5.52 (s, 1H), 6.26 (brs, 1H), 6.45-6.52 (m, 3H), 6.96-7.04 (m, 2H), 7.42 (d, J=2.0 Hz, 1H), 7.56 (d, J=1.2 Hz, 1H). MS ES+ m/z 391 [M+H]⁺.

Example 387: (8-[(1R)-1-Anilinoethyl]-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one

Step 1: 1-(3-bromo-2-hydroxy-5-methyl-phenyl)-3-[(2S,6R)-2,6-dimethylmorpholin-4-yl]propane-1,3-dione. A solution of (2S,6R)-2,6-dimethylmorpholine (1.80 g, 15.6 mmol), TEA (2.37 g, 23.4 mmol) in DCM (10 mL) was added dropwise into a solution of triphosgene (2.32 g, 7.81 mmol) in DCM (15 mL) at −10° C., and stirred at −10° C. for 1 h, then stirred at 0° C. for another 3 h. The mixture was concentrated, added EtOAc (20 mL) and filtered. The filter cake was washed with EtOAc (10 mL×2). The filtrate was concentrated and purified by silica gel chromatography eluted with 0-5% EtOAc in petroleum ether to give (2S,6R)-2,6-dimethylmorpholine-4-carbonyl chloride as oil (1.80 g, 65%). A mixture of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)ethanone (1.90 g, 8.29 mmol) in THE (25 mL) was added LiHMDS (29 mL, 1M in THF) dropwise at −65° C., then warmed to 0° C. and stirred for 1 h. Then cooled to −65° C. and added a solution of (2S,6R)-2,6-dimethylmorpholine-4-carbonyl chloride (1.77 g, 9.95 mmol) in THE (5 mL) dropwise, then slowly warmed to rt and stirred for another 5 h. The mixture was quenched with sat.NH₄Cl (30 mL), adjusted to pH=7 with HCl (2 M), extracted with EtOAc (40 mL×2). The combined extract washed with brine (50 mL×2), dried over anhydrous Na₂SO₄ and concentrated. The residue was triturated with PE/EtOAc (8/1, 50 mL) to give the product as a solid (2.1 g). The filtrate was further purified by silica gel chromatography eluted with 25%-70% EtOAc in petroleum ether to give the product (430 mg). Totally (2.53 g, 82%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.06-1.12 (m, 6H), 2.25-2.36 (m, 4H), 2.65-2.76 (m, 1H), 2.40-2.49 (m, 1H), 3.50-3.61 (m, 1H), 3.72-3.77 (m, 1H), 4.19-4.26 (m, 1H), 4.34 (s, 2H), 7.73-7.78 (m, 2H), 12.22 (brs, 1H).

Step 2: 8-bromo-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one. A mixture of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)-3-[(2S,6R)-2,6-dimethylmorpholin-4-yl]propane-1,3-dione (2.53 g, 6.83 mmol) and Tf₂O (7.71 g, 27.3 mmol) in DCE (30 mL) was stirred at 50° C. for 14 h. When cooled to rt the mixture was concentrated and quenched with MeOH (20 mL), adjusted to pH=7 with sat.NaHCO₃. The mixture was extracted with DCM (40 mL×2), washed with brine (40 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was triturated with PE/EtOAc (50 mL, 5/1) to give the product as a solid (1.70 g, 71%).

Step 3: 8-acetyl-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one. A mixture of 8-bromo-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one (1.00 g, 2.84 mmol), tributyl(1-ethoxyvinyl)stannane (1.29 g, 3.58 mmol) and Pd(PPh₃)₂Cl₂ (199 mg, 0.284 mmol) in dioxane (20 mL) was stirred at 95° C. under N₂ for 16 h. HCl (1 mL, 2 M) was added into the mixture and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was diluted with sat. KF (20 mL), stirred for 1 h and extracted with EtOAc (40 mL×2). The combined extract washed with brine (40 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was triturated with PE/EtOAc (8/1, 40 mL) to give the product as a solid (850 mg, 95%). MS ES+ m/z 316 [M+H]⁺

Step 4: (NE)-N-[i-[2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-4-oxo-chromen-8-yl]ethylidene]-2-methyl-propane-2-sulfinamide. A mixture of 8-acetyl-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one (500 mg, 1.59 mmol), (R)-2-tert-butyl-2-sulfinamide (384 mg, 3.17 mmol), Ti(i-PrO)₄ (1.80 g, 6.34 mmol) in THF (20 mL) was stirred at 70° C. under N₂ for 32 h. When cooled to rt the mixture was quenched with brine (30 mL) and filtered. The filter cake was washed with EtOAc (20 mL×3). The aqueous phase was extracted with EtOAc (30 mL×2), the combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as gum (660 mg, crude).

Step 5: N-[(1R)-1-[2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide. A mixture of (NE)-N-[1-[2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-4-oxo-chromen-8-yl]ethylidene]-2-methyl-propane-2-sulfinamide (660 mg, crude) in DCM (10 mL) and MeOH (10 mL) was added AcOH (840 mg, 14.0 mmol) and NaBH₃CN (297 mg, 4.73 mmol) at 0° C., then stirred at 20° C. for 16 h. The mixture was adjusted to pH=8 with sat.NaHCO₃, then extracted with DCM (30 mL×2), washed with brine (40 mL×2), dried over anhydrous Na₂SO₄, filtered, concentrated to give the product as gum (660 mg, crude).

Step 6: 8-[(1R)-1-aminoethyl]-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one. A mixture of N-[(1R)-1-[2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-4-oxo-chromen-8-yl]ethyl]-2-methyl-propane-2-sulfinamide (500 mg, crude) in dioxane (10 mL) was added HCl/dioxane (2 mL, 4 M) and stirred at 20° C. for 1 h. The mixture was concentrated, diluted with DCM/MeOH (1/1, 15 mL), added excess NaHCO₃ solid and filtered. The filter cake was washed with DCM (10 mL×2). The filtrate was concentrated and purified by silica gel chromatography eluted with 0-10% MeOH in EtOAc (5% TEA) to give the product as a solid (150 mg, yield for three steps: 39%). MS ES+ m/z 317 [M+H]⁺.

Step 7: 8-[(1R)-1-anilinoethyl]-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one. A mixture of 8-[(1R)-1-aminoethyl]-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one (150 mg, 0.474 mmol), phenylboronic acid (144 mg, 1.19 mmol), Cu(OAc)₂ (95 mg, 0.52 mmol), 4A MS (100 mg) and pyridine (98 mg, 1.24 mmol) in DCE (20 mL) was stirred at 30° C. under 02 atmosphere (15 psi) for 24 h. The mixture was filtered. The filter cake was washed with DCM (10 mL×2). The filtrate was diluted with water (15 mL) and extracted with DCM (20 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by preparative HPLC to give the product (80 mg, 43%, ee: 78%). Then further purified by SFC to give (8-[(1R)-1-anilinoethyl]-2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-methyl-chromen-4-one as a solid (46.38 mg, ee>99%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.13 (d, J=6.0 Hz, 3H), 1.15 (d, J=6.0 Hz, 3H), 1.49 (d, J=6.4 Hz, 3H), 2.30 (s, 3H), 2.65-2.74 (m, 2H), 3.62-3.73 (m, 2H), 3.89-4.00 (m, 2H), 4.90-4.99 (m, 1H), 5.57 (s, 1H), 6.22 (brs, 1H), 6.45-6.52 (m, 3H), 6.96-7.04 (m, 2H), 7.43 (d, J=2.0 Hz, 1H), 7.58 (d, J=1.6 Hz, 1H). MS ES+ m/z 393 [M+H]⁺.

Example 388: 8-[(1R)-1-Anilinoethyl]-6-methyl-2-(1-piperidyl)chromen-4-one

Step 1: 1-(3-bromo-2-hydroxy-5-methyl-phenyl)-3-(1-piperidyl)propane-1,3-dione. A solution of piperidine (2.00 g, 23.5 mmol), TEA (3.57 g, 35.2 mmol) in DCM (20 mL) was added dropwise into a solution of triphosgene (3.49 g, 11.7 mmol) in DCM (10 mL) at −10° C. and stirred at −10° C. for 1 h, then stirred at 0° C. for another 3 h. The mixture was concentrated, added EtOAc (20 mL) and filtered. The filter cake was washed with EtOAc (10 mL×2). The filtrate was concentrated and purified by silica gel chromatography eluted with 0-2% EtOAc in petroleum ether to give piperidine-1-carbonyl chloride as oil (3.0 g, 87%). A mixture of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)ethanone (2.1 g, 9.17 mmol) in THE (15 mL) was added LiHMDS (29.3 mL, 1M in THF) dropwise at −65° C., warmed to 0° C. and stirred for 2 h. Then cooled to −65° C. and added a solution of piperidine-1-carbonyl chloride (1.96 g, 13.3 mmol) in THE (5 mL) dropwise, then stirred at 25° C. for another 4 h. The mixture was quenched with sat.NH₄Cl (30 mL), adjusted to pH=7 with HCl (2 M), extracted with EtOAc (40 mL×2). The combined extract was washed with brine (50 mL×2), dried over anhydrous Na₂SO₄ and concentrated. The residue was triturated with PE/EtOAc (5/1, 60 mL) to give the product as a solid (3.0 g, 96%). 1H NMR (400 MHz, DMSO-d₆) δ 1.44-1.65 (m, 8H), 2.29 (s, 3H), 3.43-3.50 (m, 2H), 4.29 (s, 2H), 7.73-7.76 (m, 2H), 12.27 (brs, 1H).

Step 2: 8-bromo-6-methyl-2-(1-piperidyl)chromen-4-one. A mixture of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)-3-(1-piperidyl)propane-1,3-dione (3.00 g, 8.82 mmol) and Tf₂O (9.95 g, 35.3 mmol) in DCE (30 mL) was stirred at 50° C. for 14 h. When cooled to rt the mixture was concentrated and quenched with MeOH (30 mL), adjusted to pH=7 with sat.NaHCO₃, extracted with DCM (40 mL×2). The combined extract was washed with brine (50 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was triturated with EtOAc (20 mL) to give the product as a solid (1.8 g, 63%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.55-1.68 (m, 6H), 2.38 (s, 3H), 3.55-3.62 (m, 4H), 5.53 (s, 1H), 7.69 (d, J=1.6 Hz, 1H), 7.78 (d, J=2.0 Hz, 1H). MS ES+ m/z 323 [M+H]⁺.

Step 3: 8-acetyl-6-methyl-2-(1-piperidyl)chromen-4-one. A mixture of 8-bromo-6-methyl-2-(1-piperidyl)chromen-4-one (1.00 g, 3.10 mmol), tributyl(1-ethoxyvinyl)stannane (1.41 g, 3.91 mmol) and Pd(PPh₃)₂Cl₂ (218 mg, 0.310 mmol) in dioxane (20 mL) was stirred at 95° C. under N₂ for 16 h. HCl (1.0 mL, 2 M) was added into the mixture and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was added sat. KF (100 mL), stirred for 1 h, extracted with EtOAc (100 mL×3). The combined extract was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 50%-100% EtOAc in petroleum ether to give the product as a solid (700 mg, 79%). MS ES+ m/z 286 [M+H]⁺.

Step 4: (NE)-2-methyl-N-[1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethylidene]propane-2-sulfinamide. A mixture of 8-acetyl-6-methyl-2-(1-piperidyl)chromen-4-one (500 mg, 1.75 mmol), (R)-2-tert-butyl-2-sulfinamide (425 mg, 3.50 mmol), Ti(i-PrO)₄ (1.99 g, 7.01 mmol) in THF (20 mL) was stirred at 70° C. for 32 h. When cooled to rt the mixture was quenched with brine (30 mL) and filtered. The filter cake was washed with EtOAc (20 mL×3). The aqueous phase was extracted with EtOAc (30 mL×2), the combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as gum (680 mg, crude).

Step 5: 2-methyl-N-[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]propane-2-sulfinamide. A mixture of (NE)-2-methyl-N-[1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethylidene]propane-2-sulfinamide (680 mg, crude) in DCM (10 mL) and MeOH (10 mL) was added AcOH (840 mg, 14.0 mmol) and NaBH₃CN (330 mg, 5.25 mmol) at 0° C. and stirred at 25° C. for 16 h. The mixture was adjusted to pH=8 with sat.NaHCO₃, extracted with DCM (25 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated under to give the product as gum (680 mg, crude).

Step 6: 8-[(1R)-1-aminoethyl]-6-methyl-2-(1-piperidyl)chromen-4-one. A mixture of 2-methyl-N-[(1R)-1-[6-methyl-4-oxo-2-(1-piperidyl)chromen-8-yl]ethyl]propane-2-sulfinamide (450 mg, crude) in dioxane (20 mL) was added HCl/dioxane (2 mL, 4 M) and stirred at 25° C. for 1 h. The mixture was concentrated and diluted with DCM/MeOH (1/1, 15 mL), added excess NaHCO₃ solid and filtered. The filter cake was washed with DCM (10 mL×2). The filtrate was concentrated and purified by silica gel chromatography eluted with 0-10% MeOH in EtOAc (5% TEA) to give the product as a solid (280 mg, yield for three steps: 85%). MS ES+ m/z 287 [M+H]⁺.

Step 7: 8-[(1R)-1-anilinoethyl]-6-methyl-2-(1-piperidyl)chromen-4-one. A mixture of 8-[(1R)-1-aminoethyl]-6-methyl-2-(1-piperidyl)chromen-4-one (280 mg, 0.978 mmol), phenylboronic acid (298 mg, 2.44 mmol), copper(II) acetate (195 mg, 1.08 mmol), 4A MS (100 mg) and pyridine (194 mg, 2.46 mmol) in DCE (20 mL) was stirred at 30° C. under 02 atmosphere (15 psi) for 24 h. The mixture was filtered. The filter cake was washed with DCM (10 mL×2). The filtrate was diluted with water (20 mL), extracted with DCM (30 mL×2), the combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 50-100% EtOAc in petroleum ether, then 0-10% MeOH in DCM to give an impure product. The impure product was further purified by preparative HPLC to give the product (25 mg, 7%, ee: 68.32%). Then further purified by SFC to give 8-[(1R)-1-anilinoethyl]-6-methyl-2-(1-piperidyl)chromen-4-one as a solid (17.7 mg, ee>99%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.49 (d, J=6.8 Hz, 3H), 1.55-1.70 (m, 6H), 2.29 (s, 3H), 3.51-3.59 (m, 4H), 4.85-4.95 (m, 1H), 5.51 (s, 1H), 6.26 (brs, 1H), 6.44-6.52 (m, 3H), 6.96-7.04 (m, 2H), 7.42 (d, J=2.0 Hz, 1H), 7.58 (d, J=1.6 Hz, 1H). MS ES+ m/z 363 [M+H]⁺.

Example 389: 8-[(1R)-1-Anilinoethyl]-6-methyl-2-thiomorpholino-chromen-4-one

Step 1: 1-(3-bromo-2-hydroxy-5-methyl-phenyl)-3-thiomorpholino-propane-1,3-dione. A solution of thiomorpholine (1.09 g, 10.6 mmol), TEA (1.60 g, 15.8 mmol) in DCM (10 mL) was added dropwise into a solution of triphosgene (1.57 g, 5.28 mmol) in DCM (10 mL) at −10° C., stirred for 1 h, and then stirred at 0° C. for another 3 h. The mixture was concentrated and diluted with EtOAc (15 mL) and filtered. The filter cake was washed with EtOAc (5 mL×2). The filtrate was concentrated to give thiomorpholine-4-carbonyl chloride as yellow oil (1.50 g, crude). A mixture of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)ethanone (1.70 g, 7.42 mmol) in THE (15 mL) was added LiHMDS (26 mL, 1 M in THF) dropwise at −65° C., warmed to 0° C. and stirred for 2 h. Then cooled to −65° C. and added a solution of thiomorpholine-4-carbonyl chloride (1.50 g, crude) in THE (5 mL) dropwise, warmed to rt and stirred for another 14 h. The mixture was quenched with sat.NH₄Cl (40 mL), adjusted to pH=7 with HCl (2 M), extracted with EtOAc (50 mL×2). The combined extract was washed with brine (50 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 20%-80% EtOAc in petroleum ether to give the product as a solid (2.66 g, 100%). ¹H NMR (400 MHz, DMSO-d₆) δ 2.29 (s, 3H), 2.53-2.59 (m, 2H), 2.64-2.69 (m, 2H), 3.66-3.71 (m, 2H), 3.71-3.77 (m, 2H), 4.34 (s, 2H), 7.73-7.79 (m, 2H), 12.20 (brs, 1H). MS ES+ m/z 361 [M+H]⁺.

Step 2: 8-bromo-6-methyl-2-thiomorpholino-chromen-4-one. A mixture of 1-(3-bromo-2-hydroxy-5-methyl-phenyl)-3-thiomorpholino-propane-1,3-dione (2.66 g, 7.42 mmol) and Tf₂O (8.38 g, 29.7 mmol) in DCE (30 mL) was stirred at 50° C. for 4 h. When cooled to rt the mixture was concentrated, diluted with DCM (20 mL) and adjusted to pH=7 with sat.NaHCO₃. The aqueous phase was extracted with DCM (30 mL×2), the combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue purified by silica gel chromatography eluted with 20% EtOAc in petroleum ether, then 0-2% MeOH in DCM to give an impure product. Then triturated with EtOAc (10 mL) to give the product as a solid (330 mg, 13%). ¹H NMR (400 MHz, DMSO-d₆) δ 2.39 (s, 3H), 2.72-2.80 (m, 4H), 3.87-3.95 (m, 4H), 5.60 (s, 1H), 7.70 (d, J=1.6 Hz, 1H), 7.80 (d, J=1.6 Hz, 1H).

Step 3: 8-acetyl-6-methyl-2-thiomorpholino-chromen-4-one. A mixture of 8-bromo-6-methyl-2-thiomorpholino-chromen-4-one (330 mg, 0.970 mmol), tributyl(1-ethoxyvinyl)stannane (441 mg, 1.22 mmol) and Pd(PPh₃)₂Cl₂ (68 mg, 0.097 mmol) in dioxane (5 mL) was stirred at 95° C. under N₂ for 16 h. HCl (1.5 mL, 2 M) was added into the mixture and stirred at 50° C. for 0.5 h. When cooled to rt the mixture was added sat. KF (30 mL), stirred for 1 h, extracted with EtOAc (30 mL×3), the combined extract was washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 0-10% MeOH in EtOAc to give the product as a solid (273 mg, 93%). MS ES+ m/z 304 [M+H]⁺.

Step 4: (NE)-2-methyl-N-[1-(6-methyl-4-oxo-2-thiomorpholino-chromen-8-yl)ethylidene]propane-2-sulfinamide. A mixture of 8-acetyl-6-methyl-2-thiomorpholino-chromen-4-one (250 mg, 0.824 mmol), (R)-2-tert-butyl-2-sulfinamide (180 mg, 1.48 mmol), Ti(i-PrO)₄ (937 mg, 3.30 mmol) in THE (15 mL) was stirred at 70° C. for 32 h. When cooled to rt the mixture was quenched with brine (20 mL) and filtered. The filter cake was washed with EtOAc (20 mL×3). The filtrate was extracted with EtOAc (30 mL×2). The combined extract was washed with brine (40 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as gum (300 mg, crude). MS ES+ m/z 407 [M+H]⁺.

Step 5: 2-methyl-N-[(1R)-1-(6-methyl-4-oxo-2-thiomorpholino-chromen-8-yl)ethyl]propane-2-sulfinamide. A mixture of (NE)-2-methyl-N-[1-(6-methyl-4-oxo-2-thiomorpholino-chromen-8-yl)ethylidene]propane-2-sulfinamide (300 mg, crude) in DCM (15 mL) and MeOH (10 mL) was added AcOH (354 mg, 5.90 mmol), NaBH₃CN (139 mg, 2.21 mmol) at −15° C. and stirred for 3 h, then stirred at 0° C. for 10 h. The mixture was adjusted to pH=8 with sat.NaHCO₃ and extracted with DCM (25 mL×2). The combined extract was washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated to give the product as a gum (300 mg, crude). MS ES+ m/z 409 [M+H]⁺.

Step 6: 8-[(1R)-1-aminoethyl]-6-methyl-2-thiomorpholino-chromen-4-one. A mixture of 2-methyl-N-[(1R)-1-(6-methyl-4-oxo-2-thiomorpholino-chromen-8-yl)ethyl]propane-2-sulfinamide (300 mg, crude) in dioxane (2 mL) was added HCl/dioxane (0.3 mL) and stirred at 25° C. for 30 min. The mixture was concentrated and diluted with DCM/MeOH (1/1, 15 mL), added excess NaHCO₃ solid and filtered. The filter cake was washed with DCM (10 mL×2). The filtrate was concentrated and purified by silica gel chromatography eluted with 0-10% MeOH in DCM (5% TEA) to give the product as a solid (145 mg, yield for three steps: 75%). MS ES+ m/z 305 [M+H]⁺.

Step 7: 8-[(1R)-1-anilinoethyl]-6-methyl-2-thiomorpholino-chromen-4-one. A mixture of 8-[(1R)-1-aminoethyl]-6-methyl-2-thiomorpholino-chromen-4-one (145 mg, 0.476 mmol), phenylboronic acid (145 mg, 1.19 mmol), Cu(OAc)₂ (95 mg, 0.52 mmol), 4A MS (100 mg) and pyridine (95 mg, 1.20 mmol) in DCE (20 mL) was stirred at 30° C. under 02 atmosphere (15 psi) for 24 h. The mixture was filtered, the filter cake was washed with DCM (10 mL×2). The filtrate was diluted with water (15 mL) and extracted with DCM (20 mL×2), washed with brine (30 mL×2), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by silica gel chromatography eluted with 40%-100% EtOAc in petroleum ether, then 0-10% MeOH in DCM. Then further purified by preparative HPLC to give the product (30 mg, 16%, ee: 81.79%).

Then further purified by SFC to give 8-[(1R)-1-anilinoethyl]-6-methyl-2-thiomorpholino-chromen-4-one as a solid (16.8 mg, ee>99%). ¹H NMR (400 MHz, DMSO-d₆) δ 1.49 (d, J=6.8 Hz, 3H), 2.30 (s, 3H), 2.69-2.75 (m, 4H), 3.85-3.93 (m, 4H), 4.85-4.95 (m, 1H), 5.57 (s, 1H), 6.51 (brs, 1H), 6.45-6.52 (m, 3H), 6.95-7.05 (m, 2H), 7.43 (d, J=2.0 Hz, 1H), 7.58 (d, J=2.0 Hz, 1H). MS ES+ m/z 381 [M+H]⁺.

Example 390: 2-[1-[2-(4,4-Dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]propylamino]benzoic acid 2,2,2-trifluoroacetic acid

Step 1: methyl 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]propylamino]benzoate. A mixture of 8-(1-bromopropyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (26.0 mg, 1 eq., 66.3 μmol) and methyl 2-aminobenzoate (10.0 mg, 1 eq., 66.3 μmol) in DMF (2 mL) was stirred at 80° C. for 15 h. After completion of the reaction, the reaction mixture was concentrated to give crude product. MS ES+ m/z 463.4 [M+H]⁺.

Step 2: 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]propylamino]benzoic acid 2,2,2-trifluoroacetic acid. A 20 mL vial was charged with methyl 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]propylamino]benzoate (35.0 mg, 1 eq., 75.7 μmol) and LiOH (5.44 mg, 227 μL, 1 molar, 3 eq., 227 μmol) in THE (3 mL) and stirred at 50° C. for 5 hours. After completion of the reaction, 1N aq HCl (5 mL) was added to the reaction and the mixture was diluted with water (10 mL) and extracted with ethyl acetate (2×20 mL). The combined organic layers were dried over sodium sulfate and concentrated and purified by reverse phase C18 column using 10-90% acetonitrile in water (0-0.1% TFA as modifier) to afford 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]propylamino]benzoic acid 2,2,2-trifluoroacetic acid (4.1 mg, 9.1 μmol, 12%). MS ES+ m/z 449.4 [M+H]⁺.

The following compounds in Table 26 were prepared essentially as described for 2-[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]propylamino]benzoic acid 2,2,2-trifluoroacetic acid.

TABLE 26 ES/MS Example m/z # Chemical Name Structure (M + H) 391 2-[1-(6-chloro-2-isoindolin-2- yl-4-oxo-chromen-8- yl)ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

461

Example 392: 2-[1-[3-Cyano-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

Step 1: 8-bromo-6-methyl-4-oxo-chromene-3-carbaldehyde. 1-(3-bromo-2-hydroxy-5-methyl-phenyl)ethanone (7 g, 1 eq., 0.03 mol) was stirred in DMF (70 mL) at −10° C. for 20 min. POCl₃ (9 g, 6 mL, 2 eq., 0.06 mol) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 18 hours. After 18 h, the reaction mixture was diluted with 25 mL water. The reaction mixture was filtered. The collected solid was dissolved in DCM (100 mL), dried (Na₂SO₄), and concentrated on a rotary evaporator to give crude product (8 g, 0.03 mol, 100%).

Step 2: 2-anilino-8-bromo-6-methyl-4-oxo-chromene-3-carbaldehyde. 8-bromo-6-methyl-4-oxo-chromene-3-carbaldehyde (2.4981 g, 1 eq., 9.3534 mmol) was stirred in anhydrous toluene (50 mL) at room temperature. N-phenylhydroxylamine (1.0207 g, 1 eq., 9.3534 mmol) was added to the reaction mixture. After 15 min at rt, the reaction was heated to 80° C. for 3 h to induce rearrangement. After 3 h, the reaction was concentrated and purified by column chromatography (SiO₂, DCM/EtOAc 0-100%) to provide the product (1.5 g, 4.2 mmol, 45%). MS ES+ m/z 358.2, 360.2 [M+H]⁺.

Step 3: 2-anilino-8-bromo-6-methyl-4-oxo-chromene-3-carbonitrile. Propanephosphonic acid anhydride (8.0 g, 7.3 mL, 50% wt in DMF, 3 eq., 13 mmol) was added to a stirring mixture of 2-anilino-8-bromo-6-methyl-4-oxo-chromene-3-carbaldehyde (1.5 g, 1 eq., 4.2 mmol), hydroxylamine hydrochloride (1.2 g, 4 eq., 17 mmol), and triethylamine (0.42 g, 0.58 mL, 1 eq., 4.2 mmol) in DMF (50 mL). The reaction solution was heated to 60° C. and stirred for 70 min. After 70 min, the reaction was partitioned between water (25 mL) and DCM (200 mL). The organic layer was dried (Na₂SO₄), concentrated and purified by column chromatography (SiO₂, DCM/EtOAc 0-50%) to provide the product (698.9 mg, 1.968 mmol, 47%). MS ES+ m/z 355.2, 357.2 [M+H]⁺.

Step 4: 8-bromo-6-methyl-2-(N-methylanilino)-4-oxo-chromene-3-carbonitrile. 2-anilino-8-bromo-6-methyl-4-oxo-chromene-3-carbonitrile (698.9 mg, 1 eq., 1.968 mmol), iodomethane (5.586 g, 2.45 mL, 20 eq., 39.35 mmol), and potassium carbonate (1.360 g, 5 eq., 9.838 mmol) in MeCN (75 mL) was heated to 50° C. for 1 hour. After 1 hour, the reaction mixture was partitioned between brine (25 mL) and DCM (100 mL). The organic layer was dried (Na₂SO₄), concentrated on a rotary evaporator and purified by column chromatography (SiO₂, DCM/EtOAc 0-70%) to provide the product (559.6 mg, 1.516 mmol, 77.03%). MS ES+ m/z 370.2, 372.2 [M+H]⁺.

Step 5: 8-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromene-3-carbonitrile. 8-bromo-6-methyl-2-(N-methylanilino)-4-oxo-chromene-3-carbonitrile (559.6 mg, 1 eq., 1.516 mmol), 4,4-dimethylpiperidine, HCl (453.7 mg, 2 eq., 3.031 mmol), and K₂CO₃ (418.9 mg, 2 eq., 3.031 mmol) were stirred in acetonitrile (100 mL) at 65° C. for 18 h and 80° C. for 48 h. The reaction mixture was then partitioned between brine (50 mL) and DCM (100 mL). The organic layer was dried (Na₂SO₄), concentrated on a rotary evaporator and purified by column chromatography (SiO₂, DCM/EtOAc 0-70%) to provide the product (169.3 mg, 451.1 μmol, 29.77%). MS ES+ m/z 375.2, 377.2 [M+H]⁺.

Step 6: 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromene-3-carbonitrile. 8-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromene-3-carbonitrile (169.3 mg, 1 eq., 451.1 μmol), tributyl(1-ethoxyvinyl)stannane (195.5 mg, 183.2 μL, 1.2 eq., 541.4 μmol), and PdCl₂(dppf) (16.51 mg, 0.05 eq., 22.56 μmol) were stirred together in 1,4-dioxane (8 mL) at 95° C. for 1 h. After 1 h, reaction was cooled to rt. 2 M HCl (5 mL) was added, the reaction mixture was stirred at 50° C. for 30 minutes. After 30 min, saturated KF (5 mL) was added to the reaction mixture. The suspension was stirred at rt for 30 minutes. After 30 minutes, the reaction mixture was filtered through celite. The filter cake was rinsed with DCM (25 mL). The organic layer was washed with H₂O (10 mL), washed with brine (10 mL), dried (Na₂SO₄), concentrated on a rotary evaporator, and purified by column chromatography (SiO₂, DCM/EtOAc 0-40%) to provide the product (96.7 mg, 286 μmol, 63.3%). MS ES+ m/z 339.2 [M+H]⁺.

Step 7: 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-6-methyl-4-oxo-chromene-3-carbonitrile. NaBH₄ (13.0 mg, 1.2 eq., 343 μmol) was added to a stirring solution of 8-acetyl-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromene-3-carbonitrile (96.7 mg, 1 eq., 286 μmol) in methanol (2 mL) and DCM (2 mL) at −10° C. The reaction mixture was let warm to rt and stirred. After 30 minutes, the reaction mixture was quenched with saturated NH₄Cl (1 mL) and extracted with DCM (2×5 mL). The combined extracts were washed with brine (3 mL), dried (Na₂SO₄) and concentrated on a rotary evaporator to provide the product (97.2 mg, 286 μmol, 99.9%) which was taken forward crude. MS ES+ m/z 341.4 [M+H]⁺.

Step 8: 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromene-3-carbonitrile. A solution of PBr₃ (85.0 mg, 314 μL, 1 molar, 1.1 eq., 314 μmol) in DCM was added to a stirred solution of 2-(4,4-dimethyl-1-piperidyl)-8-(1-hydroxyethyl)-6-methyl-4-oxo-chromene-3-carbonitrile (97.2 mg, 1 eq., 286 μmol) in DCM (6 mL) at 0° C. The reaction was let warm to rt and stirred for 30 minutes. After 30 minutes, the reaction mixture was adjusted to pH=8 with saturated NaHCO₃. The mixture was diluted with DCM (5 mL). The organic layer was separated, dried (Na₂SO₄) and concentrated to provide the crude product (95.6 mg, 237 μmol, 83.0%). MS ES+ m/z 403.2, 405.2 [M+H]⁺.

Step 9: tert-butyl 2-[1-[3-cyano-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate. 8-(1-bromoethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromene-3-carbonitrile (95.6 mg, 1 eq., 237 μmol) and tert-butyl 2-aminobenzoate (68.7 mg, 64.8 μL, 1.5 eq., 356 μmol) were stirred together in DMF (2 mL) at 80° C. for 18 h. After 18 h, the reaction mixture was concentrated and purified by column chromatography (SiO₂, DCM/EtOAc 0-100%) to provide the product (62.3 mg, 121 μmol, 51.0%). MS ES+ m/z 516.4 [M+H]⁺.

Step 10: 2-[1-[3-cyano-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid. A trifluoroacetic acid (0.2 mL)/DCM (2 mL) solution was added to tert-butyl 2-[1-[3-cyano-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoate (62.3 mg, 1 eq., 121 μmol) at room temperature. The clear solution was stirred at 45° C. for 2 h. Reaction was stirred at 35° C. for 18 h. Toluene (2 mL) was added to the reaction mixture. The reaction mixture was concentrated on a rotary evaporator and purified by Preparative HPLC (10-100% 0.1% TFA in MeCN/0.1% TFA in water) to provide 2-[1-[3-cyano-2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid (8 mg, 0.02 mmol, 10%) as a white solid. MS ES+ m/z 460.4 [M+H]⁺.

Example 393: N-[2-[1-(2-Isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]phenyl]sulfonyl-2-phenyl-acetamide 2,2,2-trifluoroacetic acid

A suspension of 2-[1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzenesulfonamide (50 mg, 0.11 mmol), 2-phenylacetic acid (14 mg, 0.11 mmol), dicyclohexylmethanediimine (33 mg, 0.16 mmol), and N,N-dimethylpyrin-4-amine (13 mg, 0.11 mmol) was stirred in DCM (3 mL) for 16 hours. The mixture was then poured into H₂O (5 mL) and DCM (5 mL). The layers were separated and the aqueous layer extracted 3× with DCM (5 mL). The combined organic layers were concentrated and the residue purified via reverse-phase chromatography eluted with 10-100%0 MeCN(0.100 TFA) in H₂O (0.1% TFA) to give N-[2-[1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]phenyl]sulfonyl-2-phenyl-acetamide 2,2,2-trifluoroacetic acid (49 mg, 660%). MS ES+ m/z 594.4 [M+H]⁺.

The following compounds in Table 27 were prepared essentially as described for N-[2-[1-(2-isoindolin-2-yl-6-methyl-4-oxo-chromen-8-yl)ethylamino]phenyl]sulfonyl-2-phenyl-acetamide 2,2,2-trifluoroacetic acid.

TABLE 27 ES/MS Example m/z # Chemical Name Structure (M + H) 394 2-[1-(2-Isoindolin-2-yl-6-methyl-4- oxo-chromen-8-yl)ethylamino]-N- methylsulfonyl-benzamide 2,2,2- trifluoroacetic acid, Isomer 1

518 395 N-(Difluoromethylsulfonyl)-2-[1- (2-isoindolin-2-yl-6-methyl-4-oxo- chromen-8- yl)ethylamino]benzamide 2,2,2- trifluoroacetic acid, Isomer 1

554

Example 396: 2-[1-[2-(4,4-Difluoro-1-piperidyl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

A solution of 2-[1-[2-ethylsulfanyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid (73 mg, 0.19 mmol) in DCM (2.5 mL) was cooled to 0° C. and to this was added 3-chloroperoxybenzoic acid (51 mg, 77% wt, 0.23 mmol). The mixture was warmed to 25° C. and stirred for 3 hrs. The mixture was again cooled to 0° C. and to this was added 4,4-difluoropiperidine (68 mg, 0.57 mmol) and N,N-diisopropylethylamine (0.20 mL, 1.2 mmol). The mixture was warmed to 25° C. and stirred for 3 hrs. The mixture was then concentrated and the residue purified via reverse-phase chromatography eluted with 10-100% MeCN(0.1% TFA) in H₂O (0.1% TFA) to give 2-[1-[2-(4,4-difluoro-1-piperidyl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid (40 mg, 39%). MS ES+ m/z 497.6 [M+H]⁺.

Example 397: 2-[1-[2-(6-Azaspiro[2.5]octan-6-yl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

A solution of 2-[1-[2-ethylsulfanyl-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid (100 mg, 1 eq., 229 μmol) in DCM (5 mL) was cooled to 0° C. and treated with mCPBA (68.1 mg, 77% wt, 1.33 eq., 304 μmol). The reaction was allowed to slowly warm to 25° C. in ice bath. After 3 hrs the mixture was cooled down again to 0° C. and 6-azaspiro[2.5]octane (25.4 mg, 1 eq., 0.23 mmol) was added followed by triethylamine (69.4 mg, 95.6 μL, 3 eq., 686 μmol).

The reaction was allowed to slowly warm to 25° C. and stirred for 16 hrs. The mixture was concentrated and the residue purified by reverse-phase chromatography eluted with 20-100% acetonitrile (with 0.1% TFA) in water (with 0.1% TF) to give 2-[1-[2-(6-azaspiro[2.5]octan-6-yl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid (67 mg, 49%) as a solid. MS ES+ m/z 487.4 [M+H]⁺.

Example 398: 2-[1-[2-(6-Azaspiro[2.5]octan-6-yl)-6-fluoro-4-oxo-chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

A solution of 2-[1-(2-ethylsulfanyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid (150 mg, 0.39 mmol) in DCM (2.5 mL) was cooled to 0° C. and to this was added 3-chloroperoxybenzoic acid (100 mg, 77% wt, 0.47 mmol). The mixture was warmed to 25° C. and stirred for 3 hrs. The mixture was again cooled to 0° C. and to this was added 6-azaspiro[2.5]octane (130 mg, 1.2 mmol) and N,N-diisopropylethylamine (0.47 mL, 2.7 mmol). The mixture was warmed to 25° C. and stirred for 3 hrs. The mixture was then concentrated and the residue purified via reverse-phase chromatography eluted with 10-100% MeCN(0.1% TFA) in H₂O (0.1% TFA) to give 2-[1-[2-(6-azaspiro[2.5]octan-6-yl)-6-fluoro-4-oxo-chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid (61 mg, 29%). MS ES+ m/z 437.2 [M+H]⁺.

Example 399: 2-[1-[2-(4,4-Difluoro-1-piperidyl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid

A solution of 2-[1-(2-ethylsulfanyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]benzoic acid (28 mg, 0.07 mmol) in DCM (2.5 mL) was cooled to 0° C. and to this was added 3-chloroperoxybenzoic acid (24 mg, 77% wt, 0.11 mmol). The mixture was warmed to 25° C. and stirred for 1 hr. The mixture was again cooled to 0° C. and to this was added 4,4-difluoropiperidine (13 mg, 0.11 mmol) and N,N-diisopropylethylamine (0.038 mL, 0.22 mmol). The mixture was warmed to 25° C. and stirred for 4 hrs. The mixture was then concentrated and MeCN (2.5 mL), 4,4-difluoropiperidine (9 mg, 0.07 mmol), and N,N-Diisopropylethylamine (0.051 mL, 0.28 mmol). The mixture was warmed to 60° C. and stirred for 16 hrs. The mixture was concentrated and the residue purified via reverse-phase chromatography eluted with 10-100% MeCN (0.1% TFA) in H₂O (0.1% TFA) to give 2-[1-[2-(4,4-difluoro-1-piperidyl)-4-oxo-6-(trifluoromethyl)chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid (24 mg, 56%). MS ES+ m/z 447.4 [M+H]⁺.

Example 400: 6-Chloro-3-[1-(6-fluoro-2-isoindolin-2-yl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid 2,2,2-trifluoroacetic acid

Step 1: tert-butyl 6-chloro-3-[1-(6-fluoro-2-isoindolin-2-yl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylate. tert-butyl 6-chloro-3-[1-(2-ethylsulfanyl-6-fluoro-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylate (73 mg, 0.15 mmol) in DCM (5 mL) was cooled to 0° C. and to this was added 3-chloroperoxybenzoic acid (45 mg, 77% wt, 0.20 mmol). The mixture was warmed to 25° C. and stirred for 3 hrs. The mixture was again cooled to 0° C. and to this was added isoindoline HCl (31 mg, 0.2 mmol) and triethylamine (0.064 mL, 0.46 mmol). The mixture was warmed to 25° C. and stirred for 16 hrs. The mixture was then diluted into H₂O (10 mL) and DCM (10 mL). The organic layer was extracted from the aqueous layer 3× using DCM (5 mL), filtered through a phase separator, and concentrated. The residue purified via normal-phase chromatography eluted with 0-100% EtOAc in Heptane to give the product (68 mg, 83%). MS ES+ m/z 536.4 [M+H]⁺.

Step 2: 6-chloro-3-[1-(6-fluoro-2-isoindolin-2-yl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid 2,2,2-trifluoroacetic acid. A solution of tert-butyl 6-chloro-3-[1-(6-fluoro-2-isoindolin-2-yl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylate (68 mg, 0.13 mmol) in trifluoroacetic acid (1 mL) and DCM (1.5 mL) was stirred for 1 hour at 30° C. The mixture was concentrated and the residue purified via reverse-phase chromatography eluted with 20-100% acetonitrile (0.1% TFA) in H₂O (0.1% TFA) to give 6-chloro-3-[1-(6-fluoro-2-isoindolin-2-yl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid 2,2,2-trifluoroacetic acid (40 mg, 64%). MS ES+ m/z 480.1 [M+H]⁺.

The following compounds in Table 28 were prepared essentially as described for 6-chloro-3-[1-(6-fluoro-2-isoindolin-2-yl-4-oxo-chromen-8-yl)ethylamino]pyridine-2-carboxylic acid 2,2,2-trifluoroacetic acid.

TABLE 28 ES/MS Example m/z # Chemical Name Structure (M + H) 401 6-Chloro-3-[1-[6-fluoro-2-(5- fluoroisoindolin-2-yl)-4-oxo- chromen-8-yl]ethylamino]pyridine- 2-carboxylic acid 2,2,2- trifluoroacetic acid

498 402 3-[1-[2-(6-Azaspiro[2.5]octan-6- yl)-6-fluoro-4-oxo-chromen-8- yl]ethylamino]-6-chloro-pyridine- 2-carboxylic acid 2,2,2- trifluoroacetic acid

472 403 3-[1-[2-(6-Azaspiro[2.5]octan-6- yl)-4-oxo-6- (trifluoromethyl)chromen-8- yl]ethylamino]-6-chloro-pyridine- 2-carboxylic acid 2,2,2- trifluoroacetic acid

522 404 6-Chloro-3-[1-[2-isoindolin-2-yl-4- oxo-6-(trifluoromethyl)chromen-8- yl]ethylamino]pyridine-2- carboxylic acid 2,2,2-trifluoroacetic acid

530 405 6-Chloro-3-[1-[2-(5- fluoroisoindolin-2-yl)-4-oxo-6- (trifluoromethyl)chromen-8- yl]ethylamino]pyridine-2- carboxylic acid 2,2,2-trifluoroacetic acid

548

Example 406: 2-[1-[6-Methyl-2-(1-methyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

A solution of 2-[1-(2-ethylsulfanyl-6-methyl-4-oxo-chromen-8-yl)ethylamino]benzoic acid, Isomer 1 (90 mg, 0.23 mmol) in DCM (2 mL) was cooled to 0° C. and to this was added 3-chloroperoxybenzoic acid (58 mg, 77% wt, 0.26 mmol). The mixture was warmed to 25° C. and stirred for 3 hrs. The mixture was again cooled to 0° C. and to this was added 1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole hydrochloride (94 mg, 0.59 mmol) and triethylamine (0.23 mL, 1.6 mmol). The mixture was warmed to 25° C. and stirred for 13 hrs then poured into H₂O (5 mL). Organics were extracted 3× using DCM (5 mL), passed through a phase separator, and concentrated. The residue purified via reverse-phase chromatography eluted with 10-100% MeCN (0.1% TFA) in H₂O (0.1% TFA) to give 2-[1-[6-methyl-2-(1-methyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1 (32 mg, 24%). MS ES+ m/z 445.4 [M+H]⁺.

The following compounds in Table 29 were prepared essentially as described for 2-[1-[6-methyl-2-(1-methyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)-4-oxo-chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1.

TABLE 29 ES/MS Example m/z # Chemical Name Structure (M + H) 407 2-[1-[6-Methyl-2-[(1S)-1- methylisoindolin-2-yl]-4-oxo- chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

455 408 2-[1-[6-Methyl-2-[(1R)-1- methylisoindolin-2-yl]-4-oxo- chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

455 409 2-[1-[6-Methyl-2-(3-methyl-3- phenyl-pyrrolidin-1-yl)-4-oxo- chromen-8-yl]ethylamino]benzoic acid 2,2,2-trifluoroacetic acid, Isomer 1

483

The following compounds in Table 30 were purified from racemic examples with chiral SFC.

TABLE 30 Chiral Column, Eluent (see ES/MS Example Tables 4 m/z # Chemical Name and 5) (M + H) 410 2-[1-[6-Methyl-4-oxo-2-[3-(4-pyridyl)pyrrolidin-1- G, 16 470 yl]chromen-8-yl]ethylamino]benzoic acid, Isomer 1 411 2-[1-[6-Methyl-4-oxo-2-[3-(4-pyridyl)pyrrolidin-1- G, 16 470 yl]chromen-8-yl]ethylamino]benzoic acid, Isomer 2 412 2-[1-[6-Methyl-2-[3-(2-methylpyrazol-3-yl)pyrrolidin-1-yl]-4- B, 20 473 oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 413 2-[1-[6-Methyl-2-[3-(2-methylpyrazol-3-yl)pyrrolidin-1-yl]-4- B, 20 473 oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 414 2-[1-[6-Methyl-2-[3-(1-methylpyrazol-3-yl)pyrrolidin-1-yl]-4- C, 3 473 oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 415 2-[1-[6-Methyl-2-[3-(1-methylpyrazol-3-yl)pyrrolidin-1-yl]-4- C, 3 473 oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 416 2-[1-[6-Methyl-2-(3-methyl-3-phenyl-pyrrolidin-1-yl)-4-oxo- H, 20 483 chromen-8-yl]ethylamino]benzoic acid, Isomer 1 417 2-[1-[6-Methyl-2-(3-methyl-3-phenyl-pyrrolidin-1-yl)-4-oxo- H, 20 483 chromen-8-yl]ethylamino]benzoic acid, Isomer 2 418 2-[1-(2-Isoindolin-2-yl-6-methyl-4-oxo-chromen-8- A, 30 456 yl)ethylamino]benzenecarbohydroxamic acid, Isomer 1 419 2-[1-(2-Isoindolin-2-yl-6-methyl-4-oxo-chromen-8- A, 30 456 yl)ethylamino]benzenecarbohydroxamic acid, Isomer 2 420 N-[2-[1-(2-Isoindolin-2-yl-6-methyl-4-oxo-chromen-8- F, 33 594 yl)ethylamino]phenyl]sulfonyl-2-phenyl-acetamide, Isomer 1 421 N-[2-[1-(2-Isoindolin-2-yl-6-methyl-4-oxo-chromen-8- F, 33 594 yl)ethylamino]phenyl]sulfonyl-2-phenyl-acetamide, Isomer 2 422 2-Isoindolin-2-yl-6-methyl-8-[1-[2-(tetrazol-1- E, 6 465 yl)anilino]ethyl]chromen-4-one, Isomer 1 423 2-Isoindolin-2-yl-6-methyl-8-[1-[2-(tetrazol-1- E, 6 465 yl)anilino]ethyl]chromen-4-one, Isomer 2 424 2-[1-[2-(6-Azabicyclo[3.1.1]heptan-6-yl)-6-methyl-4-oxo- A, 8 419 chromen-8-yl]ethylamino]benzoic acid, Isomer 1 425 2-[1-[2-(6-Azabicyclo[3.1.1]heptan-6-yl)-6-methyl-4-oxo- A, 8 419 chromen-8-yl]ethylamino]benzoic acid, Isomer 2 426 2-Isoindolin-2-yl-8-[1-(2-isoxazol-5-ylanilino)ethyl]-6- C, 33 464 methyl-chromen-4-one, Isomer 1 427 2-Isoindolin-2-yl-8-[1-(2-isoxazol-5-ylanilino)ethyl]-6- C, 33 464 methyl-chromen-4-one, Isomer 2 428 2-[1-[2-[3-(1,1-Difluoroethyl)azetidin-1-yl]-6-methyl-4-oxo- C, 7 443 chromen-8-yl]ethylamino]benzoic acid, Isomer 1 429 2-[1-[2-[3-(1,1-Difluoroethyl)azetidin-1-yl]-6-methyl-4-oxo- C, 7 443 chromen-8-yl]ethylamino]benzoic acid, Isomer 2 430 2-[1-[2-[(3R,4S)-3,4-Difluoropyrrolidin-1-yl]-6-methyl-4-oxo- A, 19 429 chromen-8-yl]ethylamino]benzoic acid, Isomer 1 431 2-[1-[2-[(3R,4S)-3,4-Difluoropyrrolidin-1-yl]-6-methyl-4-oxo- A, 19 429 chromen-8-yl]ethylamino]benzoic acid, Isomer 2 432 2-[1-[6-Methyl-4-oxo-2-[(3S)-3-(trifluoromethyl)-1- A, 23 475 piperidyl]chromen-8-yl]ethylamino]benzoic acid, Isomer 1 433 2-[1-[6-Methyl-4-oxo-2-[(3S)-3-(trifluoromethyl)-1- A, 23 475 piperidyl]chromen-8-yl]ethylamino]benzoic acid, Isomer 2 434 2-[1-[6-Methyl-4-oxo-2-[(3R)-3-(trifluoromethyl)pyrrolidin-1- A, 23 461 yl]chromen-8-yl]ethylamino]benzoic acid, Isomer 1 435 2-[1-[6-Methyl-4-oxo-2-[(3R)-3-(trifluoromethyl)pyrrolidin-1- A, 23 461 yl]chromen-8-yl]ethylamino]benzoic acid, Isomer 2 436 2-[1-[2-[(3R,4R)-3,4-Difluoropyrrolidin-1-yl]-6-methyl-4- A, 32 429 oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 437 2-[1-[2-[(3R,4R)-3,4-Difluoropyrrolidin-1-yl]-6-methyl-4- A, 32 429 oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 438 2-[1-[2-[(3R)-3-Fluoro-1-piperidyl]-6-methyl-4-oxo-chromen- A, 32 425 8-yl]ethylamino]benzoic acid, Isomer 1 439 2-[1-[2-[(3R)-3-Fluoro-1-piperidyl]-6-methyl-4-oxo-chromen- A, 32 425 8-yl]ethylamino]benzoic acid, Isomer 2 440 2-[1-[2-[(3S)-3-Fluoro-1-piperidyl]-6-methyl-4-oxo-chromen- A, 32 425 8-yl]ethylamino]benzoic acid, Isomer 1 441 2-[1-[2-[(3S)-3-Fluoro-1-piperidyl]-6-methyl-4-oxo-chromen- A, 32 425 8-yl]ethylamino]benzoic acid, Isomer 2 442 2-[1-[2-(6,6-Difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-6- A, 6 455 methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 443 2-[1-[2-(6,6-Difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-6- A, 6 455 methyl-4-oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 444 2-[1-[2-(3-Carbamoyl-3-phenyl-azetidin-1-yl)-6-methyl-4- D, 4 498 oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 1 445 2-[1-[2-(3-Carbamoyl-3-phenyl-azetidin-1-yl)-6-methyl-4- D, 4 498 oxo-chromen-8-yl]ethylamino]benzoic acid, Isomer 2 446 2-[1-[6-Methyl-4-oxo-2-[(3S)-3-phenylpyrrolidin-1- A, 20 469 yl]chromen-8-yl]ethylamino]benzoic acid, Isomer 1 447 2-[1-[6-Methyl-4-oxo-2-[(3S)-3-phenylpyrrolidin-1- A, 20 469 yl]chromen-8-yl]ethylamino]benzoic acid, Isomer 2

Example 448: 2-[[1-[2-(4,4-Dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]-2,2,2-trifluoro-ethyl]amino]benzoic acid 2,2,2-trifluoroacetic acid

Step 1: 2-(4,4-dimethyl-1-piperidyl)-6-methyl-8-(2,2,2-trifluoro-1-hydroxy-ethyl)chromen-4-one. A solution of 8-bromo-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (1.40 g, 1 eq, 4.00 mmol) in THE (20 mL) was cooled to 0° C. under argon. Isopropylmagnesium chloride (2.30 mL, 2 M in THF, 1.15 eq, 4.60 mmol) was added dropwise. This mixture was stirred at 0° C. for 30 min, then cooled to −78° C. 2,2,2-trifluoro-N-methoxy-N-methylacetamide (785 mg, 1.25 eq, 5.00 mmol) was added in portions. This mixture was stirred from −78° C. to room temperature for 12 h. The reaction was quenched with water and concentrated to dryness under reduced pressure. Purification by silica gel flash column chromatography (3% MeOH/DCM) afforded a crude mixture of 2-(4,4-dimethyl-1-piperidyl)-6-methyl-8-(2,2,2-trifluoro-1,1-dihydroxy-ethyl)chromen-4-one and 2-(4,4-dimethyl-1-piperidyl)-6-methyl-8-(2,2,2-trifluoro-1-hydroxy-1-methoxy-ethyl)chromen-4-one as a pale orange solid (1.17 g). MS ES+ m/z 386, 400 [M+H]⁺. The crude mixture was dissolved in MeOH/DCM (1:1, 10 mL) and cooled to 0° C. NaBH₄ (103 mg, 1.5 eq, 2.72 mmol) was added in portions over 10 min. This mixture was stirred at 0° C. for 30 min, then at room temperature for 12 h. The reaction was quenched with water and concentrated to dryness under reduced pressure. Purification by silica gel flash column chromatography (3% MeOH/DCM) gave the product as a white solid (570 mg, 72%). MS ES+m/z 370 [M+H]⁺.

Step 2: 8-(1-bromo-2,2,2-trifluoro-ethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one. To a solution of 2-(4,4-dimethyl-1-piperidyl)-6-methyl-8-(2,2,2-trifluoro-1-hydroxy-ethyl)chromen-4-one (120 mg, 1 eq, 325 μmol) in DCM (2 mL) was added triphenyl phosphite (202 mg, 2 eq, 650 μmol) and NBS (116 mg, 2 eq, 650 μmol). The mixture was stirred at 40° C.; after 3.5 h, another equivalent of NBS was added (108 mg, 1 eq, 325 μmol), then stirred at this temperature for a total of 12 h. The reaction was quenched with water and concentrated to dryness under reduced pressure. Purification by silica gel flash column chromatography (3% MeOH/DCM) gave the product as a pale orange solid (70 mg, 35%). MS ES+ m/z 432 434 [M+H]⁺.

Step 3: 2-[[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]-2,2,2-trifluoro-ethyl]amino]benzoic acid 2,2,2-trifluoroacetic acid. To a solution of 8-(1-bromo-2,2,2-trifluoro-ethyl)-2-(4,4-dimethyl-1-piperidyl)-6-methyl-chromen-4-one (70 mg, 1 eq, 0.16 mmol) in DMF (2 mL) was added 2-aminobenzoic acid (44 mg, 2 eq, 0.32 mmol). This mixture was stirred at 125° C. for 2 h. The reaction was quenched with water and concentrated to dryness under reduced pressure. Purification by preparative reverse phase HPLC (CH₃CN/H₂O/TFA) gave 2-[[1-[2-(4,4-dimethyl-1-piperidyl)-6-methyl-4-oxo-chromen-8-yl]-2,2,2-trifluoro-ethyl]amino]benzoic acid 2,2,2-trifluoroacetic acid as a white solid (9 mg, 9%). MS ES+ m/z 489 [M+H]⁺.

PI3K-Alpha Kinase (PIK3CA) Activity, Wild-Type and H1047R Mutant and Determining IC50 Values for Inhibitors

Recombinant, catalytically active human full length PIK3KA Wild-type and H1047R mutant were purchased as 1:1 complex of N-terminal 6× his tagged p110

(catalytic) and untagged p85

(regulatory subunit) from EMD Millipore Sigma (cat. no. 14-602M and 14-792M, respectively). The enzyme stocks were diluted to 5× stocks in buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 0.5 mM EGTA, 0.01% triton-x-100) just before use. PIP2diC8 (Avanti Polar Lipids Inc., cat. no. 850185) or phosphoinositol-4,5-bisphosphate with phosphoserine (PIP2:PS) membrane (Thermo Fisher Scientific, cat. no. PV5100) was used as lipid substrates. PIP2diC8 lyophilized powder and PIP2:PS (1:19) membrane stock (1 mM in PIP2) were separately dissolved in milliQ water to a concentration of 250 uM and stored in −20° C. 10 mM stocks of compounds were serially diluted (3×) in neat DMSO and stored in a dessicator at room temperature. 5× compound stocks in 25% DMSO were prepared fresh from neat DMSO stocks.

Wild-type (WT) and H1047R mutant protein, along with buffer components (except ATP), were incubated with or without compound at 27° C. for 1 h. After incubation, the reaction was initiated by the addition of 5 uL of 125 uM ATP. A typical assay mixture (25 uL) comprised 40 mM HEPES buffer, pH 7.4, 25 mM MgCl₂, 0.01% v/v triton-X-100, 5% v/v DMSO, 20 mM NaCl, 1-5 nM wt or H1047R, 25 uM ATP, and 50 uM PIP2diC8 or PIP2 in membrane. The reaction was allowed to proceed until about 1000 conversion (2.5 uM ADP) after which time, 10 uL of reaction mixture was quenched with 25 uL of transcreener reagent (Transcreener ADP2 FI assay kit, BellBrook labs, Cat. No. 3013). The contents were incubated at rt for 1 h and fluorescence was measured using a plate reader (Paradigm, Molecular Devices). The same assay was also run at pH 6.0 or 6.4 using MOPS buffer (Fisher BioReagents, CAS 1132-61-2). A calibration curve was generated under identical buffer conditions with varying ADP amounts. Using that, the observed fluorescence was converted to uM ADP. A plot between [ADP] and log[I] yielded the dose-response curves that enabled the calculation of IC₅₀s.

For IC₅₀ values shown in Table A, “A” means IC₅₀<0.5 μM; “B” means IC₅₀ ranging between 0.5 μM and 1.0 μM; “C” means IC₅₀ ranging between 1 μM and 5 μM; “D” means IC₅₀ ranging between 5 μM and 10 μM; “E” means IC₅₀>10 μM.

TABLE A PI3K-α (PIK3CA) Biochemical IC₅₀ of PI3K wild-type (WT) and H1047R mutant Example # IC₅₀ WT IC₅₀ H1047R  1 E C  4 C C  5 E E  6 E A  8 E E  11 E E  19 B A  20 B A  29 C C  33 E E  38 B B  39 E C  45 C B  46 C B  50 C B  51 C A  53 B A  54 E E  55 C A  57 C B  61 E C  63 E A  65 D A  68 E C  74 D B  76 D B  77 E A  82 E C  85 C C  88 D A  93 D B  96 C B 105 D A 107 D C 111 E E 112 C B 117 E C 123 B A 124 E D 126 E B 130 C A 151 C B 163 E C 169 E C 171 B A 177 C A 189 C A 194 E B 203 C A 212 B A 222 C A 233 C A 236 B A 237 E D 238 E C 244 D E 245 B A 251 C C 256 A A 265 C A 272 B A 274 A A 286 A A 288 B A 289 B A 296 C B 297 C A 298 A A 299 B A 300 A A 301 A A 302 B A 305 A A 306 A A 308 A A 309 A A 310 A A 319 B A 324 A A 326 A A 328 A A 335 B A 338 A A 342 A A 343 B A 348 B A 349 A A 357 E E 362 B A 370 E A 371 E C 373 E B  376* C A 380 E C 392 B B 396 C A 398 C A 399 C A 400 A A 425 C A *For Example 376: IC₅₀ WT/IC₅₀ H1047R = 13.5

For EC₅₀ values shown in Table B, “A” means EC₅₀<1.0 μM; “B” means EC₅₀ ranging between 1.0 μM and 5.0 μM; “C” means EC₅₀ ranging between 5 μM and 15 μM; “D” means EC₅₀ ranging between 15 μM and 24 μM; “E” means EC₅₀>24 μM.

TABLE B Cellular Assay Example # Avg T-47D EC₅₀ 1 D 6 B 7 C 10 D 11 D 12 E 13 D 14 B 15 C 16 E 17 E 18 D 19 D 20 D 21 C 23 C 24 E 32 E 36 C 37 D 77 E 78 E 79 B 89 E 90 D 91 E 92 E 93 C 94 C 95 E 96 B 98 E 126 E 130 B 358 A 363 B 366 B 368 D 369 E 370 B 375 E 376 B 377 E 379 E 380 E 381 E 383 B

TABLE C Selectivity against selected lipid kinases Avg Avg Avg Avg Avg Avg PI3K-B PI3K-D PI3K-G Vps34 DNA-PK mTOR Exam- IC50: IC50 IC50: IC50: IC50: IC50: ple # (nM) (nM): (nM) (nM) (nM) (nM) 363 110 >10,000 >10,000 450 980 7800 366 >10,000 >10,000 >10,000 >10,000 >10,000 >10,000

TABLE D Mouse PK Assays: The compounds show good oral bioavailability in animal models. Example # 363 366 PK-Mouse: 1 1 IV Dose (mg/kg) PK-Mouse: 8.2 43 IV Cl (mL/min/kg) PK-Mouse: 2130 343 IV-AUC-0- last (ng*h/mL) PK-Mouse: 10 50 10 50 100 PO Dose (mg/kg) PK-Mouse: 20% DMSO/ 20% DMSO/ 30% SBE- 20% DMSO/ 20% DMSO/ PO Vehicle 60% PEG400/ 60% PEG400/ beta- 60% PEG400/ 60% PEG400/ 20% Water 20% Water cyclodextrin 20% H2O 20% H2O PK-Mouse: Solution Solution Solution Solution Solution PO Vehicle appearance PK-Mouse: 1300 5100 350 8.56 22.6 PO Cmax (ng/mL) PK-Mouse: 18,000 31,000 3.9 48 76 PO AUC-0- last (ng*h/mL) PK-Mouse: 87 33 100 PO F (%) PK-Mouse: 86 33 110 280 220 F % Calcd (%) PK-Mouse: 1800 700 390 960 760 PO AUC-last/ dose PK-Mouse: Fed Fed Fed Fed Fed PO observations

EQUIVALENTS

The details of one or more embodiments of the disclosure are set forth in the accompanying description above. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

The foregoing description has been presented only for the purposes of illustration and is not intended to limit the disclosure to the precise form disclosed, but by the claims appended hereto. 

1. A compound of the Formula:

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: X is —NR₁₂— or —O—; Y is —C(R₁₁)₂—, —O—, —NR₁₁—, or —S—; WR₁R₂ is a group of the formula:

R₁₀ at each occurrence is independently oxo, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)—OR₁₂, —(CH₂)_(n)—N(R₂)₂, —(CH₂)_(n)—C(O)R₁₂, —(CH₂)_(n)—C(O)OR₂, —(CH₂)_(n)—C(O)N(R₁₂)₂, —(CH₂)—SO₂R₁₂, —(CH₂)_(n)—O—(CH₂CH₂—O)_(t)R₁₃, C₃-C₁₀ cycloalkyl, heterocycle, —(CH₂)_(n)-aryl, or heteroaryl, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl is optionally substituted with halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, or —(CH₂)_(n)—SO₂R₂; R_(10a) at each occurrence is independently halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or —(CH₂)_(n)—OR₁₂; -L₁- is —(CH₂)— or —(CH₂)₂—; u at each occurrence is independently 0, 1, 2, 3 or 4; each R₃, R₄, R₅, and R₆ is independently H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—R₁₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, C₃-C₁₀ cycloalkyl, aryl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S; each R₇ and R₈ is independently H, halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; at least one R₉ is —C(O)OR₁₂ and each of the remaining R₉ at each occurrence is independently oxo, ═NR₁₁, halogen, —CN, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—CR₁₃(OH)—R₁₂, —(CH₂)_(m)—C(O)R₁₂, —(CH₂)_(m)—C(O)OR₁₂, —(CH₂)_(m)—C(O)N(R₁₂)₂, —(CH₂)_(m)—C(O)N(OH)R₁₂, —(CH₂)_(m)—SO₂R₁₂, —(CH₂)_(m)—SO₂—OR₁₂, —(CH₂)_(m)—SO₂N(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₂)₂, —(CH₂)_(m)—P(O)(R₁₂)₂, —(CH₂)_(m)—P(O)(OR₁₃)R₁₂, —(CH₂)_(m)—B(OH)₂, —(CH₂)_(m)—B(R₁₂)₂, —(CH₂)_(m)—O—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)O—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)NR₁₂—(CH₂CH₂—O)_(r)R₁₃, —(CH₂)_(m)—C(O)—NR₁₂—SO₂R₁₃, —(CH₂)_(m)—SO₂NR₁₂—C(O)R₁₃, —(CH₂)_(m)—S(O)(NR₁₂)—R₁₃, C₃-C₁₀ cycloalkyl, aryl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₃-C₁₀ cycloalkyl, aryl, heterocycle, or heteroaryl is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; or two R₉, together with the atoms to which they are attached form a C₃-C₁₀ cycloalkyl, an aryl, or a heterocycle comprising 1-4 heteroatoms selected from O, N, and S, wherein the cycloalkyl, aryl or heterocycle is optionally substituted with one or more oxo, halogen, —CN, —OH, —NH₂, ═NH, —NO₂, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; R₁₁ is H, C₁-C₆ alkyl, C₂-C₆ alkenyl, or C₂-C₆ alkynyl; each R₁₂ and R₁₃ at each occurrence is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—C(O)—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—R₁₄, —(CH₂)_(q)—O—(CH₂)_(r)—OR₁₄, —(CH₂)_(q)—NH—(CH₂)_(r)—OR₁₄, C₃-C₁₀ cycloalkyl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, —(CH₂)_(q)-aryl, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S, wherein the cycloalkyl, heterocycle, aryl, and heteroaryl are optionally substituted with one or more halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, or C₁-C₆ haloalkoxy; Ring A is C₃-C₁₀ cycloalkyl, aryl, heterocycle comprising 1-4 heteroatoms selected from N, O, and S, or heteroaryl comprising 1-4 heteroatoms selected from N, O, and S; R₁₄ is

each n, m, q, or r, is independently at each occurrence 0, 1, 2, 3, 4, 5, or 6; and s is 1, 2, 3, 4, 5, or
 6. 2. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having the Formula:

wherein R₇ is halogen, —CN, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, or C₁-C₆ alkoxy; and R₈ is H.
 3. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X is —NR₁₂—, and Y is —O—.
 4. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein each R₃, R₄, R₅, and R₆ is independently H, halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, —(CH₂)_(m)—OR₁₂, —(CH₂)_(m)—N(R₁₂)₂, —(CH₂)_(m)—C(O)R₁₂, C₃-C₁₀ cycloalkyl, aryl, heterocycle comprising 1-4 heteroatoms selected from O, N, and S, or heteroaryl comprising 1-4 heteroatoms selected from O, N, and S.
 5. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₃ is hydrogen.
 6. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₃ is —CN or C₁-C₃ alkyl.
 7. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₄ is H, halogen, C₁-C₆ alkyl or C₁-C₆ haloalkyl.
 8. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₅ is H, halogen, methyl or trifluoromethyl.
 9. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R₇ is C₁-C₃ alkyl and R₈ is H.
 10. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Ring A is a group of the formula:

wherein R₉ is —C(O)OH, R_(9a) is halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, or C₃-C₅ cycloalkyl, v is 0, 1, or 2, w is 0, 1, or 2, x is 0 or 1, y is 0 or 1, and z is 0, 1, or
 2. 11. The compound of claim 1, or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Ring A is a group of the formula:

wherein R_(9a) is halogen or trifluoromethyl; v is 0 or 1; and w is 0 or
 1. 12. The compound of claim 1 selected from:

or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof.
 13. A pharmaceutical composition comprising, a compound of claim 1, and a pharmaceutically acceptable carrier.
 14. A method of treating a disease or disorder associated with modulation of phosphoinositide 3-kinase (PI3K), comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim
 1. 15. The method of claim 14, wherein the PI3K is PI3Kα.
 16. The method of claim 14, wherein the PI3K associated with the disease or disorder has a H1047R mutation.
 17. The method of claim 14, wherein the disease or disorder is a cancer.
 18. The method of claim 17 wherein the cancer is endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, head and neck cancer, breast cancer, brain cancer, or prostate cancer.
 19. The method of claim 14, wherein the disease or disorder is CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome), or PIK3CA-related overgrowth syndrome (PROS).
 20. A method of inhibiting phosphoinositide 3-kinase (PI3K), comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim
 1. 21. A method of treating cancer or a disorder, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim
 1. 22. The method of claim 21, wherein the cancer is endometrial cancer, gastric cancer, leukemia, lymphoma, sarcoma, colorectal cancer, lung cancer, ovarian cancer, skin cancer, head and neck cancer, breast cancer, brain cancer, or prostate cancer.
 23. The method of claim 21, wherein the disorder is CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal syndrome) or PIK3CA-related overgrowth syndrome (PROS). 